0001136261-22-000332.txt : 20221110 0001136261-22-000332.hdr.sgml : 20221110 20221110160648 ACCESSION NUMBER: 0001136261-22-000332 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-22245 FILM NUMBER: 221377088 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 293-2100 MAIL ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 10-Q 1 body10-q.htm
0001017491 false 2022 --12-31 Q3 0001017491 2022-01-01 2022-09-30 0001017491 2022-11-04 0001017491 2022-09-30 0001017491 2021-12-31 0001017491 2020-12-31 0001017491 2021-03-31 0001017491 2022-07-01 2022-09-30 0001017491 2021-07-01 2021-09-30 0001017491 2021-01-01 2021-09-30 0001017491 us-gaap:CommonStockMember 2022-06-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001017491 us-gaap:RetainedEarningsMember 2022-06-30 0001017491 2022-06-30 0001017491 us-gaap:CommonStockMember 2021-06-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001017491 us-gaap:RetainedEarningsMember 2021-06-30 0001017491 2021-06-30 0001017491 us-gaap:CommonStockMember 2021-12-31 0001017491 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001017491 us-gaap:RetainedEarningsMember 2021-12-31 0001017491 us-gaap:CommonStockMember 2020-12-31 0001017491 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001017491 us-gaap:RetainedEarningsMember 2020-12-31 0001017491 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001017491 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001017491 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001017491 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001017491 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001017491 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001017491 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001017491 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001017491 us-gaap:CommonStockMember 2022-09-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001017491 us-gaap:RetainedEarningsMember 2022-09-30 0001017491 us-gaap:CommonStockMember 2021-09-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001017491 us-gaap:RetainedEarningsMember 2021-09-30 0001017491 2021-09-30 0001017491 SEEL:May122022SaleAgreementMember 2022-05-01 2022-05-31 0001017491 SEEL:May122022SaleAgreementMember 2022-07-01 2022-09-30 0001017491 srt:MaximumMember 2022-04-22 0001017491 srt:MinimumMember 2022-09-30 0001017491 SEEL:May242021Member 2021-05-01 2021-05-31 0001017491 SEEL:May242021Member 2021-05-24 0001017491 SEEL:January282021Member 2021-01-01 2021-01-31 0001017491 SEEL:January282021Member 2021-01-28 0001017491 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001017491 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001017491 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001017491 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0001017491 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001017491 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001017491 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001017491 us-gaap:WarrantMember 2021-07-01 2021-09-30 0001017491 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001017491 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2022-09-30 0001017491 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-09-30 0001017491 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2021-09-30 0001017491 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-09-30 0001017491 SEEL:IXLicenseAgreementMember 2022-01-01 2022-01-31 0001017491 us-gaap:LongTermDebtMember 2022-01-01 2022-09-30 0001017491 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:LongTermDebtMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:LongTermDebtMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:LongTermDebtMember 2022-09-30 0001017491 us-gaap:FairValueMeasurementsRecurringMember us-gaap:LongTermDebtMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2022-09-30 0001017491 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:LongTermDebtMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:LongTermDebtMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:LongTermDebtMember 2021-12-31 0001017491 us-gaap:FairValueMeasurementsRecurringMember us-gaap:LongTermDebtMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-12-31 0001017491 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2021-12-31 0001017491 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2021-12-31 0001017491 us-gaap:EmployeeStockOptionMember us-gaap:LongTermDebtMember 2022-01-01 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember us-gaap:LongTermDebtMember srt:MinimumMember 2021-01-01 2021-12-31 0001017491 us-gaap:EmployeeStockOptionMember us-gaap:LongTermDebtMember srt:MaximumMember 2021-01-01 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:LongTermDebtMember 2022-01-01 2022-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:LongTermDebtMember 2021-01-01 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:LongTermDebtMember 2022-01-01 2022-09-30 0001017491 us-gaap:LongTermDebtMember 2022-09-30 0001017491 us-gaap:LongTermDebtMember srt:MinimumMember 2021-12-31 0001017491 us-gaap:LongTermDebtMember srt:MaximumMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-01-01 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-01-01 2021-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2020-12-31 0001017491 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-12-31 0001017491 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:LongTermDebtMember 2021-12-31 0001017491 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:LongTermDebtMember 2022-09-30 0001017491 SEEL:May242021Member 2021-01-01 2021-12-31 0001017491 SEEL:January282021Member 2021-01-01 2021-12-31 0001017491 SEEL:IXLicenseAgreementMember 2021-11-01 2021-11-30 0001017491 SEEL:IXLicenseAgreementMember 2021-11-01 2021-12-31 0001017491 SEEL:AssetsfromVyeraPharmaceuticalsMember 2022-04-01 2022-04-30 0001017491 SEEL:AssetsfromVyeraPharmaceuticalsMember 2022-07-01 2022-07-31 0001017491 SEEL:AssetsfromVyeraPharmaceuticalsMember 2022-07-01 2022-09-30 0001017491 SEEL:AssetsfromVyeraPharmaceuticalsMember 2022-09-30 0001017491 SEEL:WegLicenseAgreementMember 2019-08-01 2019-08-31 0001017491 SEEL:WegLicenseAgreementMember 2022-01-01 2022-01-31 0001017491 SEEL:WegLicenseAgreementMember 2020-01-01 2020-01-31 0001017491 SEEL:WegLicenseAgreementMember 2021-01-01 2021-01-31 0001017491 SEEL:WegLicenseAgreementMember 2022-09-30 0001017491 SEEL:November2021LindSecuritiesPurchaseAgreementMember 2021-11-01 2021-11-30 0001017491 SEEL:FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember 2022-11-01 2022-11-30 0001017491 SEEL:August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember 2022-08-23 2024-11-23 0001017491 SEEL:AmortizeNovember2021LindSecuritiesPurchaseAgreementMember 2022-11-23 2024-11-24 0001017491 SEEL:December2021SPAsMember 2021-12-01 2021-12-31 0001017491 SEEL:December2021SPAsMember 2021-12-02 0001017491 SEEL:December2021SPAsMember 2021-12-31 0001017491 SEEL:December2021SPAsMember 2022-09-30 0001017491 SEEL:December2021SPAsMember 2022-07-01 2022-09-30 0001017491 SEEL:December2021SPAsMember 2022-01-01 2022-09-30 0001017491 SEEL:LindSecuritiesPurchaseAgreementMember 2020-12-01 2020-12-31 0001017491 SEEL:December17SPAsMember 2020-12-01 2020-12-31 0001017491 SEEL:December17SPAsMember 2021-12-01 2021-12-31 0001017491 SEEL:December17SPAsMember 2021-12-31 0001017491 SEEL:September2020WarrantsMember 2020-09-01 2020-09-30 0001017491 SEEL:September2020WarrantsMember 2020-09-01 2020-09-30 0001017491 SEEL:September2020WarrantsMember 2020-09-04 0001017491 SEEL:September2020WarrantsMember 2021-01-01 2021-09-30 0001017491 SEEL:September2020WarrantsMember 2022-01-01 2022-09-30 0001017491 SEEL:September2020WarrantsMember 2022-09-30 0001017491 SEEL:September2020WarrantsMember 2022-09-30 0001017491 SEEL:August2019WarrantsMember 2019-08-01 2019-08-31 0001017491 SEEL:August232019Member 2019-08-01 2019-08-31 0001017491 SEEL:August2019WarrantsMember 2022-01-01 2022-09-30 0001017491 SEEL:August2019WarrantsMember 2021-01-01 2021-09-30 0001017491 SEEL:August2019WarrantsMember 2022-09-30 0001017491 SEEL:August2019WarrantsMember 2022-09-30 0001017491 SEEL:SeriesAWarrantsMember 2021-01-01 2021-09-30 0001017491 SEEL:SeriesAWarrantsMember 2022-01-01 2022-09-30 0001017491 SEEL:SeriesAWarrantsMember 2022-09-30 0001017491 SEEL:WarrantDerivativeFinancialInstrumentsMember 2021-12-31 0001017491 SEEL:WarrantDerivativeFinancialInstrumentsMember 2022-01-01 2022-09-30 0001017491 SEEL:WarrantDerivativeFinancialInstrumentsMember 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-01-31 0001017491 us-gaap:EmployeeStockOptionMember 2022-09-30 0001017491 SEEL:EmployeeStockPurchasePlanMember 2020-05-01 2020-05-31 0001017491 SEEL:EmployeeStockPurchasePlanMember 2020-05-15 0001017491 SEEL:EmployeeStockPurchasePlanMember 2022-01-01 2022-01-31 0001017491 SEEL:EmployeeStockPurchasePlanMember 2022-01-01 2022-09-30 0001017491 SEEL:InducementPlanof2019Member 2022-01-01 2022-09-30 0001017491 SEEL:InducementPlanof2019Member 2022-09-30 0001017491 SEEL:IncentiveStockOptionMember 2022-01-01 2022-09-30 0001017491 SEEL:NonQualifiedStockOptionsToEmployeesMember 2022-01-01 2022-09-30 0001017491 SEEL:NonQualifiedStockOptionsToNonEmployeeDirectorsMember 2022-01-01 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001017491 us-gaap:PerformanceSharesMember SEEL:PSUtoExecutivesMember 2021-01-01 2021-12-31 0001017491 us-gaap:PerformanceSharesMember SEEL:PSUtoExecutivesMember 2022-01-01 2022-09-30 0001017491 us-gaap:PerformanceSharesMember SEEL:PSUtoExecutivesMember 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2022-01-01 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2022-01-01 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-01-01 2021-09-30 0001017491 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-01-01 2021-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2021-12-31 0001017491 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001017491 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001017491 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001017491 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001017491 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001017491 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001017491 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001017491 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001017491 SEEL:March2019LeaseMember 2022-01-01 2022-09-30 0001017491 SEEL:March2021LeaseMember 2022-01-01 2022-09-30 0001017491 SEEL:March2021LeaseMember 2022-09-30 0001017491 SEEL:October2022LeaseMember 2022-10-01 2022-10-31 0001017491 SEEL:March2021LeaseMember 2021-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:Y
 

  

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2022

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                 to

 

Commission File Number 000-22245

SEELOS THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada 87-0449967
(State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.)

 

 

300 Park Avenue, 2nd Floor, New York, NY 10022

(Address of Principal Executive Offices) (Zip Code)

(646) 293-2100

(Registrant’s telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act

Title of Each Class Trading Symbol Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share SEEL The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 4, 2022, 107,168,256 shares of the common stock, par value $0.001, of the registrant were outstanding.

 

 

 

 

 

Table of Contents

 

PART I.
     
PAGE
     
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) 1
     
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 21
     
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 32
     
ITEM 4. CONTROLS AND PROCEDURES 32
     
PART II.
     
ITEM 1. LEGAL PROCEEDINGS 33
     
ITEM 1A. RISK FACTORS 33
     
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 68
     
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 68
     
ITEM 4 MINE SAFETY DISCLOSURES 68
     
ITEM 5. OTHER INFORMATION 68
     
ITEM 6. EXHIBITS 68
     
SIGNATURES 73

 

 

 

 

 i
 

 

PART I.

 

 

ITEM 1. FINANCIAL STATEMENTS

 

Seelos Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)

 

 

 

September 30, December 31,
2022 2021
Assets
Current assets
Cash $ 30,511 $ 78,734
Prepaid expenses and other current assets 9,997 4,727
Total current assets 40,508 83,461
Operating lease right-of-use asset - 39
Total assets $ 40,508 $ 83,500
             
Liabilities and stockholders’ equity
Current liabilities
Accounts payable $ 5,952 $ 1,693
Accrued expenses 4,048 3,728
Licenses payable 1,000 200
Short-term portion of convertible notes payable, at fair value 10,655 1,030
Derivative liability     -     1,174
Warrant liabilities, at fair value 232 424
Operating lease liability - 38
Total current liabilities 21,887 8,287
             
Convertible notes payable, at fair value 10,742 17,890
Total liabilities 32,629 26,177
             
Commitments and contingencies (note 12) - -
             
Stockholders’ equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares
         issued or outstanding as of September 30, 2022 and December 31, 2021		 - -
Common stock, $0.001 par value, 240,000,000 shares authorized,
         107,168,256 and 105,500,445 issued and outstanding as of
         September 30, 2022 and December 31, 2021, respectively		 107 105
Additional paid-in-capital 203,859 198,428
Accumulated deficit (196,087) (141,210)
Total stockholders’ equity 7,879 57,323
Total liabilities and stockholders’ equity $ 40,508 $ 83,500

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 1
 

Seelos Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss

For the Three and Nine Months Ended September 30, 2022 and 2021

(In thousands, except share and per share data)

(Unaudited)

 

             
   

Three Months Ended September 30,

Nine Months Ended September 30,

    2022     2021 2022 2021
Operating expense            
Research and development $ 14,750 $ 8,683 $ 43,115 $ 27,103
General and administrative 2,660 2,227 9,544 7,192
Total operating expense 17,410 10,910 52,659 34,295
Loss from operations (17,410) (10,910) (52,659) (34,295)
                         
Other income (expense)            
Interest income 36 39 81 87
Interest expense (2) (20) (14) (1,593)
Net loss on extinguishment of debt     -     -     -     (2,387)
Gain on forgiveness of debt     -     -     -     149
Change in fair value of convertible notes     (2,137)     -     (2,477)     -
Change in fair value of warrant liabilities (91) 76 192 (750)
Total other (expense) income (2,194) 95 (2,218) (4,494)
Net loss and comprehensive loss $ (19,604) $ (10,815) $ (54,877) $ (38,789)
                         
Net loss per share basic and diluted $ (0.18) $ (0.11) $ (0.52) $ (0.45)
           
           
                         
Weighted-average common shares outstanding
    basic and diluted		 106,689,924 102,325,238 106,100,413 86,579,881

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 2
 

Seelos Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

For the Three Months Ended September 30, 2022 and 2021

(In thousands, except share data)

(Unaudited)

 

 

 

Additional Total
Common Stock Paid-In Accumulated Stockholders'
(Shares) (Amount) Capital Deficit Equity
Balance as of June 30, 2022 106,190,773 $ 106 $ 202,604 $ (176,483) $ 26,227
Stock-based compensation expense - - 973 - 973
Issuance of common stock for prepaid services 100,000     -     107     -     107
Issuance of common stock for license acquired   500,000     -     -     -     -
Issuance of common stock in at-the-market offering, net of issuance costs 350,000 1 151 - 152
Issuance of common stock, ESPP   27,483     -     24     -     24
Net loss - - - (19,604) (19,604)
Balance as of September 30, 2022 107,168,256 $ 107 $ 203,859 $ (196,087) $ 7,879

 

 

 

 

 

 

 

Additional Total
Common Stock Paid-In Accumulated Stockholders'
(Shares) (Amount) Capital Deficit Equity
Balance as of June 30, 2021 102,271,544 $ 102 $ 185,732 $ (103,136) $ 82,698
Stock-based compensation expense - - 857 - 857
Issuance of common stock, ESPP 39,491 - 74 - 74

Issuance of common stock for conversion of debt 

   43,664     -     98     -     98
Net loss - - - (10,815) (10,815)
Balance as of September 30, 2021 102,354,699 $ 102 $ 186,761 $ (113,951) $ 72,912

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 3
 

 

 

 

Seelos Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

For the Nine Months Ended September 30, 2022 and 2021

(In thousands, except share data)

(Unaudited)

  

 

Additional Total
Common Stock Paid-In Accumulated Stockholders'
(Shares) (Amount) Capital Deficit Equity
Balance as of December 31, 2021 105,500,445 $ 105 $ 198,428 $ (141,210) $ 57,323
Stock-based compensation expense - - 4,166 - 4,166
Issuance of common stock, options exercised   6,250     -     8     -     8
Issuance of common stock for prepaid services   200,000     -     167     -     167
Issuance of common stock for license acquired   1,000,000     1     840     -     841
Issuance of common stock in at-the-market offering, net of issuance costs 350,000 1 151 - 152
Issuance of common stock, ESPP   111,561     -     99     -     99
Net loss - - - (54,877) (54,877)
Balance as of September 30, 2022 107,168,256 $ 107 $ 203,859 $ (196,087) $ 7,879

 

 

 

Additional Total
Common Stock Paid-In Accumulated Stockholders'
(Shares) (Amount) Capital Deficit Equity
Balance as of December 31, 2020 54,535,891 $ 54 $ 77,680 $ (75,162) $ 2,572
Stock-based compensation expense - - 2,599 - 2,599
Issuance of common stock, options exercised 43,805 - 65 - 65
Extinguishment of beneficial conversion feature   -     -     (1,519)     -     (1,519)
Issuance of common stock for settlement of debt   406,250     1     1,376     -     1,377
Issuance of common stock for conversion of debt   69,065     -     138     -     138
Issuance of common stock, ESPP 80,009 - 104 - 104
Warrants exercised for cash 7,431,125 7 8,401 - 8,408
Issuance of common stock, net of issuance costs 39,788,554 40 97,917 - 97,957
Net loss - - - (38,789) (38,789)
Balance as of September 30, 2021 102,354,699 $ 102 $ 186,761 $ (113,951) $ 72,912

 

 

 

 

 

  

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 4
 

 

Seelos Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

For the Nine Months Ended September 30, 2022 and 2021

(In thousands)

(Unaudited)

 

 

Nine Months Ended

September 30,
2022 2021
Cash flows from operating activities
Net loss $ (54,877) $ (38,789)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense 4,166 2,599
Change in fair value of warrant liability (192) 750
Change in fair value of convertible notes payable     2,477     -
Research and development expense - license amendment     841     -
Gain on forgiveness of note payable     -     (147)
Net loss on extinguishment of convertible debt     -     2,387
Amortization of debt discount - 1,582
Changes in operating assets and liabilities
Prepaid expenses and other current assets (5,103) (2,230)
Accounts payable 4,259 1,514
Accrued expenses 289 1,803
Derivative liability     (1,174)     -
Licenses payable 800 (125)
Net cash used in operating activities (48,514) (30,656)
             

Cash flows (used in) provided by financing activities
Payment of convertible note - (13,551)
Proceeds from issuance of common stock, net of issuance costs - 97,957
Proceeds from exercise of warrants - 7,252
Proceeds from issuance of common stock in at-the-market offering     457     -
Payment of at-the-market offering issuance costs     (273)     -
Proceeds from exercise of options 8 65
Proceeds from sales of common stock under ESPP 99 104
Net cash provided by financing activities 291 91,827
Net (decrease) increase in cash (48,223) 61,171
Cash, beginning of period 78,734 15,662
Cash, end of period $ 30,511 $ 76,833
             
Supplemental disclosure of cash flow information:
Cash paid for interest $ 11 $ 10
Cash paid for income taxes $ - $ -
Non-cash investing and financing activities:
Reclass of warrant liabilities related to Series A warrants exercised for cash $ - $ 1,155
Right-of-use assets obtained in exchange for operating lease liabilities $ - $ 75
Issuance of common stock for convertible notes   $ -   $ 69
Issuance of common stock for license payable   $ 840   $ -
At-the-market offering issuance costs, accrued but not paid $ 32 $ -
Issuance of common stock for settlement of debt   $ -   $ 1,377
Extinguishment of beneficial conversion feature   $ -   $ 1,519
             

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 5
 

Seelos Therapeutics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

1. Organization and Description of Business

 

Seelos Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address significant unmet needs in Central Nervous System (“CNS”) disorders and other rare disorders. The Company’s lead programs are SLS-002 for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder (“ASIB in MDD”) and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (“ALS”) and Spinocerebellar Ataxia (“SCA”). SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which is being considered. Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms of action, including: SLS-004, SLS-006, SLS-007 for the potential treatment of Parkinson’s Disease (“PD”) and SLS-008, which is being developed for the potential treatment of an undisclosed indication, but may also be targeted at chronic inflammation in asthma and orphan indications such as pediatric esophagitis.

 

2. Liquidity and Going Concern

 

The accompanying condensed consolidated unaudited financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.

 

The Company has generated limited revenues, has incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of September 30, 2022, the Company had $30.5 million in cash and an accumulated deficit of $196.1 million. The Company has historically funded its operations through the issuance of convertible notes (see Note 9), the sale of common stock (see Note 6) and exercises of warrants (see Note 10).

 

On May 12, 2022, the Company entered into an Open Market Sale AgreementSM (the “Sale Agreement”) with Jefferies LLC, as sales agent (the “Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through the Agent (the “Offering”). The Company also filed a prospectus supplement, dated May 12, 2022, with the Securities and Exchange Commission (the “SEC”) in connection with the Offering (the “Prospectus Supplement”) under the Company’s existing shelf Registration Statement on Form S-3, as amended (File No. 333-251356), which became effective on December 23, 2020 (the “Registration Statement”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares having an aggregate offering price of up to $50.0 million. Under the terms of the Sale Agreement, the Agent is entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of shares under the Sale Agreement. The Company also reimburses the Agent for certain expenses incurred in connection with the Sale Agreement, and agreed to provide indemnification and contribution to the Agent with respect to certain liabilities, including liabilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. During the three months ended September 30, 2022, the Company sold an aggregate of 350,000 shares under the Sale Agreement, receiving net proceeds of $0.5 million. The Company currently intends to use any net proceeds from the Offering for general corporate purposes and to advance the development of its product candidates.

 

On April 22, 2022, the Company received written notice from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for its common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until October 19, 2022, to regain compliance. On September 1, 2022, the Company received a letter from Nasdaq notifying the Company that it regained full compliance with Nasdaq Listing Rule 5550(a)(2) after the closing bid price of the Company’s common stock had been at $1.00 per share or greater for ten consecutive business days, from August 18, 2022 through August 31, 2022.

 

On May 24, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 22,258,066 shares of its common stock, at a price to the public of $3.10 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net proceeds to the Company from the offering were approximately $64.5 million, after deducting underwriting discounts and commissions and other offering costs. The Company used $7.3 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.

 6
 

 

On January 28, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 17,530,488 shares of its common stock, at a price to the public of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to the Company from the offering were approximately $33.5 million, after deducting underwriting discounts, commissions and other offering costs. The Company used $3.8 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.

 

Pursuant to the Registration Statement, the Company may offer from time to time any combination of debt securities, common and preferred stock and warrants. As of September 30, 2022, the Company had approximately $94.6 million available under the Registration Statement (inclusive of the $49.5 million that remained allocated to sales of shares pursuant to the Sale Agreement as of such date). The Company also has the ability to raise funds through other means, such as through the filing of a registration statement on Form S-1 or in private placements. The rules and regulations of the SEC or any other regulatory agencies may restrict the Company’s ability to conduct certain types of financing activities or may affect the timing of and amounts it can raise by undertaking such activities.

 

The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and the Company’s current plans (including the ongoing clinical programs for SLS-002, SLS-005, and other product candidates), which are subject to change, management believes that the Company’s existing cash and cash equivalents as of September 30, 2022 are not sufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q.

 

The Company’s future liquidity and capital funding requirements will depend on numerous factors, including:

 

•its ability to raise additional funds to finance its operations;
•its ability to maintain compliance with the listing requirements of the Nasdaq Capital Market;
•the outcome, costs and timing of clinical trial results for the Company’s current or future product candidates;
•potential litigation expenses;
•the emergence and effect of competing or complementary products or product candidates;
•its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;
•its ability to retain its current employees and the need and ability to hire additional management and scientific and medical personnel;
•the terms and timing of any collaborative, licensing or other arrangements that it has or may establish;
•the trading price of its common stock; and
•its ability to increase the number of authorized shares outstanding to facilitate future financing events.

 

The Company may raise substantial additional funds, and if it does so, it may do so through one or more of the following: issuance of additional debt or equity and/or the completion of a licensing or other commercial transaction for one or more of the Company’s product candidates. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company’s business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders.

 

 

 

 7
 

 

3. Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K (the “Annual Report”) filed with the SEC on March 4, 2022. The accompanying financial statements have been prepared by the Company in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows. The December 31, 2021 condensed consolidated balance sheet was derived from audited financial statements, but it does not include all U.S. GAAP disclosures. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions.

 

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

 

Fair Value Measurements

 

The Company follows the accounting guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), for its fair value measurements of financial assets and liabilities measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

 

The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:

 

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.

 

Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. 

 

 

 8
 

 

Fair Value Option

 

As permitted under FASB ASC Topic 825, Financial Instruments (“ASC 825”), the Company elected the fair value option to account for its November 2021 and December 2021 convertible notes (collectively, the “2021 Convertible Notes”). In accordance with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed as incurred and were not deferred.

 

Stock-based Compensation

 

The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role at the Company.

 

Performance share awards are initially valued based on the Company’s closing stock price on the date of grant. The number of performance share awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period. Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense is reversed.

 

Income (Loss) Per Common Share

 

Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, performance-based restricted stock unit awards and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.

 

The following potentially dilutive securities outstanding for the three and nine months ended September 30, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):

 

Three and Nine Months
Ended September 30,
2022 2021
Outstanding stock options 10,400 7,295
Restricted stock units   - 2,400
Outstanding warrants 2,545 2,635
Convertible debt     3,704     -
16,649 12,330

 

 

Amounts in the table reflect the common stock equivalents of the noted instruments.

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06: Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This standard simplifies the accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06.

 

 9
 

Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for the Company beginning after January 1, 2024, with early adoption permitted, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related disclosures. 

 

In June 2022, the FASB issued ASU No. 2022-03: ASC Subtopic 820 - Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU 2022-03 applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in ASU 2022-03 are effective for the Company for fiscal years beginning after December 15, 2023, and the interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is evaluating the impact of this pronouncement on its consolidated financial statements and related disclosures. 

 

 

4. Fair Value Measurement

 

The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values. There were no transfers between fair value measurement levels during the three and nine months ended September 30, 2022.

 

The Company’s financial assets and liabilities measured at fair value at September 30, 2022 and December 31, 2021 are as follows (in thousands):

 

 

Fair Value Measurements
as of September 30, 2022
(Level 1) (Level 2) (Level 3) Total
Assets:
Cash $ 30,511 $ - $ - $ 30,511
Liabilities:
Convertible notes payable, at fair value   $ -   $ -   $ 21,397   $ 21,397
Warrant liabilities, at fair value - - 232 232
    $ -   $ - $ 21,629   $ 21,629

  

Fair Value Measurements
as of December 31, 2021
(Level 1) (Level 2) (Level 3) Total
Assets:
Cash $ 78,734 $ - $ - $ 78,734
Liabilities:
Convertible notes payable, at fair value   $ -   $ -   $ 18,920   $ 18,920
Derivative liability, at fair value     1,174     -     -     1,174
Warrant liabilities, at fair value - - 424 424
    $ 1,174   $ - $ 19,344   $ 20,518

 

 

 

The fair value of the Company’s money market funds is based on quoted active market prices for the funds and is determined using the market approach.

 

The Company measures the 2021 Convertible Notes and warrant liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level 3 measurement within the fair value hierarchy. These valuations use assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an on-going basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value of the convertible notes payable and warrant liabilities related to updated assumptions and estimates are recognized within the Condensed Consolidated Statements of Operations and Comprehensive Loss.

10
 

The fair value of the 2021 Convertible Notes and warrant liabilities may change significantly as additional data is obtained, impacting the Company’s assumptions regarding probabilities of outcomes used to estimate the fair value of the liabilities. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s results of operations in future periods. 

 

Derivative Liability

 

The derivative liability represented the fair value of the “Shortfall Amount” provision provided for in the license agreement with iX Biopharma Europe Limited.

 

At issuance, the fair value of the embedded derivative was estimated by using a Monte Carlo simulation model. As of December 31, 2021, the Company determined it was probable it would settle the Shortfall Amount in cash and estimated the fair value based on a probability weighted market approach. The Company paid the Shortfall Amount of $1.2 million in cash in January 2022.

 

2021 Convertible Notes

 

The 2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair value of the 2021 Convertible Notes during the nine months ended September 30, 2022 and the year ended December 31, 2021:

 

      Nine Months Ended     Year Ended
      September 30, 2022     December 31, 2021
Risk-free interest rate     4.28%     0.90% - 0.95%
Volatility     105%     113% - 114%
Dividend yield     -%     -%
Contractual term (years)     2.2     3.0
Stock price   $ 1.03   $ 1.74 - 1.95

 

 

Warrant Liabilities

 

The common stock warrant liabilities were recorded at fair value using the Black-Scholes option pricing model.  

The following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option pricing model for the nine months ended September 30, 2022 and 2021:

 

Summary of Fair Value Measurements Warrant Valuation Assumptions

 

             
Nine Months Ended September 30,
2022     2021
Risk-free interest rate 4.08%     0.36%
Volatility 80.30%     110.19%

Dividend yield

 -%     -%
Expected term (years) 1.32     2.32
Weighted-average fair value $ 0.77   $ 2.17

 

 11
 

 

The following table is a reconciliation for the common stock warrant liabilities and convertible notes measured at fair value using Level 3 unobservable inputs (in thousands): 

 

Schedule of Fair Value Level 3 Reconciliation

 

 

                   
      Warrant     Derivative     Convertible notes,
      liabilities     liability     at fair value
Balance as of December 31, 2020   $ 1,062   $       -   $       -
     Warrant liability reclassified to stockholders' equity     (1,155)           -           -
     Issuance of convertible notes, at fair value           -           -                            19,150
     Issuance of derivative liability           -       805           -
     Change in fair value measurement of derivative liability           -       369           -
     Change in fair value measurement of convertible notes           -           -     (230)
     Change in fair value measurement of warrant liability     517           -           -
Balance as of December 31, 2021   $ 424   $  1,174   $  18,920
     Settlement of derivative liability            -      (1,174)         -
     Change in fair value measurement of convertible notes           -           -     2,477
     Change in fair value measurement of warrant liability     (192)           -           -
Balance as of September 30, 2022   $ 232   $  -   $  21,397

 

For the three and nine months ended September 30, 2022 and the year ended December 31, 2021, the changes in fair value of the convertible notes, derivative liability and warrant liability primarily resulted from the volatility of the Company’s common stock. 

 

5. Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets are comprised of the following (in thousands):

 

 

             
      September 30,     December 31,
      2022     2021
Prepaid insurance   $ 329   $ 59
Prepaid clinical costs     9,254     4,481
Other     414     187
Prepaid expenses and other current assets   $ 9,997   $ 4,727

 

6. Common Stock Offerings

 

Public Offerings

 

On May 24, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 22,258,066 shares of its common stock, at a price to the public of $3.10 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net proceeds to the Company from the offering were approximately $64.5 million, after deducting underwriting discounts, commissions and other offering expenses. The Company used $7.3 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes. 

 

On January 28, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 17,530,488 shares of its common stock, at a price to the public of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to the Company from the offering were approximately $33.5 million, after deducting underwriting discounts, commissions and other offering expenses. The Company used $3.8 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes. 

 

 12
 

 

Stock Purchase Agreement with iX Biopharma Europe Limited

 

On November 24, 2021, the Company entered in an exclusive license agreement and stock purchase agreement (the “iXBEL Stock Purchase Agreement”) with iX Biopharma Europe Limited (“iXBEL”). As consideration for the license under the license agreement, the Company paid iXBEL an upfront fee of $9.0 million, comprised of $3.5 million in cash and 2,570,266 restricted shares of the Company’s common stock. Pursuant to the iXBEL Stock Purchase Agreement, the Company agreed to reimburse iXBEL for the difference in value (the “Shortfall Amount”) in the event the aggregate value of the 2,570,266 shares of the Company’s common stock at the time of registration and issuance was less than $5.5 million. The initial fair value of this Shortfall Amount was $0.8 million and in January 2022, the Company settled the Shortfall Amount by the payment of $1.2 million in cash to iXBEL. The change in fair value of the Shortfall Amount is included in Change in fair value of derivative liability on the Condensed Consolidated Statement of Operations and Comprehensive Loss (see Note 4).

 

7. License Agreements

 

Specific information pertaining to each of the Company’s significant license agreements is discussed in its audited financial statements included in the Annual Report for the years ended December 31, 2021 and 2020, including their nature and purpose, the significant rights and obligations of the parties, and specific accounting policy elections. The following represents updates for the nine months ended September 30, 2022, if applicable, to the Company’s significant license agreements:

 

Acquisition of Assets from Phoenixus AG f/k/a Vyera Pharmaceuticals, AG and Turing Pharmaceuticals AG (“Vyera”)

 

On April 8, 2022, Seelos Corporation (“STI”), a wholly-owned subsidiary of the Company, and Vyera, entered into an amendment (the “Amendment”) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018 (as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the “Vyera Purchase Agreement”). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product candidate currently referred to as SLS-002 (intranasal ketamine) (the “Vyera Assets”) and agreed, among other things, to make certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the “Milestone and Royalty Payment Obligations”) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received by the Company as an upfront payment in such sale (the “Change of Control Payment Obligation”).

 

Pursuant to the Vyera Purchase Agreement, as amended by the Amendment, STI agreed to (i) make a cash payment to Vyera in the aggregate amount of $4.0 million on or before April 8, 2022 (the “Cash Payment”); (ii) issue to Vyera on or before April 11, 2022 500,000 shares of the Company’s common stock (the “Initial Shares”); (iii) issue to Vyera on or before July 11, 2022 an additional 500,000 shares of the Company’s common stock (as adjusted for stock splits, stock dividends, combinations, recapitalizations and the like) (the “July 2022 Shares”); and (iv) issue to Vyera on or before January 11, 2023 an additional number of shares of the Company’s common stock equal to $1.0 million divided by the volume weighted average closing price of the Company’s common stock for the ten consecutive trading days ending on the fifth trading day prior to the applicable date of issuance of the shares of the Company’s common stock (the “January 2023 Shares”, and together with the Cash Payment, the Initial Shares and the July 2022 Shares, the “Final Payments”). In consideration for the Final Payments, all of STI’s contingent payment obligations under the Vyera Purchase Agreement, including the Milestone and Royalty Payment Obligations and the Change of Control Payment Obligation, as well as all commercialization covenants of STI under the Vyera Purchase Agreement, will terminate in full upon the date that all of the Final Payments have been made.

 

The Company paid the $4.0 million Cash Payment and issued the 500,000 Initial Shares to Vyera in April 2022. The Company issued the 500,000 July 2022 Shares to Vyera in July 2022. The Company recognized $5.8 million in research and development expense during the three months ended June 30, 2022 related to the Amendment, which consisted of the initial cash payment of $4.0 million and $0.8 million for the Initial Shares and the July 2022 Shares, which were measured at their grant-date fair value. The Company also recognized a liability of $1.0 million related to the January 2023 Shares within accrued licenses payable.

 

Acquisition of License from Stuart Weg, MD

 

On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $0.2 million on January 2, 2022. The Company paid the required $0.1 million on January 2, 2020, $0.125 million on January 2, 2021 and $0.2 million on January 2, 2022.

 

 

 13
 

The remaining potential regulatory and commercial milestones are not yet considered probable, and no other milestone payments have been accrued at September 30, 2022.

 

 

8. Accrued Expenses

Accrued expenses are comprised of the following (in thousands):

Schedule of Accrued Liabilities

             
      September 30,     December 31,
      2022     2021
Professional fees   $ 239    $ 181 
Personnel related     955      1,303 
Outside research and development services     2,767      2,219 
Insurance     84      - 
Other     3      25 
     Accrued expenses, net   $ 4,048    $ 3,728 

 

 

9. Debt

 

Convertible Notes

 

November 2021 and December 2021 Convertible Notes and Private Placement

 

On November 23, 2021, the Company entered into a Securities Purchase Agreement (the “2021 Lind Securities Purchase Agreement”) with Lind Global Asset Management V, LLC (“Lind V”) pursuant to which, among other things, on November 23, 2021 (the “Closing Date”), the Company issued and sold to Lind V, in a private placement transaction (the “Private Placement”), in exchange for the payment by Lind V of $20.0 million, (i) a convertible promissory note (the “2021 Note”) in an aggregate principal amount of $22.0 million (the “Principal Amount”), which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate of 5% per annum, and mature on November 23, 2024 (the “Maturity Date”), and (ii) 534,759 shares of Company common stock. 

 

At the first anniversary of the Closing Date, the Company shall have the option, at its sole discretion and subject to certain stock price and other conditions, to issue to Lind V a convertible promissory note (the “Second Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible promissory note (the “Third Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S. Food & Drug Administration for either SLS-002 or SLS-005, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible promissory note (the “Fourth Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note.

 

At any time following August 23, 2022, from time to time and before the Maturity Date, Lind V shall have the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the “Conversion Price”). At any time prior August 23, 2022, the Company had the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time during such period), up to an aggregate of $14.7 million of the outstanding Principal Amount of the 2021 Note with no penalty. The Company did not prepay any amounts of the 2021 Note prior to August 23, 2022 and has the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price.

 

Subject to certain exceptions, the Company will be required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2021 Notes, unless waived by Lind V in advance.

 

 

 14
 

 

Beginning on November 23, 2022, the 2021 Note will amortize in twenty-four monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments shall be payable, at the Company’s sole option, in cash, shares of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022, the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90% of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note, on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the Company’s assets and properties.

 

On December 2, 2021, the Company entered into two separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021 Note.

 

During the year ended December 31, 2021, the Company received aggregate gross proceeds of $20.2 million from the convertible notes offerings. The Company elected to account for these notes under the fair value option. At time of issuance, the Company recorded a liability of $19.2 million, which was determined to be the fair value at time of issuance. As of December 31, 2021 and September 30, 2022, the Company recognized a total convertible note liability of $18.9 million and $21.4 million, respectively. During the three and nine months ended September 30, 2022, the Company recognized a $2.1 million and $2.5 million loss on change in fair value of convertible notes, respectively. 

 

As of September 30, 2022, the principal contractual balance of the convertible notes totaled $22.2 million.

  

December 2020 Convertible Note and Private Placement

 

On December 11, 2020, the Company entered into a Securities Purchase Agreement (the “2020 Lind Securities Purchase Agreement”) with Lind Global Asset Management II, LLC (the “Investor”) pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the “2020 Note”) in an aggregate principal amount of $12,000,000 (the “Principal Amount”), which did not bear interest and was to mature on December 11, 2022 (the “Maturity Date”), and (2) 975,000 shares of the Company’s common stock. At any time following June 11, 2021, and from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020 Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of 406,250 additional shares of its common stock (the “Lind Shares”) and to pay the Investor the remaining principal amount of $790,804 (the “Final Payment”) in full satisfaction of the Company’s remaining obligations to the Investor under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.

 

 15
 

 

On December 17, 2020, the Company entered into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2020 Lind Securities Purchase Agreement (the “December 17 SPAs”), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1) convertible promissory notes (the “December 17 Notes”) in an aggregate principal amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with an accredited investor on substantially the same terms as the 2020 Lind Securities Purchase Agreement (the “December 18 SPA” and, together with the December 17 SPAs, the “Subsequent Securities Purchase Agreements”), pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the “December 18 Note” and, together with the December 17 Notes, the “Subsequent Notes”), and (2) 26,263 shares of the Company’s common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the 2020 Lind Securities Purchase Agreement, and the Subsequent Notes had substantially the same terms as the 2020 Note. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the “December 18 Note Holder”) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December 18 Note Holder agreed to return to the Company $42,777 in cash (the “Repayment”) previously paid by the Company to the December 18 Note Holder as a payment against the Company’s obligations under the December 18 Note, and (ii) the Company agreed to issue to the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the “December 18 Note Shares”) in full satisfaction of the Company’s remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder paid the Company the Repayment and the Company issued the December 18 Note Shares, and the December 18 SPA and the December 18 Note terminated, effective July 7, 2021.

 

The Company received aggregate net proceeds of $10.9 million from the convertible notes offering, net of $0.5 million of issuance costs. The total gross proceeds were allocated to the convertible notes and common stock issued under the agreements based on their relative fair values. Due to the principal payments made during the year, the Company remeasured the beneficial conversion feature discount at each payment date and recorded a loss on extinguishment of debt of approximately $1.0 million during the year ended December 31, 2021 as well as a reduction in additional paid-in capital of $1.5 million as of December 31, 2021.

 

During the year ended December 31, 2021, the Company paid approximately $13.6 million in principal payments on the outstanding convertible notes and issued an aggregate of 475,315 shares of its common stock upon conversion of the convertible notes, and none of the 2020 convertible notes remain outstanding as of December 31, 2021.

 

10. Stockholders’ Equity

 

Preferred Stock

 

The Company is authorized to issue 10,000,000 shares of preferred stock, par value $0.001. No shares of preferred stock were outstanding as of September 30, 2022 or December 31, 2021.

 

Common Stock

 

The Company has authorized 240,000,000 shares of common stock as of September 30, 2022 and December 31, 2021. Each share of common stock is entitled to one voting right. Common stock owners are entitled to dividends when funds are legally available and declared by the Board of Directors.

 

Warrants

 

September 2020 Warrants

 

On September 4, 2020, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in a registered direct offering and issued warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the “September 2020 Warrants”). The September 2020 Warrants are exercisable for 6,648,750 shares of common stock at an exercise price per share equal to $0.84. The September 2020 Warrants became exercisable beginning on March 9, 2021 and will expire on March 9, 2026.

 

 

 16
 

 

During the nine months ended September 30, 2022 and 2021, the September 2020 Warrants were exercised for 0 and 5.6 million shares of common stock, respectively, for approximately $0 and $4.7 million, respectively. As of September 30, 2022, the September 2020 Warrants exercisable for 1.0 million shares of common stock remain outstanding at an exercise price of $0.84 per share.

 

August 2019 Warrants

 

On August 23, 2019, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 4,475,000 shares of common stock in a registered direct offering and issued warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the “August 2019 Warrants”). The August 2019 Warrants were initially exercisable for 2,237,500 shares of common stock at an exercise price per share equal to $1.78. The August 2019 Warrants became exercisable beginning on February 27, 2020 and will expire on August 28, 2023.

 

During the nine months ended September 30, 2022 and 2021, the August 2019 Warrants for 0 and 1.3 million shares of common stock, respectively, were exercised for approximately $0 and $2.4 million, respectively. As of September 30, 2022, the August 2019 Warrants exercisable for 900,000 shares of common stock remain outstanding at an exercise price of $1.78 per share.

 

Series A Warrants

 

On January 24, 2019, STI and the Company closed a private placement with certain accredited investors pursuant to which, among other things, the Company issued warrants representing the right to acquire 1,463,519 shares of common stock (the “Series A Warrants”). The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per share) occurred during the three months ended September 30, 2020 as a result of the announcement of the registered direct offering of 8,865,000 shares of common stock in September 2020. The Series A Warrants were immediately exercisable upon issuance and will expire on January 31, 2024.

 

During the nine months ended September 30, 2022 and 2021, the Series A Warrants for 0 and 0.5 million shares of common stock, respectively, were exercised for approximately $0 and $0.1 million, respectively. As of September 30, 2022, the Series A Warrants exercisable for 0.3 million shares of common stock remain outstanding at an exercise price of $0.2957 per share.

 

 

A summary of warrant activity during the nine months ended September 30, 2022 is as follows (share amounts in thousands):

 

 

Weighted-
Weighted- Average
Average Remaining
Exercise Contractual Life
Warrants Price (in years)
Outstanding as of December 31, 2021 2,635 $ 4.29 2.4
Issued - $ -
Exercised - $ -
Cancelled (90) $ 47.06
Outstanding as of September 30, 2022 2,545 $ 2.78 1.8
Exercisable as of September 30, 2022 2,545 $ 2.78 1.8

 

 

The Series A Warrants were recognized as a liability at their fair value upon issuance. The warrant liability is remeasured to the then fair value prior to their exercise or at period end for warrants that are unexercised and the gain or loss recognized in earnings during the period.

 

 

 

 17
 

 

11. Stock-based Compensation

 

The Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the “2012 Plan”), which provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of common stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a number of shares of common stock set by the Company’s board of directors on or prior to each such January 1. On January 1, 2022, in accordance with the foregoing, an aggregate of 4,713,637 shares of common stock were added to shares authorized for issuance under the 2012 Plan. As of September 30, 2022, an aggregate of 15,817,818 shares of common stock were authorized under the 2012 Plan, of which 5.4 million shares of common stock were available for future grants. No further awards may be issued under the Seelos Therapeutics, Inc. 2016 Equity Incentive Plan.

 

On May 15, 2020, the Company's stockholders approved the Company's 2020 Employee Stock Purchase Plan (the "ESPP"), whereby qualified employees are allowed to purchase limited amounts of the Company's common stock at the lesser of 85% of the market price at the beginning or end of the offering period. The stockholders have authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding December 31, and (ii) a number of shares of common stock set by the Company's Board of Directors or the Compensation Committee of the Board of Directors (the "Compensation Committee") of the Company on or prior to each such January 1. On January 1, 2022, the Company added 1,055,004 shares for purchase by employees under the ESPP. During the nine months ended September 30, 2022, the Company sold 111,561 shares of common stock under the ESPP. The compensation costs are calculated as the fair value of the 15% discount from market price and were approximately $33,000 for the nine months ended September 30, 2022.

 

On July 28, 2019, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of the Company adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the “2019 Inducement Plan”), which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is 1,000,000 shares of the Company’s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.

 

Stock options

 

During the nine months ended September 30, 2022, the Company granted 660,605 incentive stock options and 2,299,395 non-qualified stock options to employees with a weighted average exercise price per share of $1.45 and a 10-year term, subject to the terms and conditions of the 2012 Plan above. The stock options are subject to time vesting requirements. The stock options granted to employees vest 25% on the first anniversary of the grant and monthly thereafter over the next three years.

 

During the nine months ended September 30, 2022, the Company also granted 140,000 non-qualified stock options to non-employee directors with a weighted average exercise price per share of $1.56 and a 10-year term, subject to the terms and conditions of the 2012 Plan above. The stock options granted to non-employee directors vest monthly over the 12 months following the grant.

 

 

 18
 

The fair value of stock option grants are estimated on the date of grant using the Black-Scholes option-pricing model. The Company was historically a private company and lacked sufficient company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on a weighted average blend of the historical volatility of a publicly traded set of peer companies, as well as its own historical volatility. Additionally, due to an insufficient history with respect to stock option activity and post-vesting cancellations, the expected term assumption for employee grants is based on a permitted simplified method, which is based on the vesting period and contractual term for each tranche of awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

 

During the nine months ended September 30, 2022, 6,250 stock options were exercised and no options were forfeited.

 

The following assumptions were used in determining the fair value of the stock options granted during the nine months ended September 30, 2022 and 2021:

 

 

Nine Months Ended
September 30, 2022     September 30, 2021
Risk-free interest rate 1.6% - 3.4%     0.5% - 1.2%
Volatility 111%-113%     118%-125%
Dividend yield -%     -%
Expected term (years) 5 - 6     5 - 6
Weighted-average fair value $ 1.22   $ 3.52

 

 

A summary of stock option activity during the nine months ended September 30, 2022 is as follows (share amounts in thousands):

 

Weighted-
Weighted- Average Total
Average Remaining Aggregate
Stock Exercise Contractual Intrinsic
Options Price Life (in years) Value
Outstanding as of December 31, 2021 7,306 $ 2.60
Granted 3,100 1.45
Exercised (6) 1.06
Cancelled - -
Outstanding as of September 30, 2022 10,400 $ 2.26 8.3 $ 11
Vested and expected to vest as of September 30, 2022 10,400 $ 2.26 8.3 $ 11
Exercisable as of September 30, 2022 4,053 $ 2.78 7.7 $ 9

 

The intrinsic value of options exercised during the nine months ended September 30, 2022 and 2021 was $0.1 million and $0.2 million, respectively. As of September 30, 2022, unrecognized stock-option compensation expense of $8.4 million is expected to be realized over a weighted-average period of 2.3 years. 

 

Performance Stock Award

 

During the year ended December 31, 2021, the Company’s Board of Directors awarded a performance stock unit award to the Company’s Chief Executive Officer for 2,400,000 shares of common stock, with a grant date fair value of $4.31 per unit. Vesting of this award was subject to the Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had been satisfied. The Company recognized stock-based compensation related to this award of $4.9 million during the fourth quarter of 2021, which was recorded in general and administrative expense. During the nine months ended September 30, 2022, the Company and its Chief Executive Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation expense of the three achieved milestones of $1.3 million. The two remaining milestones were not deemed probable of achievement at the time of cancellation, and no compensation cost related to these milestones was recognized.

 

 

  19
 

 

The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company’s condensed consolidated statements of operations (in thousands):

 

    Three Months Ended Nine Months Ended
    September 30, September 30,
    2022     2021 2022 2021
Research and development $ 261 $ 193 $ 721 $ 551
General and administrative 712 664 3,445 2,048
$ 973 $ 857 $ 4,166 $ 2,599

 

 

12. Commitments and Contingencies

 

Leases

 

In March 2019, the Company entered into a nine-month office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company was notified that the counterparty’s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is in breach of this rental agreement and therefore, the Company has no further obligations thereunder.

 

In March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New York, NY, which was due to expire in September 2022. The rental agreement contains a base rent of approximately $4,000 per month. This agreement included one or more renewal options. At September 30, 2022, the Company’s right-of-use assets and lease liability for operating leases was $0. In October 2022, the Company entered into a new eighteen-month office space rental agreement for its existing space, which provides for a base rent starting at approximately $4,000 per month subject to periodic increases.

Upon the commencement of the 300 Park Avenue, New York, NY office space in March 2021, in exchange for the new operating lease liability, the Company recognized a right-of-use asset of $74,000. As of September 30, 2022, the weighted-average remaining lease term of the operating lease was 0 years, and the weighted-average discount rate was 8.0%.

As of September 30, 2022, there were no future minimum lease payments for the Company’s operating leases with a non-cancelable term of more than one year as the current lease was expiring, while the Company’s new lease was not effective until October 2022.

For each of the nine months ended September 30, 2022 and 2021, rent expense totaled $0.1 million.

 

Contractual Commitments

 

The Company has entered into long-term agreements with certain manufacturers and suppliers that require it to make contractual payment to these organizations. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and long-term commitments of cash.

 

Litigation

 

As of September 30, 2022, there was no material litigation against or involving the Company.

 

 

 

 

  20
 

 

ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Disclosures Regarding Forward-Looking Statements

 

The following should be read in conjunction with the unaudited condensed consolidated financial statements and the related notes that appear elsewhere in this report as well as in conjunction with the Risk Factors section and in our Annual Report on Form 10- K for the year ended December 31, 2021 as filed with the United States Securities and Exchange Commission (“SEC”) on March 4, 2022 (the “Form 10-K”). This report and the Form 10-K include forward-looking statements made based on current management expectations pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.

 

This report includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Those statements include statements regarding the intent, belief or current expectations of Seelos Therapeutics, Inc. and its subsidiaries (“we,” “us,” “our,” the “Company” or “Seelos”) and our management team. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to those risks and uncertainties set forth in Part II, Item 1A of this report. In light of the significant risks and uncertainties inherent in the forward-looking statements included in this report, the inclusion of such statements should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Further, these forward-looking statements reflect our view only as of the date of this report. Except as required by law, we undertake no obligations to update any forward-looking statements and we disclaim any intent to update forward-looking statements after the date of this report to reflect subsequent developments. Accordingly, you should also carefully consider the factors set forth in other reports or documents that we file from time to time with the SEC.

 

We have common law trademark rights in the unregistered marks “Seelos Therapeutics, Inc.,” “Seelos,” and the Seelos logo in certain jurisdictions. Solely for convenience, trademarks and tradenames referred to in this Quarterly Report on Form 10-Q appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.

 

Overview

 

We are a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address significant unmet needs in Central Nervous System ("CNS") disorders and other rare disorders.

 

Recent Developments

 

Impact of COVID-19

 

In March 2020, we began taking precautionary measures to protect the health and safety of our employees and contractors and further assessing the actual and potential impact of the coronavirus (“COVID-19”) pandemic on our business, financial condition and operations. COVID-19 infections have been reported throughout the United States, along with other jurisdictions in which our suppliers, partners and collaborators operate. In addition, COVID-19 has caused disruption and volatility in the global capital markets, and has led to an economic slowdown. Certain national, provincial, state and local governmental authorities have issued proclamations and/or directives aimed at minimizing the spread of COVID-19 and additional, more restrictive proclamations and/or directives may be issued in the future. Before the COVID-19 outbreak, most of our employees worked remotely. Up until the fourth quarter of 2021, we had not experienced any significant delays with our past or ongoing clinical trials for SLS-002, or our start-up activities for clinical trials for SLS-005. Beginning in the fourth quarter of 2021 and through the issuance of this report, we have experienced a slowdown in patient enrollment primarily due to staffing issues at our study sites related to the spike in COVID-19 cases due to the Omicron variant and its sub-variants. Recently, we have seen staffing issues improving, but we cannot be certain that this trend will continue as additional variants emerge and COVID-19 continues to circulate and spread. However, the pandemic has not materially affected our liquidity as we maintain our resources in the form of cash.

 

 21
 

 

In addition, although we do not currently expect the preventative measures taken to date to have a material adverse impact on our business for the remainder of 2022, the continued impact of the COVID-19 pandemic on our business, financial condition and results of operations is unknown and will depend on future developments and risks, which are highly uncertain and cannot be predicted. These developments and risks include, among others, the duration and severity of the COVID-19 pandemic, the emergence or spread of new COVID-19 variants, the impact on the capital markets, the impact on our partners and the regulatory agencies that oversee our sector and any additional preventative and protective actions that governmental authorities, or we, may implement, any of which may result in an extended period of business disruption, including potential delays in commencing future clinical trials, or in completing enrollment for any clinical trials we may commence or in the U.S. Food and Drug Administration (“FDA”) or other regulatory agencies conducting in-person inspections or accommodations for alternatives to in-person inspections. Any resulting financial impact cannot be reasonably estimated at this time, but the COVID-19 pandemic may force us to make adjustments to our business, our plans and our timeline for developing assets, including our programs. In addition, the pandemic is currently not anticipated to have a material adverse impact on our business, financial condition and results of operations, including our ability to raise additional capital, although, if the pandemic continues at its current rate into the end of 2022, it could have a material adverse impact on our business. See Part I, Item 1A, Risk Factors, for an additional discussion of risks related to COVID-19.

 

Business Update

 

Our business model is to advance multiple late-stage therapeutic candidates with proven mechanisms of action that address large markets with unmet medical needs and for which there is a strong economic and scientific rationale for development.

 

Our product development pipeline is as follows:

Product   Indication   Development Phase   Development Status
             
SLS-002
Intranasal Racemic Ketamine		  
 		 Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD)     Phase II
 		  
 		 Completed open-label patient enrollment and announced the initial topline data from Part 1 of the proof-of-concept study on May 17, 2021 and initiated enrollment of Part 2 of a registration directed study 
             

SLS-005

IV Trehalose

   Amyotrophic Lateral Sclerosis (ALS)   Phase II/III   On February 28, 2022, we announced dosing of the first participants in the registrational study; enrollment ongoing
             
   Spinocerebellar Ataxia (SCA)   Phase IIb/III   In October 2022, we announced dosing of the first participant in the registrational study; enrollment ongoing
             
    Sanfilippo Syndrome   Phase II   Obtaining natural history data
             
SLS-004   Parkinson's Disease (PD)   Pre-IND   Preclinical studies ongoing
Gene Therapy            
             
SLS-006   Parkinson's Disease (PD)   Phase II/III   Not in active development; considering next steps
Partial Dopamine Agonist            
             
SLS-007   Parkinson's Disease (PD)   Pre-IND   Preclinical study ongoing
Peptide Inhibitor            
             

 

Lead Programs

 

Our lead programs are currently SLS-002 for the potential treatment of Acute Suicidal Ideation and Behavior (“ASIB”) in patients with Major Depressive Disorder (“MDD”) and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (“ALS”) and Spinocerebellar Ataxia (“SCA”). SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which is being considered.

 22 

 

SLS-002 is intranasal racemic ketamine with two investigational new drug applications (“INDs”). The lead program is focused on the treatment of ASIB in MDD. SLS-002 was originally derived from a Javelin Pharmaceuticals, Inc./Hospira, Inc. program with 16 clinical studies involving approximately 500 subjects. SLS-002 is being developed to address an unmet need for an efficacious drug to treat suicidality in the United States. Traditionally, anti-depressants have been used in this setting but many of the existing treatments are known to contribute to an increased risk of suicidal thoughts in some circumstances, and if and when they are effective, it often takes weeks for the full therapeutic effect to be manifested. We believe there is a large opportunity in the United States and European markets for products in this space. Based on information gathered from the databases of the Agency for Healthcare Research and Quality, there were approximately 1,000,000 visits to emergency rooms for suicide attempts in 2013 in the United States alone. Experimental studies suggest ketamine has the potential to be a rapid, effective treatment for depression and suicidality.

 

The clinical development program for SLS-002 includes two parallel healthy volunteer studies (Phase I). We announced interim data from our Phase I study of SLS-002 during the quarterly period ended March 31, 2020. As a result, in March 2020, we completed a Type C meeting with the FDA and received guidance to conduct a Phase II proof of concept (“PoC”) study of SLS-002 for ASIB in patients with MDD, to support the further clinical development of this product candidate, together with nonclinical data under development.

 

As a result of the Type C meeting and the Fast Track designation for SLS-002 for the treatment of ASIB in patients with MDD, we believe we are well positioned to pursue the FDA's expedited programs for drug development and review.

 

On June 23, 2020, we announced the final safety data from our Phase I pharmacokinetics/pharmacodynamics study of intranasal racemic ketamine (SLS-002) as well as the planned design of a Phase II double blind, placebo-controlled PoC study for ASIB in subjects with MDD. We initiated this PoC study in two parts: Part 1 was an open-label study of 17 subjects, and is being followed by Part 2, which is a double blind, placebo-controlled study of approximately 120 subjects. On January 15, 2021, we announced dosing of the first subjects in Part 1 of the PoC study. On March 5, 2021, we announced the completion of open-label enrollment of subjects in Part 1 of the PoC study. On May 17, 2021, we announced positive topline data from Part 1 of the POC study, the open-label cohort, of our study of SLS-002 (intranasal racemic ketamine), demonstrating a significant treatment effect and a well-tolerated safety profile for ASIB in patients with MDD. This study enrolled 17 subjects diagnosed with MDD requiring psychiatric hospitalization due to significant risk of suicide with a baseline score of ≥ 28 points on the Montgomery-Åsberg Depression Rating Scale ("MADRS"), a score of 5 or 6 on MADRS Item-10, a score of ≥ 15 points on the Sheehan-Suicidality Tracking Scale (S-STS) total score and a history of previous suicide attempt(s), as confirmed on the Columbia Suicide Severity Rating Scale (C-SSRS) with a history of at least one actual attempt, or if the attempt was interrupted or aborted, is judged to have been serious in intent. SLS-002 demonstrated a 76.5% response rate (response meaning 50% reduction from baseline) in the primary endpoint on MADRS twenty-four hours after first dose, with a mean reduction in total score from 39.4 to 14.5 points.

 

On July 6, 2021, we announced dosing of the first subject in Part 2 of the planned registration directed study. Based on feedback from a Type C meeting with the FDA in June 2021, we increased the subjects in Part 2 to increase the sample size and power to support a potential marketing application.

 

SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain-barrier and activates autophagy and the lysosomal pathway. Based on preclinical and in vitro studies, there is a sound scientific rationale for developing trehalose for the treatment of ALS, SCA and other indications such as Sanfilippo Syndrome. Trehalose is a low molecular weight disaccharide (0.342 kDa) that protects against pathological processes in cells. It has been shown to penetrate muscle and cross the blood-brain-barrier. In animal models of several diseases associated with abnormal cellular protein aggregation, it has been shown to reduce pathological aggregation of misfolded proteins as well as to activate autophagy pathways through the activation of Transcription Factor EB ("TFEB"), a key factor in lysosomal and autophagy gene expression. Activation of TFEB is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material.

 

 23 

 

Trehalose 90.5 mg/mL IV solution has demonstrated promising clinical potential in prior Phase II clinical development for oculopharyngeal muscular dystrophy ("OPMD") and spinocerebellar ataxia type 3 ("SCA3"), also known as Machado Joseph disease, with no significant safety signals to date and encouraging efficacy results. Pathological accumulation of protein aggregates within cells, whether in the CNS or in muscle, eventually leads to loss of function and ultimately cell death. Prior preclinical studies indicate that this platform has the potential to prevent mutant protein aggregation in other devastating PolyA/PolyQ diseases.

 

We own three United States patents for parenteral administration of trehalose for patients with OPMD and SCA3, all of which are expected to expire in 2034. In addition, Orphan Drug Designation ("ODD") for OPMD and SCA3 has been secured in the United States and in the European Union ("EU"). In February 2019, we assumed a collaborative agreement, turned subsequently into a research grant, with Team Sanfilippo Foundation (“TSF”), a nonprofit medical research foundation founded by parents of children with Sanfilippo Syndrome. On April 30, 2020, we were granted ODD for SLS-005 in Sanfilippo Syndrome from the FDA. SLS-005 was previously granted ODD from the FDA and European Medicines Agency for SCA3 and OPMD as well as Fast Track designation for OPMD. On August 25, 2020, we were issued U.S. patent number 10,751,353 titled "COMPOSITIONS AND METHODS FOR TREATING AN AGGREGATION DISEASE OR DISORDER" which relates to trehalose (SLS-005). The issued patent covers the method of use for trehalose (SLS-005) formulation for treating a disease or disorder selected from any one of the following: spinal and bulbar muscular atrophy, dentatombral-pallidoluysian atrophy, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia or parkinsonism linked to chromosome 17. On May 15, 2020, we were granted Rare Pediatric Disease Designation ("RPDD") for SLS-005 in Sanfilippo Syndrome from the FDA. RPDD is an incentive program created under the Federal Food, Drug, and Cosmetic Act to encourage the development of new therapies for the prevention and treatment of certain rare pediatric diseases. On May 27, 2021, we announced that we were granted ODD for SLS-005 in ALS from the European Medicines Agency. In December 2020, we announced the selection of SLS-005 for the Healey ALS platform trial led by Harvard Medical School, Massachusetts. The Healey ALS platform trial is designed to study multiple potential treatments for ALS simultaneously. The platform trial model aims to greatly accelerate the study access, reduce costs and shorten development timelines. On February 28, 2022, we announced the dosing of the first participants in the Healey ALS platform trial. In November 2021, we announced the FDA acceptance of an IND and grant of Fast Track designation for SLS-005 for the treatment of SCA. In October 2022, we announced the dosing of the first participant in the registrational phase II/III study for the treatment of SCA. In July 2022, we also announced dosing of the first patient in an open-label basket study in Australia for the treatment of patients with ALS, SCA, and Huntington’s disease.

 

Additionally, we are developing several preclinical programs, most of which have well-defined mechanisms of action, including SLS-004, licensed from Duke University, and SLS-007, licensed from The Regents of the University of California, for the potential treatment of Parkinson’s Disease (“PD”), SLS-008, targeted at chronic inflammation in asthma, atopic dermatitis and orphan indications such as pediatric esophagitis, SLS-010 in narcolepsy and related disorders and SLS-012, an injectable therapy for post-operative pain management.

 

Strategy and Ongoing Programs

 

SLS-002: The clinical development program for SLS-002 includes two parallel healthy volunteer studies (Phase I). Following these Phase I studies, we completed a Type C meeting with the FDA in March 2020 and received guidance to conduct a Phase II PoC study of SLS-002 for ASIB in subjects with MDD. We released topline data for Part 1 of our open-label study on May 17, 2021. We initiated enrollment in Part 2 of the registration directed study on July 6, 2021.

 

 

 24 

SLS-005 is undergoing enrollment in our clinical studies in ALS and in SCA. In December 2020, we announced the selection of SLS-005 for the Healey ALS platform trial led by Harvard Medical School, Massachusetts. The Healey ALS platform trial is designed to study multiple potential treatments for ALS simultaneously. The platform trial model aims to greatly accelerate the study access, reduce costs, and shorten development timelines. On February 28, 2022, we announced dosing of the first participants in the Healey ALS platform trial. In November 2021, we announced the FDA acceptance of an IND and grant of Fast Track designation for SLS-005 for the treatment of SCA. In October 2022, we announced the dosing of the first participant in the registrational phase II/III study for the treatment of SCA. In July 2022, we also announced dosing of the first patient in an open-label basket study in Australia for the treatment of patients with ALS, SCA, and Huntington’s disease. We are continuing to consider trials in Sanfilippo Syndrome and are seeking more natural history data based on the guidance from regulatory agencies.

 

SLS-004 is an all-in-one lentiviral vector, targeted for gene editing through DNA methylation within intron 1 of the synuclein alpha ("SNCA") gene responsible for expressing alpha-synuclein protein. SLS-004, when delivered to dopaminergic neurons derived from human induced pluripotent stem cells of a PD patient, modified the expression on alpha-synuclein ("α-synuclein") and exhibited reversal of the disease-related cellular-phenotype characteristics of the neurons. The role of mutated SNCA in PD pathogenesis and the need to maintain the normal physiological levels of α-synuclein protein emphasize the yet unmet need to develop new therapeutic strategies, such as SLS-004, targeting the regulatory mechanism of α-synuclein expression. On May 28, 2020, we announced the initiation of a preclinical study of SLS-004 in PD through an all-in-one lentiviral vector targeting the SNCA gene. We are constructing a bimodular viral system harboring an endogenous α-synuclein transgene and inducible regulated repressive CRISPR/Cas9-unit to achieve constitutive activation and inducible suppression of PD-related pathologies. On July 7, 2021, we announced positive in vivo data demonstrating down-regulation of SNCA mRNA and protein expression under this study.

 

SLS-006 is a true partial dopamine agonist, originally developed by Wyeth Pharmaceuticals, Inc., with previous clinical studies on 340 subjects in various Phase I and Phase II studies. It is a potent D2/D3 agonist/antagonist that has shown promising efficacy with statistical significance in Phase II studies in early-stage PD patients and an attractive safety profile. Moreover, it has also shown synergistic effect with reduced doses of L-DOPA. Currently, this program is not in active development and we are considering the next steps.

 

SLS-007 is a rationally designed peptide-based approach, targeting the nonamyloid component core ("NACore") of α-synuclein to inhibit the protein from aggregation. Recent in vitro and cell culture research has shown that SLS-007 has the ability to stop the propagation and seeding of α-synuclein aggregates. We will evaluate the potential for in vivo delivery of SLS-007 in a PD transgenic mice model. The goal will be to establish in vivo pharmacokinetics/pharmacodynamics and target engagement parameters of SLS-007, a family of anti-α-synuclein peptidic inhibitors. On June 25, 2020, we announced the initiation of a preclinical study of SLS-007 in PD delivered through an adeno associated viral ("AAV") vector targeting the non-amyloid component core of α-synuclein. We have initiated an in vivo preclinical study of SLS-007 in rodents to assess the ability of two specific novel peptides, S62 and S71, delivered via AAV1/2 viral vector, to protect dopaminergic function in the preformed α-synuclein fibril rodent model of PD. Production of AAV1/2 vectors encoding each of the two novel peptides incorporating hemagglutinin tags has already been completed. This preclinical study is designed to establish the in vivo pharmacokinetic and pharmacodynamic profiles and target engagement parameters of SLS-007.

 

We intend to become a leading biopharmaceutical company focused on neurological and psychiatric disorders, including orphan indications. Our business strategy includes:

 

·advancing SLS-002 in ASIB in MDD and post-traumatic stress disorder;
·advancing SLS-004 in PD;
·advancing SLS-005 in ALS, SCA and Sanfilippo Syndrome;
·advancing SLS-007 in PD as a monotherapy; and
·acquiring synergistic assets in the CNS therapy space through licensing and partnerships.

 

 

 25 

We also have two legacy product candidates: a product candidate in the United States for the treatment of erectile dysfunction, which we in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc; and a product candidate which has completed a Phase IIa clinical trial for the treatment of Raynaud’s Phenomenon, secondary to scleroderma, for which we own worldwide rights.

 

Liquidity, Capital Resources and Financial Condition

 

Liquidity

 

We have generated limited revenues, incurred operating losses since inception, and we expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of September 30, 2022, we had $30.5 million in cash and an accumulated deficit of $196.1 million. We have historically funded our operations through the issuance of convertible notes (the “Notes”) (see Note 9 to our condensed consolidated financial statements), the sale of common stock (see Note 6 to our condensed consolidated financial statements) and the exercise of warrants (see Note 10 to our condensed consolidated financial statements).

 

On May 12, 2022, we entered into an Open Market Sale AgreementSM (the “Sale Agreement”) with Jefferies LLC, as sales agent (the “Agent”), pursuant to which we may offer and sell shares of our common stock from time to time through the Agent (the “Offering”). We also filed a prospectus supplement, dated May 12, 2022, with the SEC in connection with the Offering (the “Prospectus Supplement”) under our existing shelf Registration Statement on Form S-3, as amended (File No. 333-251356), which became effective on December 23, 2020 (the “Registration Statement”). Pursuant to the Prospectus Supplement, we may offer and sell shares having an aggregate offering price of up to $50.0 million. Under the terms of the Sale Agreement, the Agent is entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of shares under the Sale Agreement. We also reimburse the Agent for certain expenses incurred in connection with the Sale Agreement, and agreed to provide indemnification and contribution to the Agent with respect to certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act. During the three months ended September 30, 2022, we sold an aggregate of 350,000 shares under the Sale Agreement, receiving net proceeds of $0.5 million. We currently intend to use any net proceeds from the Offering for general corporate purposes and to advance the development of our product candidates.

 

As of September 30, 2022, we had approximately $94.6 million available under the Registration Statement (inclusive of the $49.5 million that remained allocated to sales of shares of our common stock pursuant to the Sale Agreement as of such date).

 

On November 23, 2021, we entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with Lind Global Asset Management V, LLC (“Lind V”) pursuant to which, among other things, on November 23, 2021 (the “Closing Date”), we issued and sold to Lind V, in a private placement transaction (the “Private Placement”), in exchange for the payment by Lind V of $20.0 million, (1) a convertible promissory note (the “2021 Note”) in an aggregate principal amount of $22.0 million (the “Principal Amount”), which will bear no interest until the first anniversary of the issuance of the First Note and will thereafter bear interest at a rate of 5% per annum, and mature on November 23, 2024 (the “Maturity Date”), and (2) 534,759 shares (the “2021 Closing Shares”) of our common stock.

 

At the first anniversary of the Closing Date, we shall have the option, at our sole discretion and subject to certain stock price and other conditions, to issue to Lind V a convertible promissory note (the “Second Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of us and Lind V, we shall issue to Lind V a convertible promissory note (the “Third Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the FDA for either SLS-002 or SLS-005, and subject to the mutual agreement of us and Lind V, we shall issue to Lind a convertible promissory note (the “Fourth Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note. See Note 9 to our condensed consolidated financial statements for further discussion.

 

On December 2, 2021, we entered into two separate securities purchase agreements with certain accredited investors on substantially the same terms as the Securities Purchase Agreement, pursuant to which we sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $201,534, (i) convertible promissory notes (the “December 2021 Notes”) in an aggregate principal amount of $221,688, which will bear no interest and mature on December 2, 2024, and (ii) an aggregate of 5,388 shares of our common stock. The December 2021 Notes have substantially the same terms as the 2021 Note.

 

On May 24, 2021, we completed an underwritten public offering pursuant to which we sold 22,258,066 shares of our common stock at a price to the public of $3.10 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net proceeds to us from the offering were $64.5 million, after deducting underwriting discounts and commissions and other offering expenses payable by us (see Note 6 to our condensed consolidated financial statements).

 

 26 

 

On January 28, 2021, we completed an underwritten public offering pursuant to which we sold 17,530,488 shares of our common stock at a price to the public of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to us from the offering were $33.5 million, after deducting underwriting discounts and commissions and other offering expenses payable by us (see Note 6 to our condensed consolidated financial statements).

 

We expect to use the net proceeds from the above transactions primarily for general corporate purposes, which may include financing our normal business operations, developing new or existing product candidates and funding capital expenditures, acquisitions and investments.

 

We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and our current plans (including the ongoing clinical programs for SLS-002, SLS-005, and other product candidates), which are subject to change, management believes that our existing cash and cash equivalents as of September 30, 2022 are not sufficient to satisfy our operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q.

 

The accompanying unaudited condensed consolidated financial statements have been prepared assuming we will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to our ability to continue as a going concern.

 

Our future liquidity and capital funding requirements will depend on numerous factors, including:

 

•our ability to raise additional funds to finance our operations;
•our ability to maintain compliance with the listing requirements of The Nasdaq Capital Market;
•the outcome, costs and timing of any clinical trial results for our current or future product candidates;
•potential litigation expenses;
•the emergence and effect of competing or complementary products or product candidates;
•our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;
•our ability to retain our current employees and the need and ability to hire additional management and scientific and medical personnel;
•the terms and timing of any collaborative, licensing or other arrangements that we have or may establish;
•the trading price of our common stock; and
•our ability to increase the number of authorized shares outstanding to facilitate future financing events.

 

We may need to raise substantial additional funds, and if we do so, we may do so through one or more of the following: issuance of additional debt, equity, or both and/or the completion of a licensing or other commercial transaction for one or more of our product candidates. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected. This could adversely affect future development and business activities, operations and business plans, such as future clinical studies and/or other future ventures. There can be no assurance that we will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings may have a dilutive effect on the holdings of our existing stockholders. No assurances can be given that we will be able to obtain additional financing.

 

Critical Accounting Estimates and Policies

 

The preparation of financial statements in accordance with United States generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our unaudited condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience, market and other conditions, and various other assumptions it believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact us in the future, the estimation process is, by its nature, uncertain given that estimates depend on events over which we may not have control. If market and other conditions change from those that we anticipate, our unaudited condensed consolidated financial statements may be materially affected. In addition, if our assumptions change, we may need to revise our estimates, or take other corrective actions, either of which may also have a material effect in our unaudited condensed consolidated financial statements. We review our estimates, judgments, and assumptions used in our accounting practices periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. We believe that these estimates are reasonable; however, our actual results may differ from these estimates.

 

 27 

 

Our critical accounting policies and estimates are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and there have been no material changes to such policies or estimates during the nine months ended September 30, 2022.

 

Recent Accounting Pronouncements

 

Please refer to the notes to the unaudited condensed consolidated financial statements for a discussion of recent accounting pronouncements.

 

Comparison of the Three Months Ended September 30, 2022 and 2021

 

Operating Expense

 

Operating expense was as follows (in thousands, except percentages):

 

                  Three Months Ended September 30,
      Three Months Ended September 30,     2022 vs 2021
      2022     2021     $     Change   %   Change
Operating expense                      
     Research and development   $                    14,750   $                      8,683   $                        6,067   70%
     General and administrative                          2,660                          2,227                               433   19%
          Total operating expense   $                    17,410   $                    10,910   $                        6,500   60%

 

Research and Development Expenses

 

Research and development expenses were as follows (in thousands, except percentages):

 

                  Three Months Ended September 30,
      Three Months Ended September 30,     2022 vs 2021
      2022     2021     $     Change   %   Change
Research and development expenses                      
     Clinical trial expenses   $                    10,913   $                      5,983   $                        4,930   82%
     Manufacturing expenses                          2,064                          1,214                               850   70%
     Employee compensation                             973                             795                               178   22%
     Contract consulting expenses                             535                             499                                 36   7%
     Other research and development expenses                             265                             192                                 73   38%
          Total research and development expenses   $                    14,750   $                      8,683   $                        6,067   70%

 

Research and development (“R&D”) costs are expensed as they are incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct R&D on our behalf. The $6.1 million increase in R&D expenses during the three months ended September 30, 2022, as compared to the same period in 2021, resulted primarily from (i) an increase in clinical trial expenses of approximately $4.9 million, mainly due to the ongoing SLS-005 HEALEY clinical trial as well as start-up activities for the global Phase IIb/III clinical trial of SLS-005 for SCA, and (ii) an increase in manufacturing expenses of approximately $0.9 million, mainly related to clinical supplies needed to support the SLS-005 clinical programs.

 

General and Administrative Expenses

 

General and administrative (“G&A”) costs include expenses for personnel, finance, legal, business development and investor relations. G&A expenses increased by $0.4 million during the three months ended September 30, 2022, as compared to the same period in 2021. This increase was primarily due to an increase of $0.2 million in insurance-related costs.

 

 28 

 

Other Income and Expense

 

Other income and expense were as follows (in thousands):

 

      Three Months Ended September 30,      
      2022     2021     $     Change
Other income (expense)                  
     Interest income   $                           36   $                           39   $                             (3)
     Interest expense                               (2)                             (20)                                 18
     Change in fair value of convertible notes                        (2,137)                                  -                          (2,137)
     Change in fair value of warrant liabilities                             (91)                               76                             (167)
          Total other income (expense)   $                    (2,194)   $                           95   $                      (2,289)

 

Interest Income

 

Interest income was $36,000 and $39,000 for the three months ended September 30, 2022 and 2021, respectively. The decrease in interest income primarily related to the lower average cash balances during the three months ended September 30, 2022 compared to the three months ended September 30, 2021.

 

Interest Expense

 

Interest expense was $2,000 and $20,000 for the three months ended September 30, 2022 and 2021, respectively. This decrease in interest expense was due to our repayment of the December 2020 convertible notes during 2021.

 

Change in Fair Value of Convertible Notes

 

Change in fair value of convertible notes was $2.1 million and $0 for the three months ended September 30, 2022 and 2021, respectively. This change was due to our 2021 convertible notes issued in November 2021 and December 2021, which have been accounted for under the fair value option and are revalued at each reporting period, with changes in fair value reflected in earnings.

 

Change in Fair Value of Warrant Liability

 

The fair value of warrant liability was $232,000 at September 30, 2022. For the three months ended September 30, 2022, the change in fair value of warrant liabilities was $91,000, which expense was due to the revaluation of the Series A Warrants during such period. For the three months ended September 30, 2021, the change in fair value of warrant liabilities was $76,000, which income was due to the revaluation of the Series A Warrants during such period.

 

Comparison of the Nine Months Ended September 30, 2022 and 2021

 

Operating Expense

 

Operating expense was as follows (in thousands, except percentages):

 

                  Nine Months Ended September 30,
      Nine Months Ended September 30,     2022 vs 2021
      2022     2021     $     Change   %   Change
Operating expense                      
     Research and development   $                    43,115   $                    27,103   $                      16,012   59%
     General and administrative                          9,544                          7,192                            2,352   33%
          Total operating expense   $                    52,659   $                    34,295   $                      18,364   54%

 

 

 

 

 

 29 

 

Research and Development Expenses

 

Research and development expenses were as follows (in thousands, except percentages):

 

                  Nine Months Ended September 30,
      Nine Months Ended September 30,     2022 vs 2021
      2022     2021     $     Change   %   Change
Research and development expenses                      
     License payments   $                      5,840   $                      9,000   $                      (3,160)   -35%
     Clinical trial expenses                        26,657                        10,556                          16,101   153%
     Manufacturing expenses                          5,476                          3,263                            2,213   68%
     Employee compensation                          2,841                          2,441                               400   16%
     Contract consulting expenses                          1,586                          1,241                               345   28%
     Other research and development expenses                             715                             602                               113   19%
          Total research and development expenses   $                    43,115   $                    27,103   $                      16,012   59%

 

R&D costs are expensed as they are incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct R&D on our behalf. The $16.0 million increase in R&D expenses during the nine months ended September 30, 2022, as compared to the same period in 2021, resulted primarily from an increase of $16.1 million in clinical trial costs, mainly due to the ongoing SLS-005 HEALEY clinical trial as well as our SLS-002 Phase II clinical trial and start-up activities for the global Phase IIb/III clinical trial of SLS-005 for SCA, as well as an increase in manufacturing expenses of approximately $2.2 million. These increases were partially offset by decreases in R&D license expenses of approximately $3.2 million.

 

General and Administrative Expenses

 

G&A costs include expenses for personnel, finance, legal, business development and investor relations. G&A expenses increased by $2.4 million during the nine months ended September 30, 2022, as compared to the same period in 2021. This increase was primarily due to an increase of $1.4 million for stock compensation expense, primarily related to the cancellation of performance-based restricted stock units in the first nine months of 2022, as well as an increase of $0.3 million in personnel costs, an increase of $0.3 million in commercial readiness costs, and $0.2 million in external legal costs during the nine months ended September 30, 2022. These increases were partially offset by decreases in costs including but not limited to, external investor relations costs of approximately $0.1 million during the nine months ended September 30, 2022.

 

Other Income and Expense

 

Other income and expense were as follows (in thousands):

 

      Nine Months Ended September 30,      
      2022     2021     $     Change
Other income (expense)                  
     Interest income   $                           81   $                           87   $                             (6)
     Interest expense                             (14)                        (1,593)                            1,579
     Net loss on extinguishment of debt                                  -                        (2,387)                            2,387
     Gain on forgiveness of debt                                  -                             149                             (149)
     Change in fair value of convertible notes                        (2,477)                                  -                          (2,477)
     Change in fair value of warrant liabilities                             192                           (750)                               942
          Total other income (expense)   $                    (2,218)   $                    (4,494)   $                        2,276

 

Interest Income

 

Interest income was $81,000 and $87,000 for the nine months ended September 30, 2022 and 2021, respectively. The decrease in interest income primarily related to the lower average cash balances during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021.

 

Interest Expense

 

Interest expense was $14,000 and $1.6 million for the nine months ended September 30, 2022 and 2021, respectively. This decrease in interest expense was due to our repayment of the December 2020 convertible notes during 2021.

 

 30 

 

Net Loss on Extinguishment of Debt

 

Net loss on extinguishment of debt was $0 and $2.4 million for the nine months ended September 30, 2022 and 2021, respectively. This loss during the nine months ended September 30, 2021 was primarily the result of our issuance of 406,250 shares of common stock with a fair value of $1.4 million to Lind, as well as other losses on extinguishments recognized on principal payments made on the 2020 convertible notes during the period. The 2020 convertible notes were paid off in 2021.

 

Gain on Forgiveness of Debt

 

Gain on forgiveness of debt was $0 and $149,000 for the nine months ended September 30, 2022 and 2021, respectively. The gain was due to the forgiveness of our PPP loan, which we received in June 2021.

 

Change in Fair Value of Convertible Notes

 

Change in fair value of convertible notes was $2.5 million and $0 for the nine months ended September 30, 2022 and 2021, respectively. This change was due to our 2021 convertible notes issued in November 2021 and December 2021, which have been accounted for under the fair value option and are revalued at each reporting period, with changes in fair value reflected in earnings.

 

Change in Fair Value of Warrant Liability

 

The fair value of warrant liability was $232,000 at September 30, 2022. For the nine months ended September 30, 2022, the change in fair value of warrant liabilities was $192,000, which income was due to the revaluation of the Series A Warrants during such period. For the nine months ended September 30, 2021, the change in fair value of warrant liabilities was $750,000, which expense was due to the revaluation of the Series A Warrants during such period.

 

Cash Flow Summary

 

The following table summarizes selected items in our unaudited condensed consolidated statements of cash flows (in thousands):

 

      Nine Months Ended
      September 30,
      2022     2021
Net cash (used in) provided by operations            
     Net cash used in operating activities   $               (48,514)   $               (30,656)
     Net cash provided by financing activities                          291                     91,827
Net (decrease) increase in cash   $               (48,223)   $                 61,171

 

Operating Activities

 

Cash used in operating activities of $48.5 million during the nine months ended September 30, 2022 was primarily due to a net loss of $54.9 million and changes in operating assets and liabilities of $1.0 million, which was partially offset by non-cash adjustment related to stock-based compensation expense of $4.2 million and change in fair value of our convertible notes payable of $2.5 million.

 

Cash used in operating activities of $30.7 million during the nine months ended September 30, 2021 was primarily due to a net loss of $38.8 million, which was partially offset by changes in operating assets and liabilities of $7.2 million.

 

Financing Activities

 

Cash provided by financing activities of $0.3 million during the nine months ended September 30, 2022 was primarily due to proceeds from issuances of common stock pursuant to the Sale Agreement.

 

Cash provided by financing activities of $91.8 million during the nine months ended September 30, 2021 was due to proceeds from the issuance and sale of common stock, net of costs, of approximately $98.0 million and the proceeds from the exercise of warrants of approximately $7.3 million during the nine months ended September 30, 2021. The cash provided was partially offset by the payments of $13.6 million of convertible debt principal.

 

 

 

 31 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, communicated to our management to allow timely decisions regarding required disclosure, summarized and reported within the time periods specified in the SEC’s rules and forms.

 

Under the supervision and with the participation of our management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of September 30, 2022. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of September 30, 2022 at the reasonable assurance level.

 

Changes in Internal Control over Financial Reporting

 

There were no material changes to our internal control over financial reporting during the three months ended September 30, 2022.

 

 

 

 

 

 

 32 

 PART II.

 

ITEM 1. LEGAL PROCEEDINGS

 

We are not currently party to, and none of our property is currently the subject of, any material legal proceedings. We may be a party to certain litigation that is either judged to be not material or that arises in the ordinary course of business from time to time. We intend to vigorously defend our interests in these matters. We expect that the resolution of these matters will not have a material adverse effect on our business, financial condition or results of operations. However, due to the uncertainties inherent in litigation, no assurance can be given as to the outcome of these proceedings.

 

ITEM 1A. RISK FACTORS

 

We operate in a dynamic and rapidly changing environment that involves numerous risks and uncertainties. Certain factors may have a material adverse effect on our business, prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors, in its entirety, in addition to other information contained in this Quarterly Report on Form 10-Q and our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.

 

Risk Factor Summary

 

Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below and should be carefully considered, together with all of the other information appearing in or incorporated by reference into this Quarterly Report on Form 10-Q and our other public filings with the SEC before making investment decisions regarding the common stock. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.

 

  • We are a clinical-stage company, we have a very limited operating history, are not currently profitable, do not expect to become profitable in the near future and may never become profitable.
  • We are dependent on the success of one or more of our current product candidates and we cannot be certain that any of them will receive regulatory approval or be commercialized.
  • If development of our product candidates does not produce favorable results, or encounters challenges, we and our collaborators, if any, may be unable to commercialize these products.
  • We expect to continue to incur significant research and development expenses, which may make it difficult for us to attain profitability.
  • Given our lack of current cash flow, we may need to raise additional capital; however, it may be unavailable to us or, even if capital is obtained, may cause dilution or place significant restrictions on our ability to operate our business. If we fail to raise the necessary additional capital, we may be unable to complete the development and commercialization of our product candidates, or continue our development programs.
  • Our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval or commercialization or have other significant adverse implications on our business, financial condition and results of operations.
  • Delays in the commencement or completion of clinical trials could result in increased costs to us and delay our ability to establish strategic collaborations.
  • The COVID-19 pandemic, and any other pandemic, epidemic or outbreak of an infectious disease may materially and adversely affect our business and operations.
  • Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.
  • We intend to rely on third parties to conduct our preclinical studies and clinical trials and perform other tasks. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business, financial condition and results of operations could be substantially harmed.
  • Our product candidates are subject to extensive regulation under the U.S. Food and Drug Administration (“FDA”), the European Medicines Agency (the “EMA”) or comparable foreign authorities, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.
  • If our competitors have product candidates that are approved faster, marketed more effectively, are better tolerated, have a more favorable safety profile or are demonstrated to be more effective than ours, our commercial opportunity may be reduced or eliminated.

 33 
  • We rely completely on third parties to manufacture our preclinical and clinical drug supplies, and our business, financial condition and results of operations could be harmed if those third parties fail to provide us with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.
  • The commercial success of our product candidates depends upon their market acceptance among physicians, patients, healthcare payors and the medical community.
  • If we fail to retain current members of our senior management and scientific personnel, or to attract and keep additional key personnel, we may be unable to successfully develop or commercialize our product candidates.
  • We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
  • If we fail to comply with our obligations in the agreements under which we in-license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.
  • We may not be able to protect our proprietary or licensed technology in the marketplace.
  • The market price of our common stock is expected to be volatile.

 

Risk Factors

 

The risk factors set forth below with an asterisk (*) next to the title are new risk factors or risk factors containing material changes from the risk factors previously disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 4, 2022:

 

Risks Related to the Company

 

*We are a clinical-stage company, we have a very limited operating history, are not currently profitable, do not expect to become profitable in the near future and may never become profitable.

 

We are a clinical-stage biopharmaceutical company. Since our incorporation, we have focused primarily on the development and acquisition of clinical-stage therapeutic candidates. All of our therapeutic candidates are in the clinical development stage and none of our pipeline therapeutic candidates have been approved for marketing or are being marketed or commercialized.

 

As a result, we have no meaningful historical operations upon which to evaluate our business and prospects and have not yet demonstrated an ability to obtain marketing approval for any of our product candidates or successfully overcome the risks and uncertainties frequently encountered by companies in the biopharmaceutical industry. We also have generated minimal revenues from collaboration and licensing agreements and no revenues from product sales to date and continue to incur significant research and development and other expenses. As a result, we have not been profitable and have incurred significant operating losses in every reporting period since our inception. We have incurred an accumulated deficit of $196.1 million from our inception through September 30, 2022.

 

For the foreseeable future, we expect to continue to incur losses, which will increase significantly from historical levels as we expand our drug development activities, seek partnering and/or regulatory approvals for our product candidates and begin to commercialize them if they are approved by the FDA, the EMA or comparable foreign authorities. Even if we succeed in developing and commercializing one or more product candidates, we may never become profitable.

 

We are dependent on the success of one or more of our current product candidates and we cannot be certain that any of them will receive regulatory approval or be commercialized.

 

We have spent significant time, money and effort on the licensing and development of our core assets, SLS-002, SLS-005 and SLS-006 and our other earlier-stage assets, SLS-004, SLS-007, SLS-008, SLS-010 and SLS-012. To date, no pivotal clinical trials designed to provide clinically and statistically significant proof of efficacy, or to provide sufficient evidence of safety to justify approval, have been completed with any of our pipeline product candidates. All of our product candidates will require additional development, including clinical trials as well as further preclinical studies to evaluate their toxicology, carcinogenicity and pharmacokinetics and optimize their formulation, and regulatory clearances before they can be commercialized. Positive results obtained during early development do not necessarily mean later development will succeed or that regulatory clearances will be obtained. Our drug development efforts may not lead to commercial drugs, either because our product candidates may fail to be safe and effective or because we have inadequate financial or other resources to advance our product candidates through the clinical development and approval processes. If any of our product candidates fail to demonstrate safety or efficacy at any time or during any phase of development, we would experience potentially significant delays in, or be required to abandon, development of the product candidate.

 34 

We do not anticipate that any of our current product candidates will be eligible to receive regulatory approval from the FDA, the EMA or comparable foreign authorities and begin commercialization for a number of years, if ever. Even if we ultimately receive regulatory approval for any of these product candidates, we or our potential future partners, if any, may be unable to commercialize them successfully for a variety of reasons. These include, for example, the availability of alternative treatments, lack of cost-effectiveness, the cost of manufacturing the product on a commercial scale and competition with other drugs. The success of our product candidates may also be limited by the prevalence and severity of any adverse side effects. If we fail to commercialize one or more of our current product candidates, we may be unable to generate sufficient revenues to attain or maintain profitability, and our financial condition and stock price may decline.

 

If development of our product candidates does not produce favorable results, or encounters challenges, we and our collaborators, if any, may be unable to commercialize these products.

 

To receive regulatory approval for the commercialization of our core assets, SLS-002, SLS-005 and SLS-006 and our earlier-stage assets, SLS-004, SLS-007, SLS-008, SLS-010 and SLS-012, or any other product candidates that we may develop, adequate and well-controlled clinical trials must be conducted to demonstrate safety and efficacy in humans to the satisfaction of the FDA, the EMA and comparable foreign authorities. In order to support marketing approval, these agencies typically require successful results in one or more Phase III clinical trials, which our current product candidates have not yet reached and may never reach. The development process is expensive, can take many years and has an uncertain outcome. Failure can occur at any stage of the process. We may experience numerous unforeseen events during, or as a result of, the development process that could delay or prevent commercialization of our current or future product candidates, including the following:

 

  • clinical trials may produce negative or inconclusive results;
  • preclinical studies conducted with product candidates during clinical development to, among other things, evaluate their toxicology, carcinogenicity and pharmacokinetics and optimize their formulation may produce unfavorable results;
  • we or our contract manufacturers may encounter manufacturing challenges or the FDA may raise concerns regarding Chemistry, Manufacturing, and Controls (CMC) data or GMP compliance, or biocompatibility or drug-device interaction concerns for our combination product candidates;
  • patient recruitment and enrollment in clinical trials may be slower than we anticipate;
  • costs of development may be greater than we anticipate;
  • our product candidates may cause undesirable side effects that delay or preclude regulatory approval or limit their commercial use or market acceptance, if approved;
  • collaborators who may be responsible for the development of our product candidates may not devote sufficient resources to these clinical trials or other preclinical studies of these candidates or conduct them in a timely manner; or
  • we may face delays in obtaining regulatory approvals to commence one or more clinical trials.

Success in early development does not mean that later development will be successful because, for example, product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy despite having progressed through initial clinical trials.

 

We have licensed or acquired all of the intellectual property related to our product candidates from third parties. All clinical trials, preclinical studies and other analyses performed to date with respect to our product candidates have been conducted by their original owners. Therefore, as a company, we have limited experience in conducting clinical trials for our product candidates. Since our experience with our product candidates is limited, we will need to train our existing personnel and hire additional personnel in order to successfully administer and manage our clinical trials and other studies as planned, which may result in delays in completing such planned clinical trials and preclinical studies. Moreover, to date our product candidates have been tested in less than the number of patients that will likely need to be studied to obtain regulatory approval. The data collected from clinical trials with larger patient populations may not demonstrate sufficient safety and efficacy to support regulatory approval of these product candidates.

 

We currently do not have strategic collaborations in place for clinical development of any of our current product candidates, except for our collaborative agreement with Team Sanfilippo Foundation ("TSF"), which we assumed in connection with the asset purchase agreement with Bioblast Pharma Ltd. for IV Trehalose, which is now known as SLS-005. Therefore, in the future, we or any potential future collaborative partner will be responsible for establishing the targeted endpoints and goals for development of our product candidates. These targeted endpoints and goals may be inadequate to demonstrate the safety and efficacy levels required for regulatory approvals. Even if we believe data collected during the development of our product candidates are promising, such data may not be sufficient to support marketing approval by the FDA, the EMA or comparable foreign authorities. Further, data generated during development can be interpreted in different ways, and the FDA, the EMA or comparable foreign authorities may interpret such data in different ways than us or our collaborators. Our failure to adequately demonstrate the safety and efficacy of our product candidates would prevent our receipt of regulatory approval, and ultimately the potential commercialization of these product candidates.

 

 35 

  

Since we do not currently possess the resources necessary to independently develop and commercialize our product candidates or any other product candidates that we may develop, we may seek to enter into collaborative agreements to assist in the development and potential future commercialization of some or all of these assets as a component of our strategic plan. However, our discussions with potential collaborators may not lead to the establishment of collaborations on acceptable terms, if at all, or it may take longer than expected to establish new collaborations, leading to development and potential commercialization delays, which would adversely affect our business, financial condition and results of operations.

 

We expect to continue to incur significant research and development expenses, which may make it difficult for us to attain profitability.

 

We expect to expend substantial funds in research and development, including preclinical studies and clinical trials of our product candidates, and to manufacture and market any product candidates in the event they are approved for commercial sale. We also may need additional funding to develop or acquire complementary companies, technologies and assets, as well as for working capital requirements and other operating and general corporate purposes. Moreover, our planned increases in staffing will dramatically increase our costs in the near and long-term.

 

However, our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. Due to our limited financial and managerial resources, we must focus on a limited number of research programs and product candidates and on specific indications. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.

 

Because the successful development of our product candidates is uncertain, we are unable to precisely estimate the actual funds we will require to develop and potentially commercialize them. In addition, we may not be able to generate sufficient revenue, even if we are able to commercialize any of our product candidates, to become profitable.

 

*Given our lack of current cash flow, we may need to raise additional capital; however, it may be unavailable to us or, even if capital is obtained, may cause dilution or place significant restrictions on our ability to operate our business. If we fail to raise the necessary additional capital, we may be unable to complete the development and commercialization of our product candidates, or continue our development programs.

 

As of September 30, 2022, we had a cash balance of approximately $30.5 million. Since we will be unable to generate sufficient, if any, cash flow to fund our operations for the foreseeable future, we may need to seek additional equity or debt financing to provide the capital required to maintain or expand our operations.

 

As a result of our recurring losses from operations, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about our ability to continue as a going concern. If we are unsuccessful in our efforts to raise outside financing, we may be required to significantly reduce or cease operations. The report of our independent registered public accounting firm on our audited financial statements for the year ended December 31, 2021 included a “going concern” explanatory paragraph indicating that our recurring losses from operations raise substantial doubt about our ability to continue as a going concern.

 

We currently have an effective shelf registration statement on Form S-3 filed with the SEC. We may use the shelf registration statement on Form S-3 to offer from time to time any combination of debt securities, common and preferred stock and warrants. Moreover, we have the ability to sell up to $50.0 million of additional shares of our common stock to the public through an “at the market” offering pursuant to the Sales Agreement we entered into with Jefferies, LLC on May 12, 2022. As of the date hereof, a total of $94.6 million of securities remains available for issuance pursuant to the shelf registration statement (inclusive of the $49.5 million that remained allocated to sales of shares pursuant to the Sales Agreement as of such date).

 

There can be no assurance that we will be able to raise sufficient additional capital on acceptable terms or at all. In addition, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively affect our liquidity and ability to continue as a going concern. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, we may be required to delay, limit or eliminate the development of business opportunities and our ability to achieve our business objectives, our competitiveness, and our business, financial condition and results of operations will be materially adversely affected. In addition, we may be required to grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our inability to fund our business could lead to the loss of your investment.

 

 36 

 

Our future capital requirements will depend on many factors, including, but not limited to:

 

  • the scope, rate of progress, results and cost of our clinical trials, preclinical studies and other related activities;
  • our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;
  • the timing of, and the costs involved in, obtaining regulatory approvals for any of our current or future product candidates;
  • the number and characteristics of the product candidates we seek to develop or commercialize;
  • the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates;
  • the cost of commercialization activities if any of our current or future product candidates are approved for sale, including marketing, sales and distribution costs;
  • the expenses needed to attract and retain skilled personnel;
  • the costs associated with being a public company;
  • the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; and
  • the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation costs and the outcome of any such litigation.

If we raise additional capital by issuing equity securities, the percentage ownership of our existing stockholders may be reduced, and accordingly these stockholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences and privileges senior to those of our common stock. Given our need for cash and that equity issuances are the most common type of fundraising for similarly situated companies, the risk of dilution is particularly significant for our stockholders. In addition, debt financing may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may be secured by all or a portion of our assets. For example, we granted to Lind Global Asset Management V, LLC (“Lind”), one of the holders of the convertible promissory notes we issued in 2021 (the “Convertible Promissory Notes”), a first priority lien on our assets and properties and the Convertible Promissory Notes include restrictive covenants and event of default provisions, including restrictions on certain sales or other dispositions of company assets, restrictions on entering into certain variable-rate transactions and a covenant requiring us to maintain an aggregate minimum balance of $12.5 million or more in cash and cash equivalents. In addition, although the Securities Purchase Agreement we entered into with Lind in November 2021 provides that we may issue and sell to Lind additional convertible promissory notes, the issuances of such additional notes are subject to the satisfaction of certain conditions and milestones, which we may not be able to satisfy or achieve.  Our inability to raise capital when needed may harm our business, financial condition and results of operations, and could cause our stock price to decline or require that we wind down our operations altogether.

 

Our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval or commercialization or have other significant adverse implications on our business, financial condition and results of operations.

 

Undesirable side effects observed in clinical trials or in supportive preclinical studies with our product candidates could interrupt, delay or halt their development and could result in the denial of regulatory approval by the FDA, the EMA or comparable foreign authorities for any or all targeted indications or adversely affect the marketability of any such product candidates that receive regulatory approval. In turn, this could eliminate or limit our ability to commercialize our product candidates.

 

Our product candidates may exhibit adverse effects in preclinical toxicology studies and adverse interactions with other drugs. There are also risks associated with additional requirements the FDA, the EMA or comparable foreign authorities may impose for marketing approval with regard to a particular disease.

 

Our product candidates may require a risk management program that could include patient and healthcare provider education, usage guidelines, appropriate promotional activities, a post-marketing observational study, and ongoing safety and reporting mechanisms, among other requirements. Prescribing could be limited to physician specialists or physicians trained in the use of the drug, or could be limited to a more restricted patient population. Any risk management program required for approval of our product candidates could potentially have an adverse effect on our business, financial condition and results of operations.

 

 37 

 

Undesirable side effects involving our product candidates may have other significant adverse implications on our business, financial condition and results of operations. For example:

 

  • we may be unable to obtain additional financing on acceptable terms, if at all;
  • our collaborators may terminate any development agreements covering these product candidates;
  • if any development agreements are terminated, we may determine not to further develop the affected product candidates due to resource constraints and may not be able to establish additional collaborations for their further development on acceptable terms, if at all;
  • if we were to later continue the development of these product candidates and receive regulatory approval, earlier findings may significantly limit their marketability and thus significantly lower our potential future revenues from their commercialization;
  • we may be subject to product liability or stockholder litigation; and
  • we may be unable to attract and retain key employees.

 

In addition, if any of our product candidates receive marketing approval and we or others later identify undesirable side effects caused by the product:

 

  • regulatory authorities may withdraw their approval of the product, or we or our partners may decide to cease marketing and sale of the product voluntarily;
  • we may be required to change the way the product is administered, conduct additional clinical trials or preclinical studies regarding the product, change the labeling of the product, or change the product's manufacturing facilities; and
  • our reputation may suffer.

 

Any of these events could prevent us from achieving or maintaining market acceptance of the affected product and could substantially increase the costs and expenses of commercializing the product, which in turn could delay or prevent us from generating significant revenues from the sale of the product.

 

*Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to additional audit, validation and verification procedures that could result in material changes in the final data.

From time to time, we may publish interim data, including interim top-line results or preliminary results from our clinical trials. Any interim data and other results from our clinical trials may materially change as more patient data become available. Preliminary or top-line results also remain subject to audit, validation and verification procedures that may result in the final data being materially different from the interim and preliminary data we previously published. As a result, interim and preliminary data may not be predictive of final results and should be viewed with caution until the final data are available. We may also arrive at different conclusions, or considerations may qualify such results, once we have received and fully evaluated additional data. Differences between preliminary or interim data and final data could adversely affect our business.

 

Our efforts to discover product candidates beyond our current product candidates may not succeed, and any product candidates we recommend for clinical development may not actually begin clinical trials.

 

We intend to use our technology, including our licensed technology, knowledge and expertise to develop novel drugs to address some of the world's most widespread and costly central nervous system, respiratory and other disorders, including orphan indications. We intend to expand our existing pipeline of core assets by advancing drug compounds from current ongoing discovery programs into clinical development. However, the process of researching and discovering drug compounds is expensive, time-consuming and unpredictable. Data from our current preclinical programs may not support the clinical development of our lead compounds or other compounds from these programs, and we may not identify any additional drug compounds suitable for recommendation for clinical development. Moreover, any drug compounds we recommend for clinical development may not demonstrate, through preclinical studies, indications of safety and potential efficacy that would support advancement into clinical trials. Such findings would potentially impede our ability to maintain or expand our clinical development pipeline. Our ability to identify new drug compounds and advance them into clinical development also depends upon our ability to fund our research and development operations, and we cannot be certain that additional funding will be available on acceptable terms, or at all.

 

 38 

 

Delays in the commencement or completion of clinical trials could result in increased costs to us and delay our ability to establish strategic collaborations.

 

Delays in the commencement or completion of clinical trials could significantly impact our drug development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. The commencement of clinical trials can be delayed for a variety of reasons, including, but not limited to, delays related to:

 

  • obtaining regulatory approval to commence one or more clinical trials;
  • reaching agreement on acceptable terms with prospective third-party contract research organizations ("CROs") and clinical trial sites;
  • manufacturing sufficient quantities of a product candidate or other materials necessary to conduct clinical trials;
  • obtaining institutional review board approval to conduct one or more clinical trials at a prospective site;
  • recruiting and enrolling patients to participate in one or more clinical trials; and
  • the failure of our collaborators to adequately resource our product candidates due to their focus on other programs or as a result of general market conditions.

In addition, once a clinical trial has begun, it may be suspended or terminated by us, our collaborators, the institutional review boards or data safety monitoring boards charged with overseeing our clinical trials, the FDA, the EMA or comparable foreign authorities due to a number of factors, including:

 

  • failure to conduct the clinical trial in accordance with regulatory requirements or clinical protocols;
  • inspection of the clinical trial operations or clinical trial site by the FDA, the EMA or comparable foreign authorities resulting in the imposition of a clinical hold;
  • unforeseen safety issues; or
  • lack of adequate funding to continue the clinical trial.

If we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to commence product sales and generate product revenues from any of our product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs and slow down our product candidate development and approval process. Delays in completing our clinical trials could also allow our competitors to obtain marketing approval before we do or shorten the patent protection period during which we may have the exclusive right to commercialize our product candidates. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

 

The COVID-19 pandemic, and any other pandemic, epidemic or outbreak of an infectious disease may materially and adversely affect our business and operations.

 

On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic is continuing to affect the United States and global economies and may affect our operations and those of third parties on which we rely, including by causing disruptions in the supply of our product candidates and the conduct of future clinical trials. In addition, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidates. Additionally, while the potential economic impact brought by, and the duration of the COVID-19 pandemic are difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. In addition, the loss of any of our employees as a result of COVID-19 or another pandemic, may have a material adverse effect on our operations. We are actively monitoring the effect of the global situation on our financial condition, liquidity, operations, suppliers, industry and workforce. While the spread of COVID-19 may eventually be contained or mitigated, we cannot predict the timing of the vaccine roll-out globally or the continued efficacy of such vaccines, and we do not yet know how businesses or our partners will operate in a post COVID-19 environment. The ultimate impact of the COVID-19 pandemic on our business, operations or the global economy as a whole remains highly uncertain, and a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material negative impact on our business, financial condition, and operating results.

 

Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.

 

The results of preclinical studies and early clinical trials of product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy results despite having progressed through preclinical studies and initial clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding promising results in earlier studies. Similarly, our future clinical trial results may not be successful for these or other reasons.

 

 39 

 

This product candidate development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical to early- to late-stage clinical trials towards approval and commercialization, it is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize the product candidates for late-stage clinical trials, approval and commercialization, such changes carry the risk that they will not achieve these intended objectives. In addition, nonclinical studies may be requested or required even after clinical trials have been commenced or completed.

 

Any of these changes could make the results of our planned clinical trials or other future clinical trials we may initiate less predictable and could cause our product candidates to perform differently, including causing toxicities, which could delay completion of our clinical trials, delay approval of our product candidates, and/or jeopardize our ability to commence product sales and generate revenues.

 

If we experience delays in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

 

We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or other regulatory authorities. In addition, the COVID-19 pandemic may result in a reduction of patient enrollment, a loss of patient enrollment and other delays affecting our clinical trials.  Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians' and patients' perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.

 

If we fail to enroll and maintain the number of patients for which the clinical trial was designed, the statistical power of that clinical trial may be reduced, which would make it harder to demonstrate that the product candidate being tested in such clinical trial is safe and effective. Additionally, enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Our inability to enroll a sufficient number of patients for any of our current or future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.

 

We intend to rely on third parties to conduct our preclinical studies and clinical trials and perform other tasks. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business, financial condition and results of operations could be substantially harmed.

 

We intend to rely upon third-party CROs, medical institutions, clinical investigators and contract laboratories to monitor and manage data for our ongoing preclinical and clinical programs. Nevertheless, we maintain responsibility for ensuring that each of our clinical trials and preclinical studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with current requirements on good manufacturing practices ("cGMP"), good clinical practices ("GCP") and good laboratory practice ("GLP"), which are a collection of laws and regulations enforced by the FDA, the EMA and comparable foreign authorities for all of our product candidates in clinical development. Regulatory authorities enforce these regulations through periodic inspections of preclinical study and clinical trial sponsors, principal investigators, preclinical study and clinical trial sites, and other contractors. If we or any of our CROs or vendors fails to comply with applicable regulations, the data generated in our preclinical studies and clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign authorities may require us to perform additional preclinical studies and clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced consistent with cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the development and regulatory approval processes.

 

 40 

 

We may not be able to enter into arrangements with CROs on commercially reasonable terms, or at all. In addition, our CROs will not be our employees, and except for remedies available to us under our agreements with such CROs, we will not be able to control whether or not they devote sufficient time and resources to our ongoing preclinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, our business, financial condition and results of operations and the commercial prospects for our product candidates could be materially and adversely affected, our costs could increase, and our ability to generate revenue could be delayed.

 

Switching or adding additional CROs, medical institutions, clinical investigators or contract laboratories involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work replacing a previous CRO. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. There can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse effect on our business, financial condition or results of operations.

 

Our product candidates are subject to extensive regulation under the FDA, the EMA or comparable foreign authorities, which can be costly and time consuming, cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.

 

The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA and other U.S. regulatory agencies, the EMA or comparable authorities in foreign markets. In the U.S., neither we nor our collaborators are permitted to market our product candidates until we or our collaborators receive approval of a new drug application ("NDA") from the FDA or receive similar approvals abroad. The process of obtaining these approvals is expensive, often takes many years, and can vary substantially based upon the type, complexity and novelty of the product candidates involved. Approval policies or regulations may change and may be influenced by the results of other similar or competitive products, making it more difficult for us to achieve such approval in a timely manner or at all. Any guidance that may result from recent FDA advisory panel discussions may make it more expensive to develop and commercialize such product candidates. In addition, as a company, we have not previously filed NDAs with the FDA or filed similar applications with other foreign regulatory agencies. This lack of experience may impede our ability to obtain FDA or other foreign regulatory agency approval in a timely manner, if at all, for our product candidates for which development and commercialization is our responsibility.

 

Despite the time and expense invested, regulatory approval is never guaranteed. The FDA, the EMA or comparable foreign authorities can delay, limit or deny approval of a product candidate for many reasons, including:

 

  • a product candidate may not be deemed safe or effective;
  • agency officials of the FDA, the EMA or comparable foreign authorities may not find the data from non-clinical or preclinical studies and clinical trials generated during development to be sufficient;
  • the FDA, the EMA or comparable foreign authorities may not approve our third-party manufacturers' processes or facilities;
  • the FDA, the EMA or a comparable foreign authority may change its approval policies or adopt new regulations; or
  • our inability to obtain these approvals would prevent us from commercializing our product candidates.

We are pursuing the FDA 505(b)(2) NDA pathway for our lead product candidate, SLS-002, which presents certain additional development and commercialization risks as compared to a conventional 505(b)(1) NDA for an innovator product candidate. We may pursue this pathway for other product candidates as well.

 

For our lead product candidate (SLS-002) we are pursuing development in order to seek potential FDA approval under an abbreviated regulatory pathway called a 505(b)(2) NDA, which permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. We may also pursue this pathway for other of our product candidates. Section 505(b)(2), if applicable to us for a particular product candidate, would allow an NDA we submit to the FDA to rely, in part, on data in the public domain or the FDA's prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the development program for a product candidate by potentially decreasing the amount of clinical data that we would need to generate in order to obtain FDA approval.

 

 41 

  

Even if the FDA allows us to rely on the 505(b)(2) regulatory pathway, there is no assurance that such marketing approval will be obtained in a timely manner, or at all. The FDA may require us to perform additional nonclinical studies and clinical trials, and conduct other development work, to support any change from the reference listed drug (including with respect to the route of administration and drug delivery method and device), which presents uncertainty about the data that may ultimately be necessary and could be time-consuming and substantially delay our application for or potential receipt of marketing approval.

Even if we are able to utilize the 505(b)(2) regulatory pathway, a drug approved via this pathway may be subject to the same post-approval limitations, conditions and requirements as any other drug, including, for example a Risk Evaluation and Mitigation Strategy ("REMS"), which we anticipate will be required for our lead product candidate.

 

Also, as has been the experience of others in our industry, our competitors may file citizens' petitions with the FDA to contest approval of our NDA, which may delay or even prevent the FDA from approving any NDA that we submit under the 505(b)(2) regulatory pathway. If an FDA decision or action relative to our product candidate, or the FDA's interpretation of Section 505(b)(2) more generally, is successfully challenged, it could result in delays or even prevent the FDA from approving a 505(b)(2) application for such product candidate.

 

In addition, we may face Hatch-Waxman litigation in relation to our NDAs submitted under the 505(b)(2) regulatory pathway, which may further delay or prevent the approval of our product candidate. The pharmaceutical industry is highly competitive, and 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a 505(b)(2) NDA. If the previously approved drugs referenced in an applicant's 505(b)(2) NDA are protected by patent(s) listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations publication, or the Orange Book, the 505(b)(2) applicant is required to make a claim after filing its NDA that each such patent is invalid, unenforceable or will not be infringed. The patent holder may thereafter bring suit for patent infringement, which will trigger a mandatory 30-month delay (or the shorter of dismissal of the lawsuit or expiration of the patent(s)) in approval of the 505(b)(2) NDA application.

 

If the FDA determines that our 505(b)(2) regulatory pathway is not viable for SLS-002 or any other applicable product candidate for any reason, we would need to reconsider our plans and might not be able to commercialize any such product candidate in a cost-efficient manner, or at all. If we were to pursue approval under the 505(b)(1) NDA pathway, we would be subject to more extensive requirements and risks such as conducting additional clinical trials, providing additional data and information or meeting additional standards for marketing approval. As a result, the time and financial resources required to obtain marketing approval for our product candidates would likely increase substantially and further complications and risks associated with our product candidates may arise. Also, new competing products may reach the market faster than ours, which may materially and adversely affect our competitive position, business and prospects.

 

Even if our product candidates receive regulatory approval in the U.S., we may never receive approval or commercialize our products outside of the U.S.

 

In order to market any products outside of the U.S., we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the U.S. as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay seeking or obtaining such approval would impair our ability to develop foreign markets for our product candidates.

 

 

 

 42 

Even if any of our product candidates receive regulatory approval, our product candidates may still face future development and regulatory difficulties.

 

If any of our product candidates receive regulatory approval, the FDA, the EMA or comparable foreign authorities may still impose significant restrictions on the indicated uses or marketing of the product candidates or impose ongoing requirements for potentially costly post-approval studies and trials. In addition, regulatory agencies subject a product, our manufacturer and the manufacturer's facilities to continual review and periodic inspections. If a regulatory agency discovers previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, our collaborators or us, including requiring withdrawal of the product from the market. Our product candidates will also be subject to ongoing FDA, EMA or comparable foreign authorities' requirements for the labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information on the drug. If our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:

  • issue warning letters or other notices of possible violations;
  • impose civil or criminal penalties or fines or seek disgorgement of revenue or profits;
  • suspend any ongoing clinical trials;
  • refuse to approve pending applications or supplements to approved applications filed by us or our collaborators;
  • withdraw any regulatory approvals;
  • impose restrictions on operations, including costly new manufacturing requirements, or shut down our manufacturing operations; or
  • seize or detain products or require a product recall.

The FDA, the EMA and comparable foreign authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.

 

The FDA, the EMA and comparable foreign authorities strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA, the EMA or comparable foreign authorities as reflected in the product's approved labeling. If we receive marketing approval for our product candidates for our proposed indications, physicians may nevertheless use our products for their patients in a manner that is inconsistent with the approved label, if the physicians personally believe in their professional medical judgment that our products could be used in such manner. However, if we are found to have promoted our products for any off-label uses, the federal government could levy civil, criminal or administrative penalties, and seek fines against us. Such enforcement has become more common in the industry. The FDA, the EMA or comparable foreign authorities could also request that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, financial condition and results of operations.

 

If our competitors have product candidates that are approved faster, marketed more effectively, are better tolerated, have a more favorable safety profile or are demonstrated to be more effective than ours, our commercial opportunity may be reduced or eliminated.

 

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including commercial biopharmaceutical enterprises, academic institutions, government agencies and private and public research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.

 

Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, clinical trials, regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our competitors may succeed in developing technologies and therapies that are more effective, better tolerated or less costly than any which we are developing, or that would render our product candidates obsolete and noncompetitive. Even if we obtain regulatory approval for any of our product candidates, our competitors may succeed in obtaining regulatory approvals for their products earlier than we do. We will also face competition from these third parties in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and patient registration for clinical trials, and in acquiring and in-licensing technologies and products complementary to our programs or advantageous to our business.

 

 

 43 

The key competitive factors affecting the success of each of our product candidates, if approved, are likely to be its efficacy, safety, tolerability, frequency and route of administration, convenience and price, the level of branded and generic competition and the availability of coverage and reimbursement from government and other third-party payors.

 

The pharmaceutical market for the treatment of major depressive disorder includes selective serotonin reuptake inhibitors ("SSRIs"), serotonin and norepinephrine reuptake inhibitors ("SNRIs") and atypical antipsychotics. A number of these marketed antidepressants will be generic, and would be key competitors to SLS-002. These products include Forest Laboratory's Lexapro/Cipralex (escitalopram) and Viibryd (vilazodone), Pfizer, Inc.'s Zoloft (sertraline), Effexor (venlafaxine) and Pristiq (desvenlafaxine), GlaxoSmithKline plc's Paxil/Seroxat (paroxetine), Eli Lilly and Company's Prozac (fluoxetine) and Cymbalta (duloxetine), AstraZeneca plc's Seroquel (quetiapine) and Bristol-Myers Squibb Company's Abilify (aripiprazole), among others.

  

Patients with treatment-resistant depression often require treatment with several antidepressants, such as an SSRI or SNRI, combined with an "adjunct" therapy such as an antipsychotic compound, such as AstraZeneca plc's Seroquel (quetiapine) and Bristol-Myers Squibb Company's Abilify (aripiprazole), or mood stabilizers, such as Janssen Pharmaceutica's Topamax (topiramate). In addition, Janssen's Spravato (intranasal esketamine), which has been approved for treatment-resistant depression and for depressive systems in adults with major depressive disorder with suicidal thoughts or actions, targets the NMDA receptor and is expected to have a faster onset of therapeutic effect as compared to currently available therapies.

 

Current treatments for Parkinson's Disease ("PD") are intended to improve the symptoms of patients. The cornerstone of PD therapy is levodopa, as it is the most effective therapy for reducing symptoms of PD. There are other drug therapies in development that will target the disease, such as gene and stem cell therapy and A2A receptor agonists.

 

We, or any future collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for our product candidates.

 

Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. In the United States and Europe, obtaining orphan drug approval may allow us to obtain financial incentives, such as an extended period of exclusivity during which only we are allowed to market the orphan drug. While we have received orphan drug designation for SLS-005 in Sanfilippo Syndrome and in spinocerebellar ataxia type 3 and in oculopharyngeal muscular dystrophy and we plan to seek orphan drug designation from the FDA for SLS-008 for the treatment of a pediatric indication, we, or any future collaborators, may not be granted orphan drug designations for our product candidates in the U.S. or in other jurisdictions.

 

Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain orphan drug exclusivity for that product candidate. Generally, a product with orphan drug designation only becomes entitled to orphan drug exclusivity if it receives the first marketing approval for the indication for which it has such designation, in which case the FDA or the EMA will be precluded from approving another marketing application for the same drug for that indication for the applicable exclusivity period. The applicable exclusivity period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.

 

Even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because FDA has taken the position that, under certain circumstances, another drug with the same active chemical and pharmacological characteristics, or moiety, can be approved for the same condition. Specifically, the FDA's regulations provide that it can approve another drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.

 

 44 

The active ingredient of our lead product candidate, SLS-002, ketamine hydrochloride, is recognized as having the potential for abuse, misuse and diversion and, as a result, is and will be subject to extensive federal and state laws and regulations governing controlled substances and the entities involved in their research, manufacturing, sale and distribution, and possession. In addition, we anticipate that if we obtain marketing approval for SLS-002 it will be the subject of an FDA Risk Evaluation and Mitigation Strategy (REMS).

 

Ketamine is listed by the Drug Enforcement Administration ("DEA") as a Schedule III controlled substance under the Controlled Substances Act. The DEA classifies substances as Schedule I, II, III, IV or V controlled substances, with Schedule I controlled substances considered to present the highest risk of substance abuse and Schedule V controlled substances the lowest risk. Scheduled controlled substances are subject to DEA regulations relating to supply, procurement, manufacturing, storage, distribution and physician prescription procedures. In addition to federal scheduling, some drugs may be subject to state-level controlled substance laws and regulations and in some cases more broadly applicable or more extensive requirements than those determined by the DEA and FDA. Federal and state-level controlled substance laws impose a broad range of registration and licensure requirements along with requirements for systems and controls intended to provide security and reduce the risk of diversion and misuse, and to identify suspicious activities.

 

Compliance with these laws can be expensive and time consuming. Failure to follow these requirements can lead to significant civil and/or criminal penalties and possibly even lead to a revocation of a DEA registration and state-level licenses.

If SLS-002 receives marketing approval from the FDA or other regulatory authority, we may be required to implement REMS to address the potential for abuse and misuse of our product candidate. As a result, our product candidate may only be available through a restricted or limited distribution system to which only certain prescribing healthcare professionals may have access for their patients or healthcare professionals may be limited in their prescribing.

 

Furthermore, product candidates containing controlled substances may generate public controversy. As a result, these products may be at risk of having their sale and distribution and marketing approvals further restricted or in extreme cases withdrawn in the event that regulators were to assess that the benefits of a product no longer outweigh emerging risks. Political pressures or adverse publicity could lead to delays in, and increased expenses for, and limit or restrict, the commercialization of our product or product candidates.

 

We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.

 

The process of manufacturing our product candidates is complex, highly regulated, and subject to several risks. For example, the process of manufacturing our product candidates is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes for any of our product candidates could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. In addition, the manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, natural disasters, public health crises, pandemics and epidemics, such as the COVID-19 pandemic, power failures and numerous other factors.

 

In addition, any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls or other interruptions in the supply of our product candidates. We also may need to take inventory write-offs and incur other charges and expenses for product candidates that fail to meet specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives.

 

 45 

 

We rely completely on third parties to manufacture our preclinical and clinical drug supplies, and our business, financial condition and results of operations could be harmed if those third parties fail to provide us with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices.

 

We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture our preclinical and clinical drug supplies for use in our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials. There are a limited number of suppliers for raw materials that we use to manufacture our product candidates, and there may be a need to identify alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials, and, if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete such clinical trial, any significant delay or discontinuity in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates, which could harm our business, financial condition and results of operations.

 

Product candidates that are considered combination products for FDA purposes, such as the SLS-002 drug-device combination product consisting of ketamine hydrocholoride and a USP aqueous spray solution in a bi-dose nasal delivery device, may face additional challenges, risks and delays in the product development and regulatory approval process.

 

SLS-002 is delivered by an intranasal delivery device and considered a drug-device combination product (the device having been developed by a third party is subject to a license agreement). When evaluating products that utilize a specific drug delivery system or device, the FDA will evaluate the characteristics of that delivery system and its functionality, as well as the potential for undesirable interactions between the drug and the delivery system, including the potential to negatively impact the safety or effectiveness of the drug. The FDA review process can be more complicated for combination products, and may result in delays, particularly if novel delivery systems are involved. Additionally, quality or design concerns with the delivery system could delay or prevent regulatory approval and commercialization of our product candidates.

 

We and our contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements.

 

All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA or marketing authorization application ("MAA") on a timely basis and must adhere to GLP and cGMP regulations enforced by the FDA, the EMA or comparable foreign authorities through their facilities inspection program. Some of our contract manufacturers may not have produced a commercially approved pharmaceutical product and therefore may not have obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or any of our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we plan to oversee the contract manufacturers, we cannot control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever.

 

The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly or time consuming for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business, financial condition and results of operations.

 

 46 

 

If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA, the EMA or comparable foreign authorities can impose regulatory sanctions including, among other things, refusal to approve a pending application for a product candidate, withdrawal of an approval or suspension of production. As a result, our business, financial condition and results of operations may be materially and adversely affected.

 

Additionally, if supply from one manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA supplement or MAA variation, or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies or trials if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.

 

These factors could cause us to incur higher costs and could cause the delay or termination of clinical trials, regulatory submissions, required approvals, or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.

 

Any collaboration arrangement that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our current and potential future product candidates.

 

We may seek collaboration arrangements with biopharmaceutical companies for the development or commercialization of our current and potential future product candidates. To the extent that we decide to enter into collaboration agreements, we will face significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, execute and implement. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we choose to enter into such arrangements, and the terms of the arrangements may not be favorable to us. If and when we collaborate with a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations.

Disagreements between parties to a collaboration arrangement can lead to delays in developing or commercializing the applicable product candidate and can be difficult to resolve in a mutually beneficial manner. In some cases, collaborations with biopharmaceutical companies and other third parties are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect our business, financial condition and results of operations.

 

If we are unable to develop our own commercial organization or enter into agreements with third parties to sell and market our product candidates, we may be unable to generate significant revenues.

 

We do not have a sales and marketing organization, and we have no experience as a company in the sales, marketing and distribution of pharmaceutical products. If any of our product candidates are approved for commercialization, we may be required to develop our sales, marketing and distribution capabilities, or make arrangements with a third party to perform sales and marketing services. Developing a sales force for any resulting product or any product resulting from any of our other product candidates is expensive and time consuming and could delay any product launch. We may be unable to establish and manage an effective sales force in a timely or cost-effective manner, if at all, and any sales force we do establish may not be capable of generating sufficient demand for our product candidates. To the extent that we enter into arrangements with collaborators or other third parties to perform sales and marketing services, our product revenues are likely to be lower than if we marketed and sold our product candidates independently. If we are unable to establish adequate sales and marketing capabilities, independently or with others, we may not be able to generate significant revenues and may not become profitable.

 

The commercial success of our product candidates depends upon their market acceptance among physicians, patients, healthcare payors and the medical community.

 

Even if our product candidates obtain regulatory approval, our products, if any, may not gain market acceptance among physicians, patients, healthcare payors and the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:

 

  • the effectiveness of our approved product candidates as compared to currently available products;
  • patient willingness to adopt our approved product candidates in place of current therapies;
  • our ability to provide acceptable evidence of safety and efficacy;
  • relative convenience and ease of administration;
  • the prevalence and severity of any adverse side effects;
  • restrictions on use in combination with other products;

 

 47 

 

  • availability of alternative treatments;
  • pricing and cost-effectiveness assuming either competitive or potential premium pricing requirements, based on the profile of our product candidates and target markets;
  • effectiveness of us or our partners' sales and marketing strategy;
  • our ability to obtain sufficient third-party coverage or reimbursement; and
  • potential product liability claims.

In addition, the potential market opportunity for our product candidates is difficult to precisely estimate. Our estimates of the potential market opportunity for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research reports and other surveys. Independent sources have not verified all of our assumptions. If any of these assumptions proves to be inaccurate, then the actual market for our product candidates could be smaller than our estimates of the potential market opportunity. If the actual market for our product candidates is smaller than we expect, our product revenue may be limited, it may be harder than expected to raise funds and it may be more difficult for us to achieve or maintain profitability. If we fail to achieve market acceptance of our product candidates in the U.S. and abroad, our revenue will be limited and it will be more difficult to achieve profitability.

 

If we fail to obtain and sustain an adequate level of reimbursement for our potential products by third-party payors, potential future sales would be materially adversely affected.

 

There will be no viable commercial market for our product candidates, if approved, without reimbursement from third-party payors. Reimbursement policies may be affected by future healthcare reform measures. We cannot be certain that reimbursement will be available for our current product candidates or any other product candidate we may develop. Additionally, even if there is a viable commercial market, if the level of reimbursement is below our expectations, our anticipated revenue and gross margins will be adversely affected.

Third-party payors, such as government or private healthcare insurers, carefully review and increasingly question and challenge the coverage of and the prices charged for drugs. Reimbursement rates from private health insurance companies vary depending on the company, the insurance plan and other factors. Reimbursement rates may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. There is a current trend in the U.S. healthcare industry toward cost containment.

 

Large public and private payors, managed care organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third-party payors, including Medicare, may question the coverage of, and challenge the prices charged for, medical products and services, and many third-party payors limit coverage of or reimbursement for newly approved healthcare products. In particular, third-party payors may limit the covered indications. Cost-control initiatives could decrease the price we might establish for products, which could result in product revenues being lower than anticipated. We believe our drugs will be priced significantly higher than existing generic drugs and consistent with current branded drugs. If we are unable to show a significant benefit relative to existing generic drugs, Medicare, Medicaid and private payors may not be willing to provide reimbursement for our drugs, which would significantly reduce the likelihood of our products gaining market acceptance.

 

We expect that private insurers will consider the efficacy, cost-effectiveness, safety and tolerability of our potential products in determining whether to approve reimbursement for such products and at what level. Obtaining these approvals can be a time consuming and expensive process. Our business, financial condition and results of operations would be materially adversely affected if we do not receive approval for reimbursement of our potential products from private insurers on a timely or satisfactory basis. Limitations on coverage could also be imposed at the local Medicare carrier level or by fiscal intermediaries. Medicare Part D, which provides a pharmacy benefit to Medicare patients as discussed below, does not require participating prescription drug plans to cover all drugs within a class of products. Our business, financial condition and results of operations could be materially adversely affected if Part D prescription drug plans were to limit access to, or deny or limit reimbursement of, our product candidates or other potential products.

 

Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis. In many countries, the product cannot be commercially launched until reimbursement is approved. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. The negotiation process in some countries can exceed 12 months. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our products to other available therapies.

 

If the prices for our potential products are reduced or if governmental and other third-party payors do not provide adequate coverage and reimbursement of our drugs, our future revenue, cash flows and prospects for profitability will suffer.

 

 

 48 

 

*Current and future legislation may increase the difficulty and cost of commercializing our product candidates and may affect the prices we may obtain if our product candidates are approved for commercialization.

 

In the U.S. and some foreign jurisdictions, there have been a number of adopted and proposed legislative and regulatory changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-marketing activities and affect our ability to profitably sell any of our product candidates for which we obtain regulatory approval.

 

In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 ("MMA") changed the way Medicare covers and pays for pharmaceutical products. Cost reduction initiatives and other provisions of this legislation could limit the coverage and reimbursement rate that we receive for any of our approved products. While the MMA only applies to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.

 

In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the "PPACA"), was enacted. The PPACA was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The PPACA increased manufacturers' rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate amount for both branded and generic drugs and revised the definition of "average manufacturer price", which may also increase the amount of Medicaid drug rebates manufacturers are required to pay to states. The legislation also expanded Medicaid drug rebates and created an alternative rebate formula for certain new formulations of certain existing products that is intended to increase the rebates due on those drugs. The Centers for Medicare & Medicaid Services, which administers the Medicaid Drug Rebate Program, also has proposed to expand Medicaid rebates to the utilization that occurs in the territories of the U.S., such as Puerto Rico and the Virgin Islands. Further, beginning in 2011, the PPACA imposed a significant annual fee on companies that manufacture or import branded prescription drug products and required manufacturers to provide a 50% discount off the negotiated price of prescriptions filled by beneficiaries in the Medicare Part D coverage gap, referred to as the "donut hole." Legislative and regulatory proposals have been introduced at both the state and federal level to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.

 

There have been public announcements by members of the U.S. Congress regarding plans to repeal and replace or amend and expand the PPACA and Medicare. For example, on December 22, 2017 the Tax Cuts and Jobs Act of 2017 was signed into law, which, among other things, eliminated the individual mandate requiring most Americans (other than those who qualify for a hardship exemption) to carry a minimum level of health coverage, effective January 1, 2019. We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA's approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing approval testing and other requirements.

 

In addition to the PPACA, there will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payers to reduce costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for our current and future solutions or the amounts of reimbursement available for our current and future solutions from governmental agencies or third-party payers. While in general it is difficult to predict specifically what effects the PPACA or any future healthcare reform legislation or policies will have on our business, current and future healthcare reform legislation and policies could have a material adverse effect on our business and financial condition.

 

In Europe, the United Kingdom withdrew from the European Union on January 31, 2020 and began a transition period that ended on December 31, 2020. Although the ultimate effects of Brexit have yet to be seen, Brexit has created additional uncertainties that may ultimately result in new regulatory costs and challenges for companies and increased restrictions on imports and exports throughout Europe, which could adversely affect our ability to conduct and expand our operations in Europe and which may have an adverse effect on our business, financial condition and results of operations. Additionally, Brexit may increase the possibility that other countries may decide to leave the EU in the future.

 

In addition, on August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which, among other things, includes policies that are designed to have a direct impact on drug prices and reduce drug spending by the federal government, which shall take effect in 2023. Under the Inflation Reduction Act, Congress authorized Medicare beginning in 2026 to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars. This provision is limited in terms of the number of pharmaceuticals whose prices can be negotiated in any given year and it only applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years. Drugs and biologics that have been approved for a single rare disease or condition are categorically excluded from price negotiation. Further, the new legislation provides that if pharmaceutical companies raise prices in Medicare faster than the rate of inflation, they must pay rebates back to the government for the difference. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.

 

 49 

  

Changes in government funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, properly administer drug innovation, or prevent our product candidates from being developed or commercialized, which could negatively impact our business, financial condition and results of operations.

 

The ability of the FDA to review and approve new products can be affected by a variety of factors, including budget and funding levels, ability to hire and retain key personnel, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

 

In December 2016, the 21st Century Cures Act was signed into law. This new legislation is designed to advance medical innovation and empower the FDA with the authority to directly hire positions related to drug and device development and review. However, government proposals to reduce or eliminate budgetary deficits may include reduced allocations to the FDA and other related government agencies. These budgetary pressures may result in a reduced ability by the FDA to perform their respective roles, including the related impact to academic institutions and research laboratories whose funding is fully or partially dependent on both the level and timing of funding from government sources.

 

Disruptions at the FDA and other agencies may also slow the time necessary for our product candidates to be reviewed or approved by necessary government agencies, which could adversely affect our business, financial condition and results of operations.

 

We are subject to "fraud and abuse" and similar laws and regulations, and a failure to comply with such regulations or prevail in any litigation related to noncompliance could harm our business, financial condition and results of operations.

 

In the U.S., we are subject to various federal and state healthcare "fraud and abuse" laws, including anti-kickback laws, false claims laws and other laws intended, among other things, to reduce fraud and abuse in federal and state healthcare programs. The federal Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer, or a party acting on its behalf, to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce the referral of business, including the purchase, order or prescription of a particular drug, or other good or service for which payment in whole or in part may be made under a federal healthcare program, such as Medicare or Medicaid. Although we seek to structure our business arrangements in compliance with all applicable requirements, these laws are broadly written, and it is often difficult to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our practices may be challenged under the federal Anti-Kickback Statute.

 

The federal False Claims Act prohibits anyone from, among other things, knowingly presenting or causing to be presented for payment to the government, including the federal healthcare programs, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services that were not provided as claimed, or claims for medically unnecessary items or services. Under the Health Insurance Portability and Accountability Act of 1996, we are prohibited from knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payors, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services to obtain money or property of any healthcare benefit program. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including penalties, fines or exclusion or suspension from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions on behalf of the government under the federal False Claims Act as well as under the false claims laws of several states.

 

Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not just governmental payors. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers or the Pharmaceutical Research and Manufacturers of America's Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement, we could be subject to penalties.

 

Neither the government nor the courts have provided definitive guidance on the application of fraud and abuse laws to our business. Law enforcement authorities are increasingly focused on enforcing these laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. If we are found in violation of one of these laws, we could be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from governmental funded federal or state healthcare programs and the curtailment or restructuring of our operations. If this occurs, our business, financial condition and results of operations may be materially adversely affected.

 

  

 50 

 

If we face allegations of noncompliance with the law and encounter sanctions, our reputation, revenues and liquidity may suffer, and any of our product candidates that are ultimately approved for commercialization could be subject to restrictions or withdrawal from the market.

 

Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to generate revenues from any of our product candidates that are ultimately approved for commercialization. If regulatory sanctions are applied or if regulatory approval is withdrawn, our business, financial condition and results of operations will be adversely affected. Additionally, if we are unable to generate revenues from product sales, our potential for achieving profitability will be diminished and our need to raise capital to fund our operations will increase.

 

*If we fail to retain current members of our senior management and scientific personnel, or to attract and keep additional key personnel, we may be unable to successfully develop or commercialize our product candidates.

 

Our success depends on our continued ability to attract, retain and motivate highly qualified management and scientific personnel. As of October 28, 2022, we have 16 employees. Our organization will rely primarily on outsourcing research, development and clinical trial activities, and manufacturing operations, as well as other functions critical to our business. We believe this approach enhances our ability to focus on our core product opportunities, allocate resources efficiently to different projects and allocate internal resources more effectively. We have filled several key open positions and are currently recruiting for a few remaining positions. However, competition for qualified personnel is intense. We may not be successful in attracting qualified personnel to fulfill our current or future needs and there is no guarantee that any of these individuals will join us on a full-time employment basis, or at all. In the event we are unable to fill critical open employment positions, we may need to delay our operational activities and goals, including the development of our product candidates, and may have difficulty in meeting our obligations as a public company. In addition, we may experience employee turnover as a result of the ongoing “great resignation” occurring throughout the U.S. economy, which has impacted job market dynamics. New hires require training and take time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. In the event we are unable to fill critical open employment positions, we may need to delay our operational activities and goals, including the development of our product candidates, and may have difficulty in meeting our obligations as a public company. We do not maintain "key person" insurance on any of our employees.

 

In addition, competitors and others are likely in the future to attempt to recruit our employees. The loss of the services of any of our key personnel, the inability to attract or retain highly qualified personnel in the future or delays in hiring such personnel, particularly senior management and other technical personnel, could materially and adversely affect our business, financial condition and results of operations. In addition, the replacement of key personnel likely would involve significant time and costs, and may significantly delay or prevent the achievement of our business objectives.

 

From time to time, our management seeks the advice and guidance of certain scientific advisors and consultants regarding clinical and regulatory development programs and other customary matters. These scientific advisors and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, our scientific advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with us.

 

We will need to increase the size of our organization and may not successfully manage our growth.

 

We are a clinical-stage biopharmaceutical company with a small number of planned employees, and our management system currently in place is not likely to be adequate to support our future growth plans. Our ability to grow and to manage our growth effectively will require us to hire, train, retain, manage and motivate additional employees and to implement and improve our operational, financial and management systems. These demands also may require the hiring of additional senior management personnel or the development of additional expertise by our senior management personnel. Hiring a significant number of additional employees, particularly those at the management level, would increase our expenses significantly. Moreover, if we fail to expand and enhance our operational, financial and management systems in conjunction with our potential future growth, it could have a material adverse effect on our business, financial condition and results of operations.

 

 51 

 

Our management's limited public company experience could put us at greater risk of incurring fines or regulatory actions for failure to comply with federal securities laws and could put us at a competitive disadvantage, and could require our management to devote additional time and resources to ensure compliance with applicable corporate governance requirements.

 

Our executive officers have limited prior experience as executive officers in managing and operating a public company, which could have an adverse effect on their ability to quickly respond to problems or adequately address issues and matters applicable to public companies. Any failure to comply with federal securities laws, rules or regulations could subject us to fines or regulatory actions, which may materially adversely affect our business, financial condition and results of operations. Further, since our executive officers have limited prior experience as executive officers managing and operating a public company, we may need to dedicate additional time and resources to comply with legally mandated corporate governance policies relative to our competitors whose management teams have more public company experience.

 

We are exposed to product liability, non-clinical and clinical liability risks which could place a substantial financial burden upon us, should lawsuits be filed against us.

 

Our business exposes us to potential product liability and other liability risks that are inherent in the testing, manufacturing and marketing of pharmaceutical formulations and products. In addition, the use in our clinical trials of pharmaceutical products and the subsequent sale of these products by us or our potential collaborators may cause us to bear a portion of or all product liability risks. A successful liability claim or series of claims brought against us could have a material adverse effect on our business, financial condition and results of operations.

 

We currently carry product liability insurance for our clinical development activities. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.

 

Our research and development activities involve the use of hazardous materials, which subject us to regulation, related costs and delays and potential liabilities.

 

Our research and development activities involve the controlled use of hazardous materials and chemicals, and we will need to develop additional safety procedures for the handling and disposing of hazardous materials. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate any of these laws or regulations.

 

We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.

 

Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations, and could result in a material disruption of our drug development and clinical activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The loss of drug development or clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our development programs and the development of our product candidates could be delayed.

 

 52 

Our employees and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

 

We are exposed to the risk of employee or consultant fraud or other misconduct. Misconduct by our employees or consultants could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commissions, customer incentive programs and other business arrangements. Employee and consultant misconduct also could involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business, financial condition and results of operations, and result in the imposition of significant fines or other sanctions against us.

Business disruptions such as natural disasters could seriously harm our future revenues and financial condition and increase our costs and expenses.

 

We and our suppliers may experience a disruption in our and their business as a result of natural disasters. A significant natural or man-made disaster, such as an earthquake, power outages, hurricane, flood or fire, drought and other extreme weather events and changing weather patterns, which are increasing in frequency due to the impacts of climate change, could severely damage or destroy our headquarters or facilities or the facilities of our manufacturers or suppliers, which could have a material and adverse effect on our business, financial condition and results of operations. In addition, terrorist acts or acts of war targeted at the U.S., and specifically the greater New York, New York region, could cause damage or disruption to us, our employees, facilities, partners and suppliers, which could have a material adverse effect on our business, financial condition and results of operations.

 

We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.

 

From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of products, product candidates or technologies. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our business, financial condition and results of operations. For example, these transactions may entail numerous operational and financial risks, including:

 

  • exposure to unknown liabilities;
  • disruption of our business and diversion of our management's time and attention in order to develop acquired products, product candidates or technologies;
  • incurrence of substantial debt or dilutive issuances of equity securities to pay for any of these transactions;
  • higher-than-expected transaction and integration costs;
  • write-downs of assets or goodwill or impairment charges;
  • increased amortization expenses;
  • difficulty and cost in combining the operations and personnel of any acquired businesses or product lines with our operations and personnel;
  • impairment of relationships with key suppliers or customers of any acquired businesses or product lines due to changes in management and ownership; and
  • inability to retain key employees of any acquired businesses.

Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks, and could have a material adverse effect on our business, financial condition and results of operations.

 

 53 

*Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.

 

The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the EU General Data Protection Regulation (the “GDPR”), which took effect across all member states of the European Economic Area (the “EEA”) in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to 4% of global revenues or €20 million, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.

 

Similar actions are either in place or under way in the United States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act (the “CCPA”), which went into effect on January 1, 2020, is creating similar risks and obligations as those created by the GDPR, though the CCPA does exempt certain clinical trial data. The California Privacy Rights Act (the “CPRA”), which will become effective on January 1, 2023, will significantly modify the CCPA, and also create a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. Many other states have implemented or are considering similar legislation which will change the privacy law landscape in the United States. For example, Virginia passed the Consumer Data Protection Act, Colorado passed the Colorado Privacy Act, Utah passed the Consumer Privacy Act, and Connecticut passed the Connecticut Data Privacy Act, all of which become effective in 2023. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal information could expose us to fines and penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data.

 

Given the breadth and depth of changes in data protection obligations, preparing for and complying with these requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in the European Union. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations. Similarly, failure to comply with federal and state laws regarding privacy and security of personal information could expose us to fines and penalties under such laws. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.

 

 54 

We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. If we fail to comply with these laws, we could be subject to civil or criminal liabilities, other remedial measures and legal expenses, be precluded from developing, manufacturing and selling certain products outside the United States or be required to develop and implement costly compliance programs, which could adversely affect our business, results of operations and financial condition.

 

Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (the “FCPA”), the U.K. Bribery Act 2010 (the “Bribery Act”) and other anti-corruption laws that apply in countries where we do business and may do business in the future. The FCPA, the Bribery Act and these other laws generally prohibit us, our officers, and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. Compliance with the FCPA, in particular, is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.

 

We may in the future operate in jurisdictions that pose a high risk of potential FCPA or Bribery Act violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA, the Bribery Act or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. If we expand our operations outside of the United States, we will need to dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate.

 

We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States, the United Kingdom and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations (collectively referred to as “Trade Control Laws”). In addition, various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.

 

There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act or other legal requirements, including Trade Control Laws. If we are not in compliance with the FCPA, the Bribery Act and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. The Securities and Exchange Commission also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions. Any investigation of any potential violations of the FCPA, the Bribery Act, other anti-corruption laws or Trade Control Laws by U.S., United Kingdom or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition.

 

Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any.

 

In some countries, particularly member states of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we, or our future collaborators, may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.

 

 55 

*Investors’ expectations of our performance relating to environmental, social and governance factors may impose additional costs and expose us to new risks.

 

There is an increasing focus from certain investors, employees, regulators and other stakeholders concerning corporate responsibility, specifically related to environmental, social and governance, or ESG, factors. Some investors and investor advocacy groups may use these factors to guide investment strategies and, in some cases, investors may choose not to invest in our company if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased to meet growing investor demand for measurement of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investors, particularly institutional investors, use these ratings to benchmark companies against their peers and if we are perceived as lagging with respect to ESG initiatives, certain investors may engage with us to improve ESG disclosures or performance and may also make voting decisions, or take other actions, to hold us and our board of directors accountable. In addition, the criteria by which our corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to satisfy such new criteria, investors may conclude that our policies with respect to corporate responsibility are inadequate.

 

We may face reputational damage in the event our corporate responsibility initiatives or objectives do not meet the standards set by our investors, stockholders, lawmakers, listing exchanges or other constituencies, or if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our common stock from consideration by certain investors who may elect to invest with our competition instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, share price, financial condition, or results of operations, including the sustainability of our business over time.

 

In addition, the SEC has announced proposed rules that, among other matters, will establish a framework for reporting of climate-related risks. To the extent the proposed rules impose additional reporting obligations, we could face increased costs. Separately, the SEC has also announced that it is scrutinizing existing climate-change related disclosures in public filings, increasing the potential for enforcement if the SEC were to allege our existing climate disclosures are misleading or deficient.

 

Risks Related to Our Intellectual Property

 

We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.

 

Because several of our programs require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to maintain and exploit these proprietary rights. In addition, we may need to acquire or in-license additional intellectual property in the future. We may be unable to acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for our product candidates. We face competition with regard to acquiring and in-licensing third-party intellectual property rights, including from a number of more established companies. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license intellectual property rights to us. We also may be unable to acquire or in-license third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.

 

We may enter into collaboration agreements with U.S. and foreign academic institutions to accelerate development of our current or future preclinical product candidates. Typically, these agreements include an option for the company to negotiate a license to the institution's intellectual property rights resulting from the collaboration. Even with such an option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to license rights from a collaborating institution, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our desired program.

 

If we are unable to successfully obtain required third-party intellectual property rights or maintain our existing intellectual property rights, including if our patent applications do not result in the issuance of patents, we may need to abandon development of the related program and our business, financial condition and results of operations could be materially and adversely affected.

 

 

 56 

If we fail to comply with our obligations in the agreements under which we in-license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.

 

Our license agreement with Ligand Pharmaceuticals Incorporated, Neurogen Corporation and CyDex Pharmaceuticals, Inc. (the "Ligand License Agreement"), our license agreement with the Regents of the University of California (the "UC Regents License Agreement"), our license agreement with Duke University (the "Duke License Agreement) and our license agreement with iX Biopharma Ltd. (the “iX License Agreement”, together with the Ligand License Agreement, the UC Regents License Agreement and the Duke License Agreement, the “License Agreements”) are important to our business and we expect to enter into additional license agreements in the future. The License Agreements impose, and we expect that future license agreements will impose, various milestone payments, royalties and other obligations on us. If we fail to comply with our obligations under these agreements, or if we file for bankruptcy, we may be required to make certain payments to the licensor, we may lose the exclusivity of our license, or the licensor may have the right to terminate the license, in which event we would not be able to develop or market products covered by the license. Additionally, the milestone and other payments associated with these licenses could materially and adversely affect our business, financial condition and results of operations.

 

Pursuant to the terms of the Ligand License Agreement, the licensors each have the right to terminate the Ligand License Agreement with respect to the programs licensed by such licensor under certain circumstances, including, but not limited to: (i) if we do not pay an amount that is not disputed in good faith, (ii) if we willfully breach the Ligand License Agreement in a manner for which legal remedies would not be expected to make such licensor whole, or (iii) if we file or have filed against us a petition in bankruptcy or make an assignment for the benefit of creditors. In the event the Ligand License Agreement is terminated by a licensor, all licenses granted to us by such licensor will terminate immediately. Further, pursuant to the terms of the UC Regents License Agreement, the licensor has the right to terminate the UC Regents License Agreement or reduce our license to a nonexclusive license if we fail to achieve certain milestones within a specified timeframe. Similarly, pursuant to the terms of the Duke License Agreement and the iX License Agreement, each licensor has the right to terminate the Duke License Agreement or the iX License Agreement, as applicable, if we fail to achieve certain milestones within a specified timeframe.

 

In some cases, patent prosecution of our licensed technology may be controlled solely by the licensor. If our licensor fails to obtain and maintain patent or other protection for the proprietary intellectual property we in-license, then we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. In certain cases, we may control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise regarding intellectual property subject to a licensing agreement, including, but not limited to:

 

  • the scope of rights granted under the license agreement and other interpretation-related issues;
  • the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
  • the sublicensing of patent and other rights;
  • our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
  • the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us, our licensors and our collaborators; and
  • the priority of invention of patented technology.

 If disputes over intellectual property and other rights that we have in-licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with any such obligations to our licensor, such licensor may terminate its licenses to us, in which case we would not be able to market products covered by these licenses. The loss of our licenses would have a material adverse effect on our business.

 

 

 57 

*We are required to make certain cash payments and may be required to pay milestones and royalties pursuant to certain commercial agreements, which could adversely affect the overall profitability for us of any products that we may seek to commercialize.

 

Under the terms of the Ligand License Agreement, we may be obligated to pay the licensor under the Ligand License Agreement up to an aggregate of approximately $126.7 million in development, regulatory and sales milestones. Similarly, under the terms of the iX License Agreement, we may be obligated to pay the licensor under the iX License Agreement up to an aggregate of approximately $239 million in development, regulatory and sales milestones. We will also be required to pay royalties on future worldwide net product sales. We will also be required to pay up to an aggregate of approximately $17 million in development and regulatory milestones and royalties on any net sales of SLS-005 pursuant to our asset purchase agreement with Bioblast Pharma Ltd. These cash, milestone and royalty payments could adversely affect the overall profitability for us of any products that we may seek to commercialize.

 

We may not be able to protect our proprietary or licensed technology in the marketplace.

 

We depend on our ability to protect our proprietary or licensed technology. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. Our success depends in large part on our ability and any licensor's or licensee's ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary or licensed technology and products. We currently in-license some of our intellectual property rights to develop our product candidates and may in-license additional intellectual property rights in the future. We cannot be certain that patent enforcement activities by our current or future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. We also cannot be certain that our current or future licensors will allocate sufficient resources or prioritize their or our enforcement of such patents. Even if we are not a party to these legal actions, an adverse outcome could prevent us from continuing to license intellectual property that we may need to operate our business, which would have a material adverse effect on our business, financial condition and results of operations.

 

Although we believe we will be able to obtain, through prosecution of patent applications covering our owned technology and technology licensed from others, adequate patent protection for our proprietary drug technology, including those related to our in-licensed intellectual property, if we are compelled to spend significant time and money protecting or enforcing our licensed patents and future patents we may own, designing around patents held by others or licensing or acquiring, potentially for large fees, patents or other proprietary rights held by others, our business, financial condition and results of operations may be materially and adversely affected. If we are unable to effectively protect the intellectual property that we own or in-license, other companies may be able to offer the same or similar products for sale, which could materially adversely affect our business, financial condition and results of operations. The patents of others from whom we may license technology, and any future patents we may own, may be challenged, narrowed, invalidated or circumvented, which could limit our ability to stop competitors from marketing the same or similar products or limit the length of term of patent protection that we may have for our products.

 

Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection for licensed patents, pending patent applications and potential future patent applications and patents could be reduced or eliminated for non-compliance with these requirements.

 

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or patent applications will be due to be paid to the U.S. Patent and Trademark Office ("USPTO") and various governmental patent agencies outside of the U.S. in several stages over the lifetime of the applicable patent and/or patent application. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If this occurs with respect to our in-licensed patents or patent applications we may file in the future, our competitors might be able to use our technologies, which would have a material adverse effect on our business, financial condition and results of operations.

 

 58 

The patent positions of pharmaceutical products are often complex and uncertain. The breadth of claims allowed in pharmaceutical patents in the U.S. and many jurisdictions outside of the U.S. is not consistent. For example, in many jurisdictions, the support standards for pharmaceutical patents are becoming increasingly strict. Some countries prohibit method of treatment claims in patents. Changes in either the patent laws or interpretations of patent laws in the U.S. and other countries may diminish the value of our licensed or owned intellectual property or create uncertainty. In addition, publication of information related to our current product candidates and potential products may prevent us from obtaining or enforcing patents relating to these product candidates and potential products, including without limitation composition-of-matter patents, which are generally believed to offer the strongest patent protection.

 

Patents that we currently license and patents that we may own or license in the future do not necessarily ensure the protection of our licensed or owned intellectual property for a number of reasons, including, without limitation, the following:

 

  • the patents may not be broad or strong enough to prevent competition from other products that are identical or similar to our product candidates;
  • there can be no assurance that the term of a patent can be extended under the provisions of patent term extensions afforded by U.S. law or similar provisions in foreign countries, where available;
  • the issued patents and patents that we may obtain or license in the future may not prevent generic entry into the market for our product candidates;
  • we, or third parties from whom we in-license or may license patents, may be required to disclaim part of the term of one or more patents;
  • there may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim;
  • there may be prior art of which we are aware, which we do not believe affects the validity or enforceability of a patent claim, but which, nonetheless, ultimately may be found to affect the validity or enforceability of a patent claim;
  • there may be other patents issued to others that will affect our freedom to operate;
  • if the patents are challenged, a court could determine that they are invalid or unenforceable;
  • there might be a significant change in the law that governs patentability, validity and infringement of our licensed patents or any future patents we may own that adversely affects the scope of our patent rights;
  • a court could determine that a competitor's technology or product does not infringe our licensed patents or any future patents we may own; and
  • the patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations or could be subject to compulsory licensing.

 If we encounter delays in our development or clinical trials, the period of time during which we could market our potential products under patent protection would be reduced.

 

Our competitors may be able to circumvent our licensed patents or future patents we may own by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting abbreviated new drug applications to the FDA in which our competitors claim that our licensed patents or any future patents we may own are invalid, unenforceable or not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or assert our licensed patents or any future patents we may own, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our licensed patents or any future patents we may own invalid or unenforceable. We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Even if we own or in-license valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.

 

The issuance of a patent is not conclusive as to its inventorship, scope, ownership, priority, validity or enforceability. In this regard, third parties may challenge our licensed patents or any future patents we may own in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and potential products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized.

 

 

 59 

We may infringe the intellectual property rights of others, which may prevent or delay our drug development efforts and prevent us from commercializing or increase the costs of commercializing our products.

 

Our commercial success depends significantly on our ability to operate without infringing the patents and other intellectual property rights of third parties. For example, there could be issued patents of which we are not aware that our current or potential future product candidates infringe. There also could be patents that we believe we do not infringe, but that we may ultimately be found to infringe.

 

Moreover, patent applications are in some cases maintained in secrecy until patents are issued. The publication of discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the underlying discoveries were made and patent applications were filed. Because patents can take many years to issue, there may be currently pending applications of which we are unaware that may later result in issued patents that our product candidates or potential products infringe. For example, pending applications may exist that claim or can be amended to claim subject matter that our product candidates or potential products infringe. Competitors may file continuing patent applications claiming priority to already issued patents in the form of continuation, divisional, or continuation-in-part applications, in order to maintain the pendency of a patent family and attempt to cover our product candidates.

 

Third parties may assert that we are employing their proprietary technology without authorization and may sue us for patent or other intellectual property infringement. These lawsuits are costly and could adversely affect our business, financial condition and results of operations and divert the attention of managerial and scientific personnel. If we are sued for patent infringement, we would need to demonstrate that our product candidates, potential products or methods either do not infringe the claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. If a court holds that any third-party patents are valid, enforceable and cover our products or their use, the holders of any of these patents may be able to block our ability to commercialize our products unless we acquire or obtain a license under the applicable patents or until the patents expire.

 

We may not be able to enter into licensing arrangements or make other arrangements at a reasonable cost or on reasonable terms. Any inability to secure licenses or alternative technology could result in delays in the introduction of our products or lead to prohibition of the manufacture or sale of products by us. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, in any such proceeding or litigation, we could be found liable for monetary damages, including treble damages and attorneys' fees, if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially and adversely affect our business, financial condition and results of operations. Any claims by third parties that we have misappropriated their confidential information or trade secrets could have a similar material and adverse effect on our business, financial condition and results of operations. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.

 

Any claims or lawsuits relating to infringement of intellectual property rights brought by or against us will be costly and time consuming and may adversely affect our business, financial condition and results of operations.

 

We may be required to initiate litigation to enforce or defend our licensed and owned intellectual property. Lawsuits to protect our intellectual property rights can be very time consuming and costly. There is a substantial amount of litigation involving patent and other intellectual property rights in the biopharmaceutical industry generally. Such litigation or proceedings could substantially increase our operating expenses and reduce the resources available for development activities or any future sales, marketing or distribution activities.

 

In any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are resolved. Further, any claims we assert against a perceived infringer could provoke these parties to assert counterclaims against us alleging that we have infringed their patents. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

 

 60 

In addition, our licensed patents and patent applications, and patents and patent applications that we may apply for, own or license in the future, could face other challenges, such as interference proceedings, opposition proceedings, re-examination proceedings and other forms of post-grant review. Any of these challenges, if successful, could result in the invalidation of, or in a narrowing of the scope of, any of our licensed patents and patent applications and patents and patent applications that we may apply for, own or license in the future subject to challenge. Any of these challenges, regardless of their success, would likely be time consuming and expensive to defend and resolve and would divert our management and scientific personnel's time and attention.

 

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.

 

As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is costly, time-consuming and inherently uncertain. For example, the U.S. previously enacted and is currently implementing wide-ranging patent reform legislation. Specifically, on September 16, 2011, the Leahy-Smith America Invents Act (the "Leahy-Smith Act") was signed into law and included a number of significant changes to U.S. patent law, and many of the provisions became effective in March 2013. However, it may take the courts years to interpret the provisions of the Leahy-Smith Act, and the implementation of the statute could increase the uncertainties and costs surrounding the prosecution of our licensed and future patent applications and the enforcement or defense of our licensed and future patents, all of which could have a material adverse effect on our business, financial condition and results of operations.

 

In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we might obtain in the future.

 

We may not be able to protect our intellectual property rights throughout the world.

 

Filing, prosecuting and defending patents on product candidates throughout the world would be prohibitively expensive. Competitors may use our licensed and owned technologies in jurisdictions where we have not licensed or obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain or license patent protection, but where patent enforcement is not as strong as that in the U.S. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.

 

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our licensed patents and future patents we may own, or marketing of competing products in violation of our proprietary rights generally. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our licensed and owned intellectual property both in the U.S. and abroad. For example, China currently affords less protection to a company's intellectual property than some other jurisdictions. As such, the lack of strong patent and other intellectual property protection in China may significantly increase our vulnerability regarding unauthorized disclosure or use of our intellectual property and undermine our competitive position. Proceedings to enforce our future patent rights, if any, in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.

 

We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.

 

In order to protect our proprietary and licensed technology and processes, we rely in part on confidentiality agreements with our corporate partners, employees, consultants, manufacturers, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of our confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

 

 

 61 

 

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

 

We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest, and it may be difficult and costly to register, maintain and/or protect our rights to these trademarks and trade names in jurisdictions in and outside of the United States. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.

 

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

 

We expect to employ individuals who were previously employed at other biopharmaceutical companies. Although we have no knowledge of any such claims against us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees' former employers or other third parties. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. To date, none of our employees have been subject to such claims.

 

We may be subject to claims challenging the inventorship of our licensed patents, any future patents we may own and other intellectual property.

 

Although we are not currently experiencing any claims challenging the inventorship of our licensed patents or our licensed or owned intellectual property, we may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our licensed patents or other licensed or owned intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arising from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, financial condition and results of operations. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

 

If we do not obtain additional protection under the Hatch-Waxman Amendments and similar foreign legislation extending the terms of our licensed patents and any future patents we may own, our business, financial condition and results of operations may be materially and adversely affected.

 

Depending upon the timing, duration and specifics of FDA regulatory approval for our product candidates, one or more of our licensed U.S. patents or future U.S. patents that we may license or own may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during drug development and the FDA regulatory review process. This period is generally one-half the time between the effective date of an investigational new drug application ("IND") (falling after issuance of the patent), and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application. Patent term restorations, however, cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval by the FDA.

 

The application for patent term extension is subject to approval by the USPTO, in conjunction with the FDA. It takes at least six months to obtain approval of the application for patent term extension. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain earlier approval of competing products, and our ability to generate revenues could be materially adversely affected.

 

 

 62 

Risks Related to Owning Our Common Stock

 

*The market price of our common stock has been and will likely continue to be volatile.

 

The trading price of our common stock has been and is likely to continue to be volatile. For example, from January 3, 2022 to September 30, 2022, our closing stock price ranged from $0.51 to $1.71 per share. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:

 

  • results from, and any delays in, planned clinical trials for our product candidates, or any other future product candidates, and the results of trials of competitors or those of other companies in our market sector;
  • any delay in filing an NDA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA's review of that NDA;
  • significant lawsuits, including patent or stockholder litigation;
  • inability to obtain additional funding;
  • failure to successfully develop and commercialize our product candidates;
  • changes in laws or regulations applicable to our product candidates;
  • inability to obtain adequate product supply for our product candidates, or the inability to do so at acceptable prices;
  • unanticipated serious safety concerns related to any of our product candidates;
  • adverse regulatory decisions;
  • introduction of new products or technologies by our competitors;
  • failure to meet or exceed drug development or financial projections we provide to the public;
  • failure to meet or exceed the estimates and projections of the investment community;
  • the perception of the biopharmaceutical industry by the public, legislatures, regulators and the investment community;
  • announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;
  • disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our licensed and owned technologies;
  • additions or departures of key scientific or management personnel;
  • changes in the market valuations of similar companies;
  • general economic and market conditions and overall fluctuations in the U.S. equity market;
  • public health crises, pandemics and epidemics, such as the COVID-19 pandemic;
  • sales of our common stock by us or our stockholders in the future; and
  • the trading volume of our common stock.

In addition, the stock market in general, and small biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. Further, a decline in the financial markets and related factors beyond our control may cause our stock price to decline rapidly and unexpectedly.

 

*If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.

 

We must continue to satisfy the Nasdaq Capital Market's continued listing requirements, including, among other things, a minimum closing bid price requirement of $1.00 per share for 30 consecutive business days. If a company fails for 30 consecutive business days to meet the $1.00 minimum closing bid price requirement, The Nasdaq Stock Market LLC ("Nasdaq") will send a deficiency notice to the company, advising that it has been afforded a "compliance period" of 180 calendar days to regain compliance with the applicable requirements.

 

A delisting of our common stock from the Nasdaq Capital Market could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors and employees.

 

 

 63 

On April 22, 2022, we received written notice from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided an initial period of 180 calendar days, or until October 19, 2022, to regain compliance. On September 1, 2022, we received a letter from Nasdaq notifying us that we regained full compliance with Nasdaq Listing Rule 5550(a)(2) after the closing bid price of our common stock had been at $1.00 per share or greater for ten consecutive business days, from August 18, 2022 through August 31, 2022.

 

In addition, we have previously received similar notices from Nasdaq that our bid price of our common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). Even though we previously regained compliance with the Nasdaq Capital Market's minimum market value of listed securities requirement and minimum closing bid price requirement, there is no guarantee that we will remain in compliance with such listing requirements or other listing requirements in the future. Any failure to maintain compliance with continued listing requirements of the Nasdaq Capital Market could result in delisting of our common stock from the Nasdaq Capital Market and negatively impact our company and holders of our common stock, including by reducing the willingness of investors to hold our common stock because of the resulting decreased price, liquidity and trading of our common stock, limited availability of price quotations and reduced news and analyst coverage. Delisting may adversely impact the perception of our financial condition, cause reputational harm with investors, our employees and parties conducting business with us and limit our access to debt and equity financing.

 

We will incur significant costs as a result of operating as a public company and our management will be required to devote substantial time to new compliance initiatives.

 

The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act") as well as rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact (in ways we cannot currently anticipate) the manner in which we operate our business. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such insurance coverage.

 

As a publicly traded company, we will incur legal, accounting and other expenses associated with the SEC reporting requirements applicable to a company whose securities are registered under the Exchange Act, as well as corporate governance requirements, including those under the Sarbanes-Oxley Act, the Dodd-Frank Act and other rules implemented by the SEC and Nasdaq. The expenses incurred by public companies generally to meet SEC reporting, finance and accounting and corporate governance requirements have been increasing in recent years as a result of changes in rules and regulations and the adoption of new rules and regulations applicable to public companies.

 

 64 

*Sales of a substantial number of shares of our common stock in the public market by our existing stockholders, future issuances of our common stock or rights to purchase our common stock, could cause our stock price to fall.

 

Sales of a substantial number of shares of our common stock by our existing stockholders in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that such sales may have on the prevailing market price of our common stock. As of September 30, 2022, we have outstanding warrants to purchase an aggregate of approximately 2.5 million shares of our common stock, which, if exercised, would further increase the number of shares of our common stock outstanding and the number of shares eligible for resale in the public market. As of September 30, 2022, 18,873,072 shares of our common stock were reserved for issuance under our equity incentive plans, of which 10,399,170 shares of our common stock were subject to options outstanding at such date at a weighted-average exercise price of $2.26 per share, 5,418,648 shares of our common stock were reserved for future issuance pursuant to our Amended and Restated 2012 Stock Long Term Incentive Plan, 646,465 shares of our common stock were reserved for future issuance pursuant to our 2019 Inducement Plan and 2,408,789 shares of our common stock were reserved for issuance pursuant to our 2020 Employee Stock Purchase Plan. To the extent outstanding options are exercised, our existing stockholders may incur dilution. Furthermore, from time to time and before the maturity date of such Convertible Promissory Note, each holder thereof currently has the option to convert any portion of the then-outstanding principal amount of such holder’s Convertible Promissory Note into shares of our common stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. We may also elect to make amortization payments on the Convertible Promissory Notes in shares of our common stock. Any issuances of shares of our common stock pursuant to the Convertible Promissory Notes will result in dilution to our then-existing stockholders and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market could depress the market price of our common stock. In addition, pursuant to the asset purchase agreement, as amended, with Phoenixus AG f/k/a Vyera Pharmaceuticals AG and Turing Pharmaceuticals AG (“Vyera”), we will issue to Vyera on or before January 11, 2023 such number of shares of common stock equal to $1.0 million divided by the volume weighted average closing price of our common stock for the ten consecutive trading days ending on the fifth trading day prior to the applicable date of issuance of the shares of common stock. Such issuances of shares of our common stock to Vyera will result in dilution to our then-existing stockholders.

 

The Financing Warrants contain price-based adjustment provisions which, if triggered, may cause substantial additional dilution to our stockholders.

 

On October 16, 2018, we entered into a Securities Purchase Agreement with the investors listed on the Schedule of Buyers attached thereto, as amended, pursuant to which, among other things, we issued warrants to purchase shares of our common stock (the "Financing Warrants").

 

The outstanding Financing Warrants contain price-based adjustment provisions, pursuant to which the exercise price of the Financing Warrants may be adjusted downward in the event of certain dilutive issuances by us.

 

If the Financing Warrants are exercised, additional shares of our common stock will be issued, which will result in dilution to our then-existing stockholders and increase the number of shares eligible for resale in the public market. As of September 30, 2022, the Financing Warrants were exercisable for approximately 0.3 million shares of our common stock at an exercise price of $0.2957 per share of common stock. Sales of substantial numbers of such shares in the public market could depress the market price of our common stock.

 

Anti-takeover provisions in our governing documents and under Nevada law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.

 

Provisions in our articles of incorporation and bylaws may delay or prevent an acquisition or a change in management. These provisions include a classified board of directors and the ability of the board of directors to issue preferred stock without stockholder approval. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.

 

 65 

Certain provisions of Nevada corporate law deter hostile takeovers. Specifically, Nevada Revised Statutes ("NRS") 78.411 through 78.444 prohibit a publicly held Nevada corporation from engaging in a "combination" with an "interested stockholder" for a period of two years following the date the person first became an interested stockholder, unless (with certain exceptions) the "combination" or the transaction by which the person became an interested stockholder is approved in a prescribed manner. Generally, a "combination" includes a merger, asset or stock sale, or certain other transactions resulting in a financial benefit to the interested stockholder. Generally, an "interested stockholder" is a person who, together with affiliates and associates, beneficially owns or within two years prior to becoming an "interested stockholder" did own, 10% or more of a corporation's voting power. While these statutes permit a corporation to opt out of these protective provisions in its articles of incorporation, our articles of incorporation do not include any such opt-out provision.

 

Nevada's "acquisition of controlling interest" statutes, NRS 78.378 through 78.3793, contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. These "control share" laws provide generally that any person that acquires a "controlling interest" in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore such voting rights. These statutes provide that a person acquires a "controlling interest" whenever a person acquires shares of a subject corporation that, but for the application of these provisions of the NRS, would enable that person to exercise (1) one-fifth or more, but less than one-third, (2) one-third or more, but less than a majority or (3) a majority or more, of all of the voting power of the corporation in the election of directors. Once an acquirer crosses one of these thresholds, shares that it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling interest become "control shares" to which the voting restrictions described above apply. While these statutes permit a corporation to opt out of these protective provisions in its articles of incorporation or bylaws, our articles of incorporation and bylaws do not include any such opt-out provision.

 

Further, NRS 78.139 also provides that directors may resist a change or potential change in control of the corporation if the board of directors determines that the change or potential change is opposed to or not in the best interest of the corporation upon consideration of any relevant facts, circumstances, contingencies or constituencies pursuant to NRS 78.138(4).

 

Our net operating loss carryforwards and certain other tax attributes may be subject to limitations. The net operating loss carryforwards and certain other tax attributes of us may also be subject to limitations as a result of certain prior ownership changes.

 

In general, a corporation that undergoes an "ownership change" as defined in Section 382 of the United States Internal Revenue Code of 1986, as amended, is subject to limitations on its ability to utilize its pre-change net operating loss carryforwards to offset future taxable income. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders, generally stockholders beneficially owning five percent or more of a corporation's common stock, applying certain look-through and aggregation rules, increases by more than 50 percentage points over such stockholders' lowest percentage ownership during the testing period, generally three years. We may have experienced ownership changes in the past and may experience ownership changes in the future. It is possible that our net operating loss carryforwards and certain other tax attributes may also be subject to limitation as a result of ownership changes in the past. Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our net operating loss carryforwards and certain other tax attributes, which could have a material adverse effect on cash flow and results of operations.

 

We are a “smaller reporting company” and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.

 

We are a smaller reporting company, as defined in Rule 12b-2 under the Exchange Act, and we will remain a smaller reporting company until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are less than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Smaller reporting companies are permitted to rely on exemptions from certain disclosure requirements that are applicable to other public companies, including not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting, reduced disclosure obligations regarding executive compensation and not being required to provide disclosures regarding quantitative and qualitative disclosures about market risk in our Annual Reports on Form 10-K.

 

We have elected to take advantage of certain of these exemptions in the past and may continue to choose to take advantage of some, but not all, of them in the future. We cannot predict whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, which may result in additional stock price volatility.

 

 

 66 

We may never pay dividends on our common stock so any returns would be limited to the appreciation of our stock.

 

We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate we will declare or pay any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.

 

General Risk Factors

 

An active trading market for our common stock may not be sustained, and you may not be able to resell your common stock at a desired market price.

 

If no active trading market for our common stock is sustained, you may be unable to sell your shares when you wish to sell them or at a price that you consider attractive or satisfactory. The lack of an active market may also adversely affect our ability to raise capital by selling securities in the future or impair our ability to acquire or in-license other product candidates, businesses or technologies using our shares as consideration.

 

Our internal control over financial reporting may not meet the standards required by Section 404 of the Sarbanes-Oxley Act, and failure to achieve and maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act, could have a material adverse effect on our business and share price.

 

Our management is required to report on the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation.

 

In connection with the implementation of the necessary procedures and practices related to internal control over financial reporting, we may identify deficiencies or material weaknesses that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. In addition, we may encounter problems or delays in completing the implementation of any requested improvements and, when required, receiving a favorable attestation in connection with the attestation provided by our independent registered public accounting firm. Failure to achieve and maintain an effective internal control environment could have a material adverse effect on our business, financial condition and results of operations and could limit our ability to report our financial results accurately and in a timely manner.

 

If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.

 

The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline.

 

*The impact of the Russian invasion of Ukraine on the global economy, energy supplies and raw materials is uncertain, but may prove to negatively impact our business and operations.

 

The short and long-term implications of Russia’s invasion of Ukraine are difficult to predict at this time. We continue to monitor any adverse impact that the outbreak of war in Ukraine and the subsequent institution of sanctions against Russia by the United States and several European and Asian countries may have on the global economy in general, on our business and operations and on the businesses and operations of our suppliers and other third parties with which we conduct business. For example, a prolonged conflict may result in increased inflation, escalating energy prices and constrained availability, and thus increasing costs, of raw materials. We will continue to monitor this fluid situation and develop contingency plans as necessary to address any disruptions to our business operations as they develop. To the extent the war in Ukraine may adversely affect our business as discussed herein, it may also have the effect of heightening many of the other risks described herein. Such risks include, but are not limited to, adverse effects on macroeconomic conditions, including inflation; disruptions to our technology infrastructure, including through cyberattack, ransom attack, or cyber-intrusion; adverse changes in international trade policies and relations; disruptions in global supply chains; and constraints, volatility, or disruption in the capital markets, any of which could negatively affect our business and financial condition.

 

 

 67 

 

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

On August 30, 2022, we entered into a consulting agreement with an advisory firm, pursuant to which the advisory firm agreed to provide us with certain management consulting, business and advisory services. As partial consideration for the services, we agreed to issue the advisory firm 100,000 unregistered shares of our common stock, which shares were issued on August 30, 2022 (the “Shares”). The issuance of the Shares was not registered under the Securities Act in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated by the SEC, and in reliance on similar exemptions under applicable state laws. Appropriate legends were affixed to the Shares. The advisory firm had adequate access, through employment, business or other relationships, to information about the Company. In connection with the foregoing issuance, the advisory firm represented to the us that it was an accredited investor and was acquiring the Shares for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that it could bear the risks of the investments and could hold the securities for an indefinite period of time. In connection with the foregoing issuance, the advisory firm received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from the registration requirements of the Securities Act. Shares are deemed restricted securities for purposes of the Securities Act. There were no underwriters employed in connection with this transaction. 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

 

ITEM 6. EXHIBITS

EXHIBITS
NO.		 DESCRIPTION
2.1* Agreement and Plan of Merger and Reorganization, dated July 30, 2018, by and among the Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 30, 2018).
2.2 Amendment No. 1 Agreement and Plan of Merger and Reorganization, dated October 16, 2018, by and among the Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 17, 2018).
2.3 Amendment No. 2 Agreement and Plan of Merger and Reorganization, dated December 14, 2018, by and among the Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 14, 2018).
2.4 Amendment No. 3 Agreement and Plan of Merger and Reorganization, dated January 16, 2019, by and among the Company, Arch Merger Sub, Inc. and Seelos Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 16, 2019).
2.5* Asset Purchase Agreement, dated February 15, 2019, by and between the Company and Bioblast Pharma Ltd. (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 19, 2019).

 68 

 

3.1 Amended and Restated Articles of Incorporation of the Company (incorporated herein by reference to Exhibit 2.1 to the Company's Registration Statement on Form 10-SB filed with the Securities and Exchange Commission on March 14, 1997).
3.2 Certificate of Amendment to Articles of Incorporation of the Company, dated June 22, 2000 (incorporated herein by reference to Exhibit 3.2 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2003).
3.3 Certificate of Amendment to Articles of Incorporation of the Company, dated June 14, 2005 (incorporated herein by reference to Exhibit 3.4 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2006).
3.4 Certificate of Amendment to Amended and Restated Articles of Incorporation of the Company, dated March 3, 2010 (incorporated herein by reference to Exhibit 3.6 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010).
3.5 Certificate of Correction to Certificate of Amendment to Amended and Restated Articles of Incorporation of the Company, dated March 3, 2010 (incorporated herein by reference to Exhibit 3.7 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010).
3.6 Certificate of Designation for Series D Junior-Participating Cumulative Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-A12G filed with the Securities and Exchange Commission on March 24, 2011).
3.7 Certificate of Change filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 17, 2010).
3.8 Certificate of Amendment to Amended and Restated Articles of Incorporation of the Company, dated September 10, 2010 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 10, 2010).
3.9 Certificate of Withdrawal of Series D Junior Participating Cumulative Preferred Stock, dated May 15, 2013 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 16, 2013).
3.10 Certificate of Change filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 25, 2016).
3.11 Certificate of Amendment filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.10 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 2, 2017).
3.12 Certificate of Amendment filed with the Nevada Secretary of State (incorporated herein by reference to Exhibit 3.12 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2018).
3.13 Certificate of Amendment related to the Share Increase Amendment, filed January 23, 2019 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 Eastern Time).
3.14 Certificate of Amendment related to the Name Change, filed January 23, 2019 (incorporated herein by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 Eastern Time).
 69 
3.15 Amended and Restated Bylaws, dated January 24, 2019 (incorporated herein by reference to Exhibit 3.3 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 24, 2019 at 8:05 Eastern Time).
3.16 Certificate of Correction to Certificate of Amended and Restated Articles of Incorporation of the Company, dated March 25, 2020 (incorporated herein by reference to Exhibit 3.16 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2020).
3.17 Certificate of Amendment to the Amended and Restated Articles of Incorporation of the Company, filed May 18, 2020 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 19, 2020).
3.18 Certificate of Correction to Certificate of Amended and Restated Articles of Incorporation of the Company, filed May 20, 2020 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2020).
3.19 Certificate of Amendment to the Amended and Restated Articles of Incorporation of the Company, filed May 21, 2021 (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 21, 2021).
4.1 Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2011).
4.2 Form of Warrant issued to the lenders under the Loan and Security Agreement, dated as of October 17, 2014, by and among the Company, NexMed (U.S.A.), Inc., NexMed Holdings, Inc. and Apricus Pharmaceuticals USA, Inc., as borrowers, Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time including Oxford Finance LLC and Silicon Valley Bank (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 20, 2014).
4.3 Form of Warrant issued to Sarissa Capital Domestic Fund LP and Sarissa Capital Offshore Master Fund LP (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2016).
4.4 Form of Warrant issued to other purchasers (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 13, 2016).
4.5 Amendment to Warrant to Purchase Common Stock (incorporated herein by reference to Exhibit 4.12 of Amendment No. 1 to the Company's Registration Statement on Form S-3 (File No. 333-223353) filed with the Securities and Exchange Commission on March 22, 2018).
4.6 Amendment to Warrant to Purchase Common Stock, dated as of March 27, 2018 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 29, 2018).
4.7 Form of Warrant (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 29, 2018).
4.8 Form of Placement Agent Warrant (incorporated herein by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 29, 2018).
4.9 Amendment to Warrant to Purchase Common Stock, dated as of June 22, 2018, by and between the Company and Sarissa Offshore (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2018).
 70 
4.10 Form of Warrant (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2018).
4.11 Form of Wainwright Warrant (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2018).
4.12 Form of Investor Warrants (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 17, 2018).
4.13 Registration Rights Agreement, dated October 16, 2018, by and among the Company and certain investors named therein (incorporated herein by reference to Exhibit 4.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 17, 2018).
4.14 Form of Series A Warrant, issued to investors on January 31, 2019 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on February 6, 2019).
4.15 Form of Warrant, issued to investors on August 27, 2019 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 27, 2019).
4.16 Form of Warrant, issued to investors on September 9, 2020 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 9, 2020).
4.17 Form of Convertible Promissory Note due November 13, 2024 (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission at 7:27 a.m. Eastern Time on November 24, 2021).
4.18 Amendment to Convertible Promissory Note, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC, dated December 10, 2021 (incorporated herein by reference to Exhibit 4.22 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 4, 2022).
 71 
31.1 Certification of Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2   Certification of Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 (1) Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 (1) Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH Inline XBRL Taxonomy Extension Schema.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

 

(1)    Furnished, not filed.

*    All schedules and exhibits to the agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.

 

 72 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Seelos Therapeutics, Inc.
   
Date: November 10, 2022 /s/ Raj Mehra, Ph.D.
Raj Mehra, Ph.D.

President, Chief Executive Officer and

Chairman of the Board

(Principal Executive Officer)

   
Date: November 10, 2022 /s/ Michael Golembiewski
Michael Golembiewski

Chief Financial Officer

(Principal Financial and Accounting Officer)

   
   
   

 73 

 EX-101.SCH 2 seel-20220930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 1. Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 2. Liquidity and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 3. Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 4. Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 5. Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 6. Common Stock Offerings link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 7. License Agreements link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 8. Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 9. Debt link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 10. Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 11. Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 12. Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 3. Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 3. Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 4. Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 5. Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 8. Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 10. Stockholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 11. Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 2. Liquidity and Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Schedule of Fair Value Hierarchy Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Summary of Fair Value Measurements Warrant Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Fair Value Level 3 Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 4. Fair Value Measurement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 6. Common Stock Offerings (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 7. License Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - 9. Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Summary of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - 10. Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Valuation Assumptions for Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Schedule of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - 11. Stock-based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - 12. Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 3 seel-20220930_cal.xml XBRL CALCULATION FILE EX-101.DEF 4 seel-20220930_def.xml XBRL DEFINITION FILE EX-101.LAB 5 seel-20220930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Class of Stock [Axis] May 122022 Sale Agreement [Member] Statistical Measurement [Axis] Maximum [Member] Minimum [Member] May 242021 [Member] January 282021 [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Restricted Stock Units (RSUs) [Member] Warrant [Member] Convertible Debt Securities [Member] Business Combination, Separately Recognized Transactions [Axis] I X License Agreement [Member] Liability Class [Axis] Long-Term Debt [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Derivative Financial Instruments, Liabilities [Member] Award Type [Axis] Assetsfrom Vyera Pharmaceuticals [Member] Weg License Agreement [Member] Debt Instrument [Axis] November 2021 Lind Securities Purchase Agreement [Member] First Anniversary Of November 2021 Lind Securities Purchase Agreement [Member] August 232022 Thru Maturity November 2021 Lind Securities Purchase Agreement [Member] Amortize November 2021 Lind Securities Purchase Agreement [Member] December 2021 S P As [Member] Lind Securities Purchase Agreement [Member] December 17 S P As [Member] Class of Warrant or Right [Axis] September 2020 Warrants [Member] August 2019 Warrants [Member] August 232019 [Member] Series A Warrants [Member] Derivative Instrument [Axis] Warrant Derivative Financial Instruments [Member] Employee Stock Purchase Plan [Member] Inducement Planof 2019 [Member] Incentive Stock Option [Member] Non Qualified Stock Options To Employees [Member] Non Qualified Stock Options To Non Employee Directors [Member] Performance Shares [Member] Plan Name [Axis] P S Uto Executives [Member] Income Statement Location [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Lease Contractual Term [Axis] March 2019 Lease [Member] March 2021 Lease [Member] October 2022 Lease [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current assets Cash Prepaid expenses and other current assets Total current assets Operating lease right-of-use asset Total assets Liabilities and stockholders’ equity Current liabilities Accounts payable Accrued expenses Licenses payable Short-term portion of convertible notes payable, at fair value Derivative liability Warrant liabilities, at fair value Operating lease liability Total current liabilities Convertible notes payable, at fair value Total liabilities Commitments and contingencies (note 12) Stockholders’ equity Common stock, $0.001 par value, 240,000,000 shares authorized,          107,168,256 and 105,500,445 issued and outstanding as of          September 30, 2022 and December 31, 2021, respectively Additional paid-in-capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Preferred stock, per value (in usd per share) Preferred stock, authorized (in shares) Preferred stock, issued (in shares) Preferred stock, outstanding (in shares) Common stock, par value (in usd per share) Common stock, authorized (in shares) Common stock, issued (in shares) Common stock, outstanding (in shares) Income Statement [Abstract] Operating expense Research and development General and administrative Total operating expense Loss from operations Other income (expense) Interest income Interest expense Net loss on extinguishment of debt Gain on forgiveness of debt Change in fair value of convertible notes Change in fair value of warrant liabilities Total other (expense) income Net loss and comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Earnings Per Share, Basic Earnings Per Share, Diluted Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Statement [Table] Statement [Line Items] Beginning balance, value Common Stock, Shares, Outstanding, Beginning Balance Stock-based compensation expense Extinguishment of beneficial conversion feature Issuance of common stock, options exercised Issuance of common stock for settlement of debt Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock for prepaid services [custom:IssuanceOfCommonStockForPrepaidServicesShares] Issuance of common stock for license acquired [custom:IssuanceOfCommonStockForExtinguishmentOfDebtShares] [custom:IssuanceOfCommonStockInAtthemarketOfferingSharesNetOfIssuanceCosts] [custom:Issuanceofcommonstockforlicenseacquiredshares] Issuance of common stock in at-the-market offering, net of issuance costs Issuance of common stock, ESPP Stock Issued During Period, Shares, Employee Stock Ownership Plan Net loss Issuance of common stock for conversion of debt Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments Issuance of common stock, net of issuance costs Stock Issued During Period, Shares, Conversion of Convertible Securities Warrants exercised for cash Issuance of common stock for conversion of debt, shares Stock Issued During Period, Shares, New Issues Ending balance, value Common Stock, Shares, Outstanding, Ending Balance Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities Stock-based compensation expense Change in fair value of warrant liability Change in fair value of convertible notes payable Research and development expense - license amendment Gain on forgiveness of note payable Net loss on extinguishment of convertible debt Amortization of debt discount Changes in operating assets and liabilities Prepaid expenses and other current assets Accounts payable Accrued expenses Derivative liability Licenses payable Net cash used in operating activities Cash flows (used in) provided by financing activities Payment of convertible note Proceeds from issuance of common stock, net of issuance costs Proceeds from exercise of warrants Proceeds from issuance of common stock in at-the-market offering Payment of at-the-market offering issuance costs Proceeds from exercise of options Proceeds from sales of common stock under ESPP Net cash provided by financing activities Net (decrease) increase in cash Cash, beginning of period Cash, end of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for income taxes Non-cash investing and financing activities: Reclass of warrant liabilities related to Series A warrants exercised for cash Right-of-use assets obtained in exchange for operating lease liabilities Issuance of common stock for convertible notes Issuance of common stock for license payable At-the-market offering issuance costs, accrued but not paid Issuance of common stock for settlement of debt Extinguishment of beneficial conversion feature Organization, Consolidation and Presentation of Financial Statements [Abstract] 1. Organization and Description of Business 2. Liquidity and Going Concern Accounting Policies [Abstract] 3. Significant Accounting Policies Fair Value Disclosures [Abstract] 4. Fair Value Measurement Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] 5. Prepaid Expenses and Other Current Assets Business Combination and Asset Acquisition [Abstract] 6. Common Stock Offerings Research and Development [Abstract] 7. License Agreements Payables and Accruals [Abstract] 8. Accrued Expenses Debt Disclosure [Abstract] 9. Debt Equity [Abstract] 10. Stockholders’ Equity Share-Based Payment Arrangement [Abstract] 11. Stock-based Compensation Commitments and Contingencies Disclosure [Abstract] 12. Commitments and Contingencies Basis of Presentation Use of Estimates Fair Value Measurements Stock-based Compensation Income (Loss) Per Common Share Recent Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Schedule of Fair Value Hierarchy Assets and Liabilities Summary of Fair Value Measurements Warrant Valuation Assumptions Schedule of Fair Value Level 3 Reconciliation Schedule of Prepaid Expenses and Other Current Assets Schedule of Accrued Liabilities Summary of Warrant Activity Schedule of Valuation Assumptions for Stock Options Summary of Stock Option Activity Schedule of Stock-Based Compensation Expense Accumlated deficit Aggregate future offering amount Commission rate on gross proceeds of common stock sale Number of shares of common stock issued Cash received from stock sale Shares Issued, Price Per Share [custom:InitialNumberOfCalendarDaysToRegainCommonStockPriceCompliance] Offering proceeds used to partially repay certain convertible promissory notes [custom:FinancingAvailableUnderFormS3ShelfRegistrationStatement-0] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets [Abstract] Cash Liabilities [Abstract] Warrant liabilities, at fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Dividend yield (in percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 Business Combination, Separately Recognized Transactions [Table] Business Combination, Separately Recognized Transactions [Line Items] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [custom:NonrefundableCashPayment] Prepaid insurance Prepaid clinical costs Other Prepaid expenses and other current assets Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Sale of Stock, Price Per Share Stock Issued During Period, Value, New Issues [custom:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes] Research and Development Expense [custom:MinimumStockValueOfSharesIssued] [custom:InitialStockValuationShortfallFrom5.5MillionValue] Business Combination, Separately Recognized Transactions, Description [custom:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement] Research and development expense Other Accrued Liabilities, Current Asset Acquisition, Contingent Consideration, Liability, Current Professional fees Personnel related Outside research and development services Insurance Other      Accrued expenses, net Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Long-Term Debt, Description Proceeds from Convertible Debt Convertible Subordinated Debt [custom:GainLossInFairValueOfConvertibleNotes] Convertible Notes Payable Repayments of Convertible Debt Long-Term Debt Offsetting Assets [Table] Offsetting Assets [Line Items] Outstanding as of December 31, 2021 Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share) Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years) Issued Issued, warrant exercise price Exercised Exercised, exercise price of warrants Cancelled Cancelled, exercise price of warrants Outstanding as of March 31, 2022 Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share) Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years) Warrants exercisable as of March 31, 2022 Exercisable, weighted-average exercise price (in usd per share) Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years) Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Common stock voting right Warrant description Class of Warrant or Right, Exercise Price of Warrants or Rights Date on which warrants became exercisable Number of warrants exercised Warrants exercisable as of June 30, 2021 Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Risk-free interest rate, minimum Risk-free interest rate, maximum Volatility, minimum Volatility, maximum Dividend yield Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Outstanding as of December 31, 2020 Outstanding, beginning of period (USD per share) Granted Granted in period (USD per share) Exercised Exercised in period (USD per share) Cancelled Cancelled (USD per share) Outstanding as of March 31, 2022 Outstanding, end of period (USD per share) Outstanding - weighted-average remaining contractual life (in years) Total aggregate intrinsic value shares outstanding Vested and expected to vest, end of period (shares) Vested and expected to vest stock, end of period (USD per share) Weighted-average remaining contractual life (in years) of vested and expected to vest stock options Total aggregate intrinsic value of vested or expected to vest stock options Exercisable, end of period (shares) Exercisable, end of period (USD per share) Weighted-average remaining contractual life (in years) of exercisable stock options Total aggregate intrinsic value of exercisable stock options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Noncash Expense Description of share-based compensation arrangement by share-based payment award Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Stock Issued During Period, Shares, Employee Stock Purchase Plans Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price Discount of Common Stock, Percent Options granted in period Weighted-average exercise price per share granted in period Term of option grant Vesting percentage on the first anniversary Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-Based Payment Arrangement, Nonvested and Canceled Award, Excluding Option, Cost Not yet Recognized, Amount Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Lessee, Operating Lease, Description Operating Lease, Right-of-Use Asset Operating Lease, Liability, Current Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Liability Operating Lease, Expense Assets, Current Assets [Default Label] Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense Gain (Loss) on Extinguishment of Debt Nonoperating Income (Expense) ChangeInFairValueOfConvertibleNotesPayable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Derivative, Loss on Derivative Increase (Decrease) in Other Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Repayments of Notes Payable Payments of Financing Costs Cash and Cash Equivalents, at Carrying Value NonCashIssuanceOfCommonStockForSettlementOfDebt NonCashExtinguishmentOfBeneficialConversionFeature Class of Warrant or Right, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value EX-101.PRE 6 seel-20220930_pre.xml XBRL PRESENTATION FILE EX-31.1 7 exh31-1.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Raj Mehra, Ph.D., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Seelos Therapeutics, Inc.; 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 

(c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 
 
Date: November 10, 2022
 
/s/ Raj Mehra, Ph.D.
Raj Mehra, Ph.D.
Chief Executive Officer and President

 

 

 EX-31.2 8 exh31-2.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, Michael Golembiewski, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Seelos Therapeutics, Inc.; 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 

(c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 
 
Date: November 10, 2022
 
/s/ Michael Golembiewski
Michael Golembiewski
Chief Financial Officer

 

 

 EX-32.1 9 exh32-1.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Raj Mehra, Ph.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Seelos Therapeutics, Inc. on Form 10-Q for the quarter ended September 30, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Seelos Therapeutics, Inc.

 
     
Date: November 10, 2022 By: /s/ Raj Mehra, Ph.D.
  Name: Raj Mehra, Ph.D. 
  Title: Chief Executive Officer and President

 

 

 

 

 

 EX-32.2 10 exh32-2.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael Golembiewski, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Seelos Therapeutics, Inc. on Form 10-Q for the quarter ended September 30, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Seelos Therapeutics, Inc.

 
     
Date: November 10, 2022 By: /s/ Michael Golembiewski
  Name: Michael Golembiewski 
  Title: Chief Financial Officer

 

 

 

 

 

 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
 9 Months Ended
Sep. 30, 2022
Nov. 04, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2022  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 000-22245  
Entity Registrant Name SEELOS THERAPEUTICS, INC.  
Entity Central Index Key 0001017491  
Entity Tax Identification Number 87-0449967  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 300 Park Avenue  
Entity Address, Address Line Two 2nd Floor  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10022  
City Area Code (646)  
Local Phone Number 293-2100  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol SEEL  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   107,168,256
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets    
Cash $ 30,511 $ 78,734
Prepaid expenses and other current assets 9,997 4,727
Total current assets 40,508 83,461
Operating lease right-of-use asset 39
Total assets 40,508 83,500
Current liabilities    
Accounts payable 5,952 1,693
Accrued expenses 4,048 3,728
Licenses payable 1,000 200
Short-term portion of convertible notes payable, at fair value 10,655 1,030
Derivative liability 1,174
Warrant liabilities, at fair value 232 424
Operating lease liability 38
Total current liabilities 21,887 8,287
Convertible notes payable, at fair value 10,742 17,890
Total liabilities 32,629 26,177
Commitments and contingencies (note 12)
Stockholders’ equity    
Common stock, $0.001 par value, 240,000,000 shares authorized,          107,168,256 and 105,500,445 issued and outstanding as of          September 30, 2022 and December 31, 2021, respectively 107 105
Additional paid-in-capital 203,859 198,428
Accumulated deficit (196,087) (141,210)
Total stockholders’ equity 7,879 57,323
Total liabilities and stockholders’ equity $ 40,508 $ 83,500
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]      
Preferred stock, per value (in usd per share) $ 0.001 $ 0.001  
Preferred stock, authorized (in shares) 10,000,000 10,000,000  
Preferred stock, issued (in shares) 0 0  
Preferred stock, outstanding (in shares) 0 0  
Common stock, par value (in usd per share) $ 0.001   $ 0.001
Common stock, authorized (in shares) 240,000,000 240,000,000  
Common stock, issued (in shares) 107,168,256 105,500,445  
Common stock, outstanding (in shares) 107,168,256 105,500,445  
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expense        
Research and development $ 14,750 $ 8,683 $ 43,115 $ 27,103
General and administrative 2,660 2,227 9,544 7,192
Total operating expense 17,410 10,910 52,659 34,295
Loss from operations (17,410) (10,910) (52,659) (34,295)
Other income (expense)        
Interest income 36 39 81 87
Interest expense (2) (20) (14) (1,593)
Net loss on extinguishment of debt (2,387)
Gain on forgiveness of debt 149
Change in fair value of convertible notes (2,137) (2,477)
Change in fair value of warrant liabilities (91) 76 192 (750)
Total other (expense) income (2,194) 95 (2,218) (4,494)
Net loss and comprehensive loss (19,604) (10,815) (54,877) (38,789)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $ (19,604) $ (10,815) $ (54,877) $ (38,789)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - $ / shares
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Earnings Per Share, Basic $ (0.18) $ (0.11) $ (0.52) $ (0.45)
Earnings Per Share, Diluted $ (0.18) $ (0.11) $ (0.52) $ (0.45)
Weighted Average Number of Shares Outstanding, Basic 106,689,924 102,325,238 106,100,413 86,579,881
Weighted Average Number of Shares Outstanding, Diluted 106,689,924 102,325,238 106,100,413 86,579,881
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 54 $ 77,680 $ (75,162) $ 2,572
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2020 54,535,891      
Stock-based compensation expense 2,599 2,599
Extinguishment of beneficial conversion feature (1,519) (1,519)
Issuance of common stock, options exercised 65 65
Issuance of common stock for settlement of debt $ 1 1,376 1,377
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period 43,805      
[custom:IssuanceOfCommonStockForExtinguishmentOfDebtShares] 406,250      
Issuance of common stock, ESPP 104 104
Stock Issued During Period, Shares, Employee Stock Ownership Plan 80,009      
Net loss (38,789) (38,789)
Issuance of common stock for conversion of debt 138 138
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments 7 8,401 8,408
Issuance of common stock, net of issuance costs $ 40 97,917 97,957
Stock Issued During Period, Shares, Conversion of Convertible Securities 7,431,125      
Warrants exercised for cash $ 7 8,401 8,408
Issuance of common stock for conversion of debt, shares 69,065      
Stock Issued During Period, Shares, New Issues 39,788,554      
Ending balance, value at Sep. 30, 2021 $ 102 186,761 (113,951) 72,912
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2021 102,354,699      
Beginning balance, value at Dec. 31, 2020 $ 54 77,680 (75,162) 2,572
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2020 54,535,891      
Ending balance, value at Dec. 31, 2021 $ 105 198,428 (141,210) $ 57,323
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2021 105,500,445     105,500,445
Beginning balance, value at Jun. 30, 2021 $ 102 185,732 (103,136) $ 82,698
Common Stock, Shares, Outstanding, Beginning Balance at Jun. 30, 2021 102,271,544      
Stock-based compensation expense 857 857
Issuance of common stock, ESPP 74 74
Stock Issued During Period, Shares, Employee Stock Ownership Plan 39,491      
Net loss (10,815) (10,815)
Issuance of common stock for conversion of debt 98 98
Issuance of common stock for conversion of debt, shares 43,664      
Ending balance, value at Sep. 30, 2021 $ 102 186,761 (113,951) 72,912
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2021 102,354,699      
Beginning balance, value at Dec. 31, 2021 $ 105 198,428 (141,210) $ 57,323
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2021 105,500,445     105,500,445
Stock-based compensation expense 4,166 $ 4,166
Issuance of common stock, options exercised 8 $ 8
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period 6,250     6,250
Issuance of common stock for prepaid services 167 $ 167
[custom:IssuanceOfCommonStockForPrepaidServicesShares] 200,000      
Issuance of common stock for license acquired $ 1 840 841
[custom:IssuanceOfCommonStockInAtthemarketOfferingSharesNetOfIssuanceCosts] 350,000      
[custom:Issuanceofcommonstockforlicenseacquiredshares] 1,000,000      
Issuance of common stock in at-the-market offering, net of issuance costs $ 1 151 1
Issuance of common stock, ESPP 99 99
Stock Issued During Period, Shares, Employee Stock Ownership Plan 111,561      
Net loss (54,877) (54,877)
Ending balance, value at Sep. 30, 2022 $ 107 203,859 (196,087) $ 7,879
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2022 107,168,256     107,168,256
Beginning balance, value at Jun. 30, 2022 $ 106 202 (176,483) $ 26,227
Common Stock, Shares, Outstanding, Beginning Balance at Jun. 30, 2022 106,190,773      
Stock-based compensation expense 973 973
Issuance of common stock for prepaid services 107 107
[custom:IssuanceOfCommonStockForPrepaidServicesShares] 100,000      
Issuance of common stock for license acquired
[custom:IssuanceOfCommonStockInAtthemarketOfferingSharesNetOfIssuanceCosts] 350,000      
[custom:Issuanceofcommonstockforlicenseacquiredshares] 500,000      
Issuance of common stock in at-the-market offering, net of issuance costs $ 1 151 1
Issuance of common stock, ESPP 24 24
Stock Issued During Period, Shares, Employee Stock Ownership Plan 27,483      
Net loss (19,604) (19,604)
Ending balance, value at Sep. 30, 2022 $ 107 $ 203,859 $ (196,087) $ 7,879
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2022 107,168,256     107,168,256
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities    
Net loss $ (54,877) $ (38,789)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation expense 4,166 2,599
Change in fair value of warrant liability (192) 750
Change in fair value of convertible notes payable 2,477
Research and development expense - license amendment 841
Gain on forgiveness of note payable (147)
Net loss on extinguishment of convertible debt 2,387
Amortization of debt discount 1,582
Changes in operating assets and liabilities    
Prepaid expenses and other current assets (5,103) (2,230)
Accounts payable 4,259 1,514
Accrued expenses 289 1,803
Derivative liability (1,174)
Licenses payable 800 (125)
Net cash used in operating activities (48,514) (30,656)
Cash flows (used in) provided by financing activities    
Payment of convertible note (13,551)
Proceeds from issuance of common stock, net of issuance costs 97,957
Proceeds from exercise of warrants 7,252
Proceeds from issuance of common stock in at-the-market offering 457
Payment of at-the-market offering issuance costs (273)
Proceeds from exercise of options 8 65
Proceeds from sales of common stock under ESPP 99 104
Net cash provided by financing activities 291 91,827
Net (decrease) increase in cash (48,223) 61,171
Cash, beginning of period 78,734 15,662
Cash, end of period 30,511 76,833
Supplemental disclosure of cash flow information:    
Cash paid for interest 11 10
Cash paid for income taxes
Non-cash investing and financing activities:    
Reclass of warrant liabilities related to Series A warrants exercised for cash 1,155
Right-of-use assets obtained in exchange for operating lease liabilities 75
Issuance of common stock for convertible notes 69
Issuance of common stock for license payable 840
At-the-market offering issuance costs, accrued but not paid 32
Issuance of common stock for settlement of debt 1,377
Extinguishment of beneficial conversion feature $ 1,519
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
1. Organization and Description of Business
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
1. Organization and Description of Business

1. Organization and Description of Business

 

Seelos Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address significant unmet needs in Central Nervous System (“CNS”) disorders and other rare disorders. The Company’s lead programs are SLS-002 for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder (“ASIB in MDD”) and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (“ALS”) and Spinocerebellar Ataxia (“SCA”). SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which is being considered. Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms of action, including: SLS-004, SLS-006, SLS-007 for the potential treatment of Parkinson’s Disease (“PD”) and SLS-008, which is being developed for the potential treatment of an undisclosed indication, but may also be targeted at chronic inflammation in asthma and orphan indications such as pediatric esophagitis.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
2. Liquidity and Going Concern
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
2. Liquidity and Going Concern

2. Liquidity and Going Concern

 

The accompanying condensed consolidated unaudited financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.

 

The Company has generated limited revenues, has incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of September 30, 2022, the Company had $30.5 million in cash and an accumulated deficit of $196.1 million. The Company has historically funded its operations through the issuance of convertible notes (see Note 9), the sale of common stock (see Note 6) and exercises of warrants (see Note 10).

 

On May 12, 2022, the Company entered into an Open Market Sale AgreementSM (the “Sale Agreement”) with Jefferies LLC, as sales agent (the “Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through the Agent (the “Offering”). The Company also filed a prospectus supplement, dated May 12, 2022, with the Securities and Exchange Commission (the “SEC”) in connection with the Offering (the “Prospectus Supplement”) under the Company’s existing shelf Registration Statement on Form S-3, as amended (File No. 333-251356), which became effective on December 23, 2020 (the “Registration Statement”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares having an aggregate offering price of up to $50.0 million. Under the terms of the Sale Agreement, the Agent is entitled to a commission at a fixed rate of 3.0% of the gross proceeds from each sale of shares under the Sale Agreement. The Company also reimburses the Agent for certain expenses incurred in connection with the Sale Agreement, and agreed to provide indemnification and contribution to the Agent with respect to certain liabilities, including liabilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. During the three months ended September 30, 2022, the Company sold an aggregate of 350,000 shares under the Sale Agreement, receiving net proceeds of $0.5 million. The Company currently intends to use any net proceeds from the Offering for general corporate purposes and to advance the development of its product candidates.

 

On April 22, 2022, the Company received written notice from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for its common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until October 19, 2022, to regain compliance. On September 1, 2022, the Company received a letter from Nasdaq notifying the Company that it regained full compliance with Nasdaq Listing Rule 5550(a)(2) after the closing bid price of the Company’s common stock had been at $1.00 per share or greater for ten consecutive business days, from August 18, 2022 through August 31, 2022.

 

On May 24, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 22,258,066 shares of its common stock, at a price to the public of $3.10 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net proceeds to the Company from the offering were approximately $64.5 million, after deducting underwriting discounts and commissions and other offering costs. The Company used $7.3 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.

 

On January 28, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 17,530,488 shares of its common stock, at a price to the public of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to the Company from the offering were approximately $33.5 million, after deducting underwriting discounts, commissions and other offering costs. The Company used $3.8 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.

 

Pursuant to the Registration Statement, the Company may offer from time to time any combination of debt securities, common and preferred stock and warrants. As of September 30, 2022, the Company had approximately $94.6 million available under the Registration Statement (inclusive of the $49.5 million that remained allocated to sales of shares pursuant to the Sale Agreement as of such date). The Company also has the ability to raise funds through other means, such as through the filing of a registration statement on Form S-1 or in private placements. The rules and regulations of the SEC or any other regulatory agencies may restrict the Company’s ability to conduct certain types of financing activities or may affect the timing of and amounts it can raise by undertaking such activities.

 

The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and the Company’s current plans (including the ongoing clinical programs for SLS-002, SLS-005, and other product candidates), which are subject to change, management believes that the Company’s existing cash and cash equivalents as of September 30, 2022 are not sufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q.

 

The Company’s future liquidity and capital funding requirements will depend on numerous factors, including:

 

•its ability to raise additional funds to finance its operations;
•its ability to maintain compliance with the listing requirements of the Nasdaq Capital Market;
•the outcome, costs and timing of clinical trial results for the Company’s current or future product candidates;
•potential litigation expenses;
•the emergence and effect of competing or complementary products or product candidates;
•its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;
•its ability to retain its current employees and the need and ability to hire additional management and scientific and medical personnel;
•the terms and timing of any collaborative, licensing or other arrangements that it has or may establish;
•the trading price of its common stock; and
•its ability to increase the number of authorized shares outstanding to facilitate future financing events.

 

The Company may raise substantial additional funds, and if it does so, it may do so through one or more of the following: issuance of additional debt or equity and/or the completion of a licensing or other commercial transaction for one or more of the Company’s product candidates. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company’s business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders.

 

 

 

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
3. Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
3. Significant Accounting Policies

3. Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K (the “Annual Report”) filed with the SEC on March 4, 2022. The accompanying financial statements have been prepared by the Company in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows. The December 31, 2021 condensed consolidated balance sheet was derived from audited financial statements, but it does not include all U.S. GAAP disclosures. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions.

 

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

 

Fair Value Measurements

 

The Company follows the accounting guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), for its fair value measurements of financial assets and liabilities measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

 

The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:

 

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.

 

Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. 

 

 

 

Fair Value Option

 

As permitted under FASB ASC Topic 825, Financial Instruments (“ASC 825”), the Company elected the fair value option to account for its November 2021 and December 2021 convertible notes (collectively, the “2021 Convertible Notes”). In accordance with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed as incurred and were not deferred.

 

Stock-based Compensation

 

The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role at the Company.

 

Performance share awards are initially valued based on the Company’s closing stock price on the date of grant. The number of performance share awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period. Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense is reversed.

 

Income (Loss) Per Common Share

 

Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, performance-based restricted stock unit awards and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.

 

The following potentially dilutive securities outstanding for the three and nine months ended September 30, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):

 

Three and Nine Months
Ended September 30,
2022 2021
Outstanding stock options 10,400 7,295
Restricted stock units   - 2,400
Outstanding warrants 2,545 2,635
Convertible debt     3,704     -
16,649 12,330

 

 

Amounts in the table reflect the common stock equivalents of the noted instruments.

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06: Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This standard simplifies the accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06.

 

Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for the Company beginning after January 1, 2024, with early adoption permitted, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related disclosures. 

 

In June 2022, the FASB issued ASU No. 2022-03: ASC Subtopic 820 - Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU 2022-03 applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in ASU 2022-03 are effective for the Company for fiscal years beginning after December 15, 2023, and the interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is evaluating the impact of this pronouncement on its consolidated financial statements and related disclosures. 

 

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
4. Fair Value Measurement
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
4. Fair Value Measurement

4. Fair Value Measurement

 

The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values. There were no transfers between fair value measurement levels during the three and nine months ended September 30, 2022.

 

The Company’s financial assets and liabilities measured at fair value at September 30, 2022 and December 31, 2021 are as follows (in thousands):

 

 

Fair Value Measurements
as of September 30, 2022
(Level 1) (Level 2) (Level 3) Total
Assets:
Cash $ 30,511 $ - $ - $ 30,511
Liabilities:
Convertible notes payable, at fair value   $ -   $ -   $ 21,397   $ 21,397
Warrant liabilities, at fair value - - 232 232
    $ -   $ - $ 21,629   $ 21,629

  

Fair Value Measurements
as of December 31, 2021
(Level 1) (Level 2) (Level 3) Total
Assets:
Cash $ 78,734 $ - $ - $ 78,734
Liabilities:
Convertible notes payable, at fair value   $ -   $ -   $ 18,920   $ 18,920
Derivative liability, at fair value     1,174     -     -     1,174
Warrant liabilities, at fair value - - 424 424
    $ 1,174   $ - $ 19,344   $ 20,518

 

 

 

The fair value of the Company’s money market funds is based on quoted active market prices for the funds and is determined using the market approach.

 

The Company measures the 2021 Convertible Notes and warrant liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level 3 measurement within the fair value hierarchy. These valuations use assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an on-going basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value of the convertible notes payable and warrant liabilities related to updated assumptions and estimates are recognized within the Condensed Consolidated Statements of Operations and Comprehensive Loss.

The fair value of the 2021 Convertible Notes and warrant liabilities may change significantly as additional data is obtained, impacting the Company’s assumptions regarding probabilities of outcomes used to estimate the fair value of the liabilities. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s results of operations in future periods. 

 

Derivative Liability

 

The derivative liability represented the fair value of the “Shortfall Amount” provision provided for in the license agreement with iX Biopharma Europe Limited.

 

At issuance, the fair value of the embedded derivative was estimated by using a Monte Carlo simulation model. As of December 31, 2021, the Company determined it was probable it would settle the Shortfall Amount in cash and estimated the fair value based on a probability weighted market approach. The Company paid the Shortfall Amount of $1.2 million in cash in January 2022.

 

2021 Convertible Notes

 

The 2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair value of the 2021 Convertible Notes during the nine months ended September 30, 2022 and the year ended December 31, 2021:

 

      Nine Months Ended     Year Ended
      September 30, 2022     December 31, 2021
Risk-free interest rate     4.28%     0.90% - 0.95%
Volatility     105%     113% - 114%
Dividend yield     -%     -%
Contractual term (years)     2.2     3.0
Stock price   $ 1.03   $ 1.74 - 1.95

 

 

Warrant Liabilities

 

The common stock warrant liabilities were recorded at fair value using the Black-Scholes option pricing model.  

The following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option pricing model for the nine months ended September 30, 2022 and 2021:

 

Summary of Fair Value Measurements Warrant Valuation Assumptions

 

             
Nine Months Ended September 30,
2022     2021
Risk-free interest rate 4.08%     0.36%
Volatility 80.30%     110.19%

Dividend yield

 -%     -%
Expected term (years) 1.32     2.32
Weighted-average fair value $ 0.77   $ 2.17

 

 

The following table is a reconciliation for the common stock warrant liabilities and convertible notes measured at fair value using Level 3 unobservable inputs (in thousands): 

 

Schedule of Fair Value Level 3 Reconciliation

 

 

                   
      Warrant     Derivative     Convertible notes,
      liabilities     liability     at fair value
Balance as of December 31, 2020   $ 1,062   $       -   $       -
     Warrant liability reclassified to stockholders' equity     (1,155)           -           -
     Issuance of convertible notes, at fair value           -           -                            19,150
     Issuance of derivative liability           -       805           -
     Change in fair value measurement of derivative liability           -       369           -
     Change in fair value measurement of convertible notes           -           -     (230)
     Change in fair value measurement of warrant liability     517           -           -
Balance as of December 31, 2021   $ 424   $  1,174   $  18,920
     Settlement of derivative liability            -      (1,174)         -
     Change in fair value measurement of convertible notes           -           -     2,477
     Change in fair value measurement of warrant liability     (192)           -           -
Balance as of September 30, 2022   $ 232   $  -   $  21,397

 

For the three and nine months ended September 30, 2022 and the year ended December 31, 2021, the changes in fair value of the convertible notes, derivative liability and warrant liability primarily resulted from the volatility of the Company’s common stock. 

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
5. Prepaid Expenses and Other Current Assets
 9 Months Ended
Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
5. Prepaid Expenses and Other Current Assets

5. Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets are comprised of the following (in thousands):

 

 

             
      September 30,     December 31,
      2022     2021
Prepaid insurance   $ 329   $ 59
Prepaid clinical costs     9,254     4,481
Other     414     187
Prepaid expenses and other current assets   $ 9,997   $ 4,727

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
6. Common Stock Offerings
 9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
6. Common Stock Offerings

6. Common Stock Offerings

 

Public Offerings

 

On May 24, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 22,258,066 shares of its common stock, at a price to the public of $3.10 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net proceeds to the Company from the offering were approximately $64.5 million, after deducting underwriting discounts, commissions and other offering expenses. The Company used $7.3 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes. 

 

On January 28, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold 17,530,488 shares of its common stock, at a price to the public of $2.05 per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to the Company from the offering were approximately $33.5 million, after deducting underwriting discounts, commissions and other offering expenses. The Company used $3.8 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes. 

 

 

Stock Purchase Agreement with iX Biopharma Europe Limited

 

On November 24, 2021, the Company entered in an exclusive license agreement and stock purchase agreement (the “iXBEL Stock Purchase Agreement”) with iX Biopharma Europe Limited (“iXBEL”). As consideration for the license under the license agreement, the Company paid iXBEL an upfront fee of $9.0 million, comprised of $3.5 million in cash and 2,570,266 restricted shares of the Company’s common stock. Pursuant to the iXBEL Stock Purchase Agreement, the Company agreed to reimburse iXBEL for the difference in value (the “Shortfall Amount”) in the event the aggregate value of the 2,570,266 shares of the Company’s common stock at the time of registration and issuance was less than $5.5 million. The initial fair value of this Shortfall Amount was $0.8 million and in January 2022, the Company settled the Shortfall Amount by the payment of $1.2 million in cash to iXBEL. The change in fair value of the Shortfall Amount is included in Change in fair value of derivative liability on the Condensed Consolidated Statement of Operations and Comprehensive Loss (see Note 4).

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
7. License Agreements
 9 Months Ended
Sep. 30, 2022
Research and Development [Abstract]  
7. License Agreements

7. License Agreements

 

Specific information pertaining to each of the Company’s significant license agreements is discussed in its audited financial statements included in the Annual Report for the years ended December 31, 2021 and 2020, including their nature and purpose, the significant rights and obligations of the parties, and specific accounting policy elections. The following represents updates for the nine months ended September 30, 2022, if applicable, to the Company’s significant license agreements:

 

Acquisition of Assets from Phoenixus AG f/k/a Vyera Pharmaceuticals, AG and Turing Pharmaceuticals AG (“Vyera”)

 

On April 8, 2022, Seelos Corporation (“STI”), a wholly-owned subsidiary of the Company, and Vyera, entered into an amendment (the “Amendment”) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018 (as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the “Vyera Purchase Agreement”). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product candidate currently referred to as SLS-002 (intranasal ketamine) (the “Vyera Assets”) and agreed, among other things, to make certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the “Milestone and Royalty Payment Obligations”) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received by the Company as an upfront payment in such sale (the “Change of Control Payment Obligation”).

 

Pursuant to the Vyera Purchase Agreement, as amended by the Amendment, STI agreed to (i) make a cash payment to Vyera in the aggregate amount of $4.0 million on or before April 8, 2022 (the “Cash Payment”); (ii) issue to Vyera on or before April 11, 2022 500,000 shares of the Company’s common stock (the “Initial Shares”); (iii) issue to Vyera on or before July 11, 2022 an additional 500,000 shares of the Company’s common stock (as adjusted for stock splits, stock dividends, combinations, recapitalizations and the like) (the “July 2022 Shares”); and (iv) issue to Vyera on or before January 11, 2023 an additional number of shares of the Company’s common stock equal to $1.0 million divided by the volume weighted average closing price of the Company’s common stock for the ten consecutive trading days ending on the fifth trading day prior to the applicable date of issuance of the shares of the Company’s common stock (the “January 2023 Shares”, and together with the Cash Payment, the Initial Shares and the July 2022 Shares, the “Final Payments”). In consideration for the Final Payments, all of STI’s contingent payment obligations under the Vyera Purchase Agreement, including the Milestone and Royalty Payment Obligations and the Change of Control Payment Obligation, as well as all commercialization covenants of STI under the Vyera Purchase Agreement, will terminate in full upon the date that all of the Final Payments have been made.

 

The Company paid the $4.0 million Cash Payment and issued the 500,000 Initial Shares to Vyera in April 2022. The Company issued the 500,000 July 2022 Shares to Vyera in July 2022. The Company recognized $5.8 million in research and development expense during the three months ended June 30, 2022 related to the Amendment, which consisted of the initial cash payment of $4.0 million and $0.8 million for the Initial Shares and the July 2022 Shares, which were measured at their grant-date fair value. The Company also recognized a liability of $1.0 million related to the January 2023 Shares within accrued licenses payable.

 

Acquisition of License from Stuart Weg, MD

 

On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $0.2 million on January 2, 2022. The Company paid the required $0.1 million on January 2, 2020, $0.125 million on January 2, 2021 and $0.2 million on January 2, 2022.

 

 

The remaining potential regulatory and commercial milestones are not yet considered probable, and no other milestone payments have been accrued at September 30, 2022.

 

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
8. Accrued Expenses
 9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
8. Accrued Expenses

8. Accrued Expenses

Accrued expenses are comprised of the following (in thousands):

Schedule of Accrued Liabilities

             
      September 30,     December 31,
      2022     2021
Professional fees   $ 239    $ 181 
Personnel related     955      1,303 
Outside research and development services     2,767      2,219 
Insurance     84      - 
Other     3      25 
     Accrued expenses, net   $ 4,048    $ 3,728 

 

 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
9. Debt
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
9. Debt

9. Debt

 

Convertible Notes

 

November 2021 and December 2021 Convertible Notes and Private Placement

 

On November 23, 2021, the Company entered into a Securities Purchase Agreement (the “2021 Lind Securities Purchase Agreement”) with Lind Global Asset Management V, LLC (“Lind V”) pursuant to which, among other things, on November 23, 2021 (the “Closing Date”), the Company issued and sold to Lind V, in a private placement transaction (the “Private Placement”), in exchange for the payment by Lind V of $20.0 million, (i) a convertible promissory note (the “2021 Note”) in an aggregate principal amount of $22.0 million (the “Principal Amount”), which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate of 5% per annum, and mature on November 23, 2024 (the “Maturity Date”), and (ii) 534,759 shares of Company common stock. 

 

At the first anniversary of the Closing Date, the Company shall have the option, at its sole discretion and subject to certain stock price and other conditions, to issue to Lind V a convertible promissory note (the “Second Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible promissory note (the “Third Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S. Food & Drug Administration for either SLS-002 or SLS-005, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible promissory note (the “Fourth Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note.

 

At any time following August 23, 2022, from time to time and before the Maturity Date, Lind V shall have the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the “Conversion Price”). At any time prior August 23, 2022, the Company had the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time during such period), up to an aggregate of $14.7 million of the outstanding Principal Amount of the 2021 Note with no penalty. The Company did not prepay any amounts of the 2021 Note prior to August 23, 2022 and has the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price.

 

Subject to certain exceptions, the Company will be required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2021 Notes, unless waived by Lind V in advance.

 

 

 

Beginning on November 23, 2022, the 2021 Note will amortize in twenty-four monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments shall be payable, at the Company’s sole option, in cash, shares of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022, the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90% of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note, on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the Company’s assets and properties.

 

On December 2, 2021, the Company entered into two separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021 Note.

 

During the year ended December 31, 2021, the Company received aggregate gross proceeds of $20.2 million from the convertible notes offerings. The Company elected to account for these notes under the fair value option. At time of issuance, the Company recorded a liability of $19.2 million, which was determined to be the fair value at time of issuance. As of December 31, 2021 and September 30, 2022, the Company recognized a total convertible note liability of $18.9 million and $21.4 million, respectively. During the three and nine months ended September 30, 2022, the Company recognized a $2.1 million and $2.5 million loss on change in fair value of convertible notes, respectively. 

 

As of September 30, 2022, the principal contractual balance of the convertible notes totaled $22.2 million.

  

December 2020 Convertible Note and Private Placement

 

On December 11, 2020, the Company entered into a Securities Purchase Agreement (the “2020 Lind Securities Purchase Agreement”) with Lind Global Asset Management II, LLC (the “Investor”) pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the “2020 Note”) in an aggregate principal amount of $12,000,000 (the “Principal Amount”), which did not bear interest and was to mature on December 11, 2022 (the “Maturity Date”), and (2) 975,000 shares of the Company’s common stock. At any time following June 11, 2021, and from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020 Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of 406,250 additional shares of its common stock (the “Lind Shares”) and to pay the Investor the remaining principal amount of $790,804 (the “Final Payment”) in full satisfaction of the Company’s remaining obligations to the Investor under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.

 

 

On December 17, 2020, the Company entered into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2020 Lind Securities Purchase Agreement (the “December 17 SPAs”), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1) convertible promissory notes (the “December 17 Notes”) in an aggregate principal amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with an accredited investor on substantially the same terms as the 2020 Lind Securities Purchase Agreement (the “December 18 SPA” and, together with the December 17 SPAs, the “Subsequent Securities Purchase Agreements”), pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the “December 18 Note” and, together with the December 17 Notes, the “Subsequent Notes”), and (2) 26,263 shares of the Company’s common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the 2020 Lind Securities Purchase Agreement, and the Subsequent Notes had substantially the same terms as the 2020 Note. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the “December 18 Note Holder”) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December 18 Note Holder agreed to return to the Company $42,777 in cash (the “Repayment”) previously paid by the Company to the December 18 Note Holder as a payment against the Company’s obligations under the December 18 Note, and (ii) the Company agreed to issue to the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the “December 18 Note Shares”) in full satisfaction of the Company’s remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder paid the Company the Repayment and the Company issued the December 18 Note Shares, and the December 18 SPA and the December 18 Note terminated, effective July 7, 2021.

 

The Company received aggregate net proceeds of $10.9 million from the convertible notes offering, net of $0.5 million of issuance costs. The total gross proceeds were allocated to the convertible notes and common stock issued under the agreements based on their relative fair values. Due to the principal payments made during the year, the Company remeasured the beneficial conversion feature discount at each payment date and recorded a loss on extinguishment of debt of approximately $1.0 million during the year ended December 31, 2021 as well as a reduction in additional paid-in capital of $1.5 million as of December 31, 2021.

 

During the year ended December 31, 2021, the Company paid approximately $13.6 million in principal payments on the outstanding convertible notes and issued an aggregate of 475,315 shares of its common stock upon conversion of the convertible notes, and none of the 2020 convertible notes remain outstanding as of December 31, 2021.

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
10. Stockholders’ Equity
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
10. Stockholders’ Equity

10. Stockholders’ Equity

 

Preferred Stock

 

The Company is authorized to issue 10,000,000 shares of preferred stock, par value $0.001. No shares of preferred stock were outstanding as of September 30, 2022 or December 31, 2021.

 

Common Stock

 

The Company has authorized 240,000,000 shares of common stock as of September 30, 2022 and December 31, 2021. Each share of common stock is entitled to one voting right. Common stock owners are entitled to dividends when funds are legally available and declared by the Board of Directors.

 

Warrants

 

September 2020 Warrants

 

On September 4, 2020, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in a registered direct offering and issued warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the “September 2020 Warrants”). The September 2020 Warrants are exercisable for 6,648,750 shares of common stock at an exercise price per share equal to $0.84. The September 2020 Warrants became exercisable beginning on March 9, 2021 and will expire on March 9, 2026.

 

 

 

During the nine months ended September 30, 2022 and 2021, the September 2020 Warrants were exercised for 0 and 5.6 million shares of common stock, respectively, for approximately $0 and $4.7 million, respectively. As of September 30, 2022, the September 2020 Warrants exercisable for 1.0 million shares of common stock remain outstanding at an exercise price of $0.84 per share.

 

August 2019 Warrants

 

On August 23, 2019, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 4,475,000 shares of common stock in a registered direct offering and issued warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the “August 2019 Warrants”). The August 2019 Warrants were initially exercisable for 2,237,500 shares of common stock at an exercise price per share equal to $1.78. The August 2019 Warrants became exercisable beginning on February 27, 2020 and will expire on August 28, 2023.

 

During the nine months ended September 30, 2022 and 2021, the August 2019 Warrants for 0 and 1.3 million shares of common stock, respectively, were exercised for approximately $0 and $2.4 million, respectively. As of September 30, 2022, the August 2019 Warrants exercisable for 900,000 shares of common stock remain outstanding at an exercise price of $1.78 per share.

 

Series A Warrants

 

On January 24, 2019, STI and the Company closed a private placement with certain accredited investors pursuant to which, among other things, the Company issued warrants representing the right to acquire 1,463,519 shares of common stock (the “Series A Warrants”). The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per share) occurred during the three months ended September 30, 2020 as a result of the announcement of the registered direct offering of 8,865,000 shares of common stock in September 2020. The Series A Warrants were immediately exercisable upon issuance and will expire on January 31, 2024.

 

During the nine months ended September 30, 2022 and 2021, the Series A Warrants for 0 and 0.5 million shares of common stock, respectively, were exercised for approximately $0 and $0.1 million, respectively. As of September 30, 2022, the Series A Warrants exercisable for 0.3 million shares of common stock remain outstanding at an exercise price of $0.2957 per share.

 

 

A summary of warrant activity during the nine months ended September 30, 2022 is as follows (share amounts in thousands):

 

 

Weighted-
Weighted- Average
Average Remaining
Exercise Contractual Life
Warrants Price (in years)
Outstanding as of December 31, 2021 2,635 $ 4.29 2.4
Issued - $ -
Exercised - $ -
Cancelled (90) $ 47.06
Outstanding as of September 30, 2022 2,545 $ 2.78 1.8
Exercisable as of September 30, 2022 2,545 $ 2.78 1.8

 

 

The Series A Warrants were recognized as a liability at their fair value upon issuance. The warrant liability is remeasured to the then fair value prior to their exercise or at period end for warrants that are unexercised and the gain or loss recognized in earnings during the period.

 

 

 

 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
11. Stock-based Compensation
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
11. Stock-based Compensation

11. Stock-based Compensation

 

The Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the “2012 Plan”), which provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of common stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a number of shares of common stock set by the Company’s board of directors on or prior to each such January 1. On January 1, 2022, in accordance with the foregoing, an aggregate of 4,713,637 shares of common stock were added to shares authorized for issuance under the 2012 Plan. As of September 30, 2022, an aggregate of 15,817,818 shares of common stock were authorized under the 2012 Plan, of which 5.4 million shares of common stock were available for future grants. No further awards may be issued under the Seelos Therapeutics, Inc. 2016 Equity Incentive Plan.

 

On May 15, 2020, the Company's stockholders approved the Company's 2020 Employee Stock Purchase Plan (the "ESPP"), whereby qualified employees are allowed to purchase limited amounts of the Company's common stock at the lesser of 85% of the market price at the beginning or end of the offering period. The stockholders have authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding December 31, and (ii) a number of shares of common stock set by the Company's Board of Directors or the Compensation Committee of the Board of Directors (the "Compensation Committee") of the Company on or prior to each such January 1. On January 1, 2022, the Company added 1,055,004 shares for purchase by employees under the ESPP. During the nine months ended September 30, 2022, the Company sold 111,561 shares of common stock under the ESPP. The compensation costs are calculated as the fair value of the 15% discount from market price and were approximately $33,000 for the nine months ended September 30, 2022.

 

On July 28, 2019, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of the Company adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the “2019 Inducement Plan”), which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is 1,000,000 shares of the Company’s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.

 

Stock options

 

During the nine months ended September 30, 2022, the Company granted 660,605 incentive stock options and 2,299,395 non-qualified stock options to employees with a weighted average exercise price per share of $1.45 and a 10-year term, subject to the terms and conditions of the 2012 Plan above. The stock options are subject to time vesting requirements. The stock options granted to employees vest 25% on the first anniversary of the grant and monthly thereafter over the next three years.

 

During the nine months ended September 30, 2022, the Company also granted 140,000 non-qualified stock options to non-employee directors with a weighted average exercise price per share of $1.56 and a 10-year term, subject to the terms and conditions of the 2012 Plan above. The stock options granted to non-employee directors vest monthly over the 12 months following the grant.

 

 

The fair value of stock option grants are estimated on the date of grant using the Black-Scholes option-pricing model. The Company was historically a private company and lacked sufficient company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on a weighted average blend of the historical volatility of a publicly traded set of peer companies, as well as its own historical volatility. Additionally, due to an insufficient history with respect to stock option activity and post-vesting cancellations, the expected term assumption for employee grants is based on a permitted simplified method, which is based on the vesting period and contractual term for each tranche of awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

 

During the nine months ended September 30, 2022, 6,250 stock options were exercised and no options were forfeited.

 

The following assumptions were used in determining the fair value of the stock options granted during the nine months ended September 30, 2022 and 2021:

 

 

Nine Months Ended
September 30, 2022     September 30, 2021
Risk-free interest rate 1.6% - 3.4%     0.5% - 1.2%
Volatility 111%-113%     118%-125%
Dividend yield -%     -%
Expected term (years) 5 - 6     5 - 6
Weighted-average fair value $ 1.22   $ 3.52

 

 

A summary of stock option activity during the nine months ended September 30, 2022 is as follows (share amounts in thousands):

 

Weighted-
Weighted- Average Total
Average Remaining Aggregate
Stock Exercise Contractual Intrinsic
Options Price Life (in years) Value
Outstanding as of December 31, 2021 7,306 $ 2.60
Granted 3,100 1.45
Exercised (6) 1.06
Cancelled - -
Outstanding as of September 30, 2022 10,400 $ 2.26 8.3 $ 11
Vested and expected to vest as of September 30, 2022 10,400 $ 2.26 8.3 $ 11
Exercisable as of September 30, 2022 4,053 $ 2.78 7.7 $ 9

 

The intrinsic value of options exercised during the nine months ended September 30, 2022 and 2021 was $0.1 million and $0.2 million, respectively. As of September 30, 2022, unrecognized stock-option compensation expense of $8.4 million is expected to be realized over a weighted-average period of 2.3 years. 

 

Performance Stock Award

 

During the year ended December 31, 2021, the Company’s Board of Directors awarded a performance stock unit award to the Company’s Chief Executive Officer for 2,400,000 shares of common stock, with a grant date fair value of $4.31 per unit. Vesting of this award was subject to the Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had been satisfied. The Company recognized stock-based compensation related to this award of $4.9 million during the fourth quarter of 2021, which was recorded in general and administrative expense. During the nine months ended September 30, 2022, the Company and its Chief Executive Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation expense of the three achieved milestones of $1.3 million. The two remaining milestones were not deemed probable of achievement at the time of cancellation, and no compensation cost related to these milestones was recognized.

 

 

 

The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company’s condensed consolidated statements of operations (in thousands):

 

    Three Months Ended Nine Months Ended
    September 30, September 30,
    2022     2021 2022 2021
Research and development $ 261 $ 193 $ 721 $ 551
General and administrative 712 664 3,445 2,048
$ 973 $ 857 $ 4,166 $ 2,599

 

 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
12. Commitments and Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
12. Commitments and Contingencies

12. Commitments and Contingencies

 

Leases

 

In March 2019, the Company entered into a nine-month office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company was notified that the counterparty’s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is in breach of this rental agreement and therefore, the Company has no further obligations thereunder.

 

In March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New York, NY, which was due to expire in September 2022. The rental agreement contains a base rent of approximately $4,000 per month. This agreement included one or more renewal options. At September 30, 2022, the Company’s right-of-use assets and lease liability for operating leases was $0. In October 2022, the Company entered into a new eighteen-month office space rental agreement for its existing space, which provides for a base rent starting at approximately $4,000 per month subject to periodic increases.

Upon the commencement of the 300 Park Avenue, New York, NY office space in March 2021, in exchange for the new operating lease liability, the Company recognized a right-of-use asset of $74,000. As of September 30, 2022, the weighted-average remaining lease term of the operating lease was 0 years, and the weighted-average discount rate was 8.0%.

As of September 30, 2022, there were no future minimum lease payments for the Company’s operating leases with a non-cancelable term of more than one year as the current lease was expiring, while the Company’s new lease was not effective until October 2022.

For each of the nine months ended September 30, 2022 and 2021, rent expense totaled $0.1 million.

 

Contractual Commitments

 

The Company has entered into long-term agreements with certain manufacturers and suppliers that require it to make contractual payment to these organizations. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and long-term commitments of cash.

 

Litigation

 

As of September 30, 2022, there was no material litigation against or involving the Company.

 

 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
3. Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K (the “Annual Report”) filed with the SEC on March 4, 2022. The accompanying financial statements have been prepared by the Company in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows. The December 31, 2021 condensed consolidated balance sheet was derived from audited financial statements, but it does not include all U.S. GAAP disclosures. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions.

 

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

 
Fair Value Measurements

Fair Value Measurements

 

The Company follows the accounting guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), for its fair value measurements of financial assets and liabilities measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

 

The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:

 

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.

 

Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. 

 

 

 

Fair Value Option

 

As permitted under FASB ASC Topic 825, Financial Instruments (“ASC 825”), the Company elected the fair value option to account for its November 2021 and December 2021 convertible notes (collectively, the “2021 Convertible Notes”). In accordance with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed as incurred and were not deferred.

 
Stock-based Compensation

Stock-based Compensation

 

The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role at the Company.

 

Performance share awards are initially valued based on the Company’s closing stock price on the date of grant. The number of performance share awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period. Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense is reversed.

 
Income (Loss) Per Common Share

Income (Loss) Per Common Share

 

Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, performance-based restricted stock unit awards and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.

 

The following potentially dilutive securities outstanding for the three and nine months ended September 30, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):

 

Three and Nine Months
Ended September 30,
2022 2021
Outstanding stock options 10,400 7,295
Restricted stock units   - 2,400
Outstanding warrants 2,545 2,635
Convertible debt     3,704     -
16,649 12,330

 

 

Amounts in the table reflect the common stock equivalents of the noted instruments.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06: Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This standard simplifies the accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06.

 

Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for the Company beginning after January 1, 2024, with early adoption permitted, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related disclosures. 

 

In June 2022, the FASB issued ASU No. 2022-03: ASC Subtopic 820 - Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU 2022-03 applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in ASU 2022-03 are effective for the Company for fiscal years beginning after December 15, 2023, and the interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is evaluating the impact of this pronouncement on its consolidated financial statements and related disclosures. 

 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
3. Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following potentially dilutive securities outstanding for the three and nine months ended September 30, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):

 

Three and Nine Months
Ended September 30,
2022 2021
Outstanding stock options 10,400 7,295
Restricted stock units   - 2,400
Outstanding warrants 2,545 2,635
Convertible debt     3,704     -
16,649 12,330
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
4. Fair Value Measurement (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Schedule of Fair Value Hierarchy Assets and Liabilities

The Company’s financial assets and liabilities measured at fair value at September 30, 2022 and December 31, 2021 are as follows (in thousands):

 

 

Fair Value Measurements
as of September 30, 2022
(Level 1) (Level 2) (Level 3) Total
Assets:
Cash $ 30,511 $ - $ - $ 30,511
Liabilities:
Convertible notes payable, at fair value   $ -   $ -   $ 21,397   $ 21,397
Warrant liabilities, at fair value - - 232 232
    $ -   $ - $ 21,629   $ 21,629

  

Fair Value Measurements
as of December 31, 2021
(Level 1) (Level 2) (Level 3) Total
Assets:
Cash $ 78,734 $ - $ - $ 78,734
Liabilities:
Convertible notes payable, at fair value   $ -   $ -   $ 18,920   $ 18,920
Derivative liability, at fair value     1,174     -     -     1,174
Warrant liabilities, at fair value - - 424 424
    $ 1,174   $ - $ 19,344   $ 20,518

 
Schedule of Fair Value Level 3 Reconciliation

The following table is a reconciliation for the common stock warrant liabilities and convertible notes measured at fair value using Level 3 unobservable inputs (in thousands): 

 

Schedule of Fair Value Level 3 Reconciliation

 

 

                   
      Warrant     Derivative     Convertible notes,
      liabilities     liability     at fair value
Balance as of December 31, 2020   $ 1,062   $       -   $       -
     Warrant liability reclassified to stockholders' equity     (1,155)           -           -
     Issuance of convertible notes, at fair value           -           -                            19,150
     Issuance of derivative liability           -       805           -
     Change in fair value measurement of derivative liability           -       369           -
     Change in fair value measurement of convertible notes           -           -     (230)
     Change in fair value measurement of warrant liability     517           -           -
Balance as of December 31, 2021   $ 424   $  1,174   $  18,920
     Settlement of derivative liability            -      (1,174)         -
     Change in fair value measurement of convertible notes           -           -     2,477
     Change in fair value measurement of warrant liability     (192)           -           -
Balance as of September 30, 2022   $ 232   $  -   $  21,397
Long-Term Debt [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Summary of Fair Value Measurements Warrant Valuation Assumptions

The 2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair value of the 2021 Convertible Notes during the nine months ended September 30, 2022 and the year ended December 31, 2021:

 

      Nine Months Ended     Year Ended
      September 30, 2022     December 31, 2021
Risk-free interest rate     4.28%     0.90% - 0.95%
Volatility     105%     113% - 114%
Dividend yield     -%     -%
Contractual term (years)     2.2     3.0
Stock price   $ 1.03   $ 1.74 - 1.95
Warrant [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Summary of Fair Value Measurements Warrant Valuation Assumptions

The following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option pricing model for the nine months ended September 30, 2022 and 2021:

 

Summary of Fair Value Measurements Warrant Valuation Assumptions

 

             
Nine Months Ended September 30,
2022     2021
Risk-free interest rate 4.08%     0.36%
Volatility 80.30%     110.19%

Dividend yield

 -%     -%
Expected term (years) 1.32     2.32
Weighted-average fair value $ 0.77   $ 2.17

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
5. Prepaid Expenses and Other Current Assets (Tables)
 9 Months Ended
Sep. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets are comprised of the following (in thousands):

 

 

             
      September 30,     December 31,
      2022     2021
Prepaid insurance   $ 329   $ 59
Prepaid clinical costs     9,254     4,481
Other     414     187
Prepaid expenses and other current assets   $ 9,997   $ 4,727
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
8. Accrued Expenses (Tables)
 9 Months Ended
Sep. 30, 2022
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities

Accrued expenses are comprised of the following (in thousands):

Schedule of Accrued Liabilities

             
      September 30,     December 31,
      2022     2021
Professional fees   $ 239    $ 181 
Personnel related     955      1,303 
Outside research and development services     2,767      2,219 
Insurance     84      - 
Other     3      25 
     Accrued expenses, net   $ 4,048    $ 3,728 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
10. Stockholders’ Equity (Tables)
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Summary of Warrant Activity

A summary of warrant activity during the nine months ended September 30, 2022 is as follows (share amounts in thousands):

 

 

Weighted-
Weighted- Average
Average Remaining
Exercise Contractual Life
Warrants Price (in years)
Outstanding as of December 31, 2021 2,635 $ 4.29 2.4
Issued - $ -
Exercised - $ -
Cancelled (90) $ 47.06
Outstanding as of September 30, 2022 2,545 $ 2.78 1.8
Exercisable as of September 30, 2022 2,545 $ 2.78 1.8
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
11. Stock-based Compensation (Tables)
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Valuation Assumptions for Stock Options

The following assumptions were used in determining the fair value of the stock options granted during the nine months ended September 30, 2022 and 2021:

 

 

Nine Months Ended
September 30, 2022     September 30, 2021
Risk-free interest rate 1.6% - 3.4%     0.5% - 1.2%
Volatility 111%-113%     118%-125%
Dividend yield -%     -%
Expected term (years) 5 - 6     5 - 6
Weighted-average fair value $ 1.22   $ 3.52

 
Summary of Stock Option Activity

A summary of stock option activity during the nine months ended September 30, 2022 is as follows (share amounts in thousands):

 

Weighted-
Weighted- Average Total
Average Remaining Aggregate
Stock Exercise Contractual Intrinsic
Options Price Life (in years) Value
Outstanding as of December 31, 2021 7,306 $ 2.60
Granted 3,100 1.45
Exercised (6) 1.06
Cancelled - -
Outstanding as of September 30, 2022 10,400 $ 2.26 8.3 $ 11
Vested and expected to vest as of September 30, 2022 10,400 $ 2.26 8.3 $ 11
Exercisable as of September 30, 2022 4,053 $ 2.78 7.7 $ 9
Schedule of Stock-Based Compensation Expense

The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company’s condensed consolidated statements of operations (in thousands):

 

    Three Months Ended Nine Months Ended
    September 30, September 30,
    2022     2021 2022 2021
Research and development $ 261 $ 193 $ 721 $ 551
General and administrative 712 664 3,445 2,048
$ 973 $ 857 $ 4,166 $ 2,599
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
2. Liquidity and Going Concern (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 31, 2022
May 31, 2021
Jan. 31, 2021
Sep. 30, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Apr. 22, 2022
May 24, 2021
Jan. 28, 2021
Cash       $ 30,511 $ 30,511   $ 78,734      
Accumlated deficit       196,087 $ 196,087   $ 141,210      
Cash received from stock sale           $ 97,957        
[custom:InitialNumberOfCalendarDaysToRegainCommonStockPriceCompliance]         180 days          
[custom:FinancingAvailableUnderFormS3ShelfRegistrationStatement-0]       $ 94,600 $ 94,600          
Maximum [Member]                    
Shares Issued, Price Per Share               $ 1.00    
Minimum [Member]                    
Shares Issued, Price Per Share       $ 1.00 $ 1.00          
May 122022 Sale Agreement [Member]                    
Aggregate future offering amount $ 50,000     $ 49,500            
Commission rate on gross proceeds of common stock sale 300.00%                  
Number of shares of common stock issued       350,000            
Cash received from stock sale       $ 500            
May 242021 [Member]                    
Number of shares of common stock issued   22,258,066         22,258,066      
Cash received from stock sale   $ 64,500         $ 64,500      
Shares Issued, Price Per Share                 $ 3.10  
Offering proceeds used to partially repay certain convertible promissory notes   $ 7,300         $ 7,300      
January 282021 [Member]                    
Number of shares of common stock issued     17,530,488       17,530,488      
Cash received from stock sale     $ 33,500       $ 33,500      
Shares Issued, Price Per Share                   $ 2.05
Offering proceeds used to partially repay certain convertible promissory notes     $ 3,800       $ 3,800      
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 16,649,000 12,330,000 16,649,000 12,330,000
Share-Based Payment Arrangement, Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 10,400,000 7,295,000 10,400,000 7,295,000
Restricted Stock Units (RSUs) [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2,400,000 2,400,000
Warrant [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2,545,000 2,635,000 2,545,000 2,635,000
Convertible Debt Securities [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3,704,000 3,704,000
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Schedule of Fair Value Hierarchy Assets and Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2020
Assets [Abstract]        
Cash $ 30,511 $ 78,734 $ 76,833 $ 15,662
Liabilities [Abstract]        
Warrant liabilities, at fair value 1,174    
Fair Value, Recurring [Member]        
Assets [Abstract]        
Cash 30,511 78,734    
Liabilities [Abstract]        
Warrant liabilities, at fair value 21,629 20,518    
Fair Value, Recurring [Member] | Long-Term Debt [Member]        
Liabilities [Abstract]        
Warrant liabilities, at fair value 21,397 18,920    
Fair Value, Recurring [Member] | Warrant [Member]        
Liabilities [Abstract]        
Warrant liabilities, at fair value 232 424    
Fair Value, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]        
Liabilities [Abstract]        
Warrant liabilities, at fair value   1,174    
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]        
Assets [Abstract]        
Cash 30,511 78,734    
Liabilities [Abstract]        
Warrant liabilities, at fair value 1,174    
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Long-Term Debt [Member]        
Liabilities [Abstract]        
Warrant liabilities, at fair value    
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Warrant [Member]        
Liabilities [Abstract]        
Warrant liabilities, at fair value    
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]        
Liabilities [Abstract]        
Warrant liabilities, at fair value   1,174    
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]        
Assets [Abstract]        
Cash    
Liabilities [Abstract]        
Warrant liabilities, at fair value    
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Long-Term Debt [Member]        
Liabilities [Abstract]        
Warrant liabilities, at fair value    
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Warrant [Member]        
Liabilities [Abstract]        
Warrant liabilities, at fair value    
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Derivative Financial Instruments, Liabilities [Member]        
Liabilities [Abstract]        
Warrant liabilities, at fair value      
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]        
Assets [Abstract]        
Cash    
Liabilities [Abstract]        
Warrant liabilities, at fair value 21,629 19,344    
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Long-Term Debt [Member]        
Liabilities [Abstract]        
Warrant liabilities, at fair value 21,397 18,920    
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Warrant [Member]        
Liabilities [Abstract]        
Warrant liabilities, at fair value $ 232 $ 424    
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details) - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Long-Term Debt [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price $ 1.03      
Long-Term Debt [Member] | Fair Value, Inputs, Level 3 [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate    
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 2 years 2 months 12 days     3 years
Long-Term Debt [Member] | Minimum [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price       $ 1.74
Long-Term Debt [Member] | Maximum [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price       $ 1.95
Share-Based Payment Arrangement, Option [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate    
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 5 years 5 years    
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 6 years 6 years    
Share-Based Payment Arrangement, Option [Member] | Long-Term Debt [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 428.00%      
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 1050000.00%      
Share-Based Payment Arrangement, Option [Member] | Long-Term Debt [Member] | Minimum [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate       90.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate       1130000.00%
Share-Based Payment Arrangement, Option [Member] | Long-Term Debt [Member] | Maximum [Member]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate       95.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate       1140000.00%
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Fair Value Measurements Warrant Valuation Assumptions (Details) - Fair Value, Inputs, Level 3 [Member] - Warrant [Member] - $ / shares
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 4.08% 0.36%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 8030.00% 11019.00%
Dividend yield (in percent)
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 1 year 3 months 25 days 2 years 3 months 25 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value $ 0.77 $ 2.17
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Schedule of Fair Value Level 3 Reconciliation (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Warrant [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 232 $ 424 $ 1,062
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3   (1,155)  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings (192) 517  
Long-Term Debt [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 21,397 18,920  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3   19,150  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 2,477 (230)  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3   (19,150)  
Derivative Financial Instruments, Liabilities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 1,174  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 1,174 805  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings   369  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 $ (1,174) $ (805)  
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
4. Fair Value Measurement (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended
Jan. 31, 2022
Nov. 30, 2021
Sep. 30, 2022
Business Combination, Separately Recognized Transactions [Line Items]      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net     $ 0
I X License Agreement [Member]      
Business Combination, Separately Recognized Transactions [Line Items]      
[custom:NonrefundableCashPayment] $ 1,200,000 $ 3,500,000  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid insurance $ 329 $ 59
Prepaid clinical costs 9,254 4,481
Other 414 187
Prepaid expenses and other current assets $ 9,997 $ 4,727
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
6. Common Stock Offerings (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2022
Nov. 30, 2021
May 31, 2021
Jan. 31, 2021
Dec. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
May 24, 2021
Jan. 28, 2021
Business Acquisition [Line Items]                        
Stock Issued During Period, Value, New Issues                 $ 97,957      
Research and Development Expense           $ 14,750 $ 8,683 $ 43,115 $ 27,103      
I X License Agreement [Member]                        
Business Acquisition [Line Items]                        
Research and Development Expense   $ 9,000                    
[custom:NonrefundableCashPayment] $ 1,200 $ 3,500                    
[custom:Issuanceofcommonstockforlicenseacquiredshares]   2,570,266                    
[custom:MinimumStockValueOfSharesIssued]   $ 5,500                    
[custom:InitialStockValuationShortfallFrom5.5MillionValue]         $ 800              
May 242021 [Member]                        
Business Acquisition [Line Items]                        
Stock Issued During Period, Shares, New Issues     22,258,066             22,258,066    
Sale of Stock, Price Per Share                     $ 3.10  
Stock Issued During Period, Value, New Issues     $ 64,500             $ 64,500    
[custom:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes]     $ 7,300             $ 7,300    
January 282021 [Member]                        
Business Acquisition [Line Items]                        
Stock Issued During Period, Shares, New Issues       17,530,488           17,530,488    
Sale of Stock, Price Per Share                       $ 2.05
Stock Issued During Period, Value, New Issues       $ 33,500           $ 33,500    
[custom:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes]       $ 3,800           $ 3,800    
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
7. License Agreements (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2022
Apr. 30, 2022
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2020
Aug. 31, 2019
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Business Combination, Separately Recognized Transactions [Line Items]                      
Research and development expense             $ 14,750,000 $ 8,683,000 $ 43,115,000 $ 27,103,000  
Stock Issued During Period, Value, New Issues                   $ 97,957,000  
Other Accrued Liabilities, Current             3,000   3,000   $ 25,000
Assetsfrom Vyera Pharmaceuticals [Member]                      
Business Combination, Separately Recognized Transactions [Line Items]                      
Business Combination, Separately Recognized Transactions, Description   On April 8, 2022, Seelos Corporation (“STI”), a wholly-owned subsidiary of the Company, and Vyera, entered into an amendment (the “Amendment”) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018 (as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the “Vyera Purchase Agreement”). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product candidate currently referred to as SLS-002 (intranasal ketamine) (the “Vyera Assets”) and agreed, among other things, to make certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the “Milestone and Royalty Payment Obligations”) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received by the Company as an upfront payment in such sale (the “Change of Control Payment Obligation”).                  
[custom:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement]   $ 4,000,000.0                  
Stock Issued During Period, Shares, New Issues 500,000 500,000                  
Research and development expense             5,800,000        
Stock Issued During Period, Value, New Issues $ 800,000                    
Other Accrued Liabilities, Current             1,000,000.0   1,000,000.0    
Weg License Agreement [Member]                      
Business Combination, Separately Recognized Transactions [Line Items]                      
Business Combination, Separately Recognized Transactions, Description           On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $          
[custom:NonrefundableCashPayment]     $ 200,000 $ 125,000 $ 100,000            
Asset Acquisition, Contingent Consideration, Liability, Current             $ 0   $ 0    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Schedule of Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Professional fees $ 239 $ 181
Personnel related 955 1,303
Outside research and development services 2,767 2,219
Insurance 84
Other 3 25
     Accrued expenses, net $ 4,048 $ 3,728
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
9. Debt (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 24 Months Ended 27 Months Ended
Nov. 30, 2022
Dec. 31, 2021
Nov. 30, 2021
Dec. 31, 2020
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Nov. 24, 2024
Nov. 23, 2024
Dec. 02, 2021
Short-Term Debt [Line Items]                      
[custom:GainLossInFairValueOfConvertibleNotes]         $ (2,137,000) $ (2,477,000)      
November 2021 Lind Securities Purchase Agreement [Member]                      
Short-Term Debt [Line Items]                      
Long-Term Debt, Description     On November 23, 2021, the Company entered into a Securities Purchase Agreement (the “2021 Lind Securities Purchase Agreement”) with Lind Global Asset Management V, LLC (“Lind V”) pursuant to which, among other things, on November 23, 2021 (the “Closing Date”), the Company issued and sold to Lind V, in a private placement transaction (the “Private Placement”), in exchange for the payment by Lind V of $20.0 million, (i) a convertible promissory note (the “2021 Note”) in an aggregate principal amount of $22.0 million (the “Principal Amount”), which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate of 5% per annum, and mature on November 23, 2024 (the “Maturity Date”), and (ii) 534,759 shares of Company common stock.                
First Anniversary Of November 2021 Lind Securities Purchase Agreement [Member]                      
Short-Term Debt [Line Items]                      
Long-Term Debt, Description At the first anniversary of the Closing Date, the Company shall have the option, at its sole discretion and subject to certain stock price and other conditions, to issue to Lind V a convertible promissory note (the “Second Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible promissory note (the “Third Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S. Food & Drug Administration for either SLS-002 or SLS-005, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible promissory note (the “Fourth Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note.                    
August 232022 Thru Maturity November 2021 Lind Securities Purchase Agreement [Member]                      
Short-Term Debt [Line Items]                      
Long-Term Debt, Description                   At any time following August 23, 2022, from time to time and before the Maturity Date, Lind V shall have the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the “Conversion Price”). At any time prior August 23, 2022, the Company had the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time during such period), up to an aggregate of $14.7 million of the outstanding Principal Amount of the 2021 Note with no penalty. The Company did not prepay any amounts of the 2021 Note prior to August 23, 2022 and has the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price.  
Amortize November 2021 Lind Securities Purchase Agreement [Member]                      
Short-Term Debt [Line Items]                      
Long-Term Debt, Description                 Beginning on November 23, 2022, the 2021 Note will amortize in twenty-four monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments shall be payable, at the Company’s sole option, in cash, shares of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022, the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90% of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note, on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the Company’s assets and properties.    
December 2021 S P As [Member]                      
Short-Term Debt [Line Items]                      
Long-Term Debt, Description   On December 2, 2021, the Company entered into two separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021 Note.                  
Proceeds from Convertible Debt   $ 20,200,000                  
Convertible Subordinated Debt   18,900,000     21,400,000   21,400,000       $ 19,200,000
[custom:GainLossInFairValueOfConvertibleNotes]         2,100,000   2,500,000        
Convertible Notes Payable         $ 22,200,000   $ 22,200,000        
Lind Securities Purchase Agreement [Member]                      
Short-Term Debt [Line Items]                      
Long-Term Debt, Description       On December 11, 2020, the Company entered into a Securities Purchase Agreement (the “2020 Lind Securities Purchase Agreement”) with Lind Global Asset Management II, LLC (the “Investor”) pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the “2020 Note”) in an aggregate principal amount of $12,000,000 (the “Principal Amount”), which did not bear interest and was to mature on December 11, 2022 (the “Maturity Date”), and (2) 975,000 shares of the Company’s common stock. At any time following June 11, 2021, and from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020 Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of 406,250 additional shares of its common stock (the “Lind Shares”) and to pay the Investor the remaining principal amount of $790,804 (the “Final Payment”) in full satisfaction of the Company’s remaining obligations to the Investor under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.              
December 17 S P As [Member]                      
Short-Term Debt [Line Items]                      
Long-Term Debt, Description       On December 17, 2020, the Company entered into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2020 Lind Securities Purchase Agreement (the “December 17 SPAs”), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1) convertible promissory notes (the “December 17 Notes”) in an aggregate principal amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with an accredited investor on substantially the same terms as the 2020 Lind Securities Purchase Agreement (the “December 18 SPA” and, together with the December 17 SPAs, the “Subsequent Securities Purchase Agreements”), pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the “December 18 Note” and, together with the December 17 Notes, the “Subsequent Notes”), and (2) 26,263 shares of the Company’s common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the 2020 Lind Securities Purchase Agreement, and the Subsequent Notes had substantially the same terms as the 2020 Note. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the “December 18 Note Holder”) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December 18 Note Holder agreed to return to the Company $42,777 in cash (the “Repayment”) previously paid by the Company to the December 18 Note Holder as a payment against the Company’s obligations under the December 18 Note, and (ii) the Company agreed to issue to the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the “December 18 Note Shares”) in full satisfaction of the Company’s remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder paid the Company the Repayment and the Company issued the December 18 Note Shares, and the December 18 SPA and the December 18 Note terminated, effective July 7, 2021.              
Repayments of Convertible Debt   $ 13,600,000                  
Stock Issued During Period, Shares, Conversion of Convertible Securities   475,315                  
Long-Term Debt   $ 0                  
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Warrant Activity (Details) - Warrant Derivative Financial Instruments [Member]
 9 Months Ended
Sep. 30, 2022
$ / shares
shares
Offsetting Assets [Line Items]  
Outstanding as of December 31, 2021 | shares 2,635,000
Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share) | $ / shares $ 4.29
Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years) 2 years 4 months 24 days
Issued | shares
Issued, warrant exercise price | $ / shares
Exercised | shares
Exercised, exercise price of warrants | $ / shares
Cancelled | shares (90,000)
Cancelled, exercise price of warrants | $ / shares $ 47.06
Outstanding as of March 31, 2022 | shares 2,545,000
Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share) | $ / shares $ 2.78
Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years) 1 year 9 months 18 days
Warrants exercisable as of March 31, 2022 | shares 2,545,000
Exercisable, weighted-average exercise price (in usd per share) | $ / shares $ 2.78
Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years) 1 year 9 months 18 days
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
10. Stockholders’ Equity (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended
Sep. 30, 2020
Aug. 31, 2019
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Mar. 31, 2021
Sep. 04, 2020
Class of Warrant or Right [Line Items]              
Preferred stock, authorized (in shares)     10,000,000   10,000,000    
Preferred stock, per value (in usd per share)     $ 0.001   $ 0.001    
Preferred stock, outstanding (in shares)     0   0    
Common stock, authorized (in shares)     240,000,000   240,000,000 240,000,000  
Common stock voting right     Each share of common stock is entitled to one voting right        
Proceeds from exercise of warrants     $ 7,252,000      
September 2020 Warrants [Member]              
Class of Warrant or Right [Line Items]              
Number of shares of common stock issued 6,648,750            
Warrants exercisable as of June 30, 2021     1.0        
August 232019 [Member]              
Class of Warrant or Right [Line Items]              
Number of shares of common stock issued   4,475,000          
August 2019 Warrants [Member]              
Class of Warrant or Right [Line Items]              
Warrants exercisable as of June 30, 2021     900,000        
September 2020 Warrants [Member]              
Class of Warrant or Right [Line Items]              
Warrant description On September 4, 2020, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in a registered direct offering and issued warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the “September 2020 Warrants”). The September 2020 Warrants are exercisable for 6,648,750 shares of common stock at an exercise price per share equal to $0.84. The September 2020 Warrants became exercisable beginning on March 9, 2021 and will expire on March 9, 2026.            
Class of Warrant or Right, Exercise Price of Warrants or Rights     $ 0.84       $ 0.84
Date on which warrants became exercisable       Mar. 09, 2021      
Number of warrants exercised     0 5,600,000      
Proceeds from exercise of warrants     $ 0 $ 4,700,000      
August 2019 Warrants [Member]              
Class of Warrant or Right [Line Items]              
Warrant description   On August 23, 2019, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 4,475,000 shares of common stock in a registered direct offering and issued warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the “August 2019 Warrants”). The August 2019 Warrants were initially exercisable for 2,237,500 shares of common stock at an exercise price per share equal to $1.78. The August 2019 Warrants became exercisable beginning on February 27, 2020 and will expire on August 28, 2023.          
Class of Warrant or Right, Exercise Price of Warrants or Rights     $ 1.78        
Date on which warrants became exercisable     Feb. 27, 2020        
Number of warrants exercised     0 1,300,000      
Proceeds from exercise of warrants     $ 0 $ 2,400,000      
Series A Warrants [Member]              
Class of Warrant or Right [Line Items]              
Warrant description       On January 24, 2019, STI and the Company closed a private placement with certain accredited investors pursuant to which, among other things, the Company issued warrants representing the right to acquire 1,463,519 shares of common stock (the “Series A Warrants”). The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per share) occurred during the three months ended September 30, 2020 as a result of the announcement of the registered direct offering of 8,865,000 shares of common stock in September 2020. The Series A Warrants were immediately exercisable upon issuance and will expire on January 31, 2024.      
Class of Warrant or Right, Exercise Price of Warrants or Rights     $ 0.2957        
Number of warrants exercised     0 500,000      
Proceeds from exercise of warrants     $ 0 $ 100,000      
Warrants exercisable as of June 30, 2021     300,000        
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Schedule of Valuation Assumptions for Stock Options (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Risk-free interest rate, minimum 160.00% 50.00%
Risk-free interest rate, maximum 340.00% 120.00%
Dividend yield
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value   $ 3.52
Minimum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Volatility, minimum 111.00% 118.00%
Expected term (in years) 5 years 5 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 1.22  
Maximum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Volatility, maximum 113.00% 125.00%
Expected term (in years) 6 years 6 years
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Stock Option Activity (Details)
$ / shares in Units, $ in Thousands
 9 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Exercised (6,250)
Outstanding, end of period (USD per share) | $ / shares $ 2.26
Share-Based Payment Arrangement, Option [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Outstanding as of December 31, 2020 7,306,000
Outstanding, beginning of period (USD per share) | $ / shares $ 2.60
Granted 3,100,000
Granted in period (USD per share) | $ / shares $ 1.45
Exercised (6,000)
Exercised in period (USD per share) | $ / shares $ 1.06
Cancelled
Cancelled (USD per share) | $ / shares $ (0)
Outstanding as of March 31, 2022 10,400,000
Outstanding - weighted-average remaining contractual life (in years) 8 years 3 months 18 days
Total aggregate intrinsic value shares outstanding | $ $ 11
Vested and expected to vest, end of period (shares) 10,400,000
Vested and expected to vest stock, end of period (USD per share) | $ / shares $ 2.26
Weighted-average remaining contractual life (in years) of vested and expected to vest stock options 8 years 3 months 18 days
Total aggregate intrinsic value of vested or expected to vest stock options | $ $ 11
Exercisable, end of period (shares) 4,053,000
Exercisable, end of period (USD per share) | $ / shares $ 2.78
Weighted-average remaining contractual life (in years) of exercisable stock options 7 years 8 months 12 days
Total aggregate intrinsic value of exercisable stock options | $ $ 9
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Schedule of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-Based Payment Arrangement, Noncash Expense $ 973 $ 857 $ 4,166 $ 2,599
Research and Development Expense [Member]        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-Based Payment Arrangement, Noncash Expense 261 193 721 551
General and Administrative Expense [Member]        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-Based Payment Arrangement, Noncash Expense $ 712 $ 664 $ 3,445 $ 2,048
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
11. Stock-based Compensation (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2022
May 31, 2020
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
May 15, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Share-Based Payment Arrangement, Noncash Expense     $ 973,000 $ 857,000 $ 4,166,000 $ 2,599,000    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period         6,250      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period         0      
Share-Based Payment Arrangement, Option [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Description of share-based compensation arrangement by share-based payment award         The Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the “2012 Plan”), which provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of common stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a number of shares of common stock set by the Company’s board of directors on or prior to each such January 1. On January 1, 2022, in accordance with the foregoing, an aggregate of 4,713,637 shares of common stock were added to shares authorized for issuance under the 2012 Plan. As of September 30, 2022, an aggregate of      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized 4,713,637,000,000              
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized     15,817,818   15,817,818      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant     5,400,000   5,400,000      
Options granted in period         3,100,000      
Weighted-average exercise price per share granted in period         $ 1.45      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period         6,000      
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value         $ 100,000 $ 200,000    
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount     $ 8,400,000   $ 8,400,000      
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition         2 years 3 months 18 days      
Employee Stock Purchase Plan [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Description of share-based compensation arrangement by share-based payment award   On May 15, 2020, the Company's stockholders approved the Company's 2020 Employee Stock Purchase Plan (the "ESPP"), whereby qualified employees are allowed to purchase limited amounts of the Company's common stock at the lesser of 85% of the market price at the beginning or end of the offering period. The stockholders have authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding December 31, and (ii) a number of shares of common stock set by the Company's Board of Directors or the Compensation Committee of the Board of Directors (the "Compensation Committee") of the Company on or prior to each such January 1. On January 1, 2022, the Company added 1,055,004 shares for purchase by employees under the ESPP. During the nine months ended September 30, 2022, the Company sold 111,561 shares of common stock under the ESPP. The compensation costs are calculated as the fair value of the 15% discount from market price and were approximately $33,000 for the nine months ended September 30, 2022.            
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized 1,055,004,000,000              
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized               1,000,000.0
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent   0.85%            
Stock Issued During Period, Shares, Employee Stock Purchase Plans         111,561      
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price Discount of Common Stock, Percent         0.15%      
Share-Based Payment Arrangement, Noncash Expense         $ 33,000      
Inducement Planof 2019 [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Description of share-based compensation arrangement by share-based payment award         On July 28, 2019, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of the Company adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the “2019 Inducement Plan”), which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is 1,000,000 shares of the Company’s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized     1,000,000   1,000,000      
Incentive Stock Option [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Options granted in period         660,605      
Weighted-average exercise price per share granted in period         $ 1.45      
Term of option grant         10 years      
Vesting percentage on the first anniversary         25.00%      
Non Qualified Stock Options To Employees [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Options granted in period         2,299,395      
Non Qualified Stock Options To Non Employee Directors [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Options granted in period         140,000      
Weighted-average exercise price per share granted in period         $ 1.56      
Term of option grant         10 years      
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period         12 months      
Performance Shares [Member] | P S Uto Executives [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Share-Based Payment Arrangement, Noncash Expense         $ 1,300,000   $ 4,900,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award             During the year ended December 31, 2021, the Company’s Board of Directors awarded a performance stock unit award to the Company’s Chief Executive Officer for 2,400,000 shares of common stock, with a grant date fair value of $4.31 per unit. Vesting of this award was subject to the Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had been satisfied. The Company recognized stock-based compensation related to this award of $4.9 million during the fourth quarter of 2021, which was recorded in general and administrative expense. During the nine months ended September 30, 2022, the Company and its Chief Executive Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation expense of the three achieved milestones of $1.3 million. The two remaining milestones were not deemed probable of achievement at the time of cancellation, and no compensation cost related to these milestones was recognized.  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period             2,400,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value             $ 4.31  
Share-Based Payment Arrangement, Nonvested and Canceled Award, Excluding Option, Cost Not yet Recognized, Amount     $ 0   $ 0      
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
12. Commitments and Contingencies (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended
Oct. 31, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Mar. 31, 2021
Lessee, Lease, Description [Line Items]          
Operating Lease, Right-of-Use Asset     $ 39,000  
Operating Lease, Liability, Current     $ 38,000  
Operating Lease, Weighted Average Remaining Lease Term   0 years      
Operating Lease, Weighted Average Discount Rate, Percent   800.00%      
Operating Lease, Liability   $ 0      
Operating Lease, Expense   $ 100,000 $ 100,000    
March 2019 Lease [Member]          
Lessee, Lease, Description [Line Items]          
Lessee, Operating Lease, Description   In March 2019, the Company entered into a nine-month office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company was notified that the counterparty’s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is in breach of this rental agreement and therefore, the Company has no further obligations thereunder.      
March 2021 Lease [Member]          
Lessee, Lease, Description [Line Items]          
Lessee, Operating Lease, Description   n March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New York, NY, which was due to expire in September 2022. The rental agreement contains a base rent of approximately $4,000 per month. This agreement included one or more renewal options. At September 30, 2022, the Company’s right-of-use assets and lease liability for operating leases was $0.      
Operating Lease, Right-of-Use Asset   $ 0     $ 74,000
Operating Lease, Liability, Current   $ 0      
October 2022 Lease [Member]          
Lessee, Lease, Description [Line Items]          
Lessee, Operating Lease, Description In October 2022, the Company entered into a new eighteen-month office space rental agreement for its existing space, which provides for a base rent starting at approximately $4,000 per month        
XML 56 body10-q_htm.xml IDEA: XBRL DOCUMENT 0001017491 2022-01-01 2022-09-30 0001017491 2022-11-04 0001017491 2022-09-30 0001017491 2021-12-31 0001017491 2020-12-31 0001017491 2021-03-31 0001017491 2022-07-01 2022-09-30 0001017491 2021-07-01 2021-09-30 0001017491 2021-01-01 2021-09-30 0001017491 us-gaap:CommonStockMember 2022-06-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001017491 us-gaap:RetainedEarningsMember 2022-06-30 0001017491 2022-06-30 0001017491 us-gaap:CommonStockMember 2021-06-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001017491 us-gaap:RetainedEarningsMember 2021-06-30 0001017491 2021-06-30 0001017491 us-gaap:CommonStockMember 2021-12-31 0001017491 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001017491 us-gaap:RetainedEarningsMember 2021-12-31 0001017491 us-gaap:CommonStockMember 2020-12-31 0001017491 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001017491 us-gaap:RetainedEarningsMember 2020-12-31 0001017491 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001017491 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001017491 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001017491 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001017491 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001017491 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001017491 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001017491 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001017491 us-gaap:CommonStockMember 2022-09-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001017491 us-gaap:RetainedEarningsMember 2022-09-30 0001017491 us-gaap:CommonStockMember 2021-09-30 0001017491 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001017491 us-gaap:RetainedEarningsMember 2021-09-30 0001017491 2021-09-30 0001017491 SEEL:May122022SaleAgreementMember 2022-05-01 2022-05-31 0001017491 SEEL:May122022SaleAgreementMember 2022-07-01 2022-09-30 0001017491 srt:MaximumMember 2022-04-22 0001017491 srt:MinimumMember 2022-09-30 0001017491 SEEL:May242021Member 2021-05-01 2021-05-31 0001017491 SEEL:May242021Member 2021-05-24 0001017491 SEEL:January282021Member 2021-01-01 2021-01-31 0001017491 SEEL:January282021Member 2021-01-28 0001017491 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001017491 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001017491 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001017491 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0001017491 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001017491 us-gaap:WarrantMember 2022-07-01 2022-09-30 0001017491 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001017491 us-gaap:WarrantMember 2021-07-01 2021-09-30 0001017491 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001017491 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2022-09-30 0001017491 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-09-30 0001017491 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2021-09-30 0001017491 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-09-30 0001017491 SEEL:IXLicenseAgreementMember 2022-01-01 2022-01-31 0001017491 us-gaap:LongTermDebtMember 2022-01-01 2022-09-30 0001017491 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:LongTermDebtMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:LongTermDebtMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:LongTermDebtMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:LongTermDebtMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:LongTermDebtMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:LongTermDebtMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:LongTermDebtMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:LongTermDebtMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel1Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel2Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001017491 us-gaap:EmployeeStockOptionMember us-gaap:LongTermDebtMember 2022-01-01 2022-09-30 0001017491 srt:MinimumMember us-gaap:EmployeeStockOptionMember us-gaap:LongTermDebtMember 2021-01-01 2021-12-31 0001017491 srt:MaximumMember us-gaap:EmployeeStockOptionMember us-gaap:LongTermDebtMember 2021-01-01 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:LongTermDebtMember 2022-01-01 2022-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:LongTermDebtMember 2021-01-01 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:LongTermDebtMember 2022-01-01 2022-09-30 0001017491 us-gaap:LongTermDebtMember 2022-09-30 0001017491 srt:MinimumMember us-gaap:LongTermDebtMember 2021-12-31 0001017491 srt:MaximumMember us-gaap:LongTermDebtMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-01-01 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-01-01 2021-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2020-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-01-01 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-01-01 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:LongTermDebtMember 2021-12-31 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2022-01-01 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2022-09-30 0001017491 us-gaap:FairValueInputsLevel3Member us-gaap:LongTermDebtMember 2022-09-30 0001017491 SEEL:May242021Member 2021-01-01 2021-12-31 0001017491 SEEL:January282021Member 2021-01-01 2021-12-31 0001017491 SEEL:IXLicenseAgreementMember 2021-11-01 2021-11-30 0001017491 SEEL:IXLicenseAgreementMember 2021-11-01 2021-12-31 0001017491 SEEL:AssetsfromVyeraPharmaceuticalsMember 2022-04-01 2022-04-30 0001017491 SEEL:AssetsfromVyeraPharmaceuticalsMember 2022-07-01 2022-07-31 0001017491 SEEL:AssetsfromVyeraPharmaceuticalsMember 2022-07-01 2022-09-30 0001017491 SEEL:AssetsfromVyeraPharmaceuticalsMember 2022-09-30 0001017491 SEEL:WegLicenseAgreementMember 2019-08-01 2019-08-31 0001017491 SEEL:WegLicenseAgreementMember 2022-01-01 2022-01-31 0001017491 SEEL:WegLicenseAgreementMember 2020-01-01 2020-01-31 0001017491 SEEL:WegLicenseAgreementMember 2021-01-01 2021-01-31 0001017491 SEEL:WegLicenseAgreementMember 2022-09-30 0001017491 SEEL:November2021LindSecuritiesPurchaseAgreementMember 2021-11-01 2021-11-30 0001017491 SEEL:FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember 2022-11-01 2022-11-30 0001017491 SEEL:August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember 2022-08-23 2024-11-23 0001017491 SEEL:AmortizeNovember2021LindSecuritiesPurchaseAgreementMember 2022-11-23 2024-11-24 0001017491 SEEL:December2021SPAsMember 2021-12-01 2021-12-31 0001017491 SEEL:December2021SPAsMember 2021-12-02 0001017491 SEEL:December2021SPAsMember 2021-12-31 0001017491 SEEL:December2021SPAsMember 2022-09-30 0001017491 SEEL:December2021SPAsMember 2022-07-01 2022-09-30 0001017491 SEEL:December2021SPAsMember 2022-01-01 2022-09-30 0001017491 SEEL:LindSecuritiesPurchaseAgreementMember 2020-12-01 2020-12-31 0001017491 SEEL:December17SPAsMember 2020-12-01 2020-12-31 0001017491 SEEL:December17SPAsMember 2021-12-01 2021-12-31 0001017491 SEEL:December17SPAsMember 2021-12-31 0001017491 SEEL:September2020WarrantsMember 2020-09-01 2020-09-30 0001017491 SEEL:September2020WarrantsMember 2020-09-01 2020-09-30 0001017491 SEEL:September2020WarrantsMember 2020-09-04 0001017491 SEEL:September2020WarrantsMember 2021-01-01 2021-09-30 0001017491 SEEL:September2020WarrantsMember 2022-01-01 2022-09-30 0001017491 SEEL:September2020WarrantsMember 2022-09-30 0001017491 SEEL:September2020WarrantsMember 2022-09-30 0001017491 SEEL:August2019WarrantsMember 2019-08-01 2019-08-31 0001017491 SEEL:August232019Member 2019-08-01 2019-08-31 0001017491 SEEL:August2019WarrantsMember 2022-01-01 2022-09-30 0001017491 SEEL:August2019WarrantsMember 2021-01-01 2021-09-30 0001017491 SEEL:August2019WarrantsMember 2022-09-30 0001017491 SEEL:August2019WarrantsMember 2022-09-30 0001017491 SEEL:SeriesAWarrantsMember 2021-01-01 2021-09-30 0001017491 SEEL:SeriesAWarrantsMember 2022-01-01 2022-09-30 0001017491 SEEL:SeriesAWarrantsMember 2022-09-30 0001017491 SEEL:WarrantDerivativeFinancialInstrumentsMember 2021-12-31 0001017491 SEEL:WarrantDerivativeFinancialInstrumentsMember 2022-01-01 2022-09-30 0001017491 SEEL:WarrantDerivativeFinancialInstrumentsMember 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-01-31 0001017491 us-gaap:EmployeeStockOptionMember 2022-09-30 0001017491 SEEL:EmployeeStockPurchasePlanMember 2020-05-01 2020-05-31 0001017491 SEEL:EmployeeStockPurchasePlanMember 2020-05-15 0001017491 SEEL:EmployeeStockPurchasePlanMember 2022-01-01 2022-01-31 0001017491 SEEL:EmployeeStockPurchasePlanMember 2022-01-01 2022-09-30 0001017491 SEEL:InducementPlanof2019Member 2022-01-01 2022-09-30 0001017491 SEEL:InducementPlanof2019Member 2022-09-30 0001017491 SEEL:IncentiveStockOptionMember 2022-01-01 2022-09-30 0001017491 SEEL:NonQualifiedStockOptionsToEmployeesMember 2022-01-01 2022-09-30 0001017491 SEEL:NonQualifiedStockOptionsToNonEmployeeDirectorsMember 2022-01-01 2022-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001017491 us-gaap:PerformanceSharesMember SEEL:PSUtoExecutivesMember 2021-01-01 2021-12-31 0001017491 us-gaap:PerformanceSharesMember SEEL:PSUtoExecutivesMember 2022-01-01 2022-09-30 0001017491 us-gaap:PerformanceSharesMember SEEL:PSUtoExecutivesMember 2022-09-30 0001017491 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001017491 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001017491 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001017491 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001017491 us-gaap:EmployeeStockOptionMember 2021-12-31 0001017491 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001017491 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001017491 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001017491 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001017491 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001017491 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001017491 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001017491 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001017491 SEEL:March2019LeaseMember 2022-01-01 2022-09-30 0001017491 SEEL:March2021LeaseMember 2022-01-01 2022-09-30 0001017491 SEEL:March2021LeaseMember 2022-09-30 0001017491 SEEL:October2022LeaseMember 2022-10-01 2022-10-31 0001017491 SEEL:March2021LeaseMember 2021-03-31 iso4217:USD shares iso4217:USD shares pure utr:Y 0001017491 false 2022 --12-31 Q3 10-Q true 2022-09-30 false 000-22245 SEELOS THERAPEUTICS, INC. NV 87-0449967 300 Park Avenue 2nd Floor New York NY 10022 (646) 293-2100 Common Stock, par value $0.001 per share SEEL NASDAQ Yes Yes Non-accelerated Filer true false false false 107168256 30511000 78734000 9997000 4727000 40508000 83461000 39000 40508000 83500000 5952000 1693000 4048000 3728000 1000000 200000 10655000 1030000 1174000 232000 424000 38000 21887000 8287000 10742000 17890000 32629000 26177000 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 240000000 240000000 107168256 107168256 105500445 105500445 107000 105000 203859000 198428000 196087000 141210000 7879000 57323000 40508000 83500000 14750000 8683000 43115000 27103000 2660000 2227000 9544000 7192000 17410000 10910000 52659000 34295000 -17410000 -10910000 -52659000 -34295000 36000 39000 81000 87000 2000 20000 14000 1593000 2387000 149000 -2137000 -2477000 -91000 76000 192000 -750000 -2194000 95000 -2218000 -4494000 -19604000 -19604000 -10815000 -10815000 -54877000 -54877000 -38789000 -38789000 -0.18 -0.18 -0.11 -0.11 -0.52 -0.52 -0.45 -0.45 106689924 106689924 102325238 102325238 106100413 106100413 86579881 86579881 106190773 106000 202000 -176483000 26227000 973000 973000 100000 107000 107000 500000 350000 1000 151000 1000 27483 24000 24000 -19604000 -19604000 107168256 107000 203859000 -196087000 7879000 102271544 102000 185732000 -103136000 82698000 857000 857000 39491 74000 74000 43664 98000 98000 -10815000 -10815000 102354699 102000 186761000 -113951000 72912000 105500445 105000 198428000 -141210000 57323000 4166000 4166000 6250 8000 8000 200000 167000 167000 1000000 1000 840000 841000 350000 1000 151000 1000 111561 99000 99000 -54877000 -54877000 107168256 107000 203859000 -196087000 7879000 54535891 54000 77680000 -75162000 2572000 2599000 2599000 43805 65000 65000 -1519000 -1519000 406250 1000 1376000 1377000 69065 138000 138000 80009 104000 104000 7431125 7000 8401000 8408000 39788554 40000 97917000 97957000 -38789000 -38789000 102354699 102000 186761000 -113951000 72912000 -54877000 -38789000 4166000 2599000 -192000 750000 -2477000 841000 -147000 2387000 1582000 -5103000 -2230000 4259000 1514000 289000 1803000 1174000 800000 -125000 -48514000 -30656000 13551000 97957000 7252000 457000 273000 8000 65000 99000 104000 291000 91827000 -48223000 61171000 78734000 15662000 30511000 76833000 11000 10000 1155000 75000 69000 840000 32000 1377000 1519000 <p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z7EGwvIUIQ98" style="font: 11pt Times New Roman, Times, Serif; margin: 0 142.6pt 0 5pt; text-align: justify; text-indent: 0in"><span style="font-size: 10pt; letter-spacing: -0.8pt"><b/></span><b><span style="font: 7pt Times New Roman, Times, Serif; letter-spacing: -0.8pt"> </span><span style="font-size: 10pt">1. Organization and Description of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 142.6pt 0 5pt; text-align: justify; text-indent: 0in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt">Seelos Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage biopharmaceutical company focused on achieving efficient development of products that address significant unmet needs in Central Nervous System (“CNS”) disorders and other rare disorders. The Company’s lead programs are SLS-002 for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder (“ASIB in MDD”) and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis (“ALS”) and Spinocerebellar Ataxia (“SCA”). SLS-005 for the potential treatment of Sanfilippo Syndrome currently requires additional natural history data, which is being considered. Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms of action, including: SLS-004, SLS-006, SLS-007 for the potential treatment of Parkinson’s Disease (“PD”) and SLS-008, which is being developed for the potential treatment of an undisclosed indication, but may also be targeted at chronic inflammation in asthma and orphan indications such as pediatric esophagitis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"><b> </b></p> <p id="xdx_800_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zUlIFHdf9E01" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">2. Liquidity and Going Concern</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.85pt 0 5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The accompanying condensed consolidated unaudited financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The Company has generated limited revenues, has incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of September 30, 2022, the Company had $<span id="xdx_90F_eus-gaap--Cash_iI_pn5n6_c20220930_z1g3E8cpL6Md" title="Cash">30.5</span> million in cash and an accumulated deficit of $<span id="xdx_904_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn5n6_c20220930_zCK1bmk9Oxjk" title="Accumlated deficit">196.1</span> million. The Company has historically funded its operations through the issuance of convertible notes (see Note 9), the sale of common stock (see Note 6) and exercises of warrants (see Note 10).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On May 12, 2022, the Company entered into an Open Market Sale Agreement<span style="font-size: 8.5pt; background-color: white"><sup>SM</sup></span> (the “Sale Agreement”) with Jefferies LLC, as sales agent (the “Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through the Agent (the “Offering”). The Company also filed a prospectus supplement, dated May 12, 2022, with the Securities and Exchange Commission (the “SEC”) in connection with the Offering (the “Prospectus Supplement”) under the Company’s existing shelf Registration Statement on Form S-3, as amended (File No. 333-251356), which became effective on December 23, 2020 (the “Registration Statement”). Pursuant to the Prospectus Supplement, the Company may offer and sell shares having an aggregate offering price of up to $<span id="xdx_903_ecustom--AggregateFutureOfferingAmount_pn5n6_c20220501__20220531__us-gaap--StatementClassOfStockAxis__custom--May122022SaleAgreementMember_zCQPl17mNBti" title="Aggregate future offering amount">50.0</span> million. Under the terms of the Sale Agreement, the Agent is entitled to a commission at a fixed rate of <span id="xdx_90B_ecustom--CommissionRateOnGrossProceedsOfCommonStockSale_pip0_uPure_c20220501__20220531__us-gaap--StatementClassOfStockAxis__custom--May122022SaleAgreementMember_ztdviGfUqYQe" title="Commission rate on gross proceeds of common stock sale">3.0</span>% of the gross proceeds from each sale of shares under the Sale Agreement. The Company also reimburses the Agent for certain expenses incurred in connection with the Sale Agreement, and agreed to provide indemnification and contribution to the Agent with respect to certain liabilities, including liabilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. During the three months ended September 30, 2022, the Company sold an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220701__20220930__us-gaap--StatementClassOfStockAxis__custom--May122022SaleAgreementMember_ztVlSCpnGtd2">350,000</span> shares under the Sale Agreement, receiving net proceeds of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220701__20220930__us-gaap--StatementClassOfStockAxis__custom--May122022SaleAgreementMember_zMMo0bDRO7n6">0.5</span> million. The Company currently intends to use any net proceeds from the Offering for general corporate purposes and to advance the development of its product candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On April 22, 2022, the Company received written notice from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for its common stock had closed below the minimum $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220422__srt--RangeAxis__srt--MaximumMember_zlr2df2ZU9Gg">1.00</span> per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of <span id="xdx_90C_ecustom--InitialNumberOfCalendarDaysToRegainCommonStockPriceCompliance_dtD_c20220101__20220930_z9Bm1i4t72Nb">180</span> calendar days, or until October 19, 2022, to regain compliance. On September 1, 2022, the Company received a letter from Nasdaq notifying the Company that it regained full compliance with Nasdaq Listing Rule 5550(a)(2) after the closing bid price of the Company’s common stock had been at $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220930__srt--RangeAxis__srt--MinimumMember_zxs3CGN0mmx7">1.00</span> per share or greater for ten consecutive business days, from August 18, 2022 through August 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On May 24, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210501__20210531__us-gaap--StatementClassOfStockAxis__custom--May242021Member_z6pU7T7uL1nb" title="Number of shares of common stock issued">22,258,066</span> shares of its common stock, at a price to the public of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210524__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zPIih6iQzU53" title="Shares Issued, Price Per Share">3.10</span> per share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net proceeds to the Company from the offering were approximately $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210501__20210531__us-gaap--StatementClassOfStockAxis__custom--May242021Member_znvCOQEUOEA3" title="Cash received from stock sale">64.5</span> million, after deducting underwriting discounts and commissions and other offering costs. The Company used $<span id="xdx_90B_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210501__20210531__us-gaap--StatementClassOfStockAxis__custom--May242021Member_z3cGiDLwmfm4" title="Offering proceeds used to partially repay certain convertible promissory notes">7.3</span> million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">On January 28, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20210131__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zSk5mfKSduR5">17,530,488 </span>shares of its common stock, at a price to the public of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210128__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zeNhjQ7tklc2">2.05 </span>per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to the Company from the offering were approximately $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20210131__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zXbrplIummQc">33.5 </span>million, after deducting underwriting discounts, commissions and other offering costs. The Company used $<span id="xdx_903_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20210131__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zeWIkGFTOzUa">3.8 </span>million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Pursuant to the Registration Statement, the Company may offer from time to time any combination of debt securities, common and preferred stock and warrants. As of September 30, 2022, the Company had approximately $<span id="xdx_90B_ecustom--FinancingAvailableUnderFormS3ShelfRegistrationStatement_iI_pn5n6_c20220930_z7zkPYl9swca">94.6</span> million available under the Registration Statement (inclusive of the $<span id="xdx_900_ecustom--AggregateFutureOfferingAmount_pn5n6_c20220701__20220930__us-gaap--StatementClassOfStockAxis__custom--May122022SaleAgreementMember_zYP0EQKOWPIb">49.5</span> million that remained allocated to sales of shares pursuant to the Sale Agreement as of such date). The Company also has the ability to raise funds through other means, such as through the filing of a registration statement on Form S-1 or in private placements. The rules and regulations of the SEC or any other regulatory agencies may restrict the Company’s ability to conduct certain types of financing activities or may affect the timing of and amounts it can raise by undertaking such activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and the Company’s current plans (including the ongoing clinical programs for SLS-002, SLS-005, and other product candidates), which are subject to change, management believes that the Company’s existing cash and cash equivalents as of September 30, 2022 are not sufficient to satisfy its operating cash needs for the year after the filing of this Quarterly Report on Form 10-Q.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify">The Company’s future liquidity and capital funding requirements will depend on numerous factors, including:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">•</span></td><td><span style="font-size: 10pt">its ability to raise additional funds to finance its operations;</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">•</span></td><td><span style="font-size: 10pt">its ability to maintain compliance with the listing requirements of the Nasdaq Capital Market;</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">•</span></td><td><span style="font-size: 10pt">the outcome, costs and timing of clinical trial results for the Company’s current or future product candidates;</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">•</span></td><td><span style="font-size: 10pt">potential litigation expenses;</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">•</span></td><td><span style="font-size: 10pt">the emergence and effect of competing or complementary products or product candidates;</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">•</span></td><td style="padding-right: 5.85pt"><span style="font-size: 10pt">its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">•</span></td><td style="padding-right: 5.85pt"><span style="font-size: 10pt">its ability to retain its current employees and the need and ability to hire additional management and scientific and medical personnel;</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">•</span></td><td><span style="font-size: 10pt">the terms and timing of any collaborative, licensing or other arrangements that it has or may establish;</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">•</span></td><td><span style="font-size: 10pt">the trading price of its common stock; and</span></td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td style="width: 23pt"/><td style="width: 18pt"><span style="font-size: 10pt; letter-spacing: -0.7pt">•</span></td><td><span style="font-size: 10pt">its ability to increase the number of authorized shares outstanding to facilitate future financing events.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 11.85pt 0 5pt; text-align: left"><span style="background-color: white">The Company may raise substantial additional funds, and if it does so, it may do so through one or more of the following: issuance of additional debt or equity and/or the completion of a licensing or other commercial transaction for one or more of the Company’s product candidates. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company’s business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or convertible debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 11.85pt 0 5pt; text-align: justify"><span style="background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 11.85pt 0 5pt; text-align: justify"><span style="background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> 30500000 196100000 50000000.0 3.0 350000 500000 1.00 P180D 1.00 22258066 3.10 64500000 7300000 17530488 2.05 33500000 3800000 94600000 49500000 <p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zuGSr9jROLy8" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left">3. Significant Accounting Policies</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left"> </p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zp2emxigUS7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Basis of Presentation </i></b></p> <p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt">The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K (the “Annual Report”) filed with the SEC on March 4, 2022. The accompanying financial statements have been prepared by the Company in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows. The December 31, 2021 condensed consolidated balance sheet was derived from audited financial statements, but it does not include all U.S. GAAP disclosures. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p id="xdx_848_eus-gaap--UseOfEstimates_zsG5uQdUXm5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><span style="font-weight: normal"> </span></p> <p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjtmXpmZ5WGe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left"><i>Fair Value Measurements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The Company follows the accounting guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), for its fair value measurements of financial assets and liabilities measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 1: Quoted prices in active markets for identical assets or liabilities. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Fair Value Option</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">As permitted under FASB ASC Topic 825, Financial Instruments (“ASC 825”), the Company elected the fair value option to account for its November 2021 and December 2021 convertible notes (collectively, the “2021 Convertible Notes”). In accordance with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed as incurred and were not deferred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"/> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zylUSVrXTDr3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><i>Stock-based Compensation</i></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role at the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">Performance share awards are initially valued based on the Company’s closing stock price on the date of grant. The number of performance share awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period. Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense is reversed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJOg7I8WZ1Vg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Income (Loss) Per Common Share</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, performance-based restricted stock unit awards and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKQMCpo58Tdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The following potentially dilutive securities outstanding for the three and nine months ended September 30, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):</p> <p id="xdx_8BF_z66xDxRI5f8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td colspan="4" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Three and Nine Months</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td colspan="4" style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Ended September 30,</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; width: 62%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%; margin-right: auto">2022</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%; margin-right: auto">2021</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding stock options</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhM8GrTf16Uh"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zymC3MI4GfT">10,400</span></span></td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAsltcD4L42f"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zBF3Po8oZ2ki">7,295</span></span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Restricted stock units</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqrhy8qXLpx"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zQ5qISNc2v2e">  <span style="-sec-ix-hidden: xdx2ixbrl0602"><span style="-sec-ix-hidden: xdx2ixbrl0603">-</span></span></span></span></td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zTC1b4OYj4ch"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zToEGH0IGZpf">2,400</span></span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding warrants</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zE0gSLaqBqbj"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3ogDEmdStW1">2,545</span></span></td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zaxdXgt2Zdwi"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTV0sDESyxl5">2,635</span></span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Convertible debt</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zSxhutOO7P9f"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zZNN9lvdr3i7">3,704</span></span></td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zCEMhzGOFm9"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z0cct3rebqad"><span style="-sec-ix-hidden: xdx2ixbrl0612"><span style="-sec-ix-hidden: xdx2ixbrl0613">-</span></span></span></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"/> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930_zhrpu2q9g2cg"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930_z2bvbPDb4czi">16,649</span></span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"/> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930_zlj0T4KLNrs4"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930_zvRmcO9gkoJa">12,330</span></span></td></tr> </table> <p id="xdx_8A9_zKZPpjg80Pv8" style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; color: Red"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Amounts in the table reflect the common stock equivalents of the noted instruments.</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: left"> </p> <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrTAZ4Okgtok" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">Recent Accounting Pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"><span style="font-weight: normal"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06: Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This standard simplifies the accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for the Company beginning after January 1, 2024, with early adoption permitted, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related disclosures. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In June 2022, the FASB issued ASU No. 2022-03: ASC Subtopic 820 - Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU 2022-03 applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in ASU 2022-03 are effective for the Company for fiscal years beginning after December 15, 2023, and the interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is evaluating the impact of this pronouncement on its consolidated financial statements and related disclosures. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"><span style="font-weight: normal"> </span></p> <p id="xdx_850_z7BVrm2KkeWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"> </span></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zp2emxigUS7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Basis of Presentation </i></b></p> <p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt">The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K (the “Annual Report”) filed with the SEC on March 4, 2022. The accompanying financial statements have been prepared by the Company in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows. The December 31, 2021 condensed consolidated balance sheet was derived from audited financial statements, but it does not include all U.S. GAAP disclosures. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.8pt 0 5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p id="xdx_848_eus-gaap--UseOfEstimates_zsG5uQdUXm5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"><span style="font-weight: normal"> </span></p> <p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjtmXpmZ5WGe" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: left"><i>Fair Value Measurements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The Company follows the accounting guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), for its fair value measurements of financial assets and liabilities measured at fair value on a recurring basis. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 1: Quoted prices in active markets for identical assets or liabilities. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 2: Observable inputs other than Level 1 prices, for similar assets or liabilities that are directly or indirectly observable in the marketplace.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: -0.5pt"><b><i>Fair Value Option</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">As permitted under FASB ASC Topic 825, Financial Instruments (“ASC 825”), the Company elected the fair value option to account for its November 2021 and December 2021 convertible notes (collectively, the “2021 Convertible Notes”). In accordance with ASC 825, the Company records these convertible notes at fair value with changes in fair value recorded in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As a result of applying the fair value option, direct costs and fees related to the convertible notes were expensed as incurred and were not deferred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"/> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zylUSVrXTDr3" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"><i>Stock-based Compensation</i></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal">The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and forfeitures rates. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role at the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal">Performance share awards are initially valued based on the Company’s closing stock price on the date of grant. The number of performance share awards that vest will be determined based on the achievement of specified performance milestones by the end of the performance period. Compensation expense for performance awards is recognized over the service period and will vary based on remeasurement during the performance period. If achievement of the performance milestone is not probable of achievement during the performance period, compensation expense is reversed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJOg7I8WZ1Vg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b><i>Income (Loss) Per Common Share</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants, performance-based restricted stock unit awards and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKQMCpo58Tdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The following potentially dilutive securities outstanding for the three and nine months ended September 30, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):</p> <p id="xdx_8BF_z66xDxRI5f8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td colspan="4" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Three and Nine Months</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td colspan="4" style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Ended September 30,</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; width: 62%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%; margin-right: auto">2022</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%; margin-right: auto">2021</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding stock options</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhM8GrTf16Uh"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zymC3MI4GfT">10,400</span></span></td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAsltcD4L42f"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zBF3Po8oZ2ki">7,295</span></span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Restricted stock units</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqrhy8qXLpx"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zQ5qISNc2v2e">  <span style="-sec-ix-hidden: xdx2ixbrl0602"><span style="-sec-ix-hidden: xdx2ixbrl0603">-</span></span></span></span></td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zTC1b4OYj4ch"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zToEGH0IGZpf">2,400</span></span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding warrants</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zE0gSLaqBqbj"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3ogDEmdStW1">2,545</span></span></td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zaxdXgt2Zdwi"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTV0sDESyxl5">2,635</span></span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Convertible debt</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zSxhutOO7P9f"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zZNN9lvdr3i7">3,704</span></span></td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zCEMhzGOFm9"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z0cct3rebqad"><span style="-sec-ix-hidden: xdx2ixbrl0612"><span style="-sec-ix-hidden: xdx2ixbrl0613">-</span></span></span></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"/> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930_zhrpu2q9g2cg"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930_z2bvbPDb4czi">16,649</span></span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"/> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930_zlj0T4KLNrs4"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930_zvRmcO9gkoJa">12,330</span></span></td></tr> </table> <p id="xdx_8A9_zKZPpjg80Pv8" style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; color: Red"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">Amounts in the table reflect the common stock equivalents of the noted instruments.</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: left"> </p> <p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKQMCpo58Tdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">The following potentially dilutive securities outstanding for the three and nine months ended September 30, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):</p> <p id="xdx_8BF_z66xDxRI5f8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td colspan="4" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Three and Nine Months</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td colspan="4" style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Ended September 30,</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; width: 62%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%; margin-right: auto">2022</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; width: 15%; margin-right: auto">2021</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding stock options</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhM8GrTf16Uh"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zymC3MI4GfT">10,400</span></span></td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAsltcD4L42f"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zBF3Po8oZ2ki">7,295</span></span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Restricted stock units</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zqrhy8qXLpx"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zQ5qISNc2v2e">  <span style="-sec-ix-hidden: xdx2ixbrl0602"><span style="-sec-ix-hidden: xdx2ixbrl0603">-</span></span></span></span></td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zTC1b4OYj4ch"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zToEGH0IGZpf">2,400</span></span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding warrants</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zE0gSLaqBqbj"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3ogDEmdStW1">2,545</span></span></td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zaxdXgt2Zdwi"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTV0sDESyxl5">2,635</span></span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Convertible debt</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zSxhutOO7P9f"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zZNN9lvdr3i7">3,704</span></span></td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zCEMhzGOFm9"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_z0cct3rebqad"><span style="-sec-ix-hidden: xdx2ixbrl0612"><span style="-sec-ix-hidden: xdx2ixbrl0613">-</span></span></span></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"/> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220701__20220930_zhrpu2q9g2cg"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20220101__20220930_z2bvbPDb4czi">16,649</span></span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"/> <td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210701__20210930_zlj0T4KLNrs4"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pin3_c20210101__20210930_zvRmcO9gkoJa">12,330</span></span></td></tr> </table> 10400000 10400000 7295000 7295000 2400000 2400000 2545000 2545000 2635000 2635000 3704000 3704000 16649000 16649000 12330000 12330000 <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrTAZ4Okgtok" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left">Recent Accounting Pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"><span style="font-weight: normal"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06: Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). This standard simplifies the accounting for convertible debt instruments by removing the separation models for convertible debt with a cash conversion feature, as well as convertible instruments with a beneficial conversion feature. As a result, entities will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce non-cash interest expense for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Additionally, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and precludes the use of the treasury stock method for certain debt instruments. The provisions of ASU 2020-06 are applicable for the Company beginning after January 1, 2024, with early adoption permitted, and an entity should adopt the provisions at the beginning of its annual fiscal year. The Company does not expect the adoption of ASU 2020-06 to have an impact on its consolidated financial statements and related disclosures. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt">In June 2022, the FASB issued ASU No. 2022-03: ASC Subtopic 820 - Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 amends ASC 820 to clarify that a contractual sales restriction is not considered in measuring an equity security at fair value and to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. ASU 2022-03 applies to both holders and issuers of equity and equity-linked securities measured at fair value. The amendments in ASU 2022-03 are effective for the Company for fiscal years beginning after December 15, 2023, and the interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company is evaluating the impact of this pronouncement on its consolidated financial statements and related disclosures. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify"><span style="font-weight: normal"> </span></p> <p id="xdx_805_eus-gaap--FairValueDisclosuresTextBlock_zMZk3J1RNT5k" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>4. Fair Value Measurement</b></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values. There were <span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_do_c20220101__20220930_zVIEDIvtCBuf">no</span> transfers between fair value measurement levels during the three and nine months ended September 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zmwG4olT1Kz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The Company’s financial assets and liabilities measured at fair value at September 30, 2022 and December 31, 2021 are as follows (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"><span id="xdx_8BE_zLdsggSUjfL6" style="display: none">Schedule of Fair Value Hierarchy Assets and Liabilities</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"/> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: middle; background-color: white"> <td style="margin-left: auto; font-weight: bold; width: 44%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td colspan="10" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">Fair Value Measurements</td></tr> <tr> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td colspan="10" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">as of September 30, 2022</td></tr> <tr> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 2%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%; margin-right: auto">(Level 1)</td> <td style="margin-left: auto; vertical-align: middle; text-align: right; background-color: white; width: 2%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%; margin-right: auto">(Level 2)</td> <td style="margin-left: auto; vertical-align: middle; text-align: right; background-color: white; width: 2%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%; margin-right: auto">(Level 3)</td> <td style="margin-left: auto; vertical-align: middle; text-align: right; background-color: white; width: 2%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%; margin-right: auto">Total</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; font-weight: bold; margin-right: auto"><span id="xdx_90B_eus-gaap--AssetsAbstract_iB_c20220101__20220930_zWdFabkXorei">Assets</span>:</td> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Cash</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_983_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zot0PPd0VX3d" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Cash">30,511</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxinhIsbA92g" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Cash"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_984_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTNxgopqclz2" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Cash"><span style="-sec-ix-hidden: xdx2ixbrl0631">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJfnL9XpkpRh" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Cash">30,511</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; font-weight: bold; margin-right: auto"><span id="xdx_904_eus-gaap--LiabilitiesAbstract_iB_c20220101__20220930_zzjUTrzf857f">Liabilities</span>:</td> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Convertible notes payable, at fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zDYtDR2WecGe" style="margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0635">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zqAcseYcNz0e" style="margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0636">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zoAjjm5NOjN8" style="margin-left: auto; text-align: right; margin-right: auto">21,397</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98E_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zPcyOdYY4Ry7" style="margin-left: auto; text-align: right; margin-right: auto">21,397</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Warrant liabilities, at fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_981_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zaBuY3Ga6X9b" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto" title="Warrant liabilities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zBIepIfguykh" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto" title="Warrant liabilities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zw0QSUeQLkDk" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto" title="Warrant liabilities, at fair value">232</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_989_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zWFB7yyzkbRk" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto" title="Warrant liabilities, at fair value">232</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_983_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zyp34N0lQM81" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_985_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIPUqg8TTs4i" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0648">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXJRmeKqmjk7" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">21,629</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z4O7Cqy7Jcd5" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">21,629</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"/> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: middle; background-color: white"> <td style="margin-left: auto; font-weight: bold; width: 44%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td colspan="10" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">Fair Value Measurements</td></tr> <tr> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td colspan="10" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">as of December 31, 2021</td></tr> <tr> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%; margin-right: auto">(Level 1)</td> <td style="margin-left: auto; vertical-align: middle; text-align: right; background-color: white; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%; margin-right: auto">(Level 2)</td> <td style="margin-left: auto; vertical-align: middle; text-align: right; background-color: white; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%; margin-right: auto">(Level 3)</td> <td style="margin-left: auto; vertical-align: middle; text-align: right; background-color: white; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%; margin-right: auto">Total</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; font-weight: bold; margin-right: auto"><span id="xdx_90C_eus-gaap--AssetsAbstract_iB_c20210101__20211231_z1NdZhfsyYU6">Assets</span>:</td> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Cash</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zphNLgkyaaSg" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">78,734</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTrI2Jcn3cac" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_984_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0vhW9igOboi" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZ0sFf2PIsVd" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">78,734</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; font-weight: bold; margin-right: auto"><span id="xdx_90E_eus-gaap--LiabilitiesAbstract_iB_c20210101__20211231_zqbnatmsvCN5">Liabilities</span>:</td> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Convertible notes payable, at fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z1Dji7GN6VXc" style="margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0657">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zZc1eDPalm1i" style="margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98E_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z6iymzVEu8el" style="margin-left: auto; text-align: right; margin-right: auto">18,920</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zMlyQogvhvz5" style="margin-left: auto; text-align: right; margin-right: auto">18,920</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Derivative liability, at fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zB0e9XsEXIV7" style="margin-left: auto; text-align: right; margin-right: auto">1,174</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z3vyQwT75uk1" style="margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0662">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zBPGwAQ3cEei" style="margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0663">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td id="xdx_98A_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zai4h0Tys5Ud" style="margin-left: auto; text-align: right; margin-right: auto">1,174</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Warrant liabilities, at fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZKHP2KXgNKf" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0665">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zpHSbRNVJiJi" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z2rtoturi0K1" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto">424</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zW1Y23DafrH3" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto">424</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkxlXzVGYAY6" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">1,174</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYs6Is3hVU9l" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zDyahd65sJWd" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">19,344</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwS6h5ca1G24" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">20,518</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"/> <p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"/> <p style="margin-top: 0; margin-bottom: 0"/> <p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"> </span></p> <p id="xdx_8AD_zWf1Uyzwva4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="background-color: white">The fair value of the Company’s money market funds is based on quoted active market prices for the funds and is determined using the market approach.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company measures the 2021 Convertible Notes and warrant liabilities <span style="background-color: white">at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level 3 measurement within the fair value hierarchy. </span>These valuations use assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an on-going basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value of the convertible notes payable and warrant liabilities related to updated assumptions and estimates are recognized within the Condensed Consolidated Statements of Operations and Comprehensive Loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The fair value of the 2021 Convertible Notes and warrant liabilities may change significantly as additional data is obtained, impacting the Company’s assumptions regarding probabilities of outcomes used to estimate the fair value of the liabilities. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s results of operations in future periods.<i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>Derivative Liability</i></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The derivative liability represented the fair value of the “Shortfall Amount” provision provided for in the license agreement with iX Biopharma Europe Limited.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At issuance, the fair value of the embedded derivative was estimated by using a Monte Carlo simulation model. As of December 31, 2021, the Company determined it was probable it would settle the Shortfall Amount in cash and estimated the fair value based on a probability weighted market approach. The Company paid the Shortfall Amount of $<span id="xdx_902_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zGsQjw9Csvmh">1.2</span> million in cash in January 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>2021 Convertible Notes</i></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zobZdwvz86B2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The 2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair value of the 2021 Convertible Notes during the nine months ended September 30, 2022 and the year ended December 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_8B1_ziFuTHcOTBZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Summary of Fair Value Measurements Convertible Notes Valuation Assumptions</p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="margin-left: auto; width: 56%; margin-right: auto"> </td> <td style="margin-left: auto; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; width: 2%; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; width: 19%; margin-right: auto">Nine Months Ended</td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; width: 2%; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; width: 19%; margin-right: auto">Year Ended</td></tr> <tr style="vertical-align: bottom"> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; margin-right: auto">September 30, 2022</td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; margin-right: auto">December 31, 2021</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Risk-free interest rate</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; text-align: center; margin-right: auto"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zOvll3JWKhD7">4.28</span>%</td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; border-top-color: Black; border-top-width: 1pt; margin-right: auto"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zZeGHvgGJ9s4">0.90</span>% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z37XKizL0Gw7">0.95</span>%</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Volatility</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; text-align: center; margin-right: auto"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zoZmJWUvIFrg">105</span>%</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zg5wBGRG8c44">113</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_zErzf8T2zyUi">114</span>%</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Dividend yield</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; text-align: center; margin-right: auto"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zW1WNfLtpRW5"><span style="-sec-ix-hidden: xdx2ixbrl0682">-</span></span>%</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_ziWfoJRwIme7"><span style="-sec-ix-hidden: xdx2ixbrl0683">-</span></span>%</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Contractual term (years)</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z6h2X2fCYeW5" style="margin-left: auto; font-size: 9pt; text-align: center; margin-right: auto">2.2</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zmlt9elrKnbd" style="margin-left: auto; vertical-align: bottom; text-align: center; margin-right: auto">3.0</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Stock price</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td style="margin-left: auto; font-size: 9pt; text-align: center; margin-right: auto"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20220930__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z6vmPs3w1Mw">1.03</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td style="margin-left: auto; vertical-align: bottom; text-align: center; margin-right: auto"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zljLj7MQFzwe">1.74</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z3kkv8fM9Zpa">1.95</span></td></tr> </table> <p id="xdx_8AF_zrGUII808ble" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: left"> </p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: left"><i>Warrant Liabilities</i></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The common stock warrant liabilities were recorded at fair value using the Black-Scholes option pricing model.  </p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"/> <p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zO2vSCDX6qTh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal"><span style="background-color: white">The following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option pricing model for the nine months ended September 30, 2022 and 2021:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal"><span style="background-color: white"> </span></span></p> <p id="xdx_8BD_zAZ6sU0ZV6p3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"><span style="display: none; background-color: white">Summary of Fair Value Measurements Warrant Valuation Assumptions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: middle"> <td style="margin-left: auto; width: 55%; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; width: 19%; margin-right: auto"> </td> <td style="margin-left: auto; width: 2%; margin-right: auto"> </td> <td style="margin-left: auto; width: 2%; margin-right: auto"> </td> <td style="margin-left: auto; width: 20%; margin-right: auto"> </td></tr> <tr style="vertical-align: middle"> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"/> <td colspan="4" style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; margin-right: auto">Nine Months Ended September 30,</td></tr> <tr style="vertical-align: middle"> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; margin-right: auto">2022</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: center; margin-right: auto"><b>2021</b></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Risk-free interest rate</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zMdsh5vwe8Ha" style="margin-left: auto; text-align: center; border-top-color: Black; border-top-width: 1pt; margin-right: auto">4.08%</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zb6jgHj0depb" style="margin-left: auto; text-align: center; border-top-color: Black; border-top-width: 1pt; margin-right: auto">0.36%</td> </tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Volatility</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zO935mlM3y82" style="margin-left: auto; text-align: center; margin-right: auto">80.30%</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zxgXfo0iVkxi" style="margin-left: auto; text-align: center; margin-right: auto">110.19%</td> </tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><p style="margin-top: 0; margin-bottom: 0">Dividend yield</p></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zTUoE1Hq2Rrc" title="Dividend yield (in percent)"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></span>%</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z9P6Rf6M6k88" title="Dividend yield (in percent)"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></span>%</td> </tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Expected term (years)</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zdi3nU0mPmpd" style="margin-left: auto; text-align: center; margin-right: auto">1.32</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zUX1MEDyAuig" style="margin-left: auto; text-align: center; margin-right: auto">2.32</td> </tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Weighted-average fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_ziIdutjUmzC6" style="margin-left: auto; text-align: center; margin-right: auto">0.77</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zJezNj6Zsfu1" style="margin-left: auto; text-align: center; margin-right: auto">2.17</td> </tr> </table> <p style="font: bold 9pt Sans-Serif; margin: 0 0 0 6pt; text-align: left; color: Red"/> <p id="xdx_8A1_zU3M9zd0geK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"> </p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zCPml5pFNX89" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The following table is a reconciliation for the common stock warrant liabilities and convertible notes measured at fair value using Level 3 unobservable inputs (in thousands): </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal; background-color: white"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal; background-color: white"> </span></p> <p id="xdx_8BF_z141aSNXGWG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="display: none; font-weight: normal; background-color: white; font-style: normal">Schedule of Fair Value Level 3 Reconciliation</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"> </p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="margin-left: auto; text-align: right; width: 56%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 1%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 2%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 11%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; width: 1%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 2%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 11%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; width: 1%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 2%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 13%; margin-right: auto"><span style="font-size: 9pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: top; text-align: center; margin-right: auto"><span style="font-size: 9pt"><b>Warrant</b></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: top; text-align: center; margin-right: auto"><span style="font-size: 9pt"><b>Derivative</b></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: top; text-align: center; margin-right: auto"><span style="font-size: 9pt"><b>Convertible notes,</b></span></td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center; margin-right: auto"><span style="font-size: 9pt">liabilities</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center; margin-right: auto"><span style="font-size: 9pt">liability</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center; margin-right: auto"><span style="font-size: 9pt">at fair value</span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; font-weight: bold; margin-right: auto"><span style="font-size: 9pt">Balance as of December 31, 2020</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZ5N7YCQckUf" style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">1,062</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Warrant liability reclassified to stockholders' equity</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zy3q2RQ3tfl9">(1,155)</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Issuance of convertible notes, at fair value</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">                       <span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2l9ITqAdDS3">19,150</span></span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Issuance of derivative liability</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">  <span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeSjkKoJkkxe">805</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Change in fair value measurement of derivative liability</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">  <span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsnriOmehMg3">369</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Change in fair value measurement of convertible notes</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"><span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1bOcwLgc6ni">(230)</span></span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Change in fair value measurement of warrant liability</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9ZMDiklTg95">517</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td></tr> <tr style="background-color: White"> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; margin-right: auto"><span style="font-size: 9pt">Balance as of December 31, 2021</span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZOckZD8d9d6" style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">424</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zqO3PH8nHf3a" style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt"> 1,174</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zzTtUmRpTS0k" style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt"> 18,920</span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Settlement of derivative liability</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">       -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> <span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01N_pn3n3_di_c20220101__20220930__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWUZ8Q3Y8img">(1,174)</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">    -</span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Change in fair value measurement of convertible notes</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220930__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlrtKI5vlwZ4">2,477</span></span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Change in fair value measurement of warrant liability</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220930__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzwioWqgOxsh">(192)</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td></tr> <tr style="background-color: White"> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; margin-right: auto"><span style="font-size: 9pt">Balance as of September 30, 2022</span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zfNvregTdolc" style="border-bottom: Black 3pt double; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">232</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zLmzdL4CAvjk" style="border-bottom: Black 3pt double; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt"> <span style="-sec-ix-hidden: xdx2ixbrl0719">-</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zIKlul0Ga2j8" style="border-bottom: Black 3pt double; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt"> 21,397</span></td></tr> </table> <p id="xdx_8A9_zTkGNxX2rtf6" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"> </p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">For the three and nine months ended September 30, 2022 and the year ended December 31, 2021, the changes in fair value of the convertible notes, derivative liability and warrant liability primarily resulted from the volatility of the Company’s common stock. </span></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"> </p> 0 <p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zmwG4olT1Kz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The Company’s financial assets and liabilities measured at fair value at September 30, 2022 and December 31, 2021 are as follows (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"><span id="xdx_8BE_zLdsggSUjfL6" style="display: none">Schedule of Fair Value Hierarchy Assets and Liabilities</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"/> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: middle; background-color: white"> <td style="margin-left: auto; font-weight: bold; width: 44%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td colspan="10" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">Fair Value Measurements</td></tr> <tr> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td colspan="10" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">as of September 30, 2022</td></tr> <tr> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 2%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%; margin-right: auto">(Level 1)</td> <td style="margin-left: auto; vertical-align: middle; text-align: right; background-color: white; width: 2%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%; margin-right: auto">(Level 2)</td> <td style="margin-left: auto; vertical-align: middle; text-align: right; background-color: white; width: 2%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%; margin-right: auto">(Level 3)</td> <td style="margin-left: auto; vertical-align: middle; text-align: right; background-color: white; width: 2%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 10%; margin-right: auto">Total</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; font-weight: bold; margin-right: auto"><span id="xdx_90B_eus-gaap--AssetsAbstract_iB_c20220101__20220930_zWdFabkXorei">Assets</span>:</td> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Cash</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_983_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zot0PPd0VX3d" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Cash">30,511</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxinhIsbA92g" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Cash"><span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_984_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTNxgopqclz2" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Cash"><span style="-sec-ix-hidden: xdx2ixbrl0631">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zJfnL9XpkpRh" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Cash">30,511</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; font-weight: bold; margin-right: auto"><span id="xdx_904_eus-gaap--LiabilitiesAbstract_iB_c20220101__20220930_zzjUTrzf857f">Liabilities</span>:</td> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Convertible notes payable, at fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zDYtDR2WecGe" style="margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0635">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zqAcseYcNz0e" style="margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0636">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zoAjjm5NOjN8" style="margin-left: auto; text-align: right; margin-right: auto">21,397</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98E_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zPcyOdYY4Ry7" style="margin-left: auto; text-align: right; margin-right: auto">21,397</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Warrant liabilities, at fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_981_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zaBuY3Ga6X9b" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto" title="Warrant liabilities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zBIepIfguykh" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto" title="Warrant liabilities, at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zw0QSUeQLkDk" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto" title="Warrant liabilities, at fair value">232</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_989_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zWFB7yyzkbRk" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto" title="Warrant liabilities, at fair value">232</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_983_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zyp34N0lQM81" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_985_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIPUqg8TTs4i" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0648">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXJRmeKqmjk7" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">21,629</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20220930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z4O7Cqy7Jcd5" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">21,629</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; background-color: white"/> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: middle; background-color: white"> <td style="margin-left: auto; font-weight: bold; width: 44%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; width: 2%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; width: 10%; margin-right: auto"/></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td colspan="10" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">Fair Value Measurements</td></tr> <tr> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td colspan="10" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">as of December 31, 2021</td></tr> <tr> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 44%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: right; background-color: white; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%; margin-right: auto">(Level 1)</td> <td style="margin-left: auto; vertical-align: middle; text-align: right; background-color: white; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%; margin-right: auto">(Level 2)</td> <td style="margin-left: auto; vertical-align: middle; text-align: right; background-color: white; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%; margin-right: auto">(Level 3)</td> <td style="margin-left: auto; vertical-align: middle; text-align: right; background-color: white; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="border-bottom: Black 0.5pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; width: 12%; margin-right: auto">Total</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; font-weight: bold; margin-right: auto"><span id="xdx_90C_eus-gaap--AssetsAbstract_iB_c20210101__20211231_z1NdZhfsyYU6">Assets</span>:</td> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Cash</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_980_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zphNLgkyaaSg" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">78,734</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTrI2Jcn3cac" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_984_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z0vhW9igOboi" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_981_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZ0sFf2PIsVd" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">78,734</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; font-weight: bold; margin-right: auto"><span id="xdx_90E_eus-gaap--LiabilitiesAbstract_iB_c20210101__20211231_zqbnatmsvCN5">Liabilities</span>:</td> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; text-align: center; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Convertible notes payable, at fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z1Dji7GN6VXc" style="margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0657">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zZc1eDPalm1i" style="margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98E_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z6iymzVEu8el" style="margin-left: auto; text-align: right; margin-right: auto">18,920</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zMlyQogvhvz5" style="margin-left: auto; text-align: right; margin-right: auto">18,920</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Derivative liability, at fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zB0e9XsEXIV7" style="margin-left: auto; text-align: right; margin-right: auto">1,174</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td id="xdx_98C_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z3vyQwT75uk1" style="margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0662">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zBPGwAQ3cEei" style="margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0663">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td id="xdx_98A_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zai4h0Tys5Ud" style="margin-left: auto; text-align: right; margin-right: auto">1,174</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto">Warrant liabilities, at fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_984_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZKHP2KXgNKf" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0665">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_98B_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zpHSbRNVJiJi" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_98F_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z2rtoturi0K1" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto">424</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_982_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zW1Y23DafrH3" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto">424</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; text-indent: 10pt; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_986_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkxlXzVGYAY6" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">1,174</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_987_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYs6Is3hVU9l" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_980_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zDyahd65sJWd" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">19,344</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_988_eus-gaap--DerivativeLiabilities_i01I_pn3n3_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwS6h5ca1G24" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto">20,518</td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"/> <p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"/> <p style="margin-top: 0; margin-bottom: 0"/> <p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; background-color: white; color: Red"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal"> </span></p> 30511000 30511000 21397000 21397000 232000 232000 21629000 21629000 78734000 78734000 18920000 18920000 1174000 1174000 424000 424000 1174000 19344000 20518000 1200000 <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zobZdwvz86B2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The 2021 Convertible Notes are valued using a Monte Carlo simulation model. The following assumptions were used in determining the fair value of the 2021 Convertible Notes during the nine months ended September 30, 2022 and the year ended December 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_8B1_ziFuTHcOTBZ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Summary of Fair Value Measurements Convertible Notes Valuation Assumptions</p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="margin-left: auto; width: 56%; margin-right: auto"> </td> <td style="margin-left: auto; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; width: 2%; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; width: 19%; margin-right: auto">Nine Months Ended</td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; width: 2%; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; width: 19%; margin-right: auto">Year Ended</td></tr> <tr style="vertical-align: bottom"> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; margin-right: auto">September 30, 2022</td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; margin-right: auto">December 31, 2021</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Risk-free interest rate</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; text-align: center; margin-right: auto"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zOvll3JWKhD7">4.28</span>%</td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; border-top-color: Black; border-top-width: 1pt; margin-right: auto"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zZeGHvgGJ9s4">0.90</span>% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z37XKizL0Gw7">0.95</span>%</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Volatility</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; text-align: center; margin-right: auto"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zoZmJWUvIFrg">105</span>%</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zg5wBGRG8c44">113</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_zErzf8T2zyUi">114</span>%</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Dividend yield</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; text-align: center; margin-right: auto"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zW1WNfLtpRW5"><span style="-sec-ix-hidden: xdx2ixbrl0682">-</span></span>%</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_ziWfoJRwIme7"><span style="-sec-ix-hidden: xdx2ixbrl0683">-</span></span>%</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Contractual term (years)</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z6h2X2fCYeW5" style="margin-left: auto; font-size: 9pt; text-align: center; margin-right: auto">2.2</td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zmlt9elrKnbd" style="margin-left: auto; vertical-align: bottom; text-align: center; margin-right: auto">3.0</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Stock price</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td style="margin-left: auto; font-size: 9pt; text-align: center; margin-right: auto"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20220930__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_z6vmPs3w1Mw">1.03</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td style="margin-left: auto; vertical-align: bottom; text-align: center; margin-right: auto"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MinimumMember_zljLj7MQFzwe">1.74</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_uUSDPShares_c20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__srt--RangeAxis__srt--MaximumMember_z3kkv8fM9Zpa">1.95</span></td></tr> </table> 4.28 0.90 0.95 10500 11300 11400 P2Y2M12D P3Y 1.03 1.74 1.95 <p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zO2vSCDX6qTh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal"><span style="background-color: white">The following assumptions were used in determining the fair value of the warrant liabilities valued using the Black-Scholes option pricing model for the nine months ended September 30, 2022 and 2021:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal"><span style="background-color: white"> </span></span></p> <p id="xdx_8BD_zAZ6sU0ZV6p3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"><span style="display: none; background-color: white">Summary of Fair Value Measurements Warrant Valuation Assumptions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"><span style="font-weight: normal"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: middle"> <td style="margin-left: auto; width: 55%; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; width: 19%; margin-right: auto"> </td> <td style="margin-left: auto; width: 2%; margin-right: auto"> </td> <td style="margin-left: auto; width: 2%; margin-right: auto"> </td> <td style="margin-left: auto; width: 20%; margin-right: auto"> </td></tr> <tr style="vertical-align: middle"> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"/> <td colspan="4" style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; margin-right: auto">Nine Months Ended September 30,</td></tr> <tr style="vertical-align: middle"> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; margin-right: auto">2022</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: center; margin-right: auto"><b>2021</b></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Risk-free interest rate</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zMdsh5vwe8Ha" style="margin-left: auto; text-align: center; border-top-color: Black; border-top-width: 1pt; margin-right: auto">4.08%</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_uPure_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zb6jgHj0depb" style="margin-left: auto; text-align: center; border-top-color: Black; border-top-width: 1pt; margin-right: auto">0.36%</td> </tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Volatility</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zO935mlM3y82" style="margin-left: auto; text-align: center; margin-right: auto">80.30%</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pin2_uPure_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zxgXfo0iVkxi" style="margin-left: auto; text-align: center; margin-right: auto">110.19%</td> </tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><p style="margin-top: 0; margin-bottom: 0">Dividend yield</p></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zTUoE1Hq2Rrc" title="Dividend yield (in percent)"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></span>%</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_z9P6Rf6M6k88" title="Dividend yield (in percent)"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></span>%</td> </tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Expected term (years)</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zdi3nU0mPmpd" style="margin-left: auto; text-align: center; margin-right: auto">1.32</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zUX1MEDyAuig" style="margin-left: auto; text-align: center; margin-right: auto">2.32</td> </tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Weighted-average fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_ziIdutjUmzC6" style="margin-left: auto; text-align: center; margin-right: auto">0.77</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20210101__20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zJezNj6Zsfu1" style="margin-left: auto; text-align: center; margin-right: auto">2.17</td> </tr> </table> <p style="font: bold 9pt Sans-Serif; margin: 0 0 0 6pt; text-align: left; color: Red"/> 0.0408 0.0036 80.30 110.19 P1Y3M25D P2Y3M25D 0.77 2.17 <p id="xdx_895_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zCPml5pFNX89" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0">The following table is a reconciliation for the common stock warrant liabilities and convertible notes measured at fair value using Level 3 unobservable inputs (in thousands): </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="font-weight: normal; background-color: white"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-weight: normal; background-color: white"> </span></p> <p id="xdx_8BF_z141aSNXGWG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left"><span style="display: none; font-weight: normal; background-color: white; font-style: normal">Schedule of Fair Value Level 3 Reconciliation</span></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"> </p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: justify"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="margin-left: auto; text-align: right; width: 56%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 1%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 2%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 11%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; width: 1%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 2%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 11%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; width: 1%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 2%; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; width: 13%; margin-right: auto"><span style="font-size: 9pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: top; text-align: center; margin-right: auto"><span style="font-size: 9pt"><b>Warrant</b></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: top; text-align: center; margin-right: auto"><span style="font-size: 9pt"><b>Derivative</b></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: top; text-align: center; margin-right: auto"><span style="font-size: 9pt"><b>Convertible notes,</b></span></td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center; margin-right: auto"><span style="font-size: 9pt">liabilities</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center; margin-right: auto"><span style="font-size: 9pt">liability</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: bottom; text-align: center; margin-right: auto"><span style="font-size: 9pt">at fair value</span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; font-weight: bold; margin-right: auto"><span style="font-size: 9pt">Balance as of December 31, 2020</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZ5N7YCQckUf" style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">1,062</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Warrant liability reclassified to stockholders' equity</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"><span id="xdx_90B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zy3q2RQ3tfl9">(1,155)</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Issuance of convertible notes, at fair value</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">                       <span id="xdx_903_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2l9ITqAdDS3">19,150</span></span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Issuance of derivative liability</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">  <span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeSjkKoJkkxe">805</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Change in fair value measurement of derivative liability</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">  <span id="xdx_90E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsnriOmehMg3">369</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Change in fair value measurement of convertible notes</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"><span id="xdx_900_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1bOcwLgc6ni">(230)</span></span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Change in fair value measurement of warrant liability</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"><span id="xdx_90A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9ZMDiklTg95">517</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td></tr> <tr style="background-color: White"> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; margin-right: auto"><span style="font-size: 9pt">Balance as of December 31, 2021</span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zZOckZD8d9d6" style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">424</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zqO3PH8nHf3a" style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt"> 1,174</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zzTtUmRpTS0k" style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt"> 18,920</span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Settlement of derivative liability</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">       -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> <span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_i01N_pn3n3_di_c20220101__20220930__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWUZ8Q3Y8img">(1,174)</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">    -</span></td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Change in fair value measurement of convertible notes</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"><span id="xdx_905_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220930__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlrtKI5vlwZ4">2,477</span></span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt">     Change in fair value measurement of warrant liability</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"><span id="xdx_909_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_i01_pn3n3_c20220101__20220930__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zzwioWqgOxsh">(192)</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 9pt">      -</span></td></tr> <tr style="background-color: White"> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; margin-right: auto"><span style="font-size: 9pt">Balance as of September 30, 2022</span></td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--WarrantMember_zfNvregTdolc" style="border-bottom: Black 3pt double; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">232</span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zLmzdL4CAvjk" style="border-bottom: Black 3pt double; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt"> <span style="-sec-ix-hidden: xdx2ixbrl0719">-</span></span></td> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 9pt"> </span></td> <td style="margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt">$</span></td> <td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_pn3n3_c20220930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--LongTermDebtMember_zIKlul0Ga2j8" style="border-bottom: Black 3pt double; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto"><span style="font-size: 9pt"> 21,397</span></td></tr> </table> 1062000 -1155000 19150000 805000 369000 -230000 517000 424000 1174000 18920000 1174000 2477000 -192000 232000 21397000 <p id="xdx_807_eus-gaap--OtherCurrentAssetsTextBlock_zxTYFBXSMjbi" style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>5. Prepaid Expenses and Other Current Assets</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_894_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z2quCZanxsAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Prepaid expenses and other current assets are comprised of the following (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_8BB_zFwXqZpjjEH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Schedule of Prepaid Expenses and Other Current Assets</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 85%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"> </td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td id="xdx_49A_20220930_zl6wElgSjKca" style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td id="xdx_495_20211231_z0xE0sLPmIEi" style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"> </td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">September 30,</td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">December 31,</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"> </td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">2022</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">2021</td></tr> <tr id="xdx_401_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAz02I_zJNUSAYIlTub" style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; width: 66%; margin-right: auto">Prepaid insurance</td> <td style="margin-left: auto; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; vertical-align: top; text-align: right; width: 1%; margin-right: auto">$</td> <td style="margin-left: auto; text-align: right; width: 15%; margin-right: auto">329</td> <td style="margin-left: auto; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; vertical-align: top; text-align: right; width: 1%; margin-right: auto">$</td> <td style="margin-left: auto; text-align: right; width: 15%; margin-right: auto">59</td></tr> <tr id="xdx_40C_ecustom--PrepaidClinicalCosts_iI_pn3n3_zCeuIdENJZpa" style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Prepaid clinical costs</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">9,254</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; vertical-align: top; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">4,481</td></tr> <tr id="xdx_407_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAz02I_zISbscDhzbyl" style="background-color: rgb(204,238,255)"> <td style="margin-left: auto; vertical-align: middle; margin-right: auto">Other</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto">414</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; vertical-align: top; text-align: right; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto">187</td></tr> <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_maACzKPF_maACzYR4_mtPEAOAz02I_zhAmDIxSO4e1" style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; padding-left: 24px; text-align: left; margin-right: auto">Prepaid expenses and other current assets</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="border-bottom: Black 2pt double; margin-left: auto; vertical-align: top; text-align: right; margin-right: auto">$</td> <td style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">9,997</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="border-bottom: Black 2pt double; margin-left: auto; vertical-align: top; text-align: right; margin-right: auto">$</td> <td style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">4,727</td></tr> </table> <p id="xdx_8A9_z5E5zcgHzLMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt; text-align: left"/> <p id="xdx_894_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z2quCZanxsAd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Prepaid expenses and other current assets are comprised of the following (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_8BB_zFwXqZpjjEH5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; display: none">Schedule of Prepaid Expenses and Other Current Assets</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 85%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"> </td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td id="xdx_49A_20220930_zl6wElgSjKca" style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td id="xdx_495_20211231_z0xE0sLPmIEi" style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"> </td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">September 30,</td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">December 31,</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"> </td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">2022</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"> </td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">2021</td></tr> <tr id="xdx_401_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAz02I_zJNUSAYIlTub" style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; width: 66%; margin-right: auto">Prepaid insurance</td> <td style="margin-left: auto; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; vertical-align: top; text-align: right; width: 1%; margin-right: auto">$</td> <td style="margin-left: auto; text-align: right; width: 15%; margin-right: auto">329</td> <td style="margin-left: auto; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; vertical-align: top; text-align: right; width: 1%; margin-right: auto">$</td> <td style="margin-left: auto; text-align: right; width: 15%; margin-right: auto">59</td></tr> <tr id="xdx_40C_ecustom--PrepaidClinicalCosts_iI_pn3n3_zCeuIdENJZpa" style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Prepaid clinical costs</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">9,254</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; vertical-align: top; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto">4,481</td></tr> <tr id="xdx_407_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAz02I_zISbscDhzbyl" style="background-color: rgb(204,238,255)"> <td style="margin-left: auto; vertical-align: middle; margin-right: auto">Other</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; vertical-align: middle; text-align: center; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto">414</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; vertical-align: top; text-align: right; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; vertical-align: middle; text-align: right; margin-right: auto">187</td></tr> <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01TI_pn3n3_maACzKPF_maACzYR4_mtPEAOAz02I_zhAmDIxSO4e1" style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; padding-left: 24px; text-align: left; margin-right: auto">Prepaid expenses and other current assets</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="border-bottom: Black 2pt double; margin-left: auto; vertical-align: top; text-align: right; margin-right: auto">$</td> <td style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">9,997</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="border-bottom: Black 2pt double; margin-left: auto; vertical-align: top; text-align: right; margin-right: auto">$</td> <td style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">4,727</td></tr> </table> 329000 59000 9254000 4481000 414000 187000 9997000 4727000 <p id="xdx_808_eus-gaap--BusinessCombinationDisclosureTextBlock_zWRxfvxCmEWd" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">6. Common Stock Offerings</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Public Offerings</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 24, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zearSnETS3e7">22,258,066 </span>shares of its common stock, at a price to the public of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210524__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zkYUNTkLxcd1">3.10 </span>per share, which included the exercise in full by the underwriter of its option to purchase up to 2,903,226 additional shares of common stock. The net proceeds to the Company from the offering were approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zhylCscaQiz">64.5 </span>million, after deducting underwriting discounts, commissions and other offering expenses. The Company used $<span id="xdx_90E_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--May242021Member_zbSSnmJkeCOh">7.3 </span>million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 28, 2021, the Company completed an underwritten public offering, pursuant to which the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_ziiVbkN1rM35">17,530,488 </span>shares of its common stock, at a price to the public of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pp2p0_uUSDPShares_c20210128__us-gaap--StatementClassOfStockAxis__custom--January282021Member_zhwuTBDaRzq1">2.05 </span>per share, which included the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to the Company from the offering were approximately $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_z86SClZKrcwl">33.5 </span>million, after deducting underwriting discounts, commissions and other offering expenses. The Company used $<span id="xdx_907_ecustom--OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes_pn5n6_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--January282021Member_z7HAPFqbneJ7">3.8 </span>million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Stock Purchase Agreement with iX Biopharma Europe Limited</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 24, 2021, the Company entered in an exclusive license agreement and stock purchase agreement (the “iXBEL Stock Purchase Agreement”) with iX Biopharma Europe Limited (“iXBEL”). As consideration for the license under the license agreement, the Company paid iXBEL an upfront fee of $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zbhykfLuIVV3">9.0</span> million, comprised of $<span id="xdx_904_ecustom--NonrefundableCashPayment_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zmPI9QRGhjX2">3.5</span> million in cash and <span id="xdx_901_ecustom--Issuanceofcommonstockforlicenseacquiredshares_pip0_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zW4EhQQTZYA3">2,570,266</span> restricted shares of the Company’s common stock. Pursuant to the iXBEL Stock Purchase Agreement, the Company agreed to reimburse iXBEL for the difference in value (the “Shortfall Amount”) in the event the aggregate value of the <span id="xdx_901_ecustom--Issuanceofcommonstockforlicenseacquiredshares_pip0_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_znU54BEBumsl">2,570,266</span> shares of the Company’s common stock at the time of registration and issuance was less than $<span id="xdx_90D_ecustom--MinimumStockValueOfSharesIssued_pn5n6_c20211101__20211130__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zpmu58Wkjku9">5.5</span> million. The initial fair value of this Shortfall Amount was $<span id="xdx_909_ecustom--InitialStockValuationShortfallFrom5.5MillionValue_pn5n6_c20211101__20211231__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_z326PtoKuTtb">0.8</span> million and in January 2022, the Company settled the Shortfall Amount by the payment of $<span id="xdx_906_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--IXLicenseAgreementMember_zwDR1YtqtHq3">1.2</span> million in cash to iXBEL. The change in fair value of the Shortfall Amount is included in Change in fair value of derivative liability on the Condensed Consolidated Statement of Operations and Comprehensive Loss (see Note 4).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 22258066 3.10 64500000 7300000 17530488 2.05 33500000 3800000 9000000.0 3500000 2570266 2570266 5500000 800000 1200000 <p id="xdx_80D_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zdB1HoTH1FWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>7. License Agreements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Specific information pertaining to each of the Company’s significant license agreements is discussed in its audited financial statements included in the Annual Report for the years ended December 31, 2021 and 2020, including their nature and purpose, the significant rights and obligations of the parties, and specific accounting policy elections. The following represents updates for the nine months ended September 30, 2022, if applicable, to the Company’s significant license agreements:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Acquisition of Assets from Phoenixus AG f/k/a Vyera Pharmaceuticals, AG and Turing Pharmaceuticals AG (“Vyera”)</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left; background-color: white"><span id="xdx_909_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zvwKKGerMXY">On April 8, 2022, Seelos Corporation (“STI”), a wholly-owned subsidiary of the Company, and Vyera, entered into an amendment (the “Amendment”) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018 (as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the “Vyera Purchase Agreement”). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product candidate currently referred to as SLS-002 (intranasal ketamine) (the “Vyera Assets”) and agreed, among other things, to make certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the “Milestone and Royalty Payment Obligations”) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received by the Company as an upfront payment in such sale (the “Change of Control Payment Obligation”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left; background-color: white">Pursuant to the Vyera Purchase Agreement, as amended by the Amendment, STI agreed to (i) make a cash payment to Vyera in the aggregate amount of $<span id="xdx_90F_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pn5n6_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zVkPLrqRAag9">4.0</span> million on or before April 8, 2022 (the “Cash Payment”); (ii) issue to Vyera on or before April 11, 2022 500,000 shares of the Company’s common stock (the “Initial Shares”); (iii) issue to Vyera on or before July 11, 2022 an additional <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zOgi1iuvgXAk">500,000</span> shares of the Company’s common stock (as adjusted for stock splits, stock dividends, combinations, recapitalizations and the like) (the “July 2022 Shares”); and (iv) issue to Vyera on or before January 11, 2023 an additional number of shares of the Company’s common stock equal to $1.0 million divided by the volume weighted average closing price of the Company’s common stock for the ten consecutive trading days ending on the fifth trading day prior to the applicable date of issuance of the shares of the Company’s common stock (the “January 2023 Shares”, and together with the Cash Payment, the Initial Shares and the July 2022 Shares, the “Final Payments”). In consideration for the Final Payments, all of STI’s contingent payment obligations under the Vyera Purchase Agreement, including the Milestone and Royalty Payment Obligations and the Change of Control Payment Obligation, as well as all commercialization covenants of STI under the Vyera Purchase Agreement, will terminate in full upon the date that all of the Final Payments have been made.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: left; background-color: white">The Company paid the $<span id="xdx_905_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pn5n6_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_z4VF9GMPDTS7">4.0</span> million Cash Payment and issued the <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zThBKNt8K3Ni">500,000</span> Initial Shares to Vyera in April 2022. The Company issued the <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20220701__20220731__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zHSwXx7YIC1k">500,000</span> July 2022 Shares to Vyera in July 2022. The Company recognized $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20220701__20220930__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zGQug7P3HYYb" title="Research and development expense">5.8</span> million in research and development expense during the three months ended June 30, 2022 related to the Amendment, which consisted of the initial cash payment of $<span id="xdx_905_ecustom--CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement_pn5n6_c20220401__20220430__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_z7uS9LkFKJY4">4.0</span> million and $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220701__20220731__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zB5nZqBrysY6">0.8</span> million for the Initial Shares and the July 2022 Shares, which were measured at their grant-date fair value. The Company also recognized a liability of $<span id="xdx_905_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn5n6_c20220930__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--AssetsfromVyeraPharmaceuticalsMember_zr87TenLB6Z6" title="Other Accrued Liabilities, Current">1.0</span> million related to the January 2023 Shares within accrued licenses payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Acquisition of License from Stuart Weg, MD</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_907_eus-gaap--BusinessCombinationSeparatelyRecognizedTransactionsDescription_c20190801__20190831__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zlZ8kLOosFO2">On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $</span><span id="xdx_905_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zGva1W1wyXU">0.2 </span>million on January 2, 2022. The Company paid the required $<span id="xdx_90E_ecustom--NonrefundableCashPayment_pn5n6_c20200101__20200131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zL51DBdLIJ7i">0.1 </span>million on January 2, 2020, $<span id="xdx_90A_ecustom--NonrefundableCashPayment_pp3n6_c20210101__20210131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zMzcpsO2NU67">0.125 </span>million on January 2, 2021 and $<span id="xdx_901_ecustom--NonrefundableCashPayment_pn5n6_c20220101__20220131__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_zh1yTMG0Ikdc">0.2 </span>million on January 2, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">The remaining potential regulatory and commercial milestones are not yet considered probable, and <span id="xdx_903_eus-gaap--AssetAcquisitionContingentConsiderationLiabilityCurrent_iI_pip0_do_c20220930__us-gaap--BusinessCombinationSeparatelyRecognizedTransactionsAxis__custom--WegLicenseAgreementMember_z3jXY2sDc6ce">no</span> other milestone payments have been accrued at September 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> On April 8, 2022, Seelos Corporation (“STI”), a wholly-owned subsidiary of the Company, and Vyera, entered into an amendment (the “Amendment”) to the Asset Purchase Agreement by and between STI and Vyera, dated March 6, 2018 (as amended by a first amendment thereto entered into on May 18, 2018, a second amendment thereto entered into on December 31, 2018, a third amendment thereto entered into on October 15, 2019 and a fourth amendment thereto entered into on February 15, 2021, the “Vyera Purchase Agreement”). Pursuant to the Vyera Purchase Agreement, STI acquired the assets and liabilities of Vyera related to a product candidate currently referred to as SLS-002 (intranasal ketamine) (the “Vyera Assets”) and agreed, among other things, to make certain development and commercialization milestone payments and royalty payments related to the Vyera Assets (the “Milestone and Royalty Payment Obligations”) and further agreed that in the event that the Company sold, directly or indirectly, all or substantially all of the Vyera Assets to a third party, then the Company would pay Vyera an amount equal to 4% of the net proceeds actually received by the Company as an upfront payment in such sale (the “Change of Control Payment Obligation”). 4000000.0 500000 4000000.0 500000 500000 5800000 4000000.0 800000 1000000.0 On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $ 200000 100000 125000 200000 0 <p id="xdx_80E_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zIsKhPRNio92" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>8. Accrued Expenses</b></p> <p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zLbnzvITG1p5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Accrued expenses are comprised of the following (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-right: 0; margin-left: 0"><span><span id="xdx_8BD_z6KWwFfJHuHk">Schedule of Accrued Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; margin-right: auto"> <tr style="vertical-align: top"> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td id="xdx_493_20220930_z5DQG8HQ9iO2" style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td id="xdx_490_20211231_zmD5DtFUaTSf" style="margin-left: auto; text-align: center; margin-right: auto"> </td></tr> <tr style="vertical-align: top"> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span style="font-size: 10pt"><b>September 30,</b></span></td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span style="font-size: 10pt"><b>December 31,</b></span></td></tr> <tr style="vertical-align: top"> <td style="margin-left: auto; width: 64%; margin-right: auto"> </td> <td style="margin-left: auto; width: 1%; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; width: 2%; text-align: right; margin-right: auto"> </td> <td style="border-bottom: black 1.5pt solid; margin-left: auto; width: 15%; text-align: center; margin-right: auto"><span style="font-size: 10pt"><b>2022</b></span></td> <td style="margin-left: auto; width: 1%; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; width: 2%; text-align: right; margin-right: auto"> </td> <td style="border-bottom: black 1.5pt solid; margin-left: auto; width: 15%; text-align: center; margin-right: auto"><span style="font-size: 10pt"><b>2021</b></span></td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZt1_ziFqceZp8kCd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 10pt">Professional fees</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">$</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">239 </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">$</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">181 </span></td></tr> <tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zct9paxXbfkh" style="vertical-align: bottom; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 10pt">Personnel related</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">955 </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">1,303 </span></td></tr> <tr id="xdx_401_ecustom--OutsideResearchAndDevelopmentServicesCurrent_iI_pn3n3_zFJGLg2nsUn5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 10pt">Outside research and development services</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">2,767 </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">2,219 </span></td></tr> <tr id="xdx_406_eus-gaap--AccruedInsuranceCurrent_iI_pn3n3_zfpu6qZ5A2Kg" style="vertical-align: bottom; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 10pt">Insurance</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">84 </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0789">-</span> </span></td></tr> <tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zVwREZNxc5Fc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 10pt">Other</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="border-bottom: black 1.5pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">3 </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="border-bottom: black 1.5pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">25 </span></td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZt1_ztGJO0fQsEb3" style="vertical-align: bottom; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 10pt">     Accrued expenses, net</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">4,048 </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">3,728 </span></td></tr> </table> <p id="xdx_8A6_zJtCCx3fxOm9" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"><b><i> </i></b></p> <p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zLbnzvITG1p5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Accrued expenses are comprised of the following (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; display: none; margin-right: 0; margin-left: 0"><span><span id="xdx_8BD_z6KWwFfJHuHk">Schedule of Accrued Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; margin-right: auto"> <tr style="vertical-align: top"> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td id="xdx_493_20220930_z5DQG8HQ9iO2" style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td id="xdx_490_20211231_zmD5DtFUaTSf" style="margin-left: auto; text-align: center; margin-right: auto"> </td></tr> <tr style="vertical-align: top"> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span style="font-size: 10pt"><b>September 30,</b></span></td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span style="font-size: 10pt"><b>December 31,</b></span></td></tr> <tr style="vertical-align: top"> <td style="margin-left: auto; width: 64%; margin-right: auto"> </td> <td style="margin-left: auto; width: 1%; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; width: 2%; text-align: right; margin-right: auto"> </td> <td style="border-bottom: black 1.5pt solid; margin-left: auto; width: 15%; text-align: center; margin-right: auto"><span style="font-size: 10pt"><b>2022</b></span></td> <td style="margin-left: auto; width: 1%; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; width: 2%; text-align: right; margin-right: auto"> </td> <td style="border-bottom: black 1.5pt solid; margin-left: auto; width: 15%; text-align: center; margin-right: auto"><span style="font-size: 10pt"><b>2021</b></span></td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZt1_ziFqceZp8kCd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 10pt">Professional fees</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">$</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">239 </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">$</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">181 </span></td></tr> <tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zct9paxXbfkh" style="vertical-align: bottom; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 10pt">Personnel related</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">955 </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">1,303 </span></td></tr> <tr id="xdx_401_ecustom--OutsideResearchAndDevelopmentServicesCurrent_iI_pn3n3_zFJGLg2nsUn5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 10pt">Outside research and development services</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">2,767 </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">2,219 </span></td></tr> <tr id="xdx_406_eus-gaap--AccruedInsuranceCurrent_iI_pn3n3_zfpu6qZ5A2Kg" style="vertical-align: bottom; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 10pt">Insurance</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">84 </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0789">-</span> </span></td></tr> <tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZt1_zVwREZNxc5Fc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 10pt">Other</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="border-bottom: black 1.5pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">3 </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="border-bottom: black 1.5pt solid; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">25 </span></td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZt1_ztGJO0fQsEb3" style="vertical-align: bottom; background-color: White"> <td style="margin-left: auto; margin-right: auto"><span style="font-size: 10pt">     Accrued expenses, net</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">4,048 </span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; margin-left: auto; text-align: right; margin-right: auto"><span style="font-size: 10pt">3,728 </span></td></tr> </table> 239000 181000 955000 1303000 2767000 2219000 84000 3000 25000 4048000 3728000 <p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zLtfGH8Xgij3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>9. Debt</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt"/><p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b>Convertible Notes</b></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>November 2021 and December 2021 Convertible Notes and Private Placement</i></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_904_eus-gaap--LongTermDebtDescription_c20211101__20211130__us-gaap--DebtInstrumentAxis__custom--November2021LindSecuritiesPurchaseAgreementMember_zfcTsRffSNl3">On November 23, 2021, the Company entered into a Securities Purchase Agreement (the “2021 Lind Securities Purchase Agreement”) with Lind Global Asset Management V, LLC (“Lind V”) pursuant to which, among other things, on November 23, 2021 (the “Closing Date”), the Company issued and sold to Lind V, in a private placement transaction (the “Private Placement”), in exchange for the payment by Lind V of $20.0 million, (i) a convertible promissory note (the “2021 Note”) in an aggregate principal amount of $22.0 million (the “Principal Amount”), which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate of 5% per annum, and mature on November 23, 2024 (the “Maturity Date”), and (ii) 534,759 shares of Company common stock.</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_904_eus-gaap--LongTermDebtDescription_c20221101__20221130__us-gaap--DebtInstrumentAxis__custom--FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember_zEV0cSbbk5d6">At the first anniversary of the Closing Date, the Company shall have the option, at its sole discretion and subject to certain stock price and other conditions, to issue to Lind V a convertible promissory note (the “Second Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible promissory note (the “Third Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S. Food &amp; Drug Administration for either SLS-002 or SLS-005, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible promissory note (the “Fourth Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90C_eus-gaap--LongTermDebtDescription_c20220823__20241123__us-gaap--DebtInstrumentAxis__custom--August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember_zE0qTVToKwsc"> At any time following August 23, 2022, from time to time and before the Maturity Date, Lind V shall have the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the “Conversion Price”). At any time prior August 23, 2022, the Company had the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time during such period), up to an aggregate of $14.7 million of the outstanding Principal Amount of the 2021 Note with no penalty. The Company did not prepay any amounts of the 2021 Note prior to August 23, 2022 and has the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Subject to certain exceptions, the Company will be required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2021 Notes, unless waived by Lind V in advance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90A_eus-gaap--LongTermDebtDescription_c20221123__20241124__us-gaap--DebtInstrumentAxis__custom--AmortizeNovember2021LindSecuritiesPurchaseAgreementMember_zJDYkPnrmip5">Beginning on November 23, 2022, the 2021 Note will amortize in twenty-four monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments shall be payable, at the Company’s sole option, in cash, shares of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022, the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90% of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note, on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the Company’s assets and properties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90F_eus-gaap--LongTermDebtDescription_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zJXT89faIVld">On December 2, 2021, the Company entered into two separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021 Note.</span></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the year ended December 31, 2021, the Company received aggregate gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zySTussPyR23">20.2</span> million from the convertible notes offerings. The Company elected to account for these notes under the fair value option. At time of issuance, the Company recorded a liability of $<span id="xdx_90F_eus-gaap--ConvertibleSubordinatedDebt_iI_pn5n6_c20211202__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zlhBlPEhsIZ7">19.2</span> million, which was determined to be the fair value at time of issuance. As of December 31, 2021 and September 30, 2022, the Company recognized a total convertible note liability of $<span id="xdx_907_eus-gaap--ConvertibleSubordinatedDebt_iI_pn5n6_c20211231__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zYKqQBEqvbY5">18.9</span> million and $<span id="xdx_904_eus-gaap--ConvertibleSubordinatedDebt_iI_pn5n6_c20220930__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zx5pYZDnGzK3">21.4</span> million, respectively. During the three and nine months ended September 30, 2022, the Company recognized a $<span id="xdx_904_ecustom--GainLossInFairValueOfConvertibleNotes_pn5n6_c20220701__20220930__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zX8JeFyvPYVa">2.1</span> million and $<span id="xdx_903_ecustom--GainLossInFairValueOfConvertibleNotes_pn5n6_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zPY5liX8ERSh">2.5</span> million loss on change in fair value of convertible notes, respectively. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of September 30, 2022, the principal contractual balance of the convertible notes totaled $<span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20220930__us-gaap--DebtInstrumentAxis__custom--December2021SPAsMember_zZxa1GbfuPfg">22.2</span> million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0"><i>December 2020 Convertible Note and Private Placement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 20pt; text-indent: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: left"><span id="xdx_901_eus-gaap--LongTermDebtDescription_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--LindSecuritiesPurchaseAgreementMember_zM4f5isFyqNg">On December 11, 2020, the Company entered into a Securities Purchase Agreement (the “2020 Lind Securities Purchase Agreement”) with Lind Global Asset Management II, LLC (the “Investor”) pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the “2020 Note”) in an aggregate principal amount of $12,000,000 (the “Principal Amount”), which did not bear interest and was to mature on December 11, 2022 (the “Maturity Date”), and (2) 975,000 shares of the Company’s common stock. At any time following June 11, 2021, and from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020 Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of 406,250 additional shares of its common stock (the “Lind Shares”) and to pay the Investor the remaining principal amount of $790,804 (the “Final Payment”) in full satisfaction of the Company’s remaining obligations to the Investor under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities Purchase Agreement and the 2020 Note terminated, effective June 15, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_902_eus-gaap--LongTermDebtDescription_c20201201__20201231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_zNaztLWBB4i4">On December 17, 2020, the Company entered into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2020 Lind Securities Purchase Agreement (the “December 17 SPAs”), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1) convertible promissory notes (the “December 17 Notes”) in an aggregate principal amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with an accredited investor on substantially the same terms as the 2020 Lind Securities Purchase Agreement (the “December 18 SPA” and, together with the December 17 SPAs, the “Subsequent Securities Purchase Agreements”), pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the “December 18 Note” and, together with the December 17 Notes, the “Subsequent Notes”), and (2) 26,263 shares of the Company’s common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the 2020 Lind Securities Purchase Agreement, and the Subsequent Notes had substantially the same terms as the 2020 Note. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the “December 18 Note Holder”) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December 18 Note Holder agreed to return to the Company $42,777 in cash (the “Repayment”) previously paid by the Company to the December 18 Note Holder as a payment against the Company’s obligations under the December 18 Note, and (ii) the Company agreed to issue to the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the “December 18 Note Shares”) in full satisfaction of the Company’s remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder paid the Company the Repayment and the Company issued the December 18 Note Shares, and the December 18 SPA and the December 18 Note terminated, effective July 7, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company received aggregate net proceeds of $10.9 million from the convertible notes offering, net of $0.5 million of issuance costs. The total gross proceeds were allocated to the convertible notes and common stock issued under the agreements based on their relative fair values. Due to the principal payments made during the year, the Company remeasured the beneficial conversion feature discount at each payment date and recorded a loss on extinguishment of debt of approximately $1.0 million during the year ended December 31, 2021 as well as a reduction in additional paid-in capital of $1.5 million as of December 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 5pt; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">During the year ended December 31, 2021, the Company paid approximately $<span id="xdx_905_eus-gaap--RepaymentsOfConvertibleDebt_pn5n6_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_zBKJoERIgJc5">13.6</span> million in principal payments on the outstanding convertible notes and issued an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pip0_c20211201__20211231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_z4zmjDAAiCB7">475,315</span> shares of its common stock upon conversion of the convertible notes, and <span id="xdx_90F_eus-gaap--LongTermDebt_iI_dn_c20211231__us-gaap--DebtInstrumentAxis__custom--December17SPAsMember_z5ixQC4kG0Q3">none</span> of the 2020 convertible notes remain outstanding as of December 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.9pt 0 0; background-color: white"> </p> On November 23, 2021, the Company entered into a Securities Purchase Agreement (the “2021 Lind Securities Purchase Agreement”) with Lind Global Asset Management V, LLC (“Lind V”) pursuant to which, among other things, on November 23, 2021 (the “Closing Date”), the Company issued and sold to Lind V, in a private placement transaction (the “Private Placement”), in exchange for the payment by Lind V of $20.0 million, (i) a convertible promissory note (the “2021 Note”) in an aggregate principal amount of $22.0 million (the “Principal Amount”), which will bear no interest until the first anniversary of the issuance of the 2021 Note and will thereafter bear interest at a rate of 5% per annum, and mature on November 23, 2024 (the “Maturity Date”), and (ii) 534,759 shares of Company common stock. At the first anniversary of the Closing Date, the Company shall have the option, at its sole discretion and subject to certain stock price and other conditions, to issue to Lind V a convertible promissory note (the “Second Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. At the earlier of (i) the two-year anniversary of the Closing Date, or (ii) the successful readout for SLS-005 in ALS, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible promissory note (the “Third Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. In the event of the filing of a new drug application with the U.S. Food & Drug Administration for either SLS-002 or SLS-005, and subject to the mutual agreement of the Company and Lind V, the Company shall issue to Lind V a convertible promissory note (the “Fourth Note”) in the principal amount of $11.0 million in exchange for the payment by Lind V of $10.0 million. The Second Note, the Third Note and the Fourth Note, if issued, would be in substantially the same form as the 2021 Note. At any time following August 23, 2022, from time to time and before the Maturity Date, Lind V shall have the option to convert any portion of the then-outstanding Principal Amount of the 2021 Note into shares of Common Stock at a price per share of $6.00, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions (the “Conversion Price”). At any time prior August 23, 2022, the Company had the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time during such period), up to an aggregate of $14.7 million of the outstanding Principal Amount of the 2021 Note with no penalty. The Company did not prepay any amounts of the 2021 Note prior to August 23, 2022 and has the right to prepay, in whole or in part (exercisable by the Company at any time or from time to time prior to the Maturity Date), up to the full remaining Principal Amount of the 2021 Note with no penalty; however, if the Company exercises such prepayment right, Lind V will have the option to convert up to thirty-three and one-third percent (33 1/3%) of the amount that the Company elects to prepay at the Conversion Price. Beginning on November 23, 2022, the 2021 Note will amortize in twenty-four monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2021 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments shall be payable, at the Company’s sole option, in cash, shares of Common Stock or a combination of both. In addition, commencing on the last business day of the first month following November 23, 2022, the Company will pay, on a monthly basis, all interest that has accrued and remains unpaid on the then-outstanding Principal Amount of the 2021 Note. Any portion of an amortization payment or interest payment that is paid in shares of Common Stock shall be priced at 90% of the average of the five lowest daily volume weighted average prices of the Common Stock during the 20 trading days prior to the date of issuance of the shares. If, after the first amortization payment, the Company elects to make any amortization payments in cash, the Company shall pay a 5% premium on each cash payment. In conjunction with the 2021 Lind Securities Purchase Agreement and the 2021 Note, on the Closing Date, the Company and Lind V entered into a security agreement, which provides Lind V with a first priority lien on the Company’s assets and properties. On December 2, 2021, the Company entered into two separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2021 Lind Securities Purchase Agreement, pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $201,534, (i) convertible promissory notes in an aggregate principal amount of $221,688, which will bear no interest and mature on December 2, 2024, and (ii) an aggregate of 5,388 shares of its common stock. These notes have substantially the same terms as the 2021 Note. 20200000 19200000 18900000 21400000 2100000 2500000 22200000 On December 11, 2020, the Company entered into a Securities Purchase Agreement (the “2020 Lind Securities Purchase Agreement”) with Lind Global Asset Management II, LLC (the “Investor”) pursuant to which, among other things, on December 11, 2020, the Company issued and sold to the Investor, in a private placement transaction, in exchange for the payment by the Investor of $10,000,000, (1) a convertible promissory note (the “2020 Note”) in an aggregate principal amount of $12,000,000 (the “Principal Amount”), which did not bear interest and was to mature on December 11, 2022 (the “Maturity Date”), and (2) 975,000 shares of the Company’s common stock. At any time following June 11, 2021, and from time to time before the Maturity Date, the Investor had the option to convert any portion of the then-outstanding Principal Amount of the Note into shares of common stock at a price per share of $1.60, subject to adjustment for stock splits, reverse stock splits, stock dividends and similar transactions. Prior to June 11, 2021, the Company had the right to prepay up to sixty-six and two-thirds percent (66 2/3%) of the then-outstanding Principal Amount of the 2020 Note with no penalty. Subject to certain exceptions, the Company was required to direct proceeds from any subsequent debt financings (including subordinated debt, convertible debt or mandatorily redeemable preferred stock but other than purchase money debt or capital lease obligations or other indebtedness incurred in the ordinary course of business) to repay the 2020 Note, unless waived by the Investor in advance. The 2020 Note began amortizing in June 2021 and was to amortize in eighteen monthly installments equal to the quotient of (i) the then-outstanding Principal Amount of the 2020 Note, divided by (ii) the number of months remaining until the Maturity Date. All amortization payments were to be payable solely in cash, plus a 2% premium. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On June 14, 2021, the Company and the Investor entered into an Acknowledgment and Termination Agreement, pursuant to which the Company agreed to issue to the Investor an aggregate of 406,250 additional shares of its common stock (the “Lind Shares”) and to pay the Investor the remaining principal amount of $790,804 (the “Final Payment”) in full satisfaction of the Company’s remaining obligations to the Investor under the 2020 Note. The Company issued the Lind Shares and made the Final Payment to the Investor, and the 2020 Lind Securities Purchase Agreement and the 2020 Note terminated, effective June 15, 2021. On December 17, 2020, the Company entered into three separate securities purchase agreements with certain accredited investors on substantially the same terms as the 2020 Lind Securities Purchase Agreement (the “December 17 SPAs”), pursuant to which the Company sold, in private placement transactions, in exchange for the payment by the accredited investors of an aggregate of $1,138,023, (1) convertible promissory notes (the “December 17 Notes”) in an aggregate principal amount of $1,365,628, which did not bear interest and were to mature on December 17, 2022, and (2) an aggregate of 110,956 shares of its common stock. On December 18, 2020, the Company entered into an additional securities purchase agreement with an accredited investor on substantially the same terms as the 2020 Lind Securities Purchase Agreement (the “December 18 SPA” and, together with the December 17 SPAs, the “Subsequent Securities Purchase Agreements”), pursuant to which the Company sold, in a private placement transaction, in exchange for the payment by the accredited investor of $269,373, (1) a convertible promissory note in an aggregate principal amount of $323,247, which did not bear interest and was to mature on December 18, 2022 (the “December 18 Note” and, together with the December 17 Notes, the “Subsequent Notes”), and (2) 26,263 shares of the Company’s common stock. The Subsequent Securities Purchase Agreements had substantially the same terms as the 2020 Lind Securities Purchase Agreement, and the Subsequent Notes had substantially the same terms as the 2020 Note. During the first half of 2021, the Company made certain repayments on the outstanding principal balance of the convertible notes. On July 7, 2021, the Company and the holder of the December 18 Note (the “December 18 Note Holder”) entered into an Acknowledgement and Termination Agreement, pursuant to which: (i) the December 18 Note Holder agreed to return to the Company $42,777 in cash (the “Repayment”) previously paid by the Company to the December 18 Note Holder as a payment against the Company’s obligations under the December 18 Note, and (ii) the Company agreed to issue to the December 18 Note Holder an aggregate of 43,664 additional shares of its common stock (the “December 18 Note Shares”) in full satisfaction of the Company’s remaining obligations to the December 18 Note Holder under the December 18 Note. The December 18 Note Holder paid the Company the Repayment and the Company issued the December 18 Note Shares, and the December 18 SPA and the December 18 Note terminated, effective July 7, 2021. 13600000 475315 0 <p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxvBJE321Eaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>10. Stockholders’ Equity</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Preferred Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company is authorized to issue <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20220930_z3M3INil6LL3" title="Preferred stock, authorized (in shares)">10,000,000</span> shares of preferred stock, par value $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20220930_zoZ8TbW98AF5" title="Preferred stock, per value (in usd per share)">0.001</span>. <span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220930_zf5lZtigDuRl" title="Preferred stock, outstanding (in shares)"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20211231_zfGV5eNrFRGl" title="Preferred stock, outstanding (in shares)">No</span></span> shares of preferred stock were outstanding as of September 30, 2022 or December 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has authorized <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20220930_z0XqhIpu1pO" title="Common stock, authorized (in shares)"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pp0p0_c20211231_zcwqnL9otRod">240,000,000</span></span> shares of common stock as of September 30, 2022 and December 31, 2021. <span id="xdx_90A_eus-gaap--CommonStockVotingRights_c20220101__20220930_z2LHr9TN8063" title="Common stock voting right">Each share of common stock is entitled to one voting right</span>. Common stock owners are entitled to dividends when funds are legally available and declared by the Board of Directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify; text-indent: -0.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrants</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify; text-indent: -0.5pt"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>September 2020 Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20200901__20200930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zKPp0HrdPCD2" title="Warrant description"> On September 4, 2020, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in a registered direct offering and issued warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the “September 2020 Warrants”). The September 2020 Warrants are exercisable for <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20200901__20200930__us-gaap--StatementClassOfStockAxis__custom--September2020WarrantsMember_zx2PxpEuEDol" title="Number of shares of common stock issued">6,648,750</span> shares of common stock at an exercise price per share equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20200904__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zVxOUsZ4SiWb">0.84</span>. The September 2020 Warrants became exercisable beginning on <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z0AFn5jPTCFb" title="Date on which warrants became exercisable">March 9, 2021</span> and will expire on March 9, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span title="Warrant description"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span title="Warrant description"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the nine months ended September 30, 2022 and 2021, the September 2020 Warrants were exercised for <span id="xdx_906_ecustom--NumberofWarrantsExercisedDuringPeriod_pip0_uShares_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zJZk2eajssXc">0</span> and <span id="xdx_907_ecustom--NumberofWarrantsExercisedDuringPeriod_pn5n6_uShares_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z5j9o9NLuoa4" title="Number of warrants exercised">5.6</span> million shares of common stock, respectively, for approximately $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pp0p0_uUSD_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_zb9E5P6i1s1d">0</span> and $<span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_pn5n6_uUSD_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z5Ocz2VZ4Tea" title="Proceeds from exercise of warrants">4.7</span> million, respectively. As of September 30, 2022, the September 2020 Warrants exercisable for <span id="xdx_90D_ecustom--WarrantsExercisable_iI_pip0_c20220930__us-gaap--StatementClassOfStockAxis__custom--September2020WarrantsMember_zEXtbeGZLrLh" title="Warrants exercisable as of March 31, 2022">1.0 million</span> shares of common stock remain outstanding at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220930__us-gaap--ClassOfWarrantOrRightAxis__custom--September2020WarrantsMember_z5Vs3TVncQu8">0.84 </span>per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>August 2019 Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20190801__20190831__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_z4gydDtfCY6a" title="Warrant description">On August 23, 2019, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20190801__20190831__us-gaap--StatementClassOfStockAxis__custom--August232019Member_zhtMha9qEnSe" title="Number of shares of common stock issued">4,475,000</span> shares of common stock in a registered direct offering and issued warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the “August 2019 Warrants”). The August 2019 Warrants were initially exercisable for 2,237,500 shares of common stock at an exercise price per share equal to $1.78. The August 2019 Warrants became exercisable beginning on <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zGjJ35EP3Msb" title="Date on which warrants became exercisable">February 27, 2020</span> and will expire on August 28, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the nine months ended September 30, 2022 and 2021, the August 2019 Warrants for <span id="xdx_90F_ecustom--NumberofWarrantsExercisedDuringPeriod_pip0_uShares_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zjOjOX2II8He">0</span> and <span id="xdx_904_ecustom--NumberofWarrantsExercisedDuringPeriod_pin6_uShares_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zFZOLHEbaCv7" title="Number of warrants exercised">1.3</span> million shares of common stock, respectively, were exercised for approximately $<span id="xdx_905_eus-gaap--ProceedsFromWarrantExercises_pip0_uUSD_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zzzYmFjMpYmc">0</span> and $<span id="xdx_907_eus-gaap--ProceedsFromWarrantExercises_pin6_uUSD_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_zVE6Fik56lC7" title="Proceeds from exercise of warrants">2.4</span> million, respectively. As of September 30, 2022, the August 2019 Warrants exercisable for <span id="xdx_90F_ecustom--WarrantsExercisable_iI_pip0_c20220930__us-gaap--StatementClassOfStockAxis__custom--August2019WarrantsMember_zo8XXlVwPGm3" title="Warrants exercisable as of June 30, 2021">900,000</span> shares of common stock remain outstanding at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220930__us-gaap--ClassOfWarrantOrRightAxis__custom--August2019WarrantsMember_z1s93KduUvg9">1.78 </span>per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Series A Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zEpmqsmW0VWe" title="Warrant description"> On January 24, 2019, STI and the Company closed a private placement with certain accredited investors pursuant to which, among other things, the Company issued warrants representing the right to acquire 1,463,519 shares of common stock (the “Series A Warrants”). The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per share) occurred during the three months ended September 30, 2020 as a result of the announcement of the registered direct offering of 8,865,000 shares of common stock in September 2020. The Series A Warrants were immediately exercisable upon issuance and will expire on January 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt">During the nine months ended September 30, 2022 and 2021, the Series A Warrants for <span id="xdx_90D_ecustom--NumberofWarrantsExercisedDuringPeriod_pip0_uShares_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zhTtpcQNdgX2" style="background-color: White">0 </span><span style="background-color: White">and <span id="xdx_903_ecustom--NumberofWarrantsExercisedDuringPeriod_pn5n6_uShares_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zTLZtvgpQ7o">0.5 million </span></span><span style="background-color: White">shares of common stock, respectively, were exercised for approximately $<span id="xdx_90D_eus-gaap--ProceedsFromWarrantExercises_pip0_uUSD_c20220101__20220930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zRXRdZuXpjSi">0 </span></span><span style="background-color: White">and $<span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_pn5n6_uUSD_c20210101__20210930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zuP8JwInlI04">0.1 </span></span><span style="background-color: White">million, respectively. As of September 30, 2022, the Series A Warrants exercisable for <span id="xdx_900_ecustom--WarrantsExercisable_iI_pn5n6_uShares_c20220930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zXkOeHGQBGnc">0.3 </span></span><span style="background-color: White">million shares of common stock remain outstanding at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220930__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zOjTdDkM2MX1">0.2957 </span></span><span style="background-color: White">per share</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt; text-align: justify"> </p> <p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zJmTqFB9NdR" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">A summary of warrant activity during the nine months ended September 30, 2022 is as follows (share amounts in thousands):</p> <p id="xdx_8B7_zAzfrCVOkjad" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none">Summary of Warrant Activity</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"> </p> <p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"><b> </b></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; vertical-align: middle; width: 52%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; width: 1%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; width: 12%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 14%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 18%; margin-right: auto">Weighted-</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Weighted-</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Average</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Average</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Remaining</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Exercise</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Contractual Life</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: bottom; text-align: center; margin-right: auto">Warrants</td> <td style="margin-left: auto; font-weight: bold; vertical-align: bottom; text-align: center; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Price</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">(in years)</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding as of December 31, 2021</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pin3_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zVsegwJaPjd9" style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto" title="Outstanding as of December 31, 2021">2,635</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pp2p0_uUSDPShares_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zk5wu7yMDzS4" style="margin-left: auto; text-align: right; margin-right: auto" title="Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share)">4.29</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_dtY_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zwR8jli0Nh1i" style="margin-left: auto; text-align: right; margin-right: auto" title="Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years)">2.4</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-align: left; margin-right: auto">Issued</td> <td style="margin-left: auto; text-align: left; margin-right: auto"/> <td id="xdx_982_ecustom--NumberofWarrantsIssuedDuringPeriod_i01_pin3_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zWDPwpTOZZE3" style="margin-left: auto; text-align: right; margin-right: auto" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98B_ecustom--ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_i01_pp0p0_uUSDPShares_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_z2rH7kka6x78" style="margin-left: auto; text-align: right; margin-right: auto" title="Issued, warrant exercise price"><span style="-sec-ix-hidden: xdx2ixbrl0880">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; text-align: left; margin-right: auto">Exercised</td> <td style="margin-left: auto; text-align: left; margin-right: auto"/> <td id="xdx_987_ecustom--NumberofWarrantsExercisedDuringPeriod_i01_pin3_uShares_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zQcbM0iCtgac" style="margin-left: auto; text-align: right; margin-right: auto" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zDz7wKwof1T2" style="margin-left: auto; text-align: right; margin-right: auto" title="Exercised, exercise price of warrants"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-align: left; margin-right: auto">Cancelled</td> <td style="margin-left: auto; text-align: left; margin-right: auto"/> <td id="xdx_98D_ecustom--NumberofWarrantsCancelledDuringPeriod_i01_pin3_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zanUN4oqzN95" style="margin-left: auto; text-align: right; margin-right: auto" title="Cancelled">(90)</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98D_ecustom--ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zzTRbdEUlo61" style="margin-left: auto; text-align: right; margin-right: auto" title="Cancelled, exercise price of warrants">47.06</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding as of September 30, 2022</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pin3_c20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zMVFK4LmZjJ1" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Outstanding as of March 31, 2022">2,545</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pp2p0_uUSDPShares_c20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zkKzonwbUDy1" style="margin-left: auto; text-align: right; margin-right: auto" title="Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share)">2.78</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_984_ecustom--ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife_dtY_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zx9zjmi3IoW2" style="margin-left: auto; text-align: right; margin-right: auto" title="Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years)">1.8</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Exercisable as of September 30, 2022</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_980_ecustom--WarrantsExercisable_iI_pin3_uShares_c20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zpMJjyrAdWT8" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Warrants exercisable as of March 31, 2022">2,545</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1_iI_pp2p0_uUSDPShares_c20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_z7LrM02b7lUj" style="margin-left: auto; text-align: right; margin-right: auto" title="Exercisable, weighted-average exercise price (in usd per share)">2.78</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife_dtY_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zit7sSBCEzhj" style="margin-left: auto; text-align: right; margin-right: auto" title="Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years)">1.8</td></tr> </table> <p id="xdx_8AA_zJWRWtXJbfXh" style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"><b> </b></p> <p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"><b> </b></p> <p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"/> <p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0">The Series A Warrants were recognized as a liability at their fair value upon issuance. The warrant liability is remeasured to the then fair value prior to their exercise or at period end for warrants that are unexercised and the gain or loss recognized in earnings during the period.</p> <p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt/103% Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 10000000 0.001 0 0 240000000 240000000 Each share of common stock is entitled to one voting right On September 4, 2020, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 8,865,000 shares of common stock in a registered direct offering and issued warrants to purchase up to 6,648,750 shares of common stock in a concurrent private placement (the “September 2020 Warrants”). The September 2020 Warrants are exercisable for 6,648,750 shares of common stock at an exercise price per share equal to $0.84. The September 2020 Warrants became exercisable beginning on March 9, 2021 and will expire on March 9, 2026. 6648750 0.84 2021-03-09 0 5600000 0 4700000 1.0 0.84 On August 23, 2019, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company issued and sold an aggregate of 4,475,000 shares of common stock in a registered direct offering and issued warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement (the “August 2019 Warrants”). The August 2019 Warrants were initially exercisable for 2,237,500 shares of common stock at an exercise price per share equal to $1.78. The August 2019 Warrants became exercisable beginning on February 27, 2020 and will expire on August 28, 2023. 4475000 2020-02-27 0 1300000 0 2400000 900000 1.78 On January 24, 2019, STI and the Company closed a private placement with certain accredited investors pursuant to which, among other things, the Company issued warrants representing the right to acquire 1,463,519 shares of common stock (the “Series A Warrants”). The Series A Warrants were initially exercisable for 1,463,519 shares of common stock at an exercise price per share equal to $4.15, which was adjusted several times pursuant to the terms thereof to 3,629,023 shares of common stock at an exercise price per share equal to $0.2957 per share. The most recent adjustment to the exercise price (from $0.60 to $0.2957 per share) occurred during the three months ended September 30, 2020 as a result of the announcement of the registered direct offering of 8,865,000 shares of common stock in September 2020. The Series A Warrants were immediately exercisable upon issuance and will expire on January 31, 2024. 0 500000 0 100000 300000 0.2957 <p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zJmTqFB9NdR" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">A summary of warrant activity during the nine months ended September 30, 2022 is as follows (share amounts in thousands):</p> <p id="xdx_8B7_zAzfrCVOkjad" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none">Summary of Warrant Activity</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"> </p> <p style="font: 9pt Sans-Serif; margin: 0 0 0 5pt; color: Red"><b> </b></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; vertical-align: middle; width: 52%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; width: 1%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; width: 12%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 14%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 18%; margin-right: auto">Weighted-</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Weighted-</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Average</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Average</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Remaining</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Exercise</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Contractual Life</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: bottom; text-align: center; margin-right: auto">Warrants</td> <td style="margin-left: auto; font-weight: bold; vertical-align: bottom; text-align: center; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Price</td> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">(in years)</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding as of December 31, 2021</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pin3_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zVsegwJaPjd9" style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto" title="Outstanding as of December 31, 2021">2,635</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pp2p0_uUSDPShares_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zk5wu7yMDzS4" style="margin-left: auto; text-align: right; margin-right: auto" title="Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share)">4.29</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife_dtY_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zwR8jli0Nh1i" style="margin-left: auto; text-align: right; margin-right: auto" title="Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years)">2.4</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-align: left; margin-right: auto">Issued</td> <td style="margin-left: auto; text-align: left; margin-right: auto"/> <td id="xdx_982_ecustom--NumberofWarrantsIssuedDuringPeriod_i01_pin3_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zWDPwpTOZZE3" style="margin-left: auto; text-align: right; margin-right: auto" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98B_ecustom--ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights_i01_pp0p0_uUSDPShares_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_z2rH7kka6x78" style="margin-left: auto; text-align: right; margin-right: auto" title="Issued, warrant exercise price"><span style="-sec-ix-hidden: xdx2ixbrl0880">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; text-align: left; margin-right: auto">Exercised</td> <td style="margin-left: auto; text-align: left; margin-right: auto"/> <td id="xdx_987_ecustom--NumberofWarrantsExercisedDuringPeriod_i01_pin3_uShares_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zQcbM0iCtgac" style="margin-left: auto; text-align: right; margin-right: auto" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_987_ecustom--ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zDz7wKwof1T2" style="margin-left: auto; text-align: right; margin-right: auto" title="Exercised, exercise price of warrants"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-align: left; margin-right: auto">Cancelled</td> <td style="margin-left: auto; text-align: left; margin-right: auto"/> <td id="xdx_98D_ecustom--NumberofWarrantsCancelledDuringPeriod_i01_pin3_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zanUN4oqzN95" style="margin-left: auto; text-align: right; margin-right: auto" title="Cancelled">(90)</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98D_ecustom--ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights_i01_pp2p0_uUSDPShares_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zzTRbdEUlo61" style="margin-left: auto; text-align: right; margin-right: auto" title="Cancelled, exercise price of warrants">47.06</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding as of September 30, 2022</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pin3_c20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zMVFK4LmZjJ1" style="border-top: Black 1pt solid; border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Outstanding as of March 31, 2022">2,545</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pp2p0_uUSDPShares_c20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zkKzonwbUDy1" style="margin-left: auto; text-align: right; margin-right: auto" title="Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share)">2.78</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_984_ecustom--ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife_dtY_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zx9zjmi3IoW2" style="margin-left: auto; text-align: right; margin-right: auto" title="Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years)">1.8</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Exercisable as of September 30, 2022</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_980_ecustom--WarrantsExercisable_iI_pin3_uShares_c20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zpMJjyrAdWT8" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Warrants exercisable as of March 31, 2022">2,545</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98F_ecustom--ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1_iI_pp2p0_uUSDPShares_c20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_z7LrM02b7lUj" style="margin-left: auto; text-align: right; margin-right: auto" title="Exercisable, weighted-average exercise price (in usd per share)">2.78</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_98E_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife_dtY_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--WarrantDerivativeFinancialInstrumentsMember_zit7sSBCEzhj" style="margin-left: auto; text-align: right; margin-right: auto" title="Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years)">1.8</td></tr> </table> 2635000 4.29 P2Y4M24D -90000 47.06 2545000 2.78 P1Y9M18D 2545000 2.78 P1Y9M18D <p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zPxW4MSS64y6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>11. Stock-based Compensation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjEXvo3BF0ll">The Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the “2012 Plan”), which provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of common stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a number of shares of common stock set by the Company’s board of directors on or prior to each such January 1. On January 1, 2022, in accordance with the foregoing, an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pn5n6_c20220101__20220131__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4ao9xz93Cyi">4,713,637</span> shares of common stock were added to shares authorized for issuance under the 2012 Plan. As of September 30, 2022, an aggregate of </span><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxCm3FSDKfnb">15,817,818 shares of common stock were authorized under the 2012 Plan, of which </span><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pin6_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNYFCsc1yCLj">5.4 million shares of common stock were available for future grants. No further awards may be issued under the Seelos Therapeutics, Inc. 2016 Equity Incentive Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20200501__20200531__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zUp64cWhap45">On May 15, 2020, the Company's stockholders approved the Company's 2020 Employee Stock Purchase Plan (the "ESPP"), whereby qualified employees are allowed to purchase limited amounts of the Company's common stock at the lesser of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pip2_dp_uPure_c20200501__20200531__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zoJp2tYn9H46">85</span>% of the market price at the beginning or end of the offering period. The stockholders have authorized an initial amount of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pn5n6_c20200515__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zkHegzw9MvS3">1.0</span> million shares for purchase by employees under the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding December 31, and (ii) a number of shares of common stock set by the Company's Board of Directors or the Compensation Committee of the Board of Directors (the "Compensation Committee") of the Company on or prior to each such January 1. On January 1, 2022, the Company added <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pn5n6_c20220101__20220131__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zGH7iOhmSb3k">1,055,004</span> shares for purchase by employees under the ESPP. During the nine months ended September 30, 2022, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_pip0_c20220101__20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zENhTgvp7H3f">111,561</span> shares of common stock under the ESPP. The compensation costs are calculated as the fair value of the <span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent_pip2_dp_uPure_c20220101__20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zXlVmqN5iIvi" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price Discount of Common Stock, Percent">15</span>% discount from market price and were approximately $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zRgDgAFNJdD8">33,000</span> for the nine months ended September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"><span style="background-color: white"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220930__us-gaap--AwardTypeAxis__custom--InducementPlanof2019Member_z9A4VSBa5K7b" title="Description of share-based compensation arrangement by share-based payment award">On July 28, 2019, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of the Company adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the “2019 Inducement Plan”), which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20220930__us-gaap--AwardTypeAxis__custom--InducementPlanof2019Member_zxhGoLZ0wQ18">1,000,000</span> shares of the Company’s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Stock options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the nine months ended September 30, 2022, the Company granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_uShares_c20220101__20220930__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_z2SgQsmP8KD2" title="Options granted in period">660,605</span> incentive stock options and <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_uShares_c20220101__20220930__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToEmployeesMember_z3a9pm0cgjw5" title="Options granted in period">2,299,395</span> non-qualified stock options to employees with a weighted average exercise price per share of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220930__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zsTu5tZrUG68" title="Weighted-average exercise price per share granted in period">1.45</span> and a <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pp0p0_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zIncsHkEArYg" title="Term of option grant">10</span>-year term, subject to the terms and conditions of the 2012 Plan above. The stock options are subject to time vesting requirements. The stock options granted to employees vest <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pip2_c20220101__20220930__us-gaap--AwardTypeAxis__custom--IncentiveStockOptionMember_zdaOBXwL2mG8" title="Vesting percentage on the first anniversary">25</span>% on the first anniversary of the grant and monthly thereafter over the next three years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the nine months ended September 30, 2022, the Company also granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0p0_uShares_c20220101__20220930__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_zu4ZGsGZls1g">140,000 </span>non-qualified stock options to non-employee directors with a weighted average exercise price per share of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220930__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_z98SQE63i3D7">1.56 </span>and a <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_pp0p0_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_zott91ostHJ8">10</span>-year term, subject to the terms and conditions of the 2012 Plan above. The stock options granted to non-employee directors vest monthly over the <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_pp0p0_dtM_c20220101__20220930__us-gaap--AwardTypeAxis__custom--NonQualifiedStockOptionsToNonEmployeeDirectorsMember_zBzq32HhVI77">12</span> months following the grant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The fair value of stock option grants are estimated on the date of grant using the Black-Scholes option-pricing model. The Company was historically a private company and lacked sufficient company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on a weighted average blend of the historical volatility of a publicly traded set of peer companies, as well as its own historical volatility. Additionally, due to an insufficient history with respect to stock option activity and post-vesting cancellations, the expected term assumption for employee grants is based on a permitted simplified method, which is based on the vesting period and contractual term for each tranche of awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the nine months ended September 30, 2022, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pip0_c20220101__20220930_zbNibUNUZnEa" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period">6,250</span> stock options were exercised and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pip0_do_c20220101__20220930_zhG9caZoSfKk">no</span> options were forfeited.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXhvmmQk8jQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following assumptions were used in determining the fair value of the stock options granted during the nine months ended September 30, 2022 and 2021:</p> <p id="xdx_8BF_zXfcPsXzw2Jd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Valuation Assumptions for Stock Options</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; text-align: center; color: Red"><b> </b></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: middle"> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"/> <td colspan="4" style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; margin-right: auto">Nine Months Ended</td></tr> <tr style="vertical-align: middle"> <td style="margin-left: auto; width: 56%; margin-right: auto"/> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; width: 1%; margin-right: auto"/> <td style="margin-left: auto; text-align: right; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; width: 19%; margin-right: auto">September 30, 2022</td> <td style="margin-left: auto; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; width: 2%; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; width: 19%; margin-right: auto">September 30, 2021</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Risk-free interest rate</td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: center; border-top-color: Black; border-top-width: 1pt; margin-right: auto"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdCBhQOESApk" title="Risk-free interest rate, minimum">1.6</span>% - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNU7E7TmXNZ2" title="Risk-free interest rate, maximum">3.4</span>%</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; vertical-align: middle; margin-right: auto"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaw9JfPbSYCf" title="Risk-free interest rate, minimum">0.5</span>% - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNFpbFl6jBx8" title="Risk-free interest rate, maximum">1.2</span>%</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Volatility</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip2_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zFavjs9sVYzg">111</span>%-<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip2_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zkQ0CIgOlsH">113</span>%</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; vertical-align: middle; margin-right: auto"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip2_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zCu5A0wIo5X" title="Volatility, minimum">118</span>%-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip2_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zbmpwtP3Dod1" title="Volatility, maximum">125</span>%</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Dividend yield</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBZ0nuYtvsgj" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></span>%</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMw7nMKk6NE8" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0954">-</span></span>%</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Expected term (years)</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zkXwwlaXcPf1" title="Expected term (in years)">5</span> - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zcIrVx6zpjf4" title="Expected term (in years)">6</span></td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zyOZouKZL2Hf" title="Expected term (in years)">5</span> - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zYMIhLURROZ8" title="Expected term (in years)">6</span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Weighted-average fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td style="margin-left: auto; vertical-align: top; text-align: center; margin-right: auto"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zS7WWcxzWJG4">1.22 </span></td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; vertical-align: middle; margin-right: auto">$</td> <td style="margin-left: auto; text-align: center; vertical-align: middle; margin-right: auto"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3QjzDilkePh">3.52</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_8A8_zYZBcd45wDAk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zHoecFH9CL2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of stock option activity during the nine months ended September 30, 2022 is as follows (share amounts in thousands):</p> <p id="xdx_8B1_z61dgi5nD0Y" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none">Summary of Stock Option Activity</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; vertical-align: middle; width: 50%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; width: 1%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; width: 10%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; width: 1%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 14%; margin-right: auto">Weighted-</td> <td style="margin-left: auto; vertical-align: middle; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 10%; margin-right: auto"/></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Weighted-</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Average</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Total</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Average</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Remaining</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Aggregate</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Stock</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Exercise</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Contractual</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Intrinsic</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: bottom; text-align: center; margin-right: auto">Options</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Price</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Life (in years)</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Value</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding as of December 31, 2021</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_uShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8DRlDoteBmd" style="margin-left: auto; text-align: right; margin-right: auto" title="Outstanding as of December 31, 2020">7,306</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2p0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNRFCa6nzHZd" style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto" title="Outstanding, beginning of period (USD per share)">2.60</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Granted</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_uShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwnupptFGlE2" style="margin-left: auto; text-align: right; margin-right: auto" title="Granted">3,100</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9zZwzdJog2a" style="margin-left: auto; text-align: right; margin-right: auto" title="Granted in period (USD per share)">1.45</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Exercised</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pin3_di_uShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlCi5aYzVFUk" style="margin-left: auto; text-align: right; margin-right: auto" title="Exercised">(6)</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK8uGvidBrPl" style="margin-left: auto; text-align: right; margin-right: auto" title="Exercised in period (USD per share)">1.06</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-align: left; margin-right: auto">Cancelled</td> <td style="margin-left: auto; text-align: left; margin-right: auto"/> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pin3_uShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkc8B5xX6D5f" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0980">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_d0_uUSDPShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxGwBF3Vrcuc" style="margin-left: auto; text-align: right; margin-right: auto" title="Cancelled (USD per share)">-</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding as of September 30, 2022</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pin3_uShares_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzm5D2xq4SNj" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Outstanding as of March 31, 2022">10,400</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2p0_uUSDPShares_c20220930_zluYR8j89ilb" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Outstanding, end of period (USD per share)">2.26</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxFZ5t8BsFIa" style="margin-left: auto; text-align: right; margin-right: auto" title="Outstanding - weighted-average remaining contractual life (in years)">8.3</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_uUSD_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmTnd2z3aFVi" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Total aggregate intrinsic value shares outstanding">11</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Vested and expected to vest as of September 30, 2022</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pin3_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZxuz0taII67" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Vested and expected to vest, end of period (shares)">10,400</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZehi5vfrYxh" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Vested and expected to vest stock, end of period (USD per share)">2.26</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9fjPU26J7jd" style="margin-left: auto; text-align: right; margin-right: auto" title="Weighted-average remaining contractual life (in years) of vested and expected to vest stock options">8.3</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pn3n3_uUSD_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7WoLf9QCUcf" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Total aggregate intrinsic value of vested or expected to vest stock options">11</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Exercisable as of September 30, 2022</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pin3_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZZkyT9PQA7l" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Exercisable, end of period (shares)">4,053</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziSc5ZlGQaEg" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Exercisable, end of period (USD per share)">2.78</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zi0CS9SqBoFh" style="margin-left: auto; text-align: right; margin-right: auto" title="Weighted-average remaining contractual life (in years) of exercisable stock options">7.7</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_uUSD_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR7kKYYOvYGf" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Total aggregate intrinsic value of exercisable stock options">9</td></tr> </table> <p style="font: 9pt Sans-Serif; margin: 0"/> <p id="xdx_8AF_zcrDRY3Pdsx" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The intrinsic value of options exercised during the nine months ended September 30, 2022 and 2021 was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeVzPL8BmmV">0.1 </span>million and $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKU1VQpJlN47">0.2 million</span>, respectively. As of September 30, 2022, unrecognized stock-option compensation expense of $<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z2Ip2j1Ku1Xi">8.4 </span>million is expected to be realized over a weighted-average period of <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_pid_dtY_uYears_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuqAgVJflJzi">2.3 </span>years. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Performance Stock Award</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_pip0_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_znt4Em1nKwp8">During the year ended December 31, 2021, the Company’s Board of Directors awarded a performance stock unit award to the Company’s Chief Executive Officer for <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zcXiSQnQOTTa">2,400,000</span> shares of common stock, with a grant date fair value of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zlAQCD3CEaqi">4.31</span> per unit. Vesting of this award was subject to the Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had been satisfied. The Company recognized stock-based compensation related to this award of $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zIRnh2jKais5">4.9</span> million during the fourth quarter of 2021, which was recorded in general and administrative expense. During the nine months ended September 30, 2022, the Company and its Chief Executive Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation expense of the three achieved milestones of $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zl8CUARNs9Hk">1.3</span> million. The two remaining milestones were not deemed probable of achievement at the time of cancellation, and <span id="xdx_90F_ecustom--SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount_iI_pn5n6_do_c20220930__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__us-gaap--PlanNameAxis__custom--PSUtoExecutivesMember_zuDJJGiI79dd" title="Share-Based Payment Arrangement, Nonvested and Canceled Award, Excluding Option, Cost Not yet Recognized, Amount">no</span> compensation cost related to these milestones was recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zKedatNYpX1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company’s condensed consolidated statements of operations (in thousands):</p> <p id="xdx_8B8_zeKdjKdluhy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Stock-Based Compensation Expense</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; vertical-align: middle; background-color: white; margin-right: auto"/> <td> </td> <td> </td> <td colspan="4" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">Three Months Ended</td> <td style="margin-left: auto; vertical-align: middle; background-color: white; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td colspan="4" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">Nine Months Ended</td> </tr> <tr> <td style="margin-left: auto; vertical-align: middle; background-color: white; margin-right: auto"/> <td> </td> <td> </td> <td colspan="4" style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">September 30,</td> <td style="margin-left: auto; vertical-align: middle; background-color: white; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td colspan="4" style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">September 30,</td> </tr> <tr> <td style="margin-left: auto; vertical-align: middle; background-color: white; width: 48%; margin-right: auto"/> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 10%; margin-right: auto">2022</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 10%; margin-right: auto">2021</td> <td style="margin-left: auto; vertical-align: middle; background-color: white; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 10%; margin-right: auto">2022</td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 10%; margin-right: auto">2021</td> </tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Research and development</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zFId1S4IGqV6" style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">261</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20210701__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zHAVzDveecy8" style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">193</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zN5QWxLluht5" style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">721</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zslE3wS0bHAf" style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">551</td> </tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">General and administrative</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zMavLKkMCv7d" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto">712</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20210701__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTMKXp4yHcT6" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto">664</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z5jUmyWwHdig" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto">3,445</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zLwC3pW69aXa" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto">2,048</td> </tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; text-align: left; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20220701__20220930_zJqodgvch84d" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">973</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20210701__20210930_zbWmrOgK0v3f" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">857</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220930_z5NcbiPvPGMg" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">4,166</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210930_ze855cQxOOKk" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">2,599</td> </tr> </table> <p id="xdx_8AE_z8btxmdDkg6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> The Company has the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan (the “2012 Plan”), which provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant. The 2012 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2012 Plan on January 1st of each year commencing on January 1, 2020 and ending on (and including) January 1, 2029. The number of shares added each year will be equal to the lesser of (a) 4% of the number of shares of common stock issued and outstanding on a fully-diluted basis as of the close of business on the immediately preceding December 31, and (b) a number of shares of common stock set by the Company’s board of directors on or prior to each such January 1. On January 1, 2022, in accordance with the foregoing, an aggregate of 4,713,637 shares of common stock were added to shares authorized for issuance under the 2012 Plan. As of September 30, 2022, an aggregate of 4713637000000 15817818 5400000 On May 15, 2020, the Company's stockholders approved the Company's 2020 Employee Stock Purchase Plan (the "ESPP"), whereby qualified employees are allowed to purchase limited amounts of the Company's common stock at the lesser of 85% of the market price at the beginning or end of the offering period. The stockholders have authorized an initial amount of 1.0 million shares for purchase by employees under the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1st of each year commencing on January 1, 2021 and ending on (and including) January 1, 2030, which amount shall be equal to the lesser of (i) 1% of the number of shares of the Company's common stock issued and outstanding on the immediately preceding December 31, and (ii) a number of shares of common stock set by the Company's Board of Directors or the Compensation Committee of the Board of Directors (the "Compensation Committee") of the Company on or prior to each such January 1. On January 1, 2022, the Company added 1,055,004 shares for purchase by employees under the ESPP. During the nine months ended September 30, 2022, the Company sold 111,561 shares of common stock under the ESPP. The compensation costs are calculated as the fair value of the 15% discount from market price and were approximately $33,000 for the nine months ended September 30, 2022. 0.0085 1000000.0 1055004000000 111561 0.0015 33000 On July 28, 2019, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of the Company adopted the Seelos Therapeutics, Inc. 2019 Inducement Plan (the “2019 Inducement Plan”), which became effective on August 12, 2019. The 2019 Inducement Plan provides for the grant of equity-based awards in the form of stock options, stock appreciation rights, restricted stock, unrestricted stock, stock units, including restricted stock units, performance units and cash awards, solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. Awards under the 2019 Inducement Plan may only be granted to an individual, as a material inducement to such individual to enter into employment with the Company, who (i) has not previously been an employee or director of the Company or (ii) is rehired following a bona fide period of non-employment with the Company. The maximum number of shares available for grant under the 2019 Inducement Plan is 1,000,000 shares of the Company’s common stock. The 2019 Inducement Plan is administered by the Compensation Committee and expires on August 12, 2029. 1000000 660605 2299395 1.45 P10Y 0.25 140000 1.56 P10Y P12M 6250 0 <p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zXhvmmQk8jQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following assumptions were used in determining the fair value of the stock options granted during the nine months ended September 30, 2022 and 2021:</p> <p id="xdx_8BF_zXfcPsXzw2Jd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Valuation Assumptions for Stock Options</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <p style="font: 9pt Sans-Serif; margin: 0 0 0 4.5pt; text-align: center; color: Red"><b> </b></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: middle"> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"/> <td colspan="4" style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; margin-right: auto">Nine Months Ended</td></tr> <tr style="vertical-align: middle"> <td style="margin-left: auto; width: 56%; margin-right: auto"/> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; width: 1%; margin-right: auto"/> <td style="margin-left: auto; text-align: right; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; width: 19%; margin-right: auto">September 30, 2022</td> <td style="margin-left: auto; width: 1%; margin-right: auto"> </td> <td style="margin-left: auto; width: 2%; margin-right: auto"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-size: 9pt; font-weight: bold; text-align: center; width: 19%; margin-right: auto">September 30, 2021</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Risk-free interest rate</td> <td style="margin-left: auto; font-size: 9pt; font-weight: bold; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: center; border-top-color: Black; border-top-width: 1pt; margin-right: auto"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdCBhQOESApk" title="Risk-free interest rate, minimum">1.6</span>% - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNU7E7TmXNZ2" title="Risk-free interest rate, maximum">3.4</span>%</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; vertical-align: middle; margin-right: auto"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaw9JfPbSYCf" title="Risk-free interest rate, minimum">0.5</span>% - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNFpbFl6jBx8" title="Risk-free interest rate, maximum">1.2</span>%</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Volatility</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip2_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zFavjs9sVYzg">111</span>%-<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip2_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zkQ0CIgOlsH">113</span>%</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; vertical-align: middle; margin-right: auto"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pip2_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zCu5A0wIo5X" title="Volatility, minimum">118</span>%-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pip2_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zbmpwtP3Dod1" title="Volatility, maximum">125</span>%</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Dividend yield</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBZ0nuYtvsgj" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></span>%</td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMw7nMKk6NE8" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0954">-</span></span>%</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Expected term (years)</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zkXwwlaXcPf1" title="Expected term (in years)">5</span> - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zcIrVx6zpjf4" title="Expected term (in years)">6</span></td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: center; margin-right: auto"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zyOZouKZL2Hf" title="Expected term (in years)">5</span> - <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zYMIhLURROZ8" title="Expected term (in years)">6</span></td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Weighted-average fair value</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td style="margin-left: auto; vertical-align: top; text-align: center; margin-right: auto"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zS7WWcxzWJG4">1.22 </span></td> <td style="margin-left: auto; margin-right: auto"> </td> <td style="margin-left: auto; text-align: right; vertical-align: middle; margin-right: auto">$</td> <td style="margin-left: auto; text-align: center; vertical-align: middle; margin-right: auto"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pp2p0_uUSDPShares_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3QjzDilkePh">3.52</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 1.6 3.4 0.5 1.2 1.11 1.13 1.18 1.25 P5Y P6Y P5Y P6Y 1.22 3.52 <p id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zHoecFH9CL2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of stock option activity during the nine months ended September 30, 2022 is as follows (share amounts in thousands):</p> <p id="xdx_8B1_z61dgi5nD0Y" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; display: none">Summary of Stock Option Activity</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; vertical-align: middle; width: 50%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; width: 1%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; width: 10%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 10%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; width: 1%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 14%; margin-right: auto">Weighted-</td> <td style="margin-left: auto; vertical-align: middle; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 1%; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; width: 10%; margin-right: auto"/></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Weighted-</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Average</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Total</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Average</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Remaining</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Aggregate</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Stock</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Exercise</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Contractual</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Intrinsic</td></tr> <tr> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: bottom; text-align: center; margin-right: auto">Options</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Price</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Life (in years)</td> <td style="margin-left: auto; vertical-align: middle; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; margin-right: auto">Value</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding as of December 31, 2021</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pin3_uShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8DRlDoteBmd" style="margin-left: auto; text-align: right; margin-right: auto" title="Outstanding as of December 31, 2020">7,306</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2p0_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNRFCa6nzHZd" style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto" title="Outstanding, beginning of period (USD per share)">2.60</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Granted</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pin3_uShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwnupptFGlE2" style="margin-left: auto; text-align: right; margin-right: auto" title="Granted">3,100</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2p0_uUSDPShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9zZwzdJog2a" style="margin-left: auto; text-align: right; margin-right: auto" title="Granted in period (USD per share)">1.45</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Exercised</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pin3_di_uShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlCi5aYzVFUk" style="margin-left: auto; text-align: right; margin-right: auto" title="Exercised">(6)</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_uUSDPShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK8uGvidBrPl" style="margin-left: auto; text-align: right; margin-right: auto" title="Exercised in period (USD per share)">1.06</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; text-align: left; margin-right: auto">Cancelled</td> <td style="margin-left: auto; text-align: left; margin-right: auto"/> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pin3_uShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkc8B5xX6D5f" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0980">-</span></td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pip0_d0_uUSDPShares_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxGwBF3Vrcuc" style="margin-left: auto; text-align: right; margin-right: auto" title="Cancelled (USD per share)">-</td> <td style="margin-left: auto; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Outstanding as of September 30, 2022</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pin3_uShares_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzm5D2xq4SNj" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Outstanding as of March 31, 2022">10,400</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2p0_uUSDPShares_c20220930_zluYR8j89ilb" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Outstanding, end of period (USD per share)">2.26</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxFZ5t8BsFIa" style="margin-left: auto; text-align: right; margin-right: auto" title="Outstanding - weighted-average remaining contractual life (in years)">8.3</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_uUSD_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmTnd2z3aFVi" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Total aggregate intrinsic value shares outstanding">11</td></tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">Vested and expected to vest as of September 30, 2022</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pin3_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZxuz0taII67" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Vested and expected to vest, end of period (shares)">10,400</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZehi5vfrYxh" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Vested and expected to vest stock, end of period (USD per share)">2.26</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9fjPU26J7jd" style="margin-left: auto; text-align: right; margin-right: auto" title="Weighted-average remaining contractual life (in years) of vested and expected to vest stock options">8.3</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pn3n3_uUSD_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7WoLf9QCUcf" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Total aggregate intrinsic value of vested or expected to vest stock options">11</td></tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Exercisable as of September 30, 2022</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pin3_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZZkyT9PQA7l" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Exercisable, end of period (shares)">4,053</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pp2p0_d0_uUSDPShares_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziSc5ZlGQaEg" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Exercisable, end of period (USD per share)">2.78</td> <td style="margin-left: auto; margin-right: auto"/> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zi0CS9SqBoFh" style="margin-left: auto; text-align: right; margin-right: auto" title="Weighted-average remaining contractual life (in years) of exercisable stock options">7.7</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_uUSD_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zR7kKYYOvYGf" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; margin-right: auto" title="Total aggregate intrinsic value of exercisable stock options">9</td></tr> </table> <p style="font: 9pt Sans-Serif; margin: 0"/> 7306000 2.60 3100000 1.45 6000 1.06 -0 10400000 2.26 P8Y3M18D 11000 10400000 2.26 P8Y3M18D 11000 4053000 2.78 P7Y8M12D 9000 100000 200000 8400000 P2Y3M18D During the year ended December 31, 2021, the Company’s Board of Directors awarded a performance stock unit award to the Company’s Chief Executive Officer for 2,400,000 shares of common stock, with a grant date fair value of $4.31 per unit. Vesting of this award was subject to the Company achieving certain performance criteria established at the grant date and the individual fulfilling a service condition (continued employment). As of December 31, 2021, all performance stock unit awards were unvested and three of the five performance conditions had been satisfied. The Company recognized stock-based compensation related to this award of $4.9 million during the fourth quarter of 2021, which was recorded in general and administrative expense. During the nine months ended September 30, 2022, the Company and its Chief Executive Officer entered into an agreement to cancel the performance stock unit award for no consideration. In connection with the cancellation of the award, no replacement awards were granted or authorized. At the time of cancellation, the Company recognized the remaining compensation expense of the three achieved milestones of $1.3 million. The two remaining milestones were not deemed probable of achievement at the time of cancellation, and no compensation cost related to these milestones was recognized. 2400000 4.31 4900000 1300000 0 <p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zKedatNYpX1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company’s condensed consolidated statements of operations (in thousands):</p> <p id="xdx_8B8_zeKdjKdluhy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; display: none">Schedule of Stock-Based Compensation Expense</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto"> <tr> <td style="margin-left: auto; vertical-align: middle; background-color: white; margin-right: auto"/> <td> </td> <td> </td> <td colspan="4" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">Three Months Ended</td> <td style="margin-left: auto; vertical-align: middle; background-color: white; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td colspan="4" style="margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">Nine Months Ended</td> </tr> <tr> <td style="margin-left: auto; vertical-align: middle; background-color: white; margin-right: auto"/> <td> </td> <td> </td> <td colspan="4" style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">September 30,</td> <td style="margin-left: auto; vertical-align: middle; background-color: white; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; margin-right: auto"/> <td colspan="4" style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; background-color: white; margin-right: auto">September 30,</td> </tr> <tr> <td style="margin-left: auto; vertical-align: middle; background-color: white; width: 48%; margin-right: auto"/> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 10%; margin-right: auto">2022</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 10%; margin-right: auto">2021</td> <td style="margin-left: auto; vertical-align: middle; background-color: white; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: bottom; text-align: right; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 10%; margin-right: auto">2022</td> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 1%; margin-right: auto"/> <td style="margin-left: auto; vertical-align: middle; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 2%; margin-right: auto"/> <td style="border-bottom: Black 1pt solid; margin-left: auto; font-weight: bold; vertical-align: middle; text-align: center; border-top-color: Black; border-top-width: 1pt; background-color: white; width: 10%; margin-right: auto">2021</td> </tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; margin-right: auto">Research and development</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zFId1S4IGqV6" style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">261</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98E_eus-gaap--ShareBasedCompensation_pn3n3_c20210701__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zHAVzDveecy8" style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">193</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zN5QWxLluht5" style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">721</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zslE3wS0bHAf" style="margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">551</td> </tr> <tr style="vertical-align: middle; background-color: White"> <td style="margin-left: auto; margin-right: auto">General and administrative</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20220701__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zMavLKkMCv7d" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto">712</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20210701__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zTMKXp4yHcT6" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto">664</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z5jUmyWwHdig" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto">3,445</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zLwC3pW69aXa" style="border-bottom: Black 1pt solid; margin-left: auto; text-align: right; margin-right: auto">2,048</td> </tr> <tr style="vertical-align: middle; background-color: rgb(204,238,255)"> <td style="margin-left: auto; text-align: left; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20220701__20220930_zJqodgvch84d" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">973</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20210701__20210930_zbWmrOgK0v3f" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">857</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_98A_eus-gaap--ShareBasedCompensation_pn3n3_c20220101__20220930_z5NcbiPvPGMg" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">4,166</td> <td style="margin-left: auto; text-align: right; margin-right: auto"/> <td style="margin-left: auto; text-align: right; margin-right: auto">$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20210101__20210930_ze855cQxOOKk" style="border-bottom: Black 2pt double; margin-left: auto; text-align: right; border-top-color: Black; border-top-width: 1pt; margin-right: auto">2,599</td> </tr> </table> 261000 193000 721000 551000 712000 664000 3445000 2048000 973000 857000 4166000 2599000 <p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_znk0rKaHgAr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>12. Commitments and Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Leases</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20220930__us-gaap--LeaseContractualTermAxis__custom--March2019LeaseMember_zUUADYPu3lMi">In March 2019, the Company entered into a nine-month office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company was notified that the counterparty’s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is in breach of this rental agreement and therefore, the Company has no further obligations thereunder.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">I<span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDescription_c20220101__20220930__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zphFLuvZpqL">n March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New York, NY, which was due to expire in September 2022. The rental agreement contains a base rent of approximately $4,000 per month. This agreement included one or more renewal options. At September 30, 2022, the Company’s right-of-use assets and lease liability for operating leases was $<span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220930__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_z64G7weAQfQ7"><span id="xdx_90C_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220930__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zq5LV7TcmY8k">0</span></span>.</span> <span id="xdx_905_eus-gaap--LesseeOperatingLeaseDescription_c20221001__20221031__us-gaap--LeaseContractualTermAxis__custom--October2022LeaseMember_zcIMhA9rLzB4">In October 2022, the Company entered into a new eighteen-month office space rental agreement for its existing space, which provides for a base rent starting at approximately $4,000 per month</span> subject to periodic increases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Upon the commencement of the 300 Park Avenue, New York, NY office space in March 2021, in exchange for the new operating lease liability, the Company recognized a right-of-use asset of $<span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210331__us-gaap--LeaseContractualTermAxis__custom--March2021LeaseMember_zJpOCdLT8u6">74,000</span>. As of September 30, 2022, the weighted-average remaining lease term of the operating lease was <span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_pp0p0_dtYo_c20220930_zaH2DihJ1Vog">0</span> years, and the weighted-average discount rate was <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pp0p0_uPure_c20220930_zkAeaOKEGw6">8.0</span>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">As of September 30, 2022, there were <span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_do_c20220930_zdLckHcmp92g">no</span> future minimum lease payments for the Company’s operating leases with a non-cancelable term of more than one year as the current lease was expiring, while the Company’s new lease was not effective until October 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For each of the nine months ended September 30, 2022 and 2021, rent expense totaled <span style="background-color: White">$<span id="xdx_900_eus-gaap--OperatingLeaseExpense_pn5n6_c20210101__20210930_zpHbQcabMbSd"><span id="xdx_902_eus-gaap--OperatingLeaseExpense_pn5n6_c20220101__20220930_zqDIm5qDTXK1">0.1</span> </span></span><span style="background-color: White">million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: White"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Contractual Commitments</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has entered into long-term agreements with certain manufacturers and suppliers that require it to make contractual payment to these organizations. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and long-term commitments of cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Litigation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.85pt 0 5pt"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of September 30, 2022, there was no material litigation against or involving the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> In March 2019, the Company entered into a nine-month office space rental agreement for its headquarters in New York, New York expiring November 2019. In November 2019, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $9,000 per month. In November 2020, the Company renewed this rental agreement for an additional twelve-months for a base rent of approximately $3,800 per month. In March 2021, the Company was notified that the counterparty’s right to occupy the space at 300 Park Avenue, New York, NY was terminated, and the Company was required to vacate by March 26, 2021. The Company vacated the premises and has advised the counterparty that the counterparty is in breach of this rental agreement and therefore, the Company has no further obligations thereunder. n March 2021, the Company entered into an eighteen-month office space rental agreement for its headquarters at 300 Park Avenue, New York, NY, which was due to expire in September 2022. The rental agreement contains a base rent of approximately $4,000 per month. This agreement included one or more renewal options. At September 30, 2022, the Company’s right-of-use assets and lease liability for operating leases was $0. 0 0 In October 2022, the Company entered into a new eighteen-month office space rental agreement for its existing space, which provides for a base rent starting at approximately $4,000 per month 74000 P0Y 8.0 0 100000 100000 EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�SRT=#VD89#G]FK-GGK.?^2)YB,53C"&[V23%@3L_J&L#2IMI6LNH MV7WG!_5DO+3:.;1:#TKS4;2VAFO/A66,;/\)#1_4KCH=R^<7^FLA]DXM0XT8 M4-H,2G.@-/?(L;1UH'/,-FHQCG7)EL%SUOFD&FK%@-)\%*T])&HWAF4.[#N; M;90\E.:C:.TE=74( MTAY]8X>=C0Q9W4)I,RC-@=)<*&T.I7E0FH^BM8= '8:TS6'(K^&U,S>A]R P M[]!/\:"YYG+8-*S\/5.6D'42+;FP26V%NTGX0EK;2,>0\:HG36@GSL>[NQ/I M.>,IITX1/J!P%?+E@.O"5(7PGD11\J3<)]L2$X6;4-K*Y U.Y>6I&]&RL 3Y MCKGH^IQ">K%4U*Z6OU"%@9G5I= MHEQCM3F&=C84$]<@TDT5*.MT--B$422$H?TT8I9;[1SU1=T#M9%+])>J4OP% M<)8-VLXRUM=9)IOQ9TUEEG3XM4UE[)"I3#B&I#6Q[$5JH]D]%KYFEM$]EM=^ MRUVY'/:2];&%A=2$P&!<4Y4-]GUAU)P/I2-L5CO"TFJ;ZJQ"'V@8Y)R7.]I1 M3HVU[F(GKVG;0:/J/^L[:S9?>\6LX6@Z'8Y&DT%OB<\*.FX-#EC:NL94ZW2]H)M2=?*AL;(H(FFOU:;<51"F[%$\ M&2Q[W:*SR3+,%E*9TA;:/JF0&I2)3IPO_P@W2CO?C=DY$ MD-<'!TISH;0YE.9!:3Z*UIZ(U"82^RN:2/K: >U]SX1%HY\&?Z<=T+PKO>?A M2)H#I;E0VAQ*\Z T'T5KR[]VG-AFQ\G7MP.:&]1[5@ZUK4!I#I3F0FES*,V# MTGQ[WZ!C[9P/VVJO;2NVV;8"4'M]0R;G**3Z6S5#DO=K\NF[6-33J7RHRT73 MA)VXZJ;1Z6AT.1TU_[/:UY 9M!$.E.9":7,HS8/2?!2M/0YJVXM]Q/8B9_.^ MNEW3=PUE%%^=Q(?&!Q%=H8P/YCI[RQMJ;('2'"C-M?>-+70;1G=A.]%3:*T> ME.:C:&T]U]86^XM;6W;.Z[/RMK37"1[J;H'29E": Z6YFK9W*;-VG8S0:CTH MS4?1VD.@-L'8GV^".9:HS%Q%;_U"O2U0F@.EN?:^ 6:\GT9M#JW4@])\%*VM MWMK^8ILM$WZ\+!;J-"WF%W32M4?6E3'*;R;V%BO4O *E.5":"Z7-H30/2O-1 MM+:F:_^*??6MH_Q0HPN4-H/2'"C-A=+F4)H'I?DH6CMI<&UT&9O7VG^-*+^Y M"7T' 90V@](<*,T];:(W$XGX^<)NS,'G9S]>QM4*7M&:C8^#U?!!O.^&K%Y9L-1#3WIG@HLIQ9 MMMK]*CW-?FU[27_DDC<9T/^]"/-G+62=GB>,R\0B,BV.BF57B7\.)NX9[B7K M&7:D!6KF Z(BE2O@0*:?H?!CR-=1*'\"?34005=YGU!E&$HBKCP.M*/95O=0 M'83>.6S4!\)2L5J%4:@SI31_UIVU5.:+!4_S@'J$3A(Y3\- 1HXW/#\=W*C> M:F7CV>_Z32 B[RK;3[G0D!HJS2/+D"HJ@F@HXL\B'Y&L(1*_E R1ED7$Z.N- M9>R>,"E]ER?:3R.WK5+"Z#T1OHI$VB5$TJDX$4%K_A@F12:;PV/1BK*71*^4 M.6HZ.DQ:'L*,CM*:-A*V$>'<$<H]S4:F@)DW)&*HROZ M[D"K=5]:[1Q:K0>E^2A:6\BU=V-L]F[4*?I4C.(%.7?-Q-Y*A!HRH#0'2G.A MM#F4YD%I/HK6UG3C12O?_$TKV%>M8-^U@GW9"O9M*]C7K6#?MX)]XE.:C:&V=UBZ* ML=E% 4Z"8ZZMMY*A_@DHS8'27$T[D@0'6J<'I?DH6EO'M7MB;'9/_*)3-*NG M4$JLG0*%VAN@M!F4YD!I[I'NMT9JO7CG+ %J>(#2?!2MK=K:\# V&QY^XUFN MEY2)NT!Q_M4+C59AFHF%73'=&:99D#YWBAGJ=8#29E": Z6YFG;5LNK8>V=; MJ-4!2O-1M+9N:ZO#V&QU^)%4^E_EBLW6@XN,_9)4MLO,_!@#:GZ TF90F@.E MN5#:'$KSH#0?16NKO#8_C+^U^6$,-3] :3,HS8'27"AM#J5Y4)J/HK5?'%N; M'R9'(NA]'F.867W5#*7-H#0'2G,G^R]4L.VKJ_'5[HP$6JT'I?DH6ENH=3QP M8HX''IF1B)^KQ2"UL\,T/3%7V%O-T'@?E.9 :2Z4-H?2/"C-1]':DJ\CAQ/[ M&T]/)M! (Y0V@](<*,V%TN90F@>E^2A:>PC4@<8)\%T#9E9O-4-CAE": Z6Y MDXZES),.DP>T5@]*\U&TMD[K:.#$' T$1UG,M?56,C1>"*4Y4)JK:>THR_1\ M5\?0:"&4YJ-H;1W7T<*).5KXTBB+&=-;H- P()3F0&GND>XW15F@#?&@-!]% M:ZNVC@U.OOC*:C5?+L,UAU^,86Y);^%#PXM0F@.EN4>.H&7KY&B=RH?&%Z$T M'T5K*[^.+T[,\<6[QM((;7(N'WFP_V-W["/[-4_$BS 6A;"@'GD@ HTV0FDS M*,V!TEPH;0ZE>5":CZ*UU5Y')2>7W_J!"#1D":7-H#0'2G.AM#F4YD%I/HK6 M'@)UR')B?M\ (H.&N8K>(H<&):$T!TIS-:WU?J-QUVH8:+5>1[63JXYJ?52U M+6E.ZU#B](N_LUSS>'%E*;V]!7NU#:#$ISH#072IM#:=X173421HN; MXX%*G]Q*R2TRC@\[5WIVK/:6:X;%6N?6PN)ZQ;':H,PZO@N\78=\5<^H!S^M M5N&"FB&6J=K#B5I^>B =^%"M@@WT>M:E6'K<3CC]W>1T;,FGA:(EI]4-J5S' M&NJVLZ<@8UEQ_S^T0[J9@VI!^H+:]RB*E,N6FSM9+6$F;' ?A=E:]$/>6! N MVR16LLIDZ/62XU41K412>[G<5QQ1\51SD<0JE3![17]20XLJO;\8U:]/V8WL M@XYC)1*\F[H_4TFUB_)]4JI):;V,?R56U+7VK6R,R-._',C5S>($E(F L5KD M6W926KV(2M7;E>TAY2HON.S?JN?5(;IB98+_9:W-55*D='!_+X(T5ZM.Y9[J MU?OBD(EJI?+HJ#SPF*?BO0&T7^4:XS10J];5E?LS,Z7+A/OY8;W*!>2R+6HM M>O! G5LN.%^('HTDSSA&A.CC1'1]%BYY*GONE/DBQ7H)T;*MU&@%U\W%5 ^+Q=+]JOENR0L)=H\W$A%--GM?F@<:_%URCBDLI38TE*DA'FU28Q&I$?V>=CDL!*%WE3TD#W-A:[H%8=K\4 M?;L4B07NY:)VPFBZVF&Y-X/NO1%'4G;R3@K[MD3I--NJ6>M-[7K7XG,?=1)O M3Q=J0\?TBR_P=F3J"M(;C9U"_)"QGZ@G1(X 4G3U'M"YD-"1%]Z:&]M[7@$U M@T!I#I3F0FES*,V;[J]>M[M>^>BCJFV/A-KG,?WBV?W_Y$@8LC)PR6YTX%)N MPF9B&N"*J0NIN'3>RHMI_4I2YX\RW]!GOW,3>XH=:332M^;Q@-TL(M$+W M>(5S:(4>E.:C:$K.9W1/Q7,Z?P;7[S8\?>"W-),3&8=(2:*2QK_UN2^?T'X+T(:3;HHBOJ FC MTPNZ(LJ$7>6'/-F^/Z%KX'V2Y\E&_KGF 4WHQ0;T^RI)\O*#J. I23_)W;S^ M?U!+ P04 " #6@&I5FJ$[2?D& $+ &0 'AL+W=OM"3Q^9T3_QW[Y,3G2RY^R1F (O=IDLF+ M]DRI_&VW*Z,9I%2>\!PRO#+A(J4*#\6T*W,!-#9&:=+U'&?032G+VN-S<^Y& MC,_Y7"4L@QM!Y#Q-J7AX#PE?7K3=]OK$%S:=*7VB.S[/Z11N07W+;P0>=4M* MS%+().,9$3"Y:%^Z;T//T0:FQ3\,EG+K-]&W/-W%$)5SSYSF(UNV@/VR2&"9TGZ@M? M_@VK&SK5O(@GTOPERZ+MH-\FT5PJGJZ,,8*49<5_>K_JB"V#H;/'P%L9>(<: M]%8&O4<&[KZ0^BN#_J$&IRN#TT,-!BN#@>G[HK-,3_M4T?&YX$LB=&NDZ1]& M+F.-'51B$1G6CEZ\1^#E2)Z3G=HCG>%Y=/,WFMY"CN;/7W#_O7K@#YUV=9#9AODU88!,6 M6H)5I.Z74O>;Z.//.>C9()NNQ3:+TAL^>?-- KG$<:#J9&Z$'BOS,V"D3F&; M004%;&!@>EU?C'LCQW'.NXMMZ2RYK$AW6DIW>IQT'QB]8PE3#QUR-1<"%X(Z MZ1JAQTKW#%BM=#:#"DYWI1ON2F?)946Z02G=X#CIOIO4"6)RN< K4R!?0.>3 M90OR%41:IV:CGV/5; [:(0] A:R3SV84@4U8: E64?FL5/GL?ZKL,QGQ>:;( M%ZKP^@V(:,]3V^CI6)T+V&CK 1E6'P[?IKO )BRT!*L(.BP%'3YSQJV3K)%U MK&3#G3GMT7SFVW07V(2%EF 5R4:E9*/C) ON\6U>0IU@C:1C!1OM".8ZSLXJ MY!_6++ 96F@)5M'#=39OJDZC(OBR$LWP3<4=K9:VGQ\AO0-1^SK1S#I6$ZLT MWRHML$H+;=&J&F]5(]P_]0*Y(MM2W";-MTH+K-)"6[2JXMY&<:_QJ5XKOC/? M;FE?*W48.8-;U)=H6KQ MR81%0$P41+]4T830J0#0E38RX8(P)^<079L8S89P0C*IRIAH8>H0EQ"TU8[+>/QBOJ24DBU7LLKAN M:K;&EO )H7DN^#U+,>-,'LC+40=7&X*J$6/R.!S/J8336H5#_E0XO!.4ED?1/'\P#0M% MT:J''F\H*H1I>3:'SK9X/XCV@KR491ABW#&EU<=1"/@]9WKXH(<%C; AN7M8 MQSTHZG(GY.N6K$6K@H0C.V42BJKM#'$T7N!QO',[]3=)F&SAB+L30-$==FF] M-JNX!: (4!UC,].19#(7N@'A=PF;4BV@+"SF60SBI'9&M/GX!E9IH2U:=4;< MU%#=QKK=>#-J#\ESK-9-K=)\J[3 *BVT1:MJO"F>NOT_EN=8+:%:I?E6:8%5 M6FB+5E5\4W-UFXNNS\YSK)9=GP@R:^U9,A^E.1DI"E*0%0LT>4:NLV?];*W7 MSPY9SAC&HI?)> YZA32)$.@LZ19R568:7K%"[KB-,#3*<"UJSASZCQ*9UE>] M#&XP+(N2>8SWSO&YY+J5@"*[0F_<""=/R*7:"FK]/;#2A]6<0G\IF6-05'\I M*5;P1 ^(5K(N#9ENX^5P,5>EZ8Z73OV::K48;I46VJ)5G[Y-V=P]LFY^V->J M9NK1#]_@R5J<58>!55I8$_Y9?[OB5-5F4^QVCZQV'_8YJIEZM#9G3VMCM;9M ME1;:HE4EW)2WW2?JVY'BZ\GXD*35:H7;*LVW2@NLTD);M*K*FXJX._IC2:O5 M$KE5FF^5%EBEA;9HU9U1FY*[UUQR?V[2^@3V.FMMSQC-!358/B_9A'LF3D, $ MD<[)&2:CHMAR6APHGILMDG=<*9Z:G_I=!81N@-YU.'!:42S(:R'EQ4Y@JF*JY-$,2MZ' W;ZF0]*-/Y+ MR8U5RH;DX>S]K[DRU^\"=S_Y<'+2>3B_WHV?U< Y";VBEP>(7G0ZN#" F'A\ MF/@^;4SZ:ENZ'GYJA1SQ%*/U/32;9SX:9$JNMSXB M+F#STX(%CU0,R9@*/M$<6!DMN%BZ< \"4R64#HRM.6NH"Y'JR<%=UX-R;'0* M+I6N<[L,[GO2#-\!5CTPR(5H#?:("XP&)36&:7EC._7@.O@""IKV_;*T#G-- ME]W>)5D3ZIM-,E$Z9;I-TR6KT&@@6 9V-,]G<#>J# $T1A6VD7*:*TEK#RM& MT["R4R;$'3RK/[,M[46VL;,=V%?9-JVAINED7 ?T-]6<]J9L[U6Z0_9PJS*:9'AGGM'Z/GOKG/.)--4;)JVM?^65_G5 MCJ.K?V6Y_JVR:]CKL7D!OW63E\=@,CX&DT=1D_UC,)F\29-A\P+?."5LG1': M: !GL2'Y 6<_L4X:3.9<&"Z;WHRG*9,OC@I6WM")_6-A2]^.3UE&Y\+MVX/0C:7%RF;,'2<=/5^:1N!K9ALS87$':1 MF_KR(QC'87X$,"P/Y@#C.!:6YW^:3Q^=C\,P;WTOTDBOT3A&5B>&CW]_L*1^%J_=4 MN/X/VN@94$L#!!0 ( -: :E67BKL

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end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 197 254 1 false 49 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://seelostx.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://seelostx.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://seelostx.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Sheet http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) Sheet http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://seelostx.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - 1. Organization and Description of Business Sheet http://seelostx.com/role/OrganizationAndDescriptionOfBusiness 1. Organization and Description of Business Notes 8 false false R9.htm 00000009 - Disclosure - 2. Liquidity and Going Concern Sheet http://seelostx.com/role/LiquidityAndGoingConcern 2. Liquidity and Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - 3. Significant Accounting Policies Sheet http://seelostx.com/role/SignificantAccountingPolicies 3. Significant Accounting Policies Notes 10 false false R11.htm 00000011 - Disclosure - 4. Fair Value Measurement Sheet http://seelostx.com/role/FairValueMeasurement 4. Fair Value Measurement Notes 11 false false R12.htm 00000012 - Disclosure - 5. Prepaid Expenses and Other Current Assets Sheet http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets 5. Prepaid Expenses and Other Current Assets Notes 12 false false R13.htm 00000013 - Disclosure - 6. Common Stock Offerings Sheet http://seelostx.com/role/CommonStockOfferings 6. Common Stock Offerings Notes 13 false false R14.htm 00000014 - Disclosure - 7. License Agreements Sheet http://seelostx.com/role/LicenseAgreements 7. License Agreements Notes 14 false false R15.htm 00000015 - Disclosure - 8. Accrued Expenses Sheet http://seelostx.com/role/AccruedExpenses 8. Accrued Expenses Notes 15 false false R16.htm 00000016 - Disclosure - 9. Debt Sheet http://seelostx.com/role/Debt 9. Debt Notes 16 false false R17.htm 00000017 - Disclosure - 10. Stockholders??? Equity Sheet http://seelostx.com/role/StockholdersEquity 10. Stockholders??? Equity Notes 17 false false R18.htm 00000018 - Disclosure - 11. Stock-based Compensation Sheet http://seelostx.com/role/Stock-basedCompensation 11. Stock-based Compensation Notes 18 false false R19.htm 00000019 - Disclosure - 12. Commitments and Contingencies Sheet http://seelostx.com/role/CommitmentsAndContingencies 12. Commitments and Contingencies Notes 19 false false R20.htm 00000020 - Disclosure - 3. Significant Accounting Policies (Policies) Sheet http://seelostx.com/role/SignificantAccountingPoliciesPolicies 3. Significant Accounting Policies (Policies) Policies http://seelostx.com/role/SignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - 3. Significant Accounting Policies (Tables) Sheet http://seelostx.com/role/SignificantAccountingPoliciesTables 3. Significant Accounting Policies (Tables) Tables http://seelostx.com/role/SignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - 4. Fair Value Measurement (Tables) Sheet http://seelostx.com/role/FairValueMeasurementTables 4. Fair Value Measurement (Tables) Tables http://seelostx.com/role/FairValueMeasurement 22 false false R23.htm 00000023 - Disclosure - 5. Prepaid Expenses and Other Current Assets (Tables) Sheet http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables 5. Prepaid Expenses and Other Current Assets (Tables) Tables http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets 23 false false R24.htm 00000024 - Disclosure - 8. Accrued Expenses (Tables) Sheet http://seelostx.com/role/AccruedExpensesTables 8. Accrued Expenses (Tables) Tables http://seelostx.com/role/AccruedExpenses 24 false false R25.htm 00000025 - Disclosure - 10. Stockholders??? Equity (Tables) Sheet http://seelostx.com/role/StockholdersEquityTables 10. Stockholders??? Equity (Tables) Tables http://seelostx.com/role/StockholdersEquity 25 false false R26.htm 00000026 - Disclosure - 11. Stock-based Compensation (Tables) Sheet http://seelostx.com/role/Stock-basedCompensationTables 11. Stock-based Compensation (Tables) Tables http://seelostx.com/role/Stock-basedCompensation 26 false false R27.htm 00000027 - Disclosure - 2. Liquidity and Going Concern (Details Narrative) Sheet http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative 2. Liquidity and Going Concern (Details Narrative) Details http://seelostx.com/role/LiquidityAndGoingConcern 27 false false R28.htm 00000028 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 28 false false R29.htm 00000029 - Disclosure - Schedule of Fair Value Hierarchy Assets and Liabilities (Details) Sheet http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails Schedule of Fair Value Hierarchy Assets and Liabilities (Details) Details 29 false false R30.htm 00000030 - Disclosure - Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details) Notes http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details) Details 30 false false R31.htm 00000031 - Disclosure - Summary of Fair Value Measurements Warrant Valuation Assumptions (Details) Sheet http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails Summary of Fair Value Measurements Warrant Valuation Assumptions (Details) Details 31 false false R32.htm 00000032 - Disclosure - Schedule of Fair Value Level 3 Reconciliation (Details) Sheet http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails Schedule of Fair Value Level 3 Reconciliation (Details) Details 32 false false R33.htm 00000033 - Disclosure - 4. Fair Value Measurement (Details Narrative) Sheet http://seelostx.com/role/FairValueMeasurementDetailsNarrative 4. Fair Value Measurement (Details Narrative) Details http://seelostx.com/role/FairValueMeasurementTables 33 false false R34.htm 00000034 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails Schedule of Prepaid Expenses and Other Current Assets (Details) Details 34 false false R35.htm 00000035 - Disclosure - 6. Common Stock Offerings (Details Narrative) Sheet http://seelostx.com/role/CommonStockOfferingsDetailsNarrative 6. Common Stock Offerings (Details Narrative) Details http://seelostx.com/role/CommonStockOfferings 35 false false R36.htm 00000036 - Disclosure - 7. License Agreements (Details Narrative) Sheet http://seelostx.com/role/LicenseAgreementsDetailsNarrative 7. License Agreements (Details Narrative) Details http://seelostx.com/role/LicenseAgreements 36 false false R37.htm 00000037 - Disclosure - Schedule of Accrued Liabilities (Details) Sheet http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails Schedule of Accrued Liabilities (Details) Details 37 false false R38.htm 00000038 - Disclosure - 9. Debt (Details Narrative) Sheet http://seelostx.com/role/DebtDetailsNarrative 9. Debt (Details Narrative) Details http://seelostx.com/role/Debt 38 false false R39.htm 00000039 - Disclosure - Summary of Warrant Activity (Details) Sheet http://seelostx.com/role/SummaryOfWarrantActivityDetails Summary of Warrant Activity (Details) Details 39 false false R40.htm 00000040 - Disclosure - 10. Stockholders??? Equity (Details Narrative) Sheet http://seelostx.com/role/StockholdersEquityDetailsNarrative 10. Stockholders??? Equity (Details Narrative) Details http://seelostx.com/role/StockholdersEquityTables 40 false false R41.htm 00000041 - Disclosure - Schedule of Valuation Assumptions for Stock Options (Details) Sheet http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails Schedule of Valuation Assumptions for Stock Options (Details) Details 41 false false R42.htm 00000042 - Disclosure - Summary of Stock Option Activity (Details) Sheet http://seelostx.com/role/SummaryOfStockOptionActivityDetails Summary of Stock Option Activity (Details) Details 42 false false R43.htm 00000043 - Disclosure - Schedule of Stock-Based Compensation Expense (Details) Sheet http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails Schedule of Stock-Based Compensation Expense (Details) Details 43 false false R44.htm 00000044 - Disclosure - 11. Stock-based Compensation (Details Narrative) Sheet http://seelostx.com/role/Stock-basedCompensationDetailsNarrative 11. Stock-based Compensation (Details Narrative) Details http://seelostx.com/role/Stock-basedCompensationTables 44 false false R45.htm 00000045 - Disclosure - 12. Commitments and Contingencies (Details Narrative) Sheet http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative 12. Commitments and Contingencies (Details Narrative) Details http://seelostx.com/role/CommitmentsAndContingencies 45 false false All Reports Book All Reports body10-q.htm exh31-1.htm exh31-2.htm exh32-1.htm exh32-2.htm seel-20220930.xsd seel-20220930_cal.xml seel-20220930_def.xml seel-20220930_lab.xml seel-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 62 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "body10-q.htm": { "axisCustom": 0, "axisStandard": 15, "contextCount": 197, "dts": { "calculationLink": { "local": [ "seel-20220930_cal.xml" ] }, "definitionLink": { "local": [ "seel-20220930_def.xml" ] }, "inline": { "local": [ "body10-q.htm" ] }, "labelLink": { "local": [ "seel-20220930_lab.xml" ] }, "presentationLink": { "local": [ "seel-20220930_pre.xml" ] }, "schema": { "local": [ "seel-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 411, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 88, "http://seelostx.com/20220930": 27, "http://xbrl.sec.gov/dei/2022": 5, "total": 120 }, "keyCustom": 43, "keyStandard": 211, "memberCustom": 27, "memberStandard": 18, "nsprefix": "SEEL", "nsuri": "http://seelostx.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://seelostx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - 3. Significant Accounting Policies", "role": "http://seelostx.com/role/SignificantAccountingPolicies", "shortName": "3. Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - 4. Fair Value Measurement", "role": "http://seelostx.com/role/FairValueMeasurement", "shortName": "4. Fair Value Measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - 5. Prepaid Expenses and Other Current Assets", "role": "http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets", "shortName": "5. Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - 6. Common Stock Offerings", "role": "http://seelostx.com/role/CommonStockOfferings", "shortName": "6. Common Stock Offerings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - 7. License Agreements", "role": "http://seelostx.com/role/LicenseAgreements", "shortName": "7. License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - 8. Accrued Expenses", "role": "http://seelostx.com/role/AccruedExpenses", "shortName": "8. Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - 9. Debt", "role": "http://seelostx.com/role/Debt", "shortName": "9. Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - 10. Stockholders\u2019 Equity", "role": "http://seelostx.com/role/StockholdersEquity", "shortName": "10. Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - 11. Stock-based Compensation", "role": "http://seelostx.com/role/Stock-basedCompensation", "shortName": "11. Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - 12. Commitments and Contingencies", "role": "http://seelostx.com/role/CommitmentsAndContingencies", "shortName": "12. Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://seelostx.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - 3. Significant Accounting Policies (Policies)", "role": "http://seelostx.com/role/SignificantAccountingPoliciesPolicies", "shortName": "3. Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - 3. Significant Accounting Policies (Tables)", "role": "http://seelostx.com/role/SignificantAccountingPoliciesTables", "shortName": "3. Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - 4. Fair Value Measurement (Tables)", "role": "http://seelostx.com/role/FairValueMeasurementTables", "shortName": "4. Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - 5. Prepaid Expenses and Other Current Assets (Tables)", "role": "http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "5. Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - 8. Accrued Expenses (Tables)", "role": "http://seelostx.com/role/AccruedExpensesTables", "shortName": "8. Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - 10. Stockholders\u2019 Equity (Tables)", "role": "http://seelostx.com/role/StockholdersEquityTables", "shortName": "10. Stockholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - 11. Stock-based Compensation (Tables)", "role": "http://seelostx.com/role/Stock-basedCompensationTables", "shortName": "11. Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - 2. Liquidity and Going Concern (Details Narrative)", "role": "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative", "shortName": "2. Liquidity and Going Concern (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "lang": "en-US", "name": "SEEL:InitialNumberOfCalendarDaysToRegainCommonStockPriceCompliance", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "role": "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Schedule of Fair Value Hierarchy Assets and Liabilities (Details)", "role": "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails", "shortName": "Schedule of Fair Value Hierarchy Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://seelostx.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30_us-gaap_LongTermDebtMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details)", "role": "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "shortName": "Summary of Fair Value Measurements Convertible Notes Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30_us-gaap_LongTermDebtMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-012022-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Summary of Fair Value Measurements Warrant Valuation Assumptions (Details)", "role": "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails", "shortName": "Summary of Fair Value Measurements Warrant Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-012022-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Schedule of Fair Value Level 3 Reconciliation (Details)", "role": "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails", "shortName": "Schedule of Fair Value Level 3 Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - 4. Fair Value Measurement (Details Narrative)", "role": "http://seelostx.com/role/FairValueMeasurementDetailsNarrative", "shortName": "4. Fair Value Measurement (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)", "role": "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Schedule of Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2021-01-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - 6. Common Stock Offerings (Details Narrative)", "role": "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "shortName": "6. Common Stock Offerings (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2021-11-012021-11-30_custom_IXLicenseAgreementMember", "decimals": "-5", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - 7. License Agreements (Details Narrative)", "role": "http://seelostx.com/role/LicenseAgreementsDetailsNarrative", "shortName": "7. License Agreements (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-04-012022-04-30_custom_AssetsfromVyeraPharmaceuticalsMember", "decimals": null, "lang": "en-US", "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Schedule of Accrued Liabilities (Details)", "role": "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails", "shortName": "Schedule of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "SEEL:GainLossInFairValueOfConvertibleNotes", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - 9. Debt (Details Narrative)", "role": "http://seelostx.com/role/DebtDetailsNarrative", "shortName": "9. Debt (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2021-11-012021-11-30_custom_November2021LindSecuritiesPurchaseAgreementMember", "decimals": null, "lang": "en-US", "name": "us-gaap:LongTermDebtDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Summary of Warrant Activity (Details)", "role": "http://seelostx.com/role/SummaryOfWarrantActivityDetails", "shortName": "Summary of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2021-12-31_custom_WarrantDerivativeFinancialInstrumentsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - 10. Stockholders\u2019 Equity (Details Narrative)", "role": "http://seelostx.com/role/StockholdersEquityDetailsNarrative", "shortName": "10. Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2021-03-31", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember39117062", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Valuation Assumptions for Stock Options (Details)", "role": "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails", "shortName": "Schedule of Valuation Assumptions for Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember39117062", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Summary of Stock Option Activity (Details)", "role": "http://seelostx.com/role/SummaryOfStockOptionActivityDetails", "shortName": "Summary of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)", "role": "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "shortName": "Schedule of Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - 11. Stock-based Compensation (Details Narrative)", "role": "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "11. Stock-based Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - 12. Commitments and Contingencies (Details Narrative)", "role": "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "12. Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EarningsPerShareBasic", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "role": "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EarningsPerShareBasic", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)", "role": "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember", "decimals": "-3", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://seelostx.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueAdjustmentOfWarrants", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - 1. Organization and Description of Business", "role": "http://seelostx.com/role/OrganizationAndDescriptionOfBusiness", "shortName": "1. Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - 2. Liquidity and Going Concern", "role": "http://seelostx.com/role/LiquidityAndGoingConcern", "shortName": "2. Liquidity and Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "body10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 49, "tag": { "SEEL_AggregateFutureOfferingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate future offering amount" } } }, "localname": "AggregateFutureOfferingAmount", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "SEEL_AmortizeNovember2021LindSecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amortize November 2021 Lind Securities Purchase Agreement [Member]" } } }, "localname": "AmortizeNovember2021LindSecuritiesPurchaseAgreementMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_AssetsfromVyeraPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assetsfrom Vyera Pharmaceuticals [Member]" } } }, "localname": "AssetsfromVyeraPharmaceuticalsMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_August2019WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "August 2019 Warrants [Member]" } } }, "localname": "August2019WarrantsMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_August232019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "August 232019 [Member]" } } }, "localname": "August232019Member", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "August 232022 Thru Maturity November 2021 Lind Securities Purchase Agreement [Member]" } } }, "localname": "August232022ThruMaturityNovember2021LindSecuritiesPurchaseAgreementMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement]" } } }, "localname": "CashPaymentsAgreedtoinAmendmenttotheAssetPurchaseAgreement", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "SEEL_ChangeInFairValueOfConvertibleNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "ChangeInFairValueOfConvertibleNotesPayable", "negatedLabel": "Change in fair value of convertible notes payable" } } }, "localname": "ChangeInFairValueOfConvertibleNotesPayable", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SEEL_ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cancelled, exercise price of warrants" } } }, "localname": "ClassOfWarrantOrRightCancelledExercisePriceOfWarrantsOrRights", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "SEEL_ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercisable, weighted-average exercise price (in usd per share)" } } }, "localname": "ClassOfWarrantOrRightExercisableExercisePriceOfWarrantsOrRights1", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "SEEL_ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercisable as of June 30, 2021, weighted-average remaing contractual life (in years)" } } }, "localname": "ClassOfWarrantOrRightExercisableWeightedAverageRemaingContractualLife", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "SEEL_ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercised, exercise price of warrants" } } }, "localname": "ClassOfWarrantOrRightExercisedExercisePriceOfWarrantsOrRights", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "SEEL_ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued, warrant exercise price" } } }, "localname": "ClassOfWarrantOrRightIssuedExercisePriceOfWarrantsOrRights", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "SEEL_ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants outstanding as of June 30, 2021, weighted-average remaing contractual life (in years)" } } }, "localname": "ClassOfWarrantOrRightOutstandingEndOfPeriodWeightedAverageRemaingContractualLife", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "SEEL_ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants outstanding as of December 31, 2020, weighted-average remaing contractual life (in years)" } } }, "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemaingContractualLife", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "SEEL_CommissionRateOnGrossProceedsOfCommonStockSale": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commission rate on gross proceeds of common stock sale" } } }, "localname": "CommissionRateOnGrossProceedsOfCommonStockSale", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "percentItemType" }, "SEEL_December17SPAsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December 17 S P As [Member]" } } }, "localname": "December17SPAsMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_December2021SPAsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December 2021 S P As [Member]" } } }, "localname": "December2021SPAsMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_ExtinguishmentOfBeneficialConversionFeature": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Extinguishment of beneficial conversion feature" } } }, "localname": "ExtinguishmentOfBeneficialConversionFeature", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "SEEL_FinancingAvailableUnderFormS3ShelfRegistrationStatement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:FinancingAvailableUnderFormS3ShelfRegistrationStatement-0]" } } }, "localname": "FinancingAvailableUnderFormS3ShelfRegistrationStatement", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "SEEL_FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "First Anniversary Of November 2021 Lind Securities Purchase Agreement [Member]" } } }, "localname": "FirstAnniversaryOfNovember2021LindSecuritiesPurchaseAgreementMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_GainLossInFairValueOfConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in fair value of convertible notes", "verboseLabel": "[custom:GainLossInFairValueOfConvertibleNotes]" } } }, "localname": "GainLossInFairValueOfConvertibleNotes", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative", "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "SEEL_GainLossOnForgivenessOfNotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gain on forgiveness of note payable" } } }, "localname": "GainLossOnForgivenessOfNotePayable", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SEEL_IXLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "I X License Agreement [Member]" } } }, "localname": "IXLicenseAgreementMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/FairValueMeasurementDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_IncentiveStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Stock Option [Member]" } } }, "localname": "IncentiveStockOptionMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_InducementPlanof2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inducement Planof 2019 [Member]" } } }, "localname": "InducementPlanof2019Member", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_InitialNumberOfCalendarDaysToRegainCommonStockPriceCompliance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:InitialNumberOfCalendarDaysToRegainCommonStockPriceCompliance]" } } }, "localname": "InitialNumberOfCalendarDaysToRegainCommonStockPriceCompliance", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "durationItemType" }, "SEEL_InitialStockValuationShortfallFrom5.5MillionValue": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:InitialStockValuationShortfallFrom5.5MillionValue]" } } }, "localname": "InitialStockValuationShortfallFrom5.5MillionValue", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "SEEL_IssuanceOfCommonStockForConversionOfDebtShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for conversion of debt, shares" } } }, "localname": "IssuanceOfCommonStockForConversionOfDebtShares", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "SEEL_IssuanceOfCommonStockForExtinguishmentOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for settlement of debt" } } }, "localname": "IssuanceOfCommonStockForExtinguishmentOfDebt", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "SEEL_IssuanceOfCommonStockForExtinguishmentOfDebtShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:IssuanceOfCommonStockForExtinguishmentOfDebtShares]" } } }, "localname": "IssuanceOfCommonStockForExtinguishmentOfDebtShares", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "SEEL_IssuanceOfCommonStockForLicenseAcquired": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for license acquired" } } }, "localname": "IssuanceOfCommonStockForLicenseAcquired", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "SEEL_IssuanceOfCommonStockForPrepaidServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for prepaid services" } } }, "localname": "IssuanceOfCommonStockForPrepaidServices", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "SEEL_IssuanceOfCommonStockForPrepaidServicesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:IssuanceOfCommonStockForPrepaidServicesShares]" } } }, "localname": "IssuanceOfCommonStockForPrepaidServicesShares", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "SEEL_IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock in at-the-market offering, net of issuance costs" } } }, "localname": "IssuanceOfCommonStockInAtthemarketOfferingNetOfIssuanceCosts", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "SEEL_IssuanceOfCommonStockInAtthemarketOfferingSharesNetOfIssuanceCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:IssuanceOfCommonStockInAtthemarketOfferingSharesNetOfIssuanceCosts]" } } }, "localname": "IssuanceOfCommonStockInAtthemarketOfferingSharesNetOfIssuanceCosts", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "SEEL_Issuanceofcommonstockforlicenseacquiredshares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:Issuanceofcommonstockforlicenseacquiredshares]" } } }, "localname": "Issuanceofcommonstockforlicenseacquiredshares", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "SEEL_January282021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "January 282021 [Member]" } } }, "localname": "January282021Member", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_LicensesPayable": { "auth_ref": [], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Licenses payable" } } }, "localname": "LicensesPayable", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "SEEL_LindSecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lind Securities Purchase Agreement [Member]" } } }, "localname": "LindSecuritiesPurchaseAgreementMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_March2019LeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "March 2019 Lease [Member]" } } }, "localname": "March2019LeaseMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_March2021LeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "March 2021 Lease [Member]" } } }, "localname": "March2021LeaseMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_May122022SaleAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "May 122022 Sale Agreement [Member]" } } }, "localname": "May122022SaleAgreementMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_May242021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "May 242021 [Member]" } } }, "localname": "May242021Member", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_MinimumStockValueOfSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:MinimumStockValueOfSharesIssued]" } } }, "localname": "MinimumStockValueOfSharesIssued", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "SEEL_NetLossOnExtinguishmentOfConvertibleDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net loss on extinguishment of convertible debt" } } }, "localname": "NetLossOnExtinguishmentOfConvertibleDebt", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SEEL_NonCashExtinguishmentOfBeneficialConversionFeature": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "NonCashExtinguishmentOfBeneficialConversionFeature", "verboseLabel": "Extinguishment of beneficial conversion feature" } } }, "localname": "NonCashExtinguishmentOfBeneficialConversionFeature", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SEEL_NonCashIssuanceOfCommonStockForConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for convertible notes" } } }, "localname": "NonCashIssuanceOfCommonStockForConvertibleNotes", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SEEL_NonCashIssuanceOfCommonStockForSettlementOfDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "NonCashIssuanceOfCommonStockForSettlementOfDebt", "verboseLabel": "Issuance of common stock for settlement of debt" } } }, "localname": "NonCashIssuanceOfCommonStockForSettlementOfDebt", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SEEL_NonQualifiedStockOptionsToEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non Qualified Stock Options To Employees [Member]" } } }, "localname": "NonQualifiedStockOptionsToEmployeesMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_NonQualifiedStockOptionsToNonEmployeeDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non Qualified Stock Options To Non Employee Directors [Member]" } } }, "localname": "NonQualifiedStockOptionsToNonEmployeeDirectorsMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_NonrefundableCashPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:NonrefundableCashPayment]" } } }, "localname": "NonrefundableCashPayment", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/FairValueMeasurementDetailsNarrative", "http://seelostx.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "SEEL_November2021LindSecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November 2021 Lind Securities Purchase Agreement [Member]" } } }, "localname": "November2021LindSecuritiesPurchaseAgreementMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_NumberofWarrantsCancelledDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cancelled" } } }, "localname": "NumberofWarrantsCancelledDuringPeriod", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "SEEL_NumberofWarrantsExercisedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercised", "verboseLabel": "Number of warrants exercised" } } }, "localname": "NumberofWarrantsExercisedDuringPeriod", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative", "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "SEEL_NumberofWarrantsIssuedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued" } } }, "localname": "NumberofWarrantsIssuedDuringPeriod", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "SEEL_October2022LeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 2022 Lease [Member]" } } }, "localname": "October2022LeaseMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Offering proceeds used to partially repay certain convertible promissory notes", "verboseLabel": "[custom:OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes]" } } }, "localname": "OfferingProceedsUsedToPartiallyRepayCertainConvertiblePromissoryNotes", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "SEEL_OutsideResearchAndDevelopmentServicesCurrent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outside research and development services" } } }, "localname": "OutsideResearchAndDevelopmentServicesCurrent", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "SEEL_PSUtoExecutivesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "P S Uto Executives [Member]" } } }, "localname": "PSUtoExecutivesMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_PrepaidClinicalCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid clinical costs" } } }, "localname": "PrepaidClinicalCosts", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "SEEL_ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reclass of warrant liabilities related to Series A warrants exercised for cash" } } }, "localname": "ReclassOfWarrantLiabilitiesRelatedToSeriesWarrantsExercisedForCash", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SEEL_September2020WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "September 2020 Warrants [Member]" } } }, "localname": "September2020WarrantsMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_SeriesAWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Warrants [Member]" } } }, "localname": "SeriesAWarrantsMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SEEL_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price Discount of Common Stock, Percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceDiscountOfCommonStockPercent", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "percentItemType" }, "SEEL_SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested and Canceled Award, Excluding Option, Cost Not yet Recognized, Amount" } } }, "localname": "SharebasedPaymentArrangementNonvestedAndCanceledAwardExcludingOptionCostNotYetRecognizedAmount", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "SEEL_WarrantDerivativeFinancialInstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Derivative Financial Instruments [Member]" } } }, "localname": "WarrantDerivativeFinancialInstrumentsMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "SEEL_WarrantsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercisable as of March 31, 2022", "verboseLabel": "Warrants exercisable as of June 30, 2021" } } }, "localname": "WarrantsExercisable", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative", "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "SEEL_WegLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weg License Agreement [Member]" } } }, "localname": "WegLicenseAgreementMember", "nsuri": "http://seelostx.com/20220930", "presentation": [ "http://seelostx.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r392", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://seelostx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [ "r137", "r138", "r139", "r140", "r156", "r191", "r217", "r218", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r366", "r367", "r377", "r378" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r137", "r138", "r139", "r140", "r156", "r191", "r217", "r218", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r366", "r367", "r377", "r378" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r132", "r137", "r138", "r139", "r140", "r156", "r191", "r208", "r217", "r218", "r249", "r250", "r251", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r366", "r367", "r377", "r378" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r132", "r137", "r138", "r139", "r140", "r156", "r191", "r208", "r217", "r218", "r249", "r250", "r251", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r366", "r367", "r377", "r378" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "8. Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r23", "r333" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInsuranceCurrent": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Insurance" } } }, "localname": "AccruedInsuranceCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses", "totalLabel": "Accrued expenses, net" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets", "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r16" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r80", "r81", "r82", "r260", "r261", "r262", "r291" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r220", "r265", "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r53", "r65", "r176", "r319" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current.", "label": "Asset Acquisition, Contingent Consideration, Liability, Current" } } }, "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r9", "r77", "r118", "r120", "r124", "r127", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r280", "r282", "r310", "r331", "r333", "r346", "r357" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets", "verboseLabel": "Assets [Abstract]" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets", "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r22", "r77", "r127", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r280", "r282", "r310", "r331", "r333" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails", "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r277", "r279" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "6. Common Stock Offerings" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommonStockOfferings" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.", "label": "Business Combination, Separately Recognized Transactions [Axis]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/FairValueMeasurementDetailsNarrative", "http://seelostx.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDescription": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "A description of each transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.", "label": "Business Combination, Separately Recognized Transactions, Description" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction." } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/FairValueMeasurementDetailsNarrative", "http://seelostx.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Combination, Separately Recognized Transactions [Line Items]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurementDetailsNarrative", "http://seelostx.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing the disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.", "label": "Business Combination, Separately Recognized Transactions [Table]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurementDetailsNarrative", "http://seelostx.com/role/LicenseAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalLeaseObligationsIncurred": { "auth_ref": [ "r69", "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in lease obligation from new lease.", "label": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "CapitalLeaseObligationsIncurred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r8", "r333", "r373", "r374" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets", "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r8", "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails", "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r60", "r311" ], "calculation": { "http://seelostx.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Net (decrease) increase in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r13", "r14", "r15", "r74", "r77", "r95", "r96", "r97", "r99", "r101", "r107", "r108", "r109", "r127", "r142", "r146", "r147", "r148", "r151", "r152", "r189", "r190", "r193", "r197", "r203", "r310", "r397" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.", "label": "Date on which warrants became exercisable" } } }, "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r206", "r222" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "periodEndLabel": "Outstanding as of June 30, 2021, weighted-average exercise price (in usd per share)", "periodStartLabel": "Outstanding as of December 31, 2020, weighted-average exercise price (in usd per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative", "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Outstanding as of March 31, 2022", "periodStartLabel": "Outstanding as of December 31, 2021" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of reason for issuing warrant or right.", "label": "Warrant description" } } }, "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r206", "r222" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r30", "r350", "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r134", "r135", "r136", "r141", "r376" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "12. Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r80", "r81", "r291" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheetsParenthetical", "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r203" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, outstanding (in shares)", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheetsParenthetical", "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r333" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value, 240,000,000 shares authorized, \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 107,168,256 and 105,500,445 issued and outstanding as of \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common stock voting right" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r39", "r41", "r42", "r48", "r352", "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r12", "r348", "r358", "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleSubordinatedDebt": { "auth_ref": [ "r12", "r348", "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, the carrying value of convertible subordinated debt, as of the balance sheet date, initially scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.", "label": "Convertible Subordinated Debt" } } }, "localname": "ConvertibleSubordinatedDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleSubordinatedDebtCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment upon liquidation of the entity's assets.", "label": "Short-term portion of convertible notes payable, at fair value" } } }, "localname": "ConvertibleSubordinatedDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleSubordinatedDebtNoncurrent": { "auth_ref": [ "r29" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid after one year or beyond the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets.", "label": "Convertible notes payable, at fair value" } } }, "localname": "ConvertibleSubordinatedDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r73", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r170", "r177", "r178", "r179", "r187" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "9. Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r10", "r11", "r12", "r76", "r78", "r153", "r154", "r155", "r156", "r157", "r158", "r160", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r176", "r181", "r182", "r183", "r184", "r321", "r347", "r348", "r356" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r29", "r76", "r78", "r153", "r154", "r155", "r156", "r157", "r158", "r160", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r176", "r181", "r182", "r183", "r184", "r321" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r69", "r70", "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "At-the-market offering issuance costs, accrued but not paid" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.", "label": "Derivative Financial Instruments, Liabilities [Member]" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails", "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r37", "r285", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r33", "r36", "r37", "r309" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability", "verboseLabel": "Warrant liabilities, at fair value" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets", "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Warrant liabilities, at fair value" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLossOnDerivative": { "auth_ref": [ "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Loss on Derivative", "negatedLabel": "Derivative liability" } } }, "localname": "DerivativeLossOnDerivative", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r223", "r224", "r254", "r255", "r257", "r268" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "11. Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r49", "r85", "r86", "r87", "r88", "r89", "r93", "r95", "r99", "r100", "r101", "r104", "r105", "r292", "r293", "r353", "r365" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r49", "r85", "r86", "r87", "r88", "r89", "r95", "r99", "r100", "r101", "r104", "r105", "r292", "r293", "r353", "r365" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r102", "r103" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Income (Loss) Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Personnel related" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails", "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r43", "r44", "r45", "r80", "r81", "r82", "r84", "r90", "r92", "r106", "r128", "r203", "r205", "r260", "r261", "r262", "r270", "r271", "r291", "r312", "r313", "r314", "r315", "r316", "r317", "r330", "r368", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r65", "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails", "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r294", "r295", "r305" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails", "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r294", "r295", "r296", "r304", "r305" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Schedule of Fair Value Hierarchy Assets and Liabilities" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Summary of Fair Value Measurements Warrant Valuation Assumptions" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r168", "r181", "r182", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r295", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails", "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r303", "r305" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurementTables", "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails", "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r294", "r295", "r298", "r299", "r306" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "4. Fair Value Measurement" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r168", "r209", "r210", "r215", "r216", "r295", "r334" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r168", "r181", "r182", "r209", "r210", "r215", "r216", "r295", "r335" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r168", "r181", "r182", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r295", "r336" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails", "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurementTables", "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails", "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurementTables", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r300", "r305" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurementTables", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r300", "r305" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Schedule of Fair Value Level 3 Reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3", "negatedLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "auth_ref": [ "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r168", "r181", "r182", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails", "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r303", "r306" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Measurements" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnContractTermination": { "auth_ref": [ "r66" ], "calculation": { "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.", "label": "Gain on forgiveness of debt" } } }, "localname": "GainLossOnContractTermination", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r65", "r185", "r186" ], "calculation": { "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Net loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r51" ], "calculation": { "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r131", "r133" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r62", "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "verboseLabel": "Licenses payable" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r46", "r117", "r318", "r320", "r355" ], "calculation": { "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeDomesticDeposits": { "auth_ref": [ "r354" ], "calculation": { "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest earned on deposits in United States money market accounts and other United States interest earning accounts.", "label": "Interest income" } } }, "localname": "InterestIncomeDomesticDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r59", "r61", "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Research and development expense - license amendment" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement." } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lessee, Operating Lease, Description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r26", "r77", "r121", "r127", "r142", "r143", "r144", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r281", "r282", "r283", "r310", "r331", "r332" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r77", "r127", "r310", "r333", "r349", "r361" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r28", "r77", "r127", "r142", "r143", "r144", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r281", "r282", "r283", "r310", "r331", "r332", "r333" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r12", "r167", "r180", "r181", "r182", "r348", "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtDescription": { "auth_ref": [ "r29", "r204" ], "lang": { "en-us": { "role": { "documentation": "Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.", "label": "Long-Term Debt, Description" } } }, "localname": "LongTermDebtDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-Term Debt [Member]" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurementTables", "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails", "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://seelostx.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r60", "r63", "r66" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r38", "r40", "r45", "r47", "r66", "r77", "r83", "r85", "r86", "r87", "r88", "r91", "r92", "r98", "r118", "r119", "r122", "r123", "r125", "r127", "r142", "r143", "r144", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r293", "r310", "r351", "r363" ], "calculation": { "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss and comprehensive loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows", "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r52" ], "calculation": { "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other (expense) income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r34", "r35" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expense" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expense" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r118", "r119", "r122", "r123", "r125" ], "calculation": { "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r323" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability", "verboseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets", "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r322" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use asset", "verboseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets", "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r327", "r329" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r284" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "1. Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/OrganizationAndDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/LicenseAgreementsDetailsNarrative", "http://seelostx.com/role/ScheduleOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "5. Prepaid Expenses and Other Current Assets" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/PrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Change in fair value of warrant liabilities" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r21", "r130" ], "calculation": { "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedLabel": "Payment of at-the-market offering issuance costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r189" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, per value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheetsParenthetical", "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheetsParenthetical", "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r189" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheetsParenthetical", "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets", "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r5", "r129", "r130" ], "calculation": { "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r55" ], "calculation": { "http://seelostx.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from issuance of common stock in at-the-market offering" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r55", "r259" ], "calculation": { "http://seelostx.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r55" ], "calculation": { "http://seelostx.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from sales of common stock under ESPP" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r55" ], "calculation": { "http://seelostx.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows", "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r57" ], "calculation": { "http://seelostx.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Payment of convertible note" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r269", "r344", "r379" ], "calculation": { "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "terseLabel": "Research and development expense", "verboseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/LicenseAgreementsDetailsNarrative", "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "7. License Agreements" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/LicenseAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r205", "r333", "r360", "r371", "r372" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumlated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets", "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r80", "r81", "r82", "r84", "r90", "r92", "r128", "r260", "r261", "r262", "r270", "r271", "r291", "r368", "r370" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Shares Issued, Price Per Share", "verboseLabel": "Sale of Stock, Price Per Share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r274", "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r253", "r264" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r219", "r221", "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails", "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative", "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Valuation Assumptions for Stock Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in stock options.", "label": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r206", "r222" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Summary of Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "http://seelostx.com/role/StatementsOfCashFlows", "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r222", "r223" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Description of share-based compensation arrangement by share-based payment award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "verboseLabel": "Dividend yield (in percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails", "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative", "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable, end of period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable, end of period (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r243" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "verboseLabel": "Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted", "verboseLabel": "Options granted in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative", "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Total aggregate intrinsic value shares outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding as of March 31, 2022", "periodStartLabel": "Outstanding as of December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of period (USD per share)", "periodStartLabel": "Outstanding, beginning of period (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r244" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Total aggregate intrinsic value of vested or expected to vest stock options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, end of period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest stock, end of period (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails", "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised in period (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Cancelled (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted in period (USD per share)", "verboseLabel": "Weighted-average exercise price per share granted in period" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative", "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r227", "r246", "r247", "r248", "r249", "r252", "r263", "r268" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Vesting percentage on the first anniversary" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Term of option grant" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/ScheduleOfValuationAssumptionsForStockOptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsConvertibleNotesValuationAssumptionsDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Total aggregate intrinsic value of exercisable stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining contractual life (in years) of exercisable stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding - weighted-average remaining contractual life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted-average remaining contractual life (in years) of vested and expected to vest stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r72", "r79" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "3. Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r13", "r14", "r15", "r74", "r77", "r95", "r96", "r97", "r99", "r101", "r107", "r108", "r109", "r127", "r142", "r146", "r147", "r148", "r151", "r152", "r189", "r190", "r193", "r197", "r203", "r310", "r397" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r32", "r43", "r44", "r45", "r80", "r81", "r82", "r84", "r90", "r92", "r106", "r128", "r203", "r205", "r260", "r261", "r262", "r270", "r271", "r291", "r312", "r313", "r314", "r315", "r316", "r317", "r330", "r368", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r80", "r81", "r82", "r106", "r345" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r69", "r70", "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Issuance of common stock for license payable" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r31", "r171", "r203", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/DebtDetailsNarrative", "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": { "auth_ref": [ "r14", "r15", "r203", "r205", "r267" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.", "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r14", "r15", "r203", "r205" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r203", "r205" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Number of shares of common stock issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/LicenseAgreementsDetailsNarrative", "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://seelostx.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r203", "r205", "r233" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit", "http://seelostx.com/role/Stock-basedCompensationDetailsNarrative", "http://seelostx.com/role/SummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r32", "r203", "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Issuance of common stock for conversion of debt" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments", "verboseLabel": "Warrants exercised for cash" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": { "auth_ref": [ "r14", "r15", "r203", "r205", "r267" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).", "label": "Issuance of common stock, ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r203", "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock, net of issuance costs", "terseLabel": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Cash received from stock sale" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/CommonStockOfferingsDetailsNarrative", "http://seelostx.com/role/LicenseAgreementsDetailsNarrative", "http://seelostx.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r32", "r203", "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Issuance of common stock, options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r18", "r19", "r77", "r126", "r127", "r310", "r333" ], "calculation": { "http://seelostx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets", "http://seelostx.com/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r75", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r205", "r207", "r290" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "10. Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "2. Liquidity and Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/LiquidityAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r110", "r111", "r112", "r113", "r114", "r115", "r116" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/FairValueMeasurementTables", "http://seelostx.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://seelostx.com/role/ScheduleOfFairValueHierarchyAssetsAndLiabilitiesDetails", "http://seelostx.com/role/ScheduleOfFairValueLevel3ReconciliationDetails", "http://seelostx.com/role/SummaryOfFairValueMeasurementsWarrantValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r94", "r101" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r93", "r101" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://seelostx.com/role/StatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "40", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r380": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "https://asc.fasb.org/subtopic&trid=2197926" }, "r381": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r382": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r383": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r384": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r385": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r386": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r387": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r388": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r389": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r390": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r391": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r392": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r393": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r394": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r395": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r396": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r397": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r398": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r399": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r400": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r401": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r79": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" } }, "version": "2.1" } ZIP 63 0001136261-22-000332-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001136261-22-000332-xbrl.zip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ʗ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�GNNIO.K]OJ9:ONO[E.7EB@0D MFK7_FS??_!@G"?FS[%K4V$)[+Y6-. MQIYE%J=+\M\1_5M)EUG9*NT-:>:GH,!,2+5UOD]ISB+__B8W7<#XHKPS?AK\ MJDYA?,&O9!(#;#G##JQV"A,)4Q@\S11FFFW791CF9"0LI VWV'K5*#G??C4: MT-N"56IX#RN#8$JW8E&E)3YSLD"5HG?&L: EK)J?9FD9IX\$&OFW(HYPWKYN MH:?BZ-*_VGYO0EVOGY.LBW& MMSAA]^)L>W@+/9\B((W133FJ(JQGO@J^)WPV>;$.<#N3L$P2#J%T M\/HY=COTN0)T^_PJ2Q]K0\S;TTIII\_%ZB&WGHR5BX+AD1Y?[^E8(KWCT:0; MNQ-<:N5G#NE1#>%P(06JL%VKX?:JJQ%Z^]Z44AP,K\P8)>MV3 /1MD&"#N.: M=WH)@.XV#UD>T1,0.-+02ZOADEX6T%LOIJO%P=#+C+'W)+I *%'%R*ZY%KYV M6?>:#!C7*P&E_&RZE1:\(S*JS&%:E^!_.=!'=!%O-M$LI[2D^R" K8H,H M"C$N2/#I8@(31Y6\=Q:QFQ+\U8V5W6!&J^&231;0V^>/E.)@6&7&V#]R5&O0 MZ3NXP8PXZK>8&/B;79FF5& H(@&EGSQYY\#U:E7@DA[3X.D+=*N#"EFG1\QT M<%O; C)!,#S1H>NM_#>R/,D8G.2:72M,2W\:>9\PN@Y1,UAY50SZCFM.QM*41K4&U0<Z[,LA+W1Z:)6;9V85* @5L;'2&0[Q^P#EZ=[Q A!/','G8>@ZV^;&H?BU4 M[Y&/+,L[8VW--=+85-#!<-O2D.&$?[M GZIW"(^"ZAU"7+_^^\QR9M!G63=% M1)]F106]-;OWXZRJ:U0&K^X\\GB+UP'Y*SWMFP=AN0F2JW@EO4([4<'N+E=- MV1"[>U93E.I]^#&Y*5V?J7V+/OXUPGER7A<*=Y6AA-3&W&B+@[R8RWT^;"BV MK D._<0KLJ:TT7*7LM?:A%WR7J,*#,I:X^P=C6."+D,NK]'0Y5B[I65I?H/K M()/U$=6J*!B17=V18:55;3<^\:$97P\ MI>?LDV1X?%0H>HN/6D.4\5&J!8-Y0Z#V=I-K69?QL:ETJOAH7Z#?^#C4<'U\ MM"T-!DNG,$')WK'Q\= 6U=V>D>)+C^>I]E5,:\SF5<8?VT M?"A?V-H0\V?_MTV*T;NW?"?E@!:62;-=KWCO.ML:\_ ZP"PWCVT>ZY7GH14 M[@?WMVK >K3)W_RM17=F^)+#/6HQ9[S7@&RH*Y&!P3XU,"6!\$YT<#\]T\H* MQ3)P,%@G&'"\<70 M4@_#+2892?0[ @ CB7E.3NG.%>L4O)^!4IXP5DM[9[ UQ-[R#U6@/*Q44)8C MI@3FS+'4I"O#P6.3DG>2]0PP$NT*W#ED*Y@#"'<%Z5!RMEYG*7\5(*-'IZ7+ MZ49IM]?YM)#;U_FDHG"8I<77O\Y'I5'!7JUZ8?(HIPK^623SD%L<%%EZD>7T MS ;!>I]]R%)<92$<%-!,)7F/1)%=GHW7NY3O-@_] MX(]KC=^Z%UR@NLSJW<2=3-$(^<_P*&N-HCP+2DP3?_S\%(=/W<90+TA.5:CO M<#>\ 4P.8E\B:#\9;$;77:@Z(EW\)ZK>[$JC!QP&:RQ.JGTD])CS\""LA![# M,'<_(M<6CQ4TJX+:HS/0-B%@?1,=PK'+4-Z[%S%M8I#C]P&A"!GETUR;[#V! M);7CD3VX4[S?[F2J-WN6A&"1;=;+/DK%Q]VFUB,;1BJB@N-)!].W1!5ISM7\"#P\^ M>_7PNOK7Y>'M1G7KX;SN?R(/;QEL[^%<[75Y.'VY-"QQ]%.6D&+HLWB.>W$# M@(/UV\7>92F_%L1_9 M%GW=<%.[^E@4!S%2V:^))^D[QD$X_#'+7G9/ONNP0!6>!>*($ D@'-,"U:A0 M!8N+(':TA2)##-K!!QKA&BX_\#'3)Y?42(C+RO MR?DZ0;!U4G7^+Z&O_4 =U:9)9W)?7=6OW*DM3->X^@(]X,3^B?'F M]R_E^3^;"<8D?>N4"$#YX_1-.\A/IZO^DCS%;Z>CCXCJ,$&!HIXLL7^&XW.2[EIIIE"RM"90S MCV^J*6=*DFI ;D3.8N)LN<3]][42HWWTMH-A@'+1F1IYTAYW((;7T^>.,USI M\E#F4(>YLP4PZ?=\1AY('OA_@KV7UTT[*].UNR_T=![P?9IN7VIJUX?OLY(X9?#XF+/="'IODRNA%ZK% MN_C6VQD'[[$_X8+&O#1J#I-G]$^NCCS:5W](_CRT4:=T;]NZ877A[@SN7>UB MZHA((MS+ M*@XI(BB;:4I/[U7R:CQ899GV&T'ZIVN M5S,LJWZ-GCS^D+34OU_92H3I\5-W2PZCD!S2VL(>33WE(L((&+#"@A?;IUL6 M$-]E 3A(GZ9UVQ,W>(P>TSC?Y!69..;TZPH"[M7E2:MR\\+2S,TE_RU MI0DK@N.C,UJGR]K69&/;10/ZH":MJ%IM/PV>8^+.M/P%6JZS30KGI?-IVNK* M\ K3Y+6X],^9FDCTS(FK ..3\]@U@S=>V;W\P^IUIE;1![$(*6F,2588A7*!>\0H8WKYR'<2 M=%; E@&/V#R$3/R%?+)!.Y^L*/=<.5U :SQ<[^);)->K913%5"5(F%RQW)1/ M64[C_=1?QZ;&@_!%^Z:;Q$7-U1V^YUK;.$-&Z-VKU[O:N7R!=O4?OJ>[\N\# M]VHGOOQZ/=B'W[Y>9WT)XH0N?5QD.YVE+,WC#2:?7>_:,U5X$+ML MU@TWR2Z;L398#CZGB3.X>%TU8G535^>UHSM^;Z@"X-_+=;E9FV5:UF1U8Y*F M4F9T'UN:4__V[#=IMY<8B7U[PXQ(M"F]!R M]_6& N.$4?SM=^_>,IK?G9]?310_SN(BI)L"%CV:LUI=N(WC)J3NY:A*[V[H MUL[Y>[D:Q*CN#N)TR_\['3 ?PIS)R%YJ)JZ"'KLI_J'RZ/6\+W%XO)O!>.-A MVNJL'4;/+/XUY^V',1;V=/[\\W.<,V%SBO)IRC^(R;JJ62:9FW<+]SY2F-,,L61E _+TZ8U:H:Y-OL?5'OJ#:!1Y1ZS0>'9 IZ0HAHD M.'P01U7O0;CMT&::6'[^ #+9W!ZRL$"R1@8,?5!11TEOE*XD'OZ3!V MXL_"]<[BX%B8^([G/E:/^ZP5U FZHY!U]+V[=B,!'" MI;5C[D!5R=5:$6&!:(7DUQ)M<8EV==97VUYO+.#!CPR7JC]1.=5$WS6(5Q$= MM WL)$Q($;S^>*$S>__ H0P8O%IV,E6HV'L &3UPHWL,Q?6*_?O4@\)VV0R"UF'?N3S_?1.7V\NT*/,-VYR_+I]P?O\4 MI-+=^*D_UN#J#\)31S;J),X\L.[#]_=Q!L\0$C@0)"!!# HJ"9;= @"',]U2 MH/$L;=U8.T-V8YHTXB\)5\.;\\]ALJ&)I3E:V=B&STKTYR/GJ='#&=HYFTYR M?G:.ZKP[N#L;]QA:\[PRO.[&G^OJ#V:J?H4+$@VN,+%8R"JAR[ZFU7#9UUI M%[M'C;AWPMMC[!*6:RP0TUD@,3,(E'1C+8?R:J6T3C99[[AE-Z'-/J0*,>R:<*NXU>A(6>KI$ MT#:%'="[7GTL\)(@EM[PU2K .ZAO![=_U:/SH9CB4;8Z(JJ(Z8+X7E=Q\! G M9$)VNLES++^2K=> _L64>(V?K-$D0UJNZSVVMTU3Y5)G/^K>#!A>C,OH/]9( M-6?-98#I'T8"-Y*Y+@E51:&F+"[!EFIA\[N^CGD;E%B?>F-X,6#XK3'2FM^2 M,@Z#WVK@P_G=7-ZEA<%)4*'HG(9U93[YVH-L,50 RKXN/OL1 3 :51F#K8QN M9/U1J -73:!*$"A]VNB,Y+%(ZSSC%V!3CD(SRF\) ,JR+8*LZ?&E_T!,"]!G4V-1CG%K4=YM?IF&V MQE>*C$82,8CM+D&G;GDNC+ZDXMIW46=L_LNTQ*0U2LW OB,"J-E5R+I-7LMY M'LC_$,1I03\V+J[3\\^4 YNX>*)'-:Y79_A!.C8R*@'Z'O98NU^(:E:.0/,] MM'7I*52J[>FS?&!\N0;0;(_-E:"?3756&U_)"U.H+FP 18OL&1,,.S_G8= M/>B?3P77_@O2$I!0A*>/>(;S^(7T\B]L"G.=[OY;]NG4TH ^F 7(_H-UM<@" M424Z(MW]#8Q_\> _TLD4RH ^W'#,ENY6]7)@G.X#+D^#XNDFSU[B"$?OMQ\+ M'!%KZP'W,B2T4WY:>VU WW8$Z-Z4!)>(EH'J0NCEI2]I.>0;?R4G[ MWN+J^J6:F9AD 7T[(\3NE]HIT(D\4_$\5KEI#+B(TR -"4W8,\ZR+Z*2 M!?1%C!"[7^1&^!Z-"KO\X\M'J">SVU'%$]T!> D2BF])HD2>;PDX988H*T5 MFUK#\/:F\33@\:M<]+7I70$+%-!PR,LPYUB::UGF0Y929/3A%7K7K/4$Q$66 MW^&R3+!\O7.,/@ ?W NV9)EM2#D>OW!W?7 M=]Z_YV"HO5!,%6D'6JDBFI2&*B^0H [U>1!#*D'! OY"I/3PR-25 *+%?+;- MF7I1J+5^VO/P"3CYVS335/TZR6IEL3,*]VX&U'CX*U\'RFTA?[*CI-A-:AC_ MXR@7UKE*?FV5X08P$05?FS\5L[*R5T1*LXW.0JM',#Q__^=W7NS>3N]/+R^^<)'7#F1M$(?GG M=V'TW;_^W__]OQSZGW_\GS=OG N?!+.?G;/(>W,9SJ._.]?NDOSL?"8AB=TT MBO_N_.(&&?M-=.$')'9.H^530%)"_Y!_^&?G^Z/C'QZ<-V\ [?Y"PED4?[V] MW+2[2-.GY.>W;[]]^W841L_NMRC^/3GRHB6LP;O43;-DT]J[EW?%?_+J_PC\ M\/>?V?\\N EQ*%YA\O-+XO_S._;=XK/?WA]%\>/;DW?OCM_^UY>K.V]!ENX; M/V2X>>2[=2W62EN]XX\?/[[E?UT7;91\>8B#]3?>OUUW9],R_:LO*5_J2>+_ MG/#N746>FW+:E9]QA"783V_6Q=ZP7[TY/GGS_OCH)9E]MP:?(QA' ;DEG$55(VE->;1&3^3^_8X5HZR=OSN)S=@&-TM"$D3U?=;"QOHQXT;DS!=D-3WW$"K4ZTU MA^DA,QFRI*TGT_GTB9DYU:-D$LZ8:<=D0<+$?R974:*$4;^E74N@14#/9H>7 M[73AAH\DN0SOTLC[?1$%,SKDGO^1^>GJC,Q]ST]U1(*W9D 2-UE:)##&$CSI0.+O%I%K-A9I(D@"E- MIXUA>DU'Q664#R;3^9S$E#1E+V5UAK(3CP$P>8Q)/HZH#41089C^4(V.,[+A M1=4;0?%A^G)&'I3:7BXSU#Q0GV[4DX"HQH ]>L,6O7QJITCS@1S4+7&UX:S* M3[DB\I4''PSIK@XPC@*J[F"T'V34-S/Z2S]Y[SX$/7M=;<+R9=5]*B M=@9"V5N061:0Z7Q"QYJ9'V3L&W?$RV(_I6/.^8L79#,RNXBC)4,R2]U\&W+N MQB%;7MV0^&Y!]ZM%-Y7$&/K>T&AL1K=_\^E./?86JWQ\H.1<^>Z#'_#>:@O= MJ=F!9,N62S=>E?I0&K@3JFS/)$Y]:A_744H25B#??B9)MN1;3["T0W]H%_+_ MRLPK3(V)#6_?F"9?D6<2O+\E'AU7J*+Q;G178$!KYE8HNF.K3AM#XP]9=6C3 MT*%1<[MR739TVC"T:]>?G($-##XKY\O /G..LHGA=O^ZL,KJ##SJ%P/PQ*/? MX$?2>H.ZO+JI];@NGO 6AM;3MHGM(HIS(]>;1WNT.;#.E+[456_430S-A&#K M4TP5VB1H-6=TY]?)&.#-&#]?ZS)-:C8ED^$I)@EMBV-P17]1J4)>4A+2;=>Z M(28+]!8^]5-6N'",.';>,"^*C/6;_C,O671DW94@\BI?#YBW052[UE][;G"? M@H1X1X_1\]L9\=\RD-@_.%H<*?K#;_Q#DXTTVV")T"B4C0T3)0]!.[07-"OS]C?;@(W,=V.&M%@'@>8P#:*@T6HJ4K M9@6PE9) ?$]0\6V1;<+?)A@3S?V9NG)(X6$&0;A0&@OT])M@""9'POJ>; MT\1G^$ ;Y8&(OX#ZL)#(",2Y'<+$@1L8^&&("UO*P^$_4=,V,5R6@#\^3.; MW^G4 L>^5 4(_T^VP-^0%HF!&Q+[T8Q.Z3$ ^T9A(.H?,5$72(B*]WDX@Z*] M*0K>_^"#71,/">H+/_'<(._1!?U=(H>[I3@4V TNPQEY^0^RD@'= M* I%&F6/*14/!>J;V&^IQXTFF6A8*/L+.4"HJ!][[Y:@:0& M75@%BCW*MA(D+@H%EZ$7Q4]1Z;CXE/F_QZO3:"8=TA45H72@[##CO* M7E0I)B;LI_2?T_@^^B:X@186AD*.LA=5B(@).)]IIO%-'#W[>?X/%>J-&E#H M$;>HN,D%W M?<"8\\X.+42N1+4B4'Q1]JJMXNP:4L9P3%RQ^E9+0 %%V8"V";-C/*\B=O>Q MB$+I>6RS%!17E)VD2*A=#[S,D3@1FG[ISV /-I1AM2[&CF'\-?93V@/F IZ% MQ1F-X%9,4!0*+\KV3RK>CJ&^X]D5F&_]%[I"C/UMQJTJSFWEH""C;/;$@NT8 MX9N8,*8)779S/RX6:1#SR+]VI&7EH8BC[/74@N(B?YDD&8EU\6^I!64!9=L' M%7K7XTR>XV!U?/)PSR)F!*-,HQ04:Y0MGTBH'6-['=W'+LM+>[=:/D2!.#RD MM2 4890-GD2T'8-*?9>:"\)!1AEIR<3 M#FWL?02-O8^:8R_*CD\D%!*VN6\XM:CI0^ _5E+7MKJ'.9GY*9GF7+OS0#3VZI=HF%!:@ MKJP%)0 GAA(H-,KQ_J\D"/XCC+Z%=\1-HI#,\J6^[(1?6 7* N(=HD)<% I^ MB8*,HA1S1]!88 ."HE#($>\.!>+A^%[F3LV;N2=_FD*&N*@&%'C$2T2YL$C^ M:2EA??:?R9F;ND4/9?B+:D#Q1[Q0E N+YC\?G]*)YS&2WYG7"D+11G2%;14- M!>2[I1L$]1<&VD"N%82"C.CSVBH:"LCG2Q(_TD'M?Q;U+D6TJ#LQ,@PBX4$BOMQB:9^1U_+2P6H"XK#\4=-;!2 M+.B.D>?Y0,OK)]Z92[IODSD]J&M!64#9KD*%QIE;2Y'\TJFU4@Z*-^+&M$TP MG)BI["'PO8L@2&O\?94^JM;N+((X1=GR0;:P-L MB( -0"E!W)]J08%S7+!-LLSSY2?3+.4O==+^20\-I/6@U& &<0($1UH%)=M M+S+[M+HE!67^58/\I1$4>,/:@R6MK7#M1HH('.')"C;FP,OW7LP(8*=]IWN@R+ MR>PJEUK80]Z]-$K=@)?$8JQX03M\O")N0F[]QP4=J[]2/6-RBAE45$/+/-M_ MW@$!8HFAJ2P,,2'M4 N /3"QTHM!=/1NOBVC7MW!6T#+A-N?;UV8T&VPU&'P M.EU6!RV-[J#\A/J?Z0NGBI?+O: 1P1=/+.2.P_\P?#2E**^1(4QTO]VY4BJ=QV MLJ(T)GDMO-3!@W)DFP%5]]CKCJZ49*GJX64A[DH7# ETPG0LJH\=&3N'T"8& M9#UC.XF0S+'74>CU6'B4J^,E3>Z_D=5"R":S!-DC9E+E00\9K&% \KBLS(XD ME?#R+ ]A/4HTT!GK=DY14KYJ2;S4S7!\ MFP;4)BTZ#9/9C"L452W7GUV&I^Z33UE"HX(.GFW[)GS MD,S.W3AD#K83S\N669 O;.8LN9F8/$A=O,317,PTU)W)58L\8BW;:J;T>X7QYB9L+M2#$5C4,)1_:5O.(X+DOI>*?ED MQ7GZ?1?G:>=OE9;_Y>!,/:QD-VNUXTI*L9[&O+LSOK:[(3$/K!#+!JT_7N=K M/830%U+5[N9A,9,L742Q_^?6M%5$-NN-V$T;!HF5S/&\/YJLK>M@^W8/S%@5 M"BO9DL?=263K$GAG<*]Z/[Y-U3F=%SX;=%_- M+[F6]#L+]LK),[F*$D%P\P?8_GS[&2>:.]L/.100I_(IAW\+18-9V/F2;+JJ MWJ,+*R!['Q4A=8!P9TD5Y,VW@@R1NY%(=/3A\9:B1S^_H*9U1IZI&3XQL8KN MRJXII-6P-]AJW.OW$P 4T+GZ3$(J5D [.9DM_=!G(C'/0R5;RHK8VVM=OH!( MH#/6D$MCR,/?/.NR(I1VQ'=!&YGR@;^\XI!P6"Z,O7ON.&,UY1TQB]=1&%4% M6X?W*Y/)LS2=*\EV?TOTGJ>V?DB6UU)&:HJH>]VX8S M$&G)91EMRF5)HR#VOKHO,>+EQ_A\63Z[?IBPX9\DT_#\A4&2^FP:B,GGLFY#1D/L4,CGL2+YEK?OOK2"5P)-6P([G[<*Y$PU#4 M\/K;E^&%Z\?\WF(Z+P5-7$=IZZ:"50;610_AUN9%0SA+ID2>0DHHIV1#H:B' M'AW>U:9@@*#SUH&R =@R=LS2E2T=HD:W-20I9&M?*X8>3-Z9RC9Q1TQ?Y9(F MEXR*.)W?NR_2VSUQ)?08]*[4 J 8UP WW>R/7?';XZ8[]VF\=Z['VL_GD M)KXG[KV@^*BN^Z0BHR]FZKT[\X,LE;FK""M@7^_U8Z4F-SHOOQ*6])+,)G3O MXCZ2_,F7Z;SAGJ$P(,UFL*_\]#CLA)&MS!8*J.&.I-T0]M7A(.RJ<+)L-7/* MGXM/+L-FC%0]R+&RB/FARR*F^)CCAT[Y=OQ7?Q(XVZ90$ M5<<*]2PZ=R_(YE<7XAZ6SZ^AV4;,4XN91LAG5:+R^2 R%]2:"7LU3;*/;RMK M&2<5C1*!7^I^.>,%,@&Y K$=512RD6KRXD.X:*\V1EK:)2FMAY&6_M5NG45+ MUY=E.O2CV-JP+$T*)T1?K@@0C M*EX4U;"W65TX B&!SE<]IXB**%%Y[*U2%X;DLJ-3LZ,\*.8'ML:"TGSZDR?^ M[C7M09QB7ZQ@Q4V9'PQ5O&I&28V3XX3R3D M1TXL,1OSQ4EH/RZ(FV:M0>BL":T6L'WIU;1JBV33E)V'[IYE,>U^KDYG\BNC3HTA>U!KS?A=X')D/VQKK ,4\SW;3-E740QT&&7M:'7 M!+;O/,P"N\!BJPGF"Y!A;%#:%K;W?5\C! "U8RLLGA(M)FB1GRZX-K;3?#_; M$X"!2TFN,_V(6;>![=\^*#U58'9,4O&*U,2C*]RX=9B32=*HC>[AWH\9 1H6 MK"@Z68^L(71_]N&7%WB&=!E.TG1!EF[\.W,#G1,V5>;=X7ZAZTJG4=(:32F4 M5+-A=+?W'J1VPM PR='M1IX4,NBD: M,,(^YH=\:#($;K9NX?CQP/GR*8A6I#@F^!:2.%GX3S>!*[F([]H>^L-L@QRH MJ!&SE?!\AAB0<76#Z$^^#;-]'P'G9B/&\(]75"%B5ED:'RBVQ^J5&. [XM&2 M\M?:>C9KS_MN?09:,'[CU@*^<"A=N!G2BN9G['ECSJB6B/"U6FNNR3?^EX[: M4*INS\MT?5ANX&$K>_EZ8?BA']RN!<_=#;'B.@S^)@?_WTZL>&P/8_AGHCY:>A[C9XX;W'-:A%O]\2R6)(9)10Y_= M9'$11-\$KS'\V"G"F;;IY(UB1R]OQ-,*6FZIA79@R?IR$T?//N7WT^HKA?XR MW*1ZGGBI_YP_\*E.A]RA+7O>2Q02V3P"[8@8^B1J]G3:6,ZK[H"/X?"ZM"NZ MCD*/2LHGD/N(N>N'GA^02K_OH\'LU?R7L8-Z!E.=79&$KHWKW%35>!+)G"8H MCQUDLS/"(A <^&<=O35CDTMW"^UT_JL;QZ[TQ$Q1#3MJ!TE/0& :\D+*TP-) MDR/?N"M!ZAK6@DX#V-$[N^97%Y^N X-%&>&W1X)\7SL)9VM%OHCBM<_X-#X- M7%^6?4>S&>Q@(Z2!HQ/8AA/03T/Z[4?_F82$_C!G"BX?0" 5L2.., 8..*"& M&*4BY=^O>ZN7QB])N""\.G:X4O^-@9Z\EJSN)\N(]NI/#G-^3W/F)UZ4A>E- M3)9^MI1L%M55L8.+Q MH4VRZ1.BUJB*'L]E0#4$^.R?%L09E(&9&%P0HC5H=SDCL M/[MI\;C&--S^+%8"61WTN++!E@EJ9,9]=M,T$3[?]1H,A$V@AYZ97#W*<1OU M\ "';0CG OBU8:\Z*_NEFGT7NBNWJP5)$=G1KX_F>(O:)-46 F]HC6T,KZR_[+PM>>W8#- M"K>$"NE[=!QG?YB$L^HO2B7S2,3F$9L79"Q.ZOS%XPYVMQ3(\_FR+1X.J%PY45*LJ>%J_*,Z&F%LF("RS<(+J '9Q\EST]!1PA-U@C=!G.HWB9DZ0.\(0V -4%F\Z_--%!']\O MPY106%/V7 Y=0_>%G93[DOURHR"4 M$'-G5ST):14+VY_*V"SS%!6A%)OSY^I*,51"H^9+ M>\\419X[:QL<*+!5[5:@K)ESM^ICF!U!0[?"4F*M8\E6H5(*RI0YAZ>>]M4F M-#H3+'"G\A; VMSSA&>%S-/XQJ5ZY ;%S_=TD$^HI-*T!P,T#>7347VVAPU!6!9F$6ST*2_J_0=FD(J@3F8B$'4()^ M;]4.H0>[SELWC1_=L C\I(B=D<2+_:<\#/13EO@L'GLC:B6-W4_.&X<%B=(& M*1STA^,CI]R:XX8SI]0>RV*W:1%E=BSW;IMJ+Q?\IH3IQIO##;9)^-0G P,U MC[-RZ-7YK1K<4_7[%$B=)8?_$G)&O4'5JK;B,$5+RP)DUR//E?]'YL_\=$5% M^1QQSRDZ_<9A^VCSL3[:G!PYFQ;X4,/;<-:-C,^(]GR N6-I7MBX^B[*' M=/(096F9=\#0H=/&'@\*^E!:8.YW_F/HT[44[7<17LPR<%-8O+(73]GFC]_5 M;?[]D5-JQMFVXVP:PDDRTA (D(I24@?)0F4,0:P36!_9,M5DUT+<9GE5%S&*Q9V7+>P#T<.J^WPZDZY/FX&QFTG :8EKX6<2[+4)X!-*:HA MFQ*$'E$:2!D.%MA0D1VER(J2K-.BG++C/CH.5+.C5&SJI&Y3WQ\Y16O.NCF^ M8.4-.D6+3M$DTK%Q?F[!SS2+BR/_3S(KNEW-";.536V)O1M&V@PWJ(;L:V65 MD UU((+KFU,U3!98FV@V.$+;W4.F>"UD%5G5)=I&0 ":$8+OBI^3,5\(EU1FU]JGI8J0WR7I6[ M%/*4[EE*XKMHGGZCVJQE@#V:1+9)&+6-Y @]$;3 +(ML/NME:KM1?E\WRI^. MG*+B9H&+8Y)%.@JV6N<=<@/ ;E%:"2EI;37_WKIGE31+6J;8N4%D0P006D]D MVP\Z"VRPXF10,;P?ZH;W\CH<6!R6[M M%[]Z6;6%'QO>!^^.G'+EO_[EIY/C'__N%(V@*%G^;;5IU,O9\N HV_XVQR?Y(>A12O\!J/:#DX$D%@PG<6I9C-X3TDK.PFP M==UVD$V[$\4MKU#K0V>!X4J=#Z3N,R<=W&>5Q=NXB?3>:UC MJ_Q_(5<7P/IC\Z31PP4]FNIK0N?]\R3UEVY[C&)1L%X.^_EH;5[:!47'O_2: MY,9)\C*DDF1\(,_5!N [(Z^._6*S-EM:L*"3V/X^<)XXD4[%EZ%'.^T_$YZD M3T5II\;0'V;6=CCL#ADZW>=N'#(/B1L2>9SC17+?HMX3^6+(NJ5W!LGTK<<_OV=HW$@TO8%M@_6U! 3*C;[@Q"T,#D&U]#V,$2KX*!DA( M_,R0OPRI*JX?Z?:YMMS+GZ49_DLJ6V_8@1&3[Q.0,!@4Y1>!1Z](=-@A/'O" M3I2I]#7+%&I@DS2GA"4(RR_4("OBI]5:LM4I2SXW>?$A&M5>[76J1CL6I;/$ MT8\U=0G/HJ7K2U)2[>#3EJF:S(S,#2DB<+;K=QS5NXK"QWL2+YE7VQ>R?""Q M6%?:RF*?_.[,=&JJ(<8-_2RJR#BJ8K-6#/N$%XO(5K30.=R@D<<$3L*9'!9: MX#H*XPI*?$;4B8\>\%NV!%4;6+R+YHC!F=H+)63U\_49\1:A_T=&=JJ7@,]C MWS2/3%?!A-JCO@-L+C2T=="O[='R"JR#>ZER,Z9'D.^=>2/#W/@M!1F\$]B M'Q$:5BU#%%FPNA$]WG!&4M-BPT)7U>V.6>V:YP(_"N;'",W MO3K-G^+EBQ"Y4Z2DRACI:$J![LI8[I+*]["MK&4TB%2KGAJC19*>GGV"]PF_ MN*OC$_;K.S?8IOX5^GJQ.O(JV,M'L<*4WQ:$B&WH05#ZZ9,/]-?'*I"KI8"X M&GNG%8QKFW"&H/QW-\S<>'7RDQ+.UI) 2(V]C@F#5"*DF9UO$J>ED9G^M!V5 MZ0^_W;KA(Q%,B_3OI3];-O:V3H'5'I<&IQT#*M3>=0>A2FL8U"I>[5BNNVK$ M%UT!YA?WQ5]F2QF:_^*$2U6H1(*K#/R6O1K5-%O0S M1/;2L61ER_^*?#,@WJ#65Z\E6="!O67'5"&9K>/!)YZ7+3-^E'C&WY&6/@NA MKHM]$@]F!0Z$H=7:Y)&NLQ_I]RZRE)_NY@_W3)8L(X!@W::H@[W94(,/$,(H MZ#S)8L+>2+^E'9B&G^,H26[BR"-DEO #]O5#3&PG)&!!MQ'LV!\8+=V@01_0 M>(\NDR2C=ILQ/^[FWIWZ>G7L!%!]F6^'8]S$NYMK\9O8]\@ZJXV$:V$- MM*6Y-KT*H0U-F9>ASY[QOL[8!H'. [07X5H#+LKR:=7>@-Q= MR>A'#XHX#([H+E?MG;MVET3E@*6N:8>2[,#X0!I31@8[<=O&+WX;>J'*^"6I M@GTK!M7A^O, *A#03_]O"5V+^5Y*\IBIKZ&?)K=W7U54*:IAG_AVI L$!CIE M1O/G&3L\Z$B)G>GO2B=1+,'B5AX5*N,D1]F\^B6F?%JNV3';28\'&HZSE8\'2XPR; M+ZQ3:+&0NM)'L(_^]O#)AKX9- %B]_^$'3NB/H\T],< _\1O"&$ QWX#?\8R MW1G*W@PHFE5G?Z74\.3JO+V%8)V\VYD^:*2!2C@K[9;.OC21?F M3C29,_\*PL#,G8R N?==F'N/'A9FF+GWMC+W:562]"(F?V0D]%;@E9"XLF4S MH/EED!@*,_&M/== FSYV6?DT*EO&MEJK 8N=AI#6+''*@]-&=<'CKK2VC8L> M@:I"UJL"=&P:?_?W.4#S8Z[D'<#W^&9Z> ?P\ [@7KX#:"Q(Z? .X&[]&/C9 M_UXQ::>KG.3,_$R3-(XXXN4"D1RFK4;@J[G]NY%R(Z0HZM*L6A2 M!X#4RMGR5N.05WEUCXA6:$8=86? F%3$]I]M9/?K^("94W)92OE#UTTN,@MO^G;?$-,W IIGNJ.Q2/^Z6Q MYR]/A"5T^R4*:#-LY[M#G15]?(^.%':JMG(R]U-QS_QG?T;"&8+:5C]MC6?> M2)6VC4@[5/9!+>F#CJ3LU/!8H:N&OHGM>+AK)35*G1W:.9P=DMCS$\+?"=K9 M2%KYIC5[GM$-H2W4V9#X4>I@6P1L:?O5'G?PJRV^=?"FM3^MWR$5Y"$5Y"$5 MI&4)%PZI($=]&W-(!7FXACE?0L?\<:@]2Z!QNZ$>>O>5P-7^XFG^U^GJXDS_/+O'2XR!^I M9A]N\%N-ER5*2U>EO(;3=$'B^X4;YB',R6>VDD\NPQL2^]'L5^(_+JCT$VJ+ M[B/A?SRCMKU!RL P/7P7K?$/L'$X-Z41-O@1-!^0S \QJWM=J=? "?#=2-ZP M\]ZI-GUP$;#INO?@(G!P$3BX"%AV^7!P$3BX"!QCW^#%W M6PG)HYL69?&<9]K *9Q9KMEA#MOPM;O,O*^[S'PX$B38V+C'.)LF#XXR/27Y ME"54[9/D-%H^T/TX4X4[0DV.JE2P8GK\&/I_DAE77=I-MD]2^,5T;]&R VRX M&TQWD?&]7CKTO3%0#J($5[;YM/0UC?Y*%"/,AKH/BT= M>JZZ+>W1Y&B50W(_V@..GO>>;*''&7_W\?T[SOK=^?G5;Y?_=>5[)$S(Y#$F M?&TFO!]AY<7%L8]@>NONFBFYF"/?:U9WUWR+M=G+7!/(BG?H#R+?8PRQ:#)R M\B'DIJ_N"08"OHF>9^&,=>_4319%K(A@(! 7Q[X1&))1N:1"/O#B76YB*JH_ M8\%K=/1BIR<\JN>4*A:+^^%'*M*PEP^RL)>B=6?=O..&,X=_P"F^X.2?P Y_ M.2N.74XI3LFI^^2G;L!(+P18PU+@L1%7O?'OW3#.=%%T[S*DG7%#6;K>9DGD M 7H@*FMCM @00X-K\;E36M+WW(#+(AA8VXMB#ZH#LR 6U)+U%9>F.I@6(YS8 M=&1UL%?'9JQ(C1(ZD=7>5>54,@JJC'V99W2 A.#6.<]#&M&N(M]VT%7BDBX0 M^5O><]IW=J,(N^WXOKY2^N'(R5MS>'/.ICU[;CM:UL:46L[JQ/LC\Q.?_TJY M#-)M!RE9PF99O.YOJ7/)IU7I)\5-B'Y+UAY> ?BN9QC0%MZ>NY!2WQJ;/+%: MM]>R@]*N2BTXB&P7%?^.XH[BRD].N!_R=,Z'5/DMA*3*7E$GD1/]!J'<)=75 M0%M92XA2*5^-D39)S!S7?W%7)Q_HKX^EI_2-4MC;1[%:E'>$ N$,[$:VNC,WO7Z&2^H]W#]?+A^-GS]_+U%MTXC MOG[FL\YEDF1D=I:Q,XX\1QQ/-)=\JQ+JA#6P%YE=V%*(/^X4MNVJR%T3NMMHO3KVS<9P-MH.3/?3 M;1+W4P#!E+D^5KZ)(X^06?(UH=-*=./&J>\&;*YYG)$[IW'(:A5014Y\N M%FGII9\D4;RZCM)6VEGC [6-O3?2T8D!Q=Z#,>.6$D6[OIB$LS,6UA(]L=5' M<0LD'BL4U;!CBCJ,$2 @,*FVQ(W+^((::L,=W+0&V<#0R8(YD$1SC]_])6QN MF4=QD"_@7=9[JA4)7_^)=C5Z;0"9^<$69CI!9(BN+W[H+[,E7P'P^9ZN_OAW M\^6 Z#Q550M(R8^V4 *$P93-A#Z;6#=?SW?+BRA.YW2ZO:#"?7_T_1<_".BO M1J?4S#*!?Q0]UOXH?CYRB*6?;ECT^%>TK!;4/ MA:K>:,Y@]SR*%,;O(8[T$$=ZB"-]W1=X^.IAB1?(X2+OU5WDY9[!3.I?5B1V M;^AN8NEZ)$N9;[\XYR:K"ZMJR^W"(!=\.F@9VH3]2AZUKEXEY6TY*AJ$&B4N MZ'=V7<0EB1?[_%FO88?8W)(^"RR\3X,C')VEYR[]P44?)BSST; I\8/*[D?FQ(%Z:6?\ M$G= 7LU>ZO6^\-\OCP_CM[GF#=XVCY!APIHGGA=304MI-6&AS9)Z(]P!J%0" M!M6>)&,Q?E>,F(QEMQ96CZT\C<*4CB MX%IP)[J-\6@.+=*\/#_*\O(4;3FEQK S\%"[9";*,A#QWKD!(*VNM!*2/>?0 MWL31G.HRU0 WN"" &5-5#_FP!$!/W?9 0*"/O^?+IR!:$7)+ IY+6V.1 ZB* M?=U1^)GWY-1P[USM9K /H[0H$A?.$N,K!@+-MFS MH*-ALP+V(4/G<5 D.SHWR%L\8[M^?::T=W#C<]?OP+/%N_C.QFB 71MR4[%7 M-F$^DS_5=PVK\/*W0#;RHZ6DC9AT!WT MJIVZ=I=$Y7\GKF$',V+]DO)1%L2,8]QU],S=AU@"'FJ1LSN6Y9TO51JN U+_ MJP[M8)]6J+2L>K#?$29#YQ87?IRDDS"D*Z8X<>/5=#X4D8.TC'W*H4/M@% : M(GN2/69)>O*>_>5^$6=?W)3U9S44Y0.VCWU@HD/\X+":HG])YW+_3S(8W=W; MPSYET:*W+VR&Z#PCWJ8_=S<3N?.YJ##V68@.$7*!#:'"K!+V'DN+'H#XZ!25^G67/5#XF.\0F M[6+[?&L1/0R(Z+I07OC"UOCX#MJ=5_82U'?N3YTME_Q(^5?FWQ"F$R_UG_UT M)?6E_MCPIX!TQM@IZ_D-CS$\)?W=C\ M,2G^FAQK*H*Z.6SK'D0]H*AAZXPH8Y%"Y7\E[!=D-J$;??>1W!(V]#VN1\/, M#:[\N2@7]$!M8]\5@-5D0)F-WBI<9VP"BC:ZVCSJ$1 *J8A]GZ#%%AP)4PG# MVM0E[X5B8-&Q.6"#V)<%_0U-"[D=6=>Z-UT,3% 7^]J@EXU)\=BEF6TZ,J"E MP=O$OA'H;VRZ^.W(WDY9!' 0=+(W05WL6X%>]B;%8Y?VMNG(@/8&;Q/[E9'^ M]J:+WQZ?+/QV B;T(SJA&C(-LE4\#V>O_G!!0T'XA9"]&@*1U :UZ7B^0+\Z MG>=SDLFC!OW/H#NZ#WKLT!5F4XGNJWL!P8UTZ42]6A+=)5Z+&XFP"-L=]OD. M@[%J%P!K%DJ<':=#0\&(Q/+@XZE^VU"^+3Y2Z@JH#8Y8S(]O$044XR3WG %E MKOGPKNZ+=?SNR"DW]M>__'1R_./?G;Q1>Q+:C,LQJU7=%-Y9LCIV.#* 7+1D M8N#[:;7VKC%R ,FYLLUC2ZUV$+*N;/+=:NVAW'%+4F6?:++$;ZNU;RJW+6DE MBTF2N&Q)13+CL75'GM)U)/J[]1)5ZJ$EK8%]1PC0I/*2#B"]V?PE[XX_@D 7 M%T<_B-"$7"6X(;SO2.R39 +4\-:R4*2-W?-H*[=$9/33_SL*'$^S4$C%-Q#R M25E2Q>+Q7IK\3RQ1R6T)=5+F70+.Q96R=E"B5+/V*;@BR0AF7HT+#6-N'V*% M 4ZYK7<59I*&'7\$9O_:%D0_58;A*Y;1[I6,SI4 C'LA5]9 ]]F%'+XT4*A L+*/LQHVG,9^\\B?M;DC,>PZE3EP? MVZU^ Y5X%C&9:YR(,\6945L;_?!+% >-X.56&6YC$+-(5-:"=O=O1-= !AL MHNJ7B%W@"9T#FT)5*UAY9*5!49OX^/2T"75+W"0*+Z*8^>'3/M]'UU%(BM>N M= _C58U9LAO2I+4[;.B46_9XN3'/^$[$=GZ>?(39R2SP[\3WR1_._'?E1F2$ M^"0]HZMTEKSRUX7O+>J=ESOX25#1:1?;M7\P5= '<^]CV(RY[^N1UB>0;7PC M?#DG;2'M6EC)_"ZOA>Z-WW%CJT9BW#[2EAP#P1VEAS GO"?&V7%6S@%=$"YY M)NZ$KOSY\G&:_RC+D_?A6/;F^*9QI]2Z,X_BW'O3*3Z G3]OVW^60G+Y1,*$ M][IX#_F48I?PA?.#2T?7FR+I*.!]PI[M(FVK2N^7T;Y]8GTK]W["C.*17W$F MGU;;,D7_)]_<>*;QZ&'/3]AQZ3N,!DE>4NR)$KX/JU($D02-$;KMB<;^;=NA M1X/;7N/MQ_Y(X;O7YF+2#\B]=VK%7@?#-:'1/6V[2[F5))S=!&X(>8'2S-?L MT)Q6K=>U[T[R]W1'ZA]&4QP]EQ:E0H^/HHZD"O9UM$F+J*F#$C@S1WA)G)9H MI3]M*:4__';+!!4,W?3OI3_;87C&ANRJL&;\+R%<"(UIW4&HZ1CFHXI7.Y;K MKAH9LQ1@?O%#?YDM97#6BJ#=UM?A:H#9*@O*X#^4MY0V^"A=G8=.7P% M2IO;*J;2KGM@_9+57JVMDKA?6GO^\D0\YI(:!;29P$]7NQ]L%7W ]AX=A^:" MB'P5NKO3,5?1!VQ7VE'K[FL8=\_\9W]&PAD3>,CU(94=^LW1TM7+Y!W1S^<2-X=+3M-6?/X MZ,%YZN \=7">LG1J; S0!^>I@_/4P7GJX#QU<)[J8-\'YRG[;Z)&[SRUPQUS M*2-&'DMF;D_<\JG#3;PF*SW?4\%_Y7= 9&IG 960Y9UHL;P#U@^3%B@WA,)7 MK_+5$[#/<928V,K)/G:XP=>GQOZ5@7"9!#EY'6JT';(3K_>R?G@J\=57EKRF M')J\27D@T<(.;>WO?7IG8/5GXH_Y3!R21W:*:_2Y:+*)X3/\WBK=SF5I.M'SM<=>M3L]]>'2I+;0$&:?#5[@EV2CA[ MA]^.I(Y^ ,8\<=7(=V\L,YVUPV\K6H.<06&_?OY:#ETUU-M8#K\QJ+<*P_U1 M^BZNMDJ\\D=VJ\_L,A_<$X4![+HSZ.D-[7.C[L_M/JT_+JF(?ICXGF%O:,DG MT5-"CF&\;N=I'\;G'OC\0A)FMN%L$P81L5_M<'D-[P'Z,U[6:KDNBZ,??M4" MXRRQ^_8+JN)[>/NV$\;M4/P>:RYM&$1+,1,QB0;Z"#6($=X@6H2R3<9A=(R8 M/#[&_!IU5XOV'EU"?U)SQ'.!@N?1:WHID;[I]7G+IZ":^?HN'X6\[)/&X2RM MP1V :N<>WA8.RZ$=.MMCB226%V%5W*DS4%T>Z3TC#K?[I-?5];L0FB9_IPD!@9@'O!OW7='Y+O.@Q9,]-Y[Y(7$)P&HY!/V='N+3AE!R# M(H:?GF,8<1J#NB0P>Z@/V:%M1BU7%-4]%(3X&3TN0SHGDCO*&I_;KXJNR_-[ M2"N]/K60PH&>!T30.U5"#T4U.U@&:"^,*UL2;MQ2%"D"BTDX.R//=-7ZQ'I9 M+!E5J3= E;&CRT'J6"-- Q7TC>YG$M(M>4"[.IDMZ9ZB92@PM+T&GM#;M]]MW^<46_-J-E_O;%H][/"MVN%W#T Z)-<\)-<\)->T+_7B$$CA;\4/R34/R34[ MC@2'Y)J'Y)JV9XT;47)-MG_@?+W[^/X=Y^SN_/RJ2MA-%GL+*@KKL9 V5DU9 MR_J$00,P!P+"*'F7X2SSN#CLD]'\Y-WQ1REOL@K6A\(/1)D:-&-L>?2C=.\, M&1SSGHHKV!_..AA=*M0,T74=A?^9N8$_]\FLG GL/EH;?2)E3Z.^_7&? Y&I MC>G.N:5_67?ES(^)1UOL2K.L*?MC((TSKD8:_;S\AL3S*%ZZ87'(+-:$HH:P M@OU!(,,M916HX;-:""$_DJB6LF-?:?I$HBIS*9$Q+E&JHP0[#P':U$R ]T"[ M=\%D=W/W-8W.7XB7L664?#83E$4?OM03C51*]#&G\VGN&4F\V'_J0\R=)%%+.[<0/Z!?FH]8=\.]<[.%7C5\<= M*F%GU7M%B6A4M.R-PCV[?L!6PA=1S-\#,*]WS2^^WB<:>I)DAQ9VB2?;7!&P M %WN@+*,POSR@,3LH%.AAX:^:?UUSNB[ D+X?V4S$>G:X/8#KSF MM*@?Q(8.L8?1;>8/%V5A"AR,V)=W\>']>Q=A5\C9,BSMUM=\7[* 6,[?'C[4 M-]*<&V:H>=U/J^SK(W\C3=BQ6RK'K_I=%A;G+T]^S N#GK\:YA/V.R_M?+\I MXL&.=4 7B?C_L'R.=+]TR\PO*9:HU -:)G\<_9[6.U3^VZ?&15] M>L^SL>^"M]%K:./!W_LH=8-=Y5.'?1W=[+,MV,IWS?QM8 E2;W_/4Z$/A/UYM.O\C\]/599BD<<9/ M[J?I@L3W"S=L/:HWH'#:/=CS1.@[9/'5J&WMAHG_\P0 M?5#\OGI@W"EL+<16Q.T2)YR=LO#,H%CMG+]X0<;>V\I%:EOJ3);,XTCI$&;F MHU"U'-'MS2Y@$RK:KC-5,CO<;X!:7ORK9\C0#5!!%V95-Z1=ZYVOM8\K0&XAKCI4DD$7I& MQ;:NJ9(9R.K80I%BC+148_2G6D*8_U'Q,+1^ M2]CY&X90"CABEHWDM8ZO8V)OW90H4RGHMX2_DAJ<:@EBEE&]&;BTQV_\G 2# M#MR6\E,\=@9E9U,<.\9_"&YJLFM=MA1_8?_#;H'H;_X_4$L! A0#% @ MUH!J50^2;9'#7 ( /"84 P ( ! &)O9'DQ,"UQ+FAT M;5!+ 0(4 Q0 ( -: :E7@*1L:*P< +$H + " >U< M @!E>&@S,2TQ+FAT;5!+ 0(4 Q0 ( -: :E6UF.KF&P< *@H + M " 4%D @!E>&@S,2TR+FAT;5!+ 0(4 Q0 ( -: :E5.?22S MNP, %,, + " 85K @!E>&@S,BTQ+FAT;5!+ 0(4 Q0 M ( -: :E7CZVV8MP, %\, + " 6EO @!E>&@S,BTR M+FAT;5!+ 0(4 Q0 ( -: :E5(U!$>)0\ ,65 1 " M 4ES @!S965L+3(P,C(P.3,P+GAS9%!+ 0(4 Q0 ( -: :E4<;4IHFPP M &Z- 5 " 9V" @!S965L+3(P,C(P.3,P7V-A;"YX;6Q0 M2P$"% ,4 " #6@&I5CN,D HXI F!0, %0 @ %KCP( M&UL4$L! A0#% @ UH!J51+.U0>,3@ MD*8$ !4 ( !++D" '-E96PM,C R,C Y,S!?;&%B+GAM;%!+ M 0(4 Q0 ( -: :E7\K])*%3T $5/! 5 " >L' P!S J965L+3(P,C(P.3,P7W!R92YX;6Q02P4& H "@!I @ ,T4# end

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